VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 19 (1-11 septiembre / 2022)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Resumen de la información publicada por la OMS sobre vacunas en desarrollo contra la COVID-19 a nivel mundial.
- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS SiViFinlay VaCyT

Resumen de la información publicada por la OMS sobre los candidatos vacunales contra la COVID-19 en desarrollo a nivel mundial

Última actualización por la OMS: 9 de septiembre de 2022.

Fuente de información utilizada: World Health Organization | R&DBlueprint Powering research to prevent epidemics

172 Vacunas en evaluación clínica y 199 en evaluación preclínica



Candidatos vacunales en evaluación clínica por plataforma

Platform		Candidate vaccines (no. and %)	
PS	Protein subunit	55	32%
VVnr	Viral Vector (non-replicating)	23	13%
DNA	DNA	16	9%
IV	Inactivated Virus	22	13%
RNA	RNA	40	23%
VVr	Viral Vector (replicating)	4	2%
VLP	Virus Like Particle	6	4%
VVr + APC	VVr + Antigen Presenting Cell	2	1%
LAV	Live Attenuated Virus	2	1%
VVnr + APC	VVnr + Antigen Presenting Cell	1	1%
BacAg-SpV	Bacterial antigen-spore expression vector	1	1%
		172	

Candidatos vacunales mucosales en evaluación clínica

Desarrollador de la vacuna/fabricante/país	Plataforma de la vacuna	Vía de administración	Fase
University of Oxford/Reino Unido	Vector viral no replicativo	Intranasal	1
CanSino Biological Inc./Beijing Institute of Biotechnology/China	Vector viral no replicativo	Inhalación	4
Vaxart/Estados Unidos	Vector viral no replicativo	Oral	2
Univ. Hong Kong, Xiamen Univ./Beiging Wantai Biol. Pharm./China	Vector viral replicativo	Intranasal	3
Symvivo/Canadá	ADN	Oral	1
Codagenix/Serum Institute of India	Virus vivo atenuado	Intranasal	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	Intranasal	1/2
Razi Vaccine and Serum Research Institute/India	Subunidad proteica	IM e IN	3
Bharat Biotech International Limited/India	Vector viral no replicativo	Intranasal	3
Meissa Vaccines, Inc./Estados Unidos	Virus vivo atenuado	Intranasal	1
Laboratorio Avi-Mex/México	Virus inactivado	IM o IN	2/3
USSF + VaxForm/Estados Unidos	Subunidad proteica	Oral	1
CyanVac LLC/Estados Unidos	Vector viral no replicativo	Intranasal	1
DreamTec Research Limited/Hong Kong	BacAg-SpV	Oral	NA
Sean Liu, Icahn School of Medicine at Mount Sinai	Vector viral replicativo	IN/IM	2/3
Hannover Medical School/Alemania	Vector viral no replicativo	Inhalación	1
ACM Biolabs/Singapur	Subunidad proteica	IN/IM	1
CanSino Biologics Inc.	Vector viral no replicativo	IN	3

Candidatos vacunales más avanzados a nivel global

Desarrollador de la vacuna/fabricante/país	Plataforma de la vacuna	Fase
Sinovac/China	Virus Inactivado	4
Sinopharm/Beijing Institute of Biological Products/China	Virus Inactivado	4
University of Oxford/AstraZeneca/Reino Unido	Vector viral no replicativo	4
CanSino Biological Inc./Beijing Institute Biotechnology/China (IM e IH)	Vector viral no replicativo	4
Gamaleya Research Institute/Rusia	Vector viral no replicativo	3
Janssen Pharmaceutical Companies/Estados Unidos	Vector viral no replicativo	4
Novavax/Estados Unidos	Subunidad proteica	3
Moderna/NIAID/Estados Unidos	ARN	4
Pfizer/BioNTech Fosun Pharma/Estados Unidos	ARN	4
Anhui Zhifei Longcom Biopharmac./Inst. Microbiol, Chin Acad Sci/China	Subunidad proteica	3
CureVac AG/Alemania	ARN	3
Institute of Medical Biology/Chinese Academy of Medical Sciences	Virus inactivado	3
Research Institute for Biological Safety Problems, Kazakhstan	Virus inactivado	3
Inovio Pharmac. + Intern. Vacc Inst. + Advaccine Biopharm Co., Ltd	ADN	3
Zydus Cadila Healthcare Ltd./India	ADN	3
Bharat Biotech International Limited/India	Virus Inactivado	3
Sanofi Pasteur + GSK/Francia/Gran Bretaña	Subunidad proteica	3
Shenzhen Kangtai Biological Products Co., Ltd./China	Virus Inactivado	3
Clover Biopharmaceuticals Inc./GSK/Dynavax/China/Reino Unido/EE.UU	Subunidad proteica	3
Vaxine Pty Ltd. + CinnaGen Co./Australia, Irán	Subunidad proteica	3
Medigen Vaccine Biol./Dynavax/NIAID/Taiwán/EE.UU	Subunidad proteica	4
Instituto Finlay de Vacunas/Cuba	Subunidad proteica	3
Federal Budget Res Inst State Res Cent Virol Biotechnol "Vector"/Rusia	Subunidad proteica	3
West China Hospital + Sichuan University/China	Subunidad proteica	3
Vaxxinity/EE.UU	Subunidad proteica	3
Univ. Hong Kong, Xiamen Univ. & Beijing Wantai Biological Pharm./China	Vector viral replicativo	3
Acad Milit Sci (AMS) Walvax Biotechnol, Suzhou Abogen Biosci/China	ARN	3
Medicago Inc./Canadá	Partícula similar a virus	3
Codagenix/Serum Institute of India	Virus vivo atenuado	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	3
Valneva, National Institute for Health Research, Reino Unido	Virus inactivado	3
Biological E. Limited/India	Subunidad proteica	3
Nanogen Pharmaceutical Biotechnology/Vietnam	Subunidad proteica	3
Shionogi/Japón	Subunidad proteica	3
Erciyes University/Turquía	Virus inactivado	3
SK Bioscience Co., Ltd./CEPI/Corea del Sur/Noruega	Subunidad proteica	3
Razi Vaccine and Serum Research Institute/Irán, India	Subunidad proteica	3
Bharat Biotech International Limited/India	Vector viral no replicativo (IN)	3
Jiangsu Rec-Biotechnology/China	Subunidad proteica	3
Radboud University/Holanda	Partícula similar a virus	3
Arcturus Therapeutics, Inc./Estados Unidos	ARN	3
Livzon Pharmaceutical/China	Subunidad proteica	3
KM Biologics Co., Ltd.	Virus inactivado	3
Bagheiat-allah University of Medical Sciences/AmitisGen/Irán	Subunidad proteica	3
Laboratorios Hipra, S.A.	Subunidad proteica	3
Sinocelltech Ltd./China	Subunidad proteica	3
Chumakov Federal Scientific Center for Research/Rusia	Virus Inactivado	3
Airlangga University/Indonesia	Virus Inactivado	3
PT Bio Farma/Indonesia	Subunidad proteica	3
AIM Vaccine and Liverna Therapeutics/China	ARN	3
China National Biotec Group Company Limited	Virus inactivado	3

Noticias en la Web

Drug regulator recommends manufacture of Biological E's pediatric pneumococcal vaccine

Sep 1. The subject expert committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) has recommended for manufacture of pediatric pneumococcal vaccine by Hyderabad based Biological E. Limited followed by review and approval of the Phase 3 infants' clinical trial data.

The vaccine is an investigational 14-valent pediatric pneumococcal vaccine named as polysaccharide conjugate vaccine (PCV14) against *Streptococcus pneumoniae* infection in single dose and multi dose presentations. The vaccine can be administered to infants at 6, 10 and 14 weeks of age.

Streptococcus pneumoniae infection continues to be a leading cause of child mortality under 5 years of age in India and in developing countries. The Biological E. has said that it would be also working with the World Health Organization (WHO) and other global regulatory agencies to make this vaccine available globally.

“The PCV14 vaccine will protect millions of infants worldwide and contribute to the prevention of invasive pneumococcal disease. With this recommendation from SEC and the anticipated formal approval from DCGI thereafter, India will have yet another important lifesaving vaccine for pediatric use,” Mahima Datla, Managing Director, Biological E. Limited said.

Biological E.’s PCV14 contains 14 serotypes, 12 of them same as in Prevnar13 from Pfizer. The US Centers for Disease Control and Prevention defines Serotypes as groups within a single species of microorganisms, such as bacteria or viruses, which share distinctive surface structures.

In addition, Biological E.’s PCV14 has 2 more Serotypes 22F and 33F for which there have been increasing cases of infections globally. Biological E in a statement said that PCV14 vaccine elicited functional immune responses. One month after third dose of vaccination, adequate increase in serotype-specific immune responses were observed for all 14 PCV serotypes.

“The safety analysis revealed that all the adverse events were mild to moderate in their intensity and with no grade-3 and 4 events reported. The safety comparison shows that BE-PCV14 vaccine was well tolerated and found to be safe,” the company statement said.

BE’s PCV14 is comparable in terms of serotype coverage for infants to the two pneumococcal conjugate vaccines Prevnar13 and Merck’s VAXNEUVANCE which are currently approved globally, the company said.

Fuente: BusinessToday.In. Disponible en https://bit.ly/3DeXPCY

First adapted COVID-19 booster vaccines recommended for approval in the EU

Sep 1. EMA's human medicines committee (CHMP) has recommended authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19. These vaccines are adapted versions of the original vaccines Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) to target the Omicron BA.1 subvariant in addition to the original strain of SARS-CoV-2.

Vaccines are adapted (i.e., updated) to better match the circulating variants of SARS-CoV-2. Adapted vaccines can broaden protection against different variants and are therefore expected to help maintain optimal protection against COVID-19 as the virus evolves.

"The adapted COVID-19 vaccines Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 are now authorised across the EU. This follows a decision from the European Commission issued on 1 September 2022."

Studies showed that Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1 can trigger strong immune responses against Omicron BA.1 and the original SARS-CoV-2 strain in people previously vaccinated. In particular, they were more effective at triggering immune responses against the BA.1 subvariant than the original vaccines.

Side effects observed with the adapted vaccines were comparable to those seen with the original ones and were typically mild and short-lived.

The two CHMP opinions will now be sent to the European Commission, which will adopt a final decision.

As the pandemic evolves, the EU's strategy is to have a broad range of adapted vaccines that target different SARS-CoV-2 variants so Member States have a plurality of options to meet their needs when they design their vaccination strategies. This is a key element in the overall strategy to combat the pandemic as it is not possible to predict how the virus will evolve in the future and which variants will be circulating this winter.

Other adapted vaccines incorporating different variants, such as the Omicron subvariants BA.4 and BA.5, are currently under review by EMA or will be submitted soon, and, if authorised, will further extend the arsenal of available vaccines. The clinical data generated with the original/BA.1 bivalent vaccines recommended today will support the evaluation and authorisation of further adapted vaccines.

The original vaccines, Comirnaty and Spikevax, are still effective at preventing severe disease, hospitalisation and death associated with COVID-19 and will continue to be used within vaccination campaigns in the EU, in particular for primary vaccinations.

National authorities in the EU Member States will determine who should receive which vaccines and when, taking into account factors such as infection and hospitalisation rates, the risk to vulnerable populations, vaccination coverage and vaccine availability.

Evidence supporting use of Comirnaty Original/Omicron BA.1

Comirnaty Original/Omicron BA.1 can be used in people aged 12 years and older, at least 3 months after the last dose of a COVID-19 vaccine.

The CHMP's opinion on Comirnaty Original/Omicron BA.1 is based on 2 studies. One study in adults over 55

years old who had previously received 3 doses of Comirnaty (primary vaccination and a booster) found that the immune response to the Omicron BA.1 subvariant was higher after a second booster dose of Comirnaty Original/Omicron BA.1 than after a second dose of the original Comirnaty vaccine (as measured by the level of antibodies against Omicron BA.1). In addition, the immune response to the original SARS-CoV-2 strain was comparable for both vaccines. The study involved more than 1,800 people, of whom about 300 received Comirnaty Original/Omicron BA.1 in its final composition.

Further data from a study involving over 600 people aged between 18 and 55 years who had previously received 3 doses of Comirnaty showed that the immune response to Omicron BA.1 was higher in people who received a booster with a vaccine containing only the Omicron BA.1 component than in those given a booster with the original Comirnaty vaccine.

Based on these data, it was concluded that the immune response to Omicron BA.1 following a booster with Comirnaty Original/Omicron BA.1 in people aged 18 to 55 years would be at least equal to that in people aged over 55. Further, based on previous data in younger people, it was also concluded that the immune response to a booster dose with Comirnaty Original/Omicron BA.1 in adolescents would be at least equal to that in adults.

Evidence supporting use of Spikevax bivalent Original/Omicron BA.1

Spikevax bivalent Original/Omicron BA.1 can be used in adults and adolescents from the age of 12 years, at least 3 months after primary vaccination or a booster dose with a COVID-19 vaccine.

The CHMP's opinion on Spikevax bivalent Original/Omicron BA.1 is based on data from a study involving more than 800 adults aged 18 years and above. The study found that a booster dose of Spikevax bivalent Original/Omicron BA.1 induced a stronger immune response against the SARS-CoV-2 strain and the Omicron subvariant BA.1 compared with a booster dose of the original Spikevax vaccine. The study compared the level of antibodies in people previously vaccinated with a primary series and booster dose of Spikevax, and who were given a second booster dose of either Spikevax or Spikevax bivalent Original/Omicron BA.1. It was also concluded that Spikevax bivalent Original/Omicron BA.1 could be used as a first booster after primary vaccination and that the immune response induced by a booster dose of Spikevax bivalent Original/Omicron BA.1 in adolescents aged 12-17 years would be at least equal to that in adults, given that previous data with Spikevax have shown a comparable effect.

How the adapted vaccines work

The adapted vaccines work in the same way as the original vaccines.

Both adapted vaccines work by preparing the body to defend itself against COVID-19. Each vaccine contains molecules called mRNA which have instructions for making the spike proteins of the original SARS-CoV-2 and the Omicron subvariant BA.1. The spike protein is a protein on the surface of the virus which the virus needs to enter the body's cells and can differ between variants of the virus. By adapting vaccines, the aim is to broaden protection against different variants.

When a person is given one of these vaccines, some of their cells will read the mRNA instructions and temporarily produce the spike proteins. The person's immune system will then recognise those proteins as foreign and activate natural defences — antibodies and T cells — against them.

If, later on, the vaccinated person comes into contact with the virus, the immune system will recognise the spike protein on its surface and be prepared to attack it. The antibodies and immune cells can protect against COVID-19 by working together to kill the virus, preventing its entry into the body's cells and destroying infected cells.

The mRNA molecules from the vaccines do not stay in the body but are broken down shortly after vaccination.

More about the procedures

The companies marketing Spikevax and Comirnaty submitted applications (called variation applications) to change the current marketing authorisations of the authorised vaccines Comirnaty and Spikevax and include the use of adapted vaccines. These applications included data on the quality and safety of the adapted vaccines, and their ability to trigger immune responses against various strains of SARS-CoV-2. The review was carried out by EMA's Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use. The CHMP opinion has been forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.

Fuente: European Medicines Agency. Disponible en https://bit.ly/3xdD4Ug

La ciencia y la innovación acercan más a BioCubaFarma y a la Universidad Central de Las Villas

2 sep. Varios proyectos encaminados a facilitar el desarrollo conjunto de la ciencia y la innovación en el campo de la biotecnología y la agricultura acaban de ser concretados entre la Universidad Central «Marta Abreu» de Las Villas (UCLV) y el grupo empresarial BioCubaFarma, lo cual constituye un paso sustancial en la integración entre la academia y el sistema empresarial cubano.

Entre los campos del conocimiento que más se benefician de esta colaboración figuran la biomedicina y la producción agropecuaria, según afirmó la doctora Dagmar García Rivera, Directora de Investigaciones del Instituto Finlay de Vacunas, quien destacó el potencial de la UCLV para el fomento de la ciencia y la innovación.

Al respecto señaló que fueron identificados tres proyectos fundamentales, uno de los cuales puede impactar a más corto plazo, relacionado con el desarrollo de la Furvina, entre los productos líderes del Centro de Bioactivos Químicos, que es un ingrediente farmacéutico activo que posee una doble acción, antifúngica y antibacteriana, en fase avanzada de investigación y aprobación.

Mencionó también el área de la producción de fitomedicamentos –a partir de plantas medicinales–, en lo que la UCLV tiene más de 20 años de experiencia de trabajo;

además de otras sustancias que pueden ser extraídas y estudiadas a fin de ser empleadas como adyuvantes para su uso en vacunas humanas y veterinarias.

De igual manera, los principales esfuerzos en el terreno agropecuario se centrarán en la obtención de semillas y su mejoramiento genético en siembras como el frijol y la caña de azúcar, así como en la producción de los medios de cultivos más empleados en la red de biofábricas de Cuba.

Al referirse a las potencialidades de la Marta Abreu de Las Villas, la viceministra de Educación Superior, Alicia Alonso Becerra, destacó que esta tiene la ventaja de ser una de las más multidisciplinarias del país, con capacitados especialistas en todas las ramas, a lo que se suma el hecho de tener la Sociedad Interfaz de Ciencia y Tecnología.

Luego de rubricarse la firma de los seis primeros acuerdos, el doctor Eduardo Martínez Díaz, presidente de BioCubaFarma, reconoció la importancia de estos proyectos, cuyo objetivo es cerrar ciclos y facilitar la introducción en la práctica de tecnologías y productos, entre otras ventajas.

Fuente: Granma. Disponible en https://bit.ly/3DkNWUj

South Africa Reaches Deal With India to Boost Domestic Vaccine Production

Sep 2. The Serum Institute of India signed a deal this week with South Africa's Aspen Pharmacare to make four vaccines used in Africa.

The deal has been hailed as saving local vaccine production, which was at risk of shutting down after receiving no orders for a COVID vaccine. But medical aid group Doctors Without Borders says more efforts are needed for vaccines to be fully produced in Africa for Africans.

GCIS/Flickr. A worker at the Aspen Pharmacare sterile manufacturing facility in Gqeberha in the Eastern Cape province in South Africa on March 29, 2021.

Four routine pediatric vaccines -- pneumococcal vaccine, rotavirus vaccine, polyvalent meningococcal vaccine and hexavalent vaccine -- will be made in South Africa with products from bulk drug substances supplied by India's Serum Institute.

In addition to the 10-year agreement, South Africa's Aspen Pharmacare also anticipates receiving grant funding from the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations, CEPI.

"The partnership represents an important step for preventing the kinds of gross inequities of access to life-saving vaccines that emerged during the COVID pandemic," said CEPI's chief executive officer, Richard Hatchett. "We are proud to be part of an effort that will secure critically needed vaccine manufacturing

capacity in Africa, for Africa so that it can be ready when it faces future epidemic or pandemic threats."

But Candice Sehoma with Doctors Without Borders' Access Campaign in South Africa is calling for more than just fill-and-finish deals.

"I think it's a great step towards realizing the improvements in the African continent's manufacturing capacity, particularly looking at vaccines. And actually looking into routine vaccines. I think that, for me, is a great step," Sehoma said. "But I think, definitely, we could do with a lot more and even a full sharing of technology, so that we don't find ourselves waiting in line for vaccines that are coming from high-income countries."

Petro Terblanche, managing director of the South African company Afrigen, which reproduced Moderna's MRNA COVID vaccine, says Aspen's deal with the Serum Institute may not be healthy for other companies on the continent, as it could drown out local competition.

"So, the manufacturing capacity and the technology capabilities and the reach of the Serum Institute is very dominant, it is very, very powerful. However, if Serum Institute is prepared to do partnerships with Africa and South Africa for end-to-end manufacturing and technology transfer to Africa, it's a positive development," Terblanche said.

Meanwhile, Dr. Ahmed Ogwell Ouma, deputy director of the Africa Centres for Disease Control and Prevention, says the agreement is an important step for African vaccine manufacturing.

"It has responded to African Union heads of state and government calls that 30 percent of our continent's requirements for human vaccines be procured from Africa manufacturers. And we look forward to this being motivation for more expanded manufacturing of vaccines here on the continent of Africa," Ouma said.

According to the Africa CDC, less than 1% of vaccines currently used on the continent are locally manufactured.

Aspen's Group Communications Consultant Shauneen Beukes says they cannot comment on calls for the full African production of vaccines at this stage.

Fuente: All Africa. Disponible en https://bit.ly/3BGzIMx

New omicron boosters are now available, but it’s unclear how effective they will be

Sep 3. The U.S. authorized the first major makeover of the COVID-19 vaccines this week in an effort to stem an expected tide of infections and hospitalizations this fall.

But it’s unclear how much protection the new booster shots will provide. The Food and Drug Administration and the Centers for Disease Control and Prevention cleared the shots without any data from clinical trials that are testing the reformulated doses in humans.

The new boosters, authorized for people ages 12 and older, target the highly contagious and immune-evasive omicron BA.5 subvariant that has caused a wave of breakthrough infections over the summer. The shots also target the original strain of the virus that first emerged in Wuhan, China, in 2019.

The nation’s top health officials acted with urgency this summer to ensure the new boosters would roll out in time for the fall. They are worried that the waning effectiveness of the old vaccines is creating an opening for omicron to cause another wave of hospitalizations this winter as people spend more time indoors where the airborne virus spreads more easily.

Deaths and hospitalizations have climbed since April among the elderly, the most vaccinated age group in America, as omicron has continued to mutate into more and more transmissible subvariants that dodge the protection of the original vaccines, according to Heather Scobie, a CDC epidemiologist.

Dr. Peter Marks, who heads the FDA office that reviews vaccines, said the new boosters aim to restore the high levels of protection that vaccines demonstrated in early 2021. But Marks acknowledged that the federal government's experts simply do not know yet whether the boosters will meet the high bar set by those doses.

"We don't know for a fact yet whether we will get to that same level, but that is the goal here. And that is what we believe the evidence that we've seen helps point to," Marks told reporters during a news conference after the FDA authorization Wednesday.

The FDA will conduct surveillance to see whether the boosters meet that goal, Marks said. When Pfizer's and Moderna's shots were authorized in December 2020, they provided more than 90% protection at preventing Covid.

Marks told reporters it will likely take at least another couple of months before human data on the BA.5 boosters is available to the public. But he said the FDA used basically the same process to authorize the new boosters that it has relied on for years to switch the virus strains in flu shots.

"We're pretty confident that what we have is very similar to the situation that we've done in the past with influenza changes where we don't do clinical studies for them in the United States," Marks said. "We know from the way the vaccine works, and from the data that we have, that we can predict how well the vaccine will be working."

A woman receives a Pfizer vaccination booster shot at Eugene A. Obregon Park in Los Angeles. Gary Coronado | Los Angeles Times | Getty Images

The new boosters could prevent 2.4 million infections, 137,000 hospitalizations and 9,700 deaths if a new variant doesn't emerge, according to a projection by a team of scientists that forecasts the trajectory of the pandemic, called the Covid-19 Scenario Modeling Hub.

But that projection is based on optimistic assumptions about booster coverage and efficacy, according to the scientists. The model assumes that the shots will prove 80% effective at preventing illness and the public will broadly embrace the new boosters. There is no efficacy data on the new shots and it's unclear how strong public demand will be for them.

The CDC estimates that an early fall vaccination campaign with boosters could save the U.S. between $63 billion and $109 billion in medical costs by preventing hospitalizations and ICU admissions.

Pfizer and Moderna were originally developing new boosters to target the first version of omicron, BA.1, that caused the massive wave of infection and hospitalization last winter. But keeping up with the rapid evolution of the virus has proved challenging.

By the time the nation's top health leaders moved in earnest in April to get new boosters ready, more transmissible subvariants had already driven omicron BA.1 out of prevalence. In June, the FDA asked the vaccine makers to switch gears and target omicron BA.5 after it rose to dominance.

This decision did not leave enough time for Pfizer and Moderna to complete human clinical trials on the new boosters before a fall vaccine rollout.

As a consequence, the FDA and the CDC are relying on human data from the clinical trials of the BA.1 shots to understand how the BA.5 boosters might perform. They also relied on data from studies in which the BA.5 boosters were tested in mice.

The CDC's independent advisory committee backed the shots on Thursday in an overwhelming vote.

But several members of the panel also had reservations about the lack of human data.

"I really do struggle with a vaccine that has no clinical data that's reported for humans, for those that would be actually receiving the vaccine," said Dr. Oliver Brooks, a committee member and the chief medical officer at Watts HealthCare Corp. in Los Angeles.

Dr. Pablo Sanchez, the only CDC committee member who voted against the shots, called the decision to recommend the new boosters without human data premature.

"There's a lot of vaccine hesitancy already — we need the human data," said Sanchez, a professor of pediatrics at Ohio State University.

Dr. Doran Fink, deputy head of the FDA's vaccine review division, told hesitant committee members that the new booster shots use the exact same manufacturing process as the old vaccines and contain the same total amount of mRNA, the code that instructs human cells to produce the proteins that provoke an immune response to defend against Covid.

Fink said the BA.1 and the BA.5 shots are similar enough to use data from the BA.1 human trials to get a good idea of how the new BA.5 boosters will perform.

Pfizer and Moderna presented data at the CDC meeting which showed that the BA.1 shots triggered a stronger immune response in humans than the old vaccines. The mouse studies from both companies on the BA.5 shots also showed a stronger immune response.

CDC Director Dr. Rochelle Walensky last week said waiting longer for human data from the BA.5 shots could mean the boosters become outdated if a new variant emerges.

"There's always a question here of being too slow versus too fast," Walensky told "Conversations on Health Care" in a radio interview. "One of the challenges is if we wait for those data to emerge in human data ... we will be using what I would consider to be a potentially outdated vaccine."

Moderna completed enrollment in its clinical trials last week and expects results by the end of the year. Pfizer's clinical trials are ongoing, though the company hasn't provided a time frame on when it will have data.

Brooks questioned why the FDA decided to go with a BA.5 vaccine when clinical data is available for the BA.1 shots that the vaccine makers were originally developing. Canada and the United Kingdom have authorized new booster shots that target omicron BA.1

Fink said the U.S. selected BA.5 based on the advice of the FDA's independent committee, data from South Africa that indicated natural infection from the subvariant provides broader protection than infection from BA.1, and the fact that BA.5 is dominant.

Though the committee members had some hesitation about proceeding without the human data, they agreed the new boosters should have a similar safety profile to the old vaccines because they use the same platform. The Covid vaccines have been administered to millions of people in the U.S. with mostly mild side effects.

The most common side effects from the human trials of the BA.1 shots was pain, redness, swelling at the injection site, fatigue, headaches, muscle pain, joint pain, chills, nausea, vomiting and fever, according to the FDA.

Dr. Sara Oliver, a CDC official, told the committee that the risk of myocarditis, inflammation of the heart muscle, after a BA.5 booster is unknown. But health officials anticipate it will be similar to the risk observed with the old vaccines.

Pfizer's and Moderna's vaccines have been associated with an elevated risk of myocarditis in young men and adolescent boys mostly after the second dose. But the risk of myocarditis is higher from Covid infection than vaccination, according to the CDC.

Dr. Grace Lee, the CDC committee chair, sought to reassure the public that there's a robust surveillance system to monitor safety, and that the panel will meet again if any new concerns emerge.

"I just want to make sure that the members of the public are aware that we're continuing to monitor closely," Lee said. "We have systems and teams that are continuing to monitor and to meet."

Fuente: CNBC. Disponible en https://cnb.cx/3U0PQPX

CanSino's inhaled COVID-19 vaccine gets emergency use approval in China

Sep 4. China's CanSino Biologics Inc. said on Sunday that its recently developed COVID-19 vaccine has been approved by the country's drug regulator for emergency use as a booster, potentially benefiting its business.

The inhaled version of Cansino's adenovirus-vectored COVID-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.

"The approval will have a positive impact on the company's performance if the vaccine is subsequently purchased and used by relevant government agencies," CanSino said.

The company cautioned, however, that it will face fierce competition from other vaccines

in China that have also obtained government approval or are in clinical trials.

China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's COVID-19 vaccine as a booster, Livzon said on Friday, one of just two new products against the disease the country had cleared in more than a year.

Cansino also said it was uncertain when its vaccine would be able to go to market, since additional administrative approvals are still needed, while sales would depend on the COVID-19 situation at home and abroad, as well as China's vaccination rate.

China has seen a recent flare-up in COVID outbreaks. The southern tech hub of Shenzhen imposed a weekend lockdown in most parts of the city on Saturday, while the southwestern metropolis of Chengdu put its 21 million people under lockdown on Thursday.

Mainland China reported 1,848 new coronavirus cases for Sept. 3, including both symptomatic and asymptomatic infections, compared with 1,988 new cases a day earlier.

Fuente: REUTERS. Disponible en https://reut.rs/3eDFHII

Swissmedic autoriza la vacuna Novavax Nuvaxovid™ COVID-19 Vaccine para adolescentes de 12 a 17 años

5 sep. Novavax, Inc. (Nasdaq: NVAX), una empresa de biotecnología dedicada a desarrollar y comercializar vacunas de nueva generación contra enfermedades infecciosas graves, ha anunciado hoy que Swissmedic, la Agencia Suiza de Productos Terapéuticos, ha ampliado su autorización temporal de la vacuna Nuvaxovid™ (NVX-CoV2373) COVID-19 en Suiza para la inmunización activa para prevenir la enfermedad por coronavirus 2019 (COVID-19) causada por el coronavirus del síndrome respiratorio agudo severo 2 (SARS-CoV-2) en adolescentes de 12 a 17 años y como dosis de refuerzo heteróloga y homóloga para adultos mayores de 18 años.

"Nos complace ofrecer la primera vacuna de COVID-19 basada en proteínas para su uso tanto en adolescentes como en dosis de refuerzo en adultos en Suiza", dijo Stanley C. Erck, presidente y consejero delegado de Novavax. "Mientras seguimos explorando las mejores prácticas para el tratamiento de la COVID -19 a largo plazo, tenemos ensayos en curso que exploran aún más la eficacia y seguridad de Nuvaxovid como refuerzo y los datos preclínicos sugieren que nuestra vacuna induce una respuesta inmune contra las variantes de Omicron, incluyendo la BA.4/5."

Adolescentes de 12 a 17 años

La autorización para los adolescentes de 12 a 17 años se basa en los datos de la ampliación pediátrica en curso del ensayo de fase 3 PREVENT-19 con 2.247 adolescentes de 12 a 17 años en 73 centros de Estados Unidos para evaluar la seguridad, efectividad (inmunogenicidad) y eficacia de Nuvaxovid. En la ampliación pediátrica, Nuvaxovid alcanzó su objetivo principal de eficacia y demostró una eficacia clínica global del 80% en un momento en el que la variante Delta era la cepa de SARS-CoV-2 predominante en Estados Unidos.

Los datos preliminares de seguridad de la expansión pediátrica mostraron que la vacuna fue generalmente bien tolerada. Los acontecimientos adversos graves y severos fueron escasos en número y equilibrados entre los grupos de vacuna y placebo, y no se consideraron relacionados con la vacuna. La reactogenicidad local y sistémica fue en general menor o similar a la de los adultos, después de la primera y segunda dosis.

Las reacciones adversas más comunes observadas fueron sensibilidad/dolor en el lugar de la inyección, dolor de cabeza, mialgia, fatiga y malestar. No hubo un aumento de la reactogenicidad en los adolescentes más jóvenes (12 a <15 años) en comparación con los adolescentes mayores (15 a <18 años). No se observó ninguna nueva señal de seguridad en la parte controlada con placebo de la expansión pediátrica.

Refuerzo en adultos mayores de 18 años

La autorización de la dosis de refuerzo en adultos mayores de 18 años está respaldada por los datos del ensayo de fase 2 de Novavax realizado en Australia, de otro ensayo de fase 2 realizado en Sudáfrica y del ensayo COV-BOOST patrocinado por el Reino Unido. Como parte de los ensayos de fase 2, se administró una dosis única de refuerzo de Nuvaxovid a participantes adultos sanos aproximadamente seis meses después de su serie de vacunación primaria de dos dosis de Nuvaxovid. La tercera dosis produjo un aumento de la respuesta inmunitaria comparable o superior a los niveles asociados a la protección en los ensayos clínicos de fase 3. En el ensayo COV-BOOST, Nuvaxovid indujo una respuesta significativa de anticuerpos cuando se utilizó como tercera dosis heteróloga de refuerzo.

En los ensayos patrocinados por Novavax, tras el refuerzo, las reacciones locales y sistémicas tuvieron una duración media de aproximadamente dos días. La incidencia de eventos de grado 3 o superior se mantuvo relativamente baja. Los informes de seguridad de los acontecimientos de reactogenicidad mostraron una incidencia creciente en las tres dosis de Nuvaxovid, a menudo observada con el aumento de la inmunogenicidad. Los acontecimientos adversos atendidos médicamente, las afecciones médicas potencialmente inmunomediadas y los acontecimientos adversos graves se produjeron con poca frecuencia tras la dosis de refuerzo y estuvieron equilibrados entre los grupos de vacuna y de placebo

En la población de 12 a 17 años, NVX-CoV2372 también ha sido autorizada en la Unión Europea, Reino Unido, Australia, Nueva Zelanda, Japón, Tailandia, India, y Corea del Sur. La vacuna también ha sido autorizada en Japón, Australia, y Nueva Zelanda como refuerzo. Nuvaxovid está siendo revisado activamente para ambas indicaciones en otros mercados.

Swissmedic concedió una autorización temporal en abril de 2022 para el uso de Nuvaxovid en adultos mayores de 18 años.

Nombre comercial en EE.UU.

El nombre comercial Nuvaxovid™ aún no ha sido aprobado por la Administración de Alimentos y Medicamentos de los Estados Unidos

Uso autorizado

Nuvaxovid está indicado para la inmunización activa para prevenir la COVID-19 causada por el SARS-CoV-2 en individuos de 12 años o más. El uso de esta vacuna debe ser conforme a las recomendaciones oficiales.

Información de seguridad importante: Suiza

- Nuvaxovid está contraindicado en personas con hipersensibilidad al principio activo o a cualquiera de los excipientes.
- Se han notificado casos de anafilaxia con la administración de las vacunas de COVID-19, incluyendo

Nuvaxovid. En caso de reacción anafiláctica tras la administración de la vacuna, debe disponerse de un tratamiento médico adecuado y de supervisión. Se recomienda observación durante al menos 15 minutos y no se debe administrar una segunda dosis de la vacuna a quienes hayan experimentado anafilaxia a la primera dosis de Nuvaxovid.

- Se han notificado casos muy raros de miocarditis y pericarditis tras el uso de Nuvaxovid. Los profesionales sanitarios deben estar atentos a los signos y síntomas de miocarditis y pericarditis. Se debe instruir a los vacunados (incluidos los padres o cuidadores) para que busquen atención médica inmediata si desarrollan síntomas indicativos de miocarditis o pericarditis, como dolor torácico (agudo y persistente), dificultad para respirar o palpitaciones tras la vacunación. Los profesionales sanitarios deben consultar a orientadores y/o especialistas para diagnosticar y tratar esta afección.
- Reacciones relacionadas con la ansiedad, incluyendo reacciones vasovagales (síncope), hiperventilación o reacciones relacionadas con el estrés pueden ocurrir en asociación con la vacunación como una respuesta psicógena a la inyección de la aguja. Es importante que se tomen precauciones para evitar lesiones por desmayo.
- La vacunación debe posponerse en personas que sufran una enfermedad febril grave o una infección aguda. La presencia de una infección menor y/o fiebre baja no debe retrasar la vacunación.
- Nuvaxovid debe administrarse con precaución en personas que reciban tratamiento anticoagulante o que padezcan trombocitopenia o cualquier trastorno de la coagulación (como la hemofilia), ya que en estas personas pueden producirse hemorragias o hematomas tras la administración intramuscular. • La eficacia de Nuvaxovid puede ser menor en individuos inmunodeprimidos.
- La administración de Nuvaxovid durante el embarazo sólo debe considerarse cuando los beneficios potenciales superen los posibles riesgos para la madre y el feto.
- Los efectos con Nuvaxovid pueden afectar temporalmente a la capacidad de conducir o utilizar máquinas.
- Se desconoce la duración de la protección proporcionada por la vacuna, ya que aún se está determinando en los ensayos clínicos en curso. Las personas pueden no estar totalmente protegidas hasta siete días después de su segunda dosis. Como ocurre con todas las vacunas, la vacunación con Nuvaxovid puede no proteger a todos los receptores de la vacuna.
- Reacciones adversas muy comunes (≥1/10) y comunes (≥1/100 a <1/10) observadas durante los estudios clínicos en personas mayores de 12 años fueron dolor de cabeza, náuseas o vómitos, mialgia, artralgia, sensibilidad/dolor en el lugar de la inyección, pirexia. La fiebre se observó con mayor frecuencia en los adolescentes de 12 a 17 años en comparación con los adultos, siendo la frecuencia muy común después de la segunda dosis en el caso de adolescentes.

Para obtener más información sobre Nuvaxovid, incluido el Resumen de las Características del Producto con el Prospecto, las instrucciones de notificación de efectos adversos, o para solicitar información adicional, visite el siguiente sitio web: Swissmedic

Acerca de Nuvaxovid™ (NVX-CoV2373)

Nuvaxovid es una vacuna basada en proteínas diseñada a partir de la primera secuencia genética del SARS-CoV-2, el virus que causa la enfermedad de la COVID-19. La vacuna fue creada utilizando la

tecnología de nanopartículas recombinantes de Novavax para generar antígenos derivados de la proteína espiga (S) del coronavirus y está formulada con Matrix-M™, el adyuvante basado en saponinas patentado de Novavax, para mejorar la respuesta inmune y estimular altos niveles de anticuerpos neutralizantes. Nuvaxovid contiene antígenos de proteína purificados y no puede replicarse ni causar la COVID-19. Nuvaxovid está empaquetada como una formulación líquida lista para usar en un vial que contiene diez dosis. El régimen de vacunación requiere dos dosis de 0,5 ml (5 mcg de antígeno y 50 mcg de adyuvante Matrix-M) administradas por vía intramuscular con 21 días de diferencia. La vacuna se almacena entre 2° y 8° Celsius, lo que permite utilizar los canales de suministro de vacunas y de cadena de frío existentes. El uso de la vacuna debe estar de acuerdo con las recomendaciones oficiales.

Novavax ha establecido asociaciones para la fabricación, comercialización y distribución de Nuvaxovid en todo el mundo. Las autorizaciones existentes aprovechan la asociación de fabricación de Novavax con Serum Institute of India, el fabricante de vacunas más grande del mundo por volumen. Posteriormente se complementarán con datos de sitios de fabricación adicionales a lo largo de la cadena de suministro global de Novavax.

Acerca de los ensayos de fase 3 de NVX-CoV2373

NVX-CoV2373 sigue siendo evaluado en dos ensayos fundamentales de fase 3. PREVENT-19 (el Ensayo de Eficacia de la Vacuna de la Subunidad de Proteínas de PRE Fusión | COVID-19) es un ensayo 2:1 aleatorio, controlado con placebo y ciego por un observador para evaluar la eficacia, seguridad e inmunogenicidad de NVX-CoV2373 con el adyuvante Matrix-M en 29.960 participantes mayores de 18 años en 119 lugares de EE.UU. y México. El criterio de valoración primario de PREVENT-19 fue la primera aparición de COVID-19 sintomática (leve, moderada o grave) confirmada por PCR con inicio al menos siete días después de la segunda dosis en participantes adultos serológicamente negativos (al SARS-CoV-2) al inicio. El criterio de éxito estadístico incluía un límite inferior de 95% CI >30%. Un criterio de valoración secundario fue la prevención de la COVID-19 sintomática y confirmada por PCR. Ambos criterios de valoración se evaluaron al menos siete días después de la segunda vacunación del estudio en voluntarios que no se habían infectado previamente con el SARS-CoV-2. En el ensayo, NVX-CoV2373 alcanzó una eficacia global del 90,4%. En general, fue bien tolerado y provocó una sólida respuesta de anticuerpos tras la segunda dosis en ambos estudios. Los resultados completos del ensayo se publicaron en la revista New England Journal of Medicine (NEJM).

La ampliación pediátrica de PREVENT-19 es un ensayo 2:1 aleatorio, controlado con placebo y ciego por un observador para evaluar la seguridad, la efectividad y la eficacia de NVX-CoV2373 con el adyuvante Matrix-M en 2.247 participantes adolescentes de 12 a 17 años de edad en 73 lugares de los Estados Unidos, en comparación con el placebo. En el ensayo pediátrico, NVX-CoV2373 alcanzó su objetivo principal de eficacia (la no inferioridad de la respuesta de anticuerpos neutralizantes en comparación con los participantes adultos jóvenes de 18 a 25 años de edad de PREVENT-19) y demostró una eficacia global del 80% en un momento en que la variante Delta era la cepa predominante que circulaba en EE.UU. Además, las respuestas inmunitarias fueron de dos a tres veces mayores en los adolescentes que en los adultos contra todas las variantes estudiadas.

Además, un ensayo llevado a cabo en Reino Unido con 14.039 participantes de 18 años o más fue diseñado como un estudio aleatorio, controlado con placebo y ciego por un observador, y alcanzó una eficacia global

del 89,7%. El criterio de valoración primario se basó en la primera aparición de COVID-19 sintomática (leve, moderada o grave) confirmada por PCR con inicio al menos siete días después de la segunda vacunación del estudio en participantes adultos serológicamente negativos (al SARS-CoV-2) al inicio. Los resultados completos del ensayo se publicaron en NEJM.

Acerca del adyuvante Matrix-M™

El adyuvante Matrix-M a base de saponina patentado de Novavax ha demostrado un efecto potente y bien tolerado al estimular la entrada de células presentadoras de antígenos en el lugar de la inyección y mejorar la presentación de antígenos en los ganglios linfáticos locales, lo que aumenta la respuesta inmunitaria.

Acerca de Novavax

Novavax, Inc. (Nasdaq: NVAX) es una empresa de biotecnología que promueve la mejora de la salud a nivel mundial mediante el descubrimiento, el desarrollo y la comercialización de vacunas innovadoras para prevenir enfermedades infecciosas graves. La plataforma de tecnología recombinante patentada de la empresa combina el poder y la velocidad de la ingeniería genética para producir de manera eficiente nanopartículas altamente inmunogénicas diseñadas para atender las necesidades urgentes de salud en todo el mundo. La vacuna COVID-19 de Novavax, NVX-CoV2373, ha recibido la autorización de múltiples autoridades reguladoras de todo el mundo, incluidas las de Estados Unidos, la Comisión Europea y la Organización Mundial de la Salud. La vacuna está siendo revisada por múltiples agencias reguladoras de todo el mundo, incluso para indicaciones y poblaciones adicionales como los adolescentes y como refuerzo. Además de su vacuna COVID-19, Novavax también está evaluando actualmente un candidato a vacuna combinada contra la gripe estacional-COVID en un ensayo clínico de fase 1/2, que combina NVX-CoV2373 y NanoFlu*, su candidato a vacuna tetravalente contra la gripe en investigación, y también está evaluando una vacuna basada en la cepa Omicron (NVX-CoV2515), así como una vacuna bivalente basada en la cepa Omicron / original. Estas vacunas candidatas incorporan el adyuvante Matrix-M, propiedad de Novavax, a base de saponina, para mejorar la respuesta inmunitaria y estimular altos niveles de anticuerpos neutralizantes.

Fuente: PR Newswire. Disponible en https://prn.to/3U1zJkZ

BioVaxys anuncia la síntesis completa de su vacuna candidata Pan-Sarbecovirus

6 sep. BioVaxys Technology Corp. anunció que Millipore-Sigma, el fabricante por contrato para su programa preclínico de vacunas virales, ha completado la bioproducción y detección de endotoxinas de liberación por lotes de BVX-1021, la vacuna de la compañía para el SARS-CoV, que se está utilizando en colaboración con la Universidad Estatal de Ohio (OSU) para desarrollar una vacuna contra el sarbecovirus. El siguiente paso es medir el desarrollo de anticuerpos neutralizantes contra los sarbecovirus luego de la inmunización de los animales de estudio con BVX-1021, seguida de la administración de una vacuna contra el SARS-CoV-2, en este caso con BVX-0320, la vacuna de la empresa candidata contra la COVID-19.

En junio, la compañía reveló que se determinó que los rendimientos de la proteína recombinante SARS-1 obtenida de un proveedor chino para la bioproducción de BVX-1021 contenían la presencia de un subproducto agregado de proteína natural además de la proteína SARS-1. Aunque no es probable que haya afectado los estudios de anticuerpos neutralizantes, la compañía consideró prudente sintetizar BVX-1021

utilizando un nuevo lote de proteína SARS-1 recombinante del proveedor que eliminó el agregado de proteína extraña. Un brote de la COVID-19 en agosto en un proveedor de los reactivos necesarios para el control de calidad/control de calidad final provocó un pequeño retraso en la liberación final de BVX-1021.

BVX-1021 es objeto de una colaboración de investigación en curso entre OSU y BioVaxys que está evaluando el enfoque novedoso de la compañía para una "vacuna universal" que pueda tratar una amplia gama de sarbecovirus. Se trata de una familia de virus que incluye el SARS-CoV-2 y variantes emergentes, el SARS-CoV-1 y una amplia gama de otros virus zoonóticos potencialmente peligrosos. La colaboración, que comenzó a principios de este año, está evaluando la combinación de BVX-0320 y BVX-1021 de BioVaxys en un modelo de cobaya. Los principales criterios de valoración del estudio son el desarrollo de anticuerpos neutralizantes de virus contra el virus vivo SARS-CoV-2 y otros sarbecovirus, incluidos los coronavirus relacionados con el SARS de murciélagos y pangolines.

Los murciélagos son un reservorio importante de muchas cepas de SARS, y se han identificado varias cepas en civetas de palma, que probablemente fueron antepasados de SARS-CoV-1 ("SARS-1") (Journal of Virology. 84 (6): 2808– 19, 2010). La presencia de anticuerpos neutralizantes en el modelo animal sugeriría fuertemente que BVX-1021 conferiría una respuesta inmunitaria adicional en todos los sarbecovirus en aquellas personas completamente vacunadas contra la COVID-19, así como en aquellas con inmunidad natural.

El director general y responsable de operaciones de BioVaxys, Kenneth Kovan, comentó: "Ahora que se ha sintetizado BVX-1021 utilizando la proteína SARS1 purificada, OSU ahora puede completar los estudios de anticuerpos neutralizantes. Salvo circunstancias imprevistas, anticipamos los datos del estudio en septiembre".

Acerca de BioVaxys Technology Corp.

Con sede en Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) es una compañía de biotecnología en etapa clínica registrada en la Columbia Británica que está desarrollando plataformas de vacunas virales y oncológicas, así como inmunodiagnósticos. La compañía está avanzando en las vacunas para el SARS-CoV-2, el SARS-CoV-1 y una vacuna contra el sarbecovirus basada en su tecnología de proteína viral haptenizada, y está planeando un ensayo clínico de su vacuna de células autólogas haptenizadas utilizada en combinación con inhibidores del punto de control anti-PD1 y anti-PDL1 que se desarrollarán inicialmente para el cáncer de ovario en estadio III/estadio IV. También se encuentra en desarrollo CoviDTH®, un diagnóstico para evaluar la presencia o ausencia de una respuesta inmune de células T al SARS-CoV-2, el virus que causa la COVID-19. BioVaxys tiene dos patentes estadounidenses emitidas y múltiples solicitudes de patentes estadounidenses e internacionales relacionadas con sus vacunas contra el cáncer, vacunas antivirales y tecnologías de diagnóstico. Las acciones ordinarias de BioVaxys cotizan en la CSE con el símbolo bursátil "BIOV" y se negocian en la Bolsa de Frankfurt (FRA: 5LB) y en Estados Unidos (OTCQB: BVAXF)

Fuente: PR Newswire. Disponible en https://prn.to/3qqEabL

Pfizer isn't sharing Covid vaccines with researchers for next-gen studies

Sep 6. Researchers studying next-generation vaccines to fight an evolving COVID-19 threat are running into problems getting existing vaccines to use in their research.

Because Pfizer and Moderna hold the patents for the current vaccines, researchers would likely have to get the companies' permission to use them for research into products like nasal or pan-coronavirus vaccines. Right now, Pfizer isn't sharing its vaccines for research purposes, a spokesperson confirmed to STAT. Moderna didn't comment when we asked.

Pfizer's stance is legal and in line with the company's commercial interests, said Ana Santos Rutschman, a professor of law at Villanova University.

"If you use this thing that has been patented, what you're doing doesn't matter. Even if you're trying to cure cancer, the law is pretty rigid," she said.

But some university researchers argue the posture slows global progress toward more effective vaccines in the future, especially since the United States has already wasted tens of millions of doses of the COVID-19 vaccines.

Yale University virologist and immunologist Akiko Iwasaki has designed a study of nasal vaccines against COVID-19, which she argues could provide better protection against infection and transmission than shots alone. The ideal study would be conducted on subjects that have already had a primary vaccine series, to simulate real-world scenarios. She inquired with Pfizer about obtaining some vaccine to use in her study of nasal vaccines, but has not received any.

"In order for us to develop a better vaccine, we need a comparator. For that reason, everyone who's doing research in this area is in the same boat, we don't have access to do a comparison," Iwasaki said.

Iwasaki brought the issue up briefly at the White House's summit on the future of Covid vaccines on July 26, and presidential science adviser Francis Collins said at the time that he "would not have thought of that" hurdle.

California Institute of Technology professor Pamela Bjorkman said her lab has had similar troubles obtaining existing COVID-19 vaccines that would otherwise be discarded in order to research a vaccine candidate that could provide protection against a variety of COVID-19 variants.

"Whatever policy prevents using such vials does a great disservice to global efforts to develop new and improved vaccines," Bjorkman said.

When asked whether Pfizer has provided any vaccines for research purposes, spokesperson Sharon Castillo said, "We are not accepting or reviewing applications for possible clinical research that studies the COVID-19 vaccine."

Another Pfizer spokesperson also said the company has its own "extensive studies" of the vaccine underway, and will continue to share information from those studies as it becomes available.

Fuente: STAT News. Disponible en https://bit.ly/3d5JGNP

Varios biomarcadores predicen la progresión de la infección por SARS-CoV-2

6 sep. Después de dos años de pandemia, la COVID-19 se mantiene como una amenaza global inminente. Aunque la mayoría de las infecciones permanecen asintomáticas o solo causan síntomas leves, los casos graves aún causan una morbilidad y mortalidad significativas.

Sobre la base del conocimiento actual, la hiperinflamación desempeña un papel fundamental en la progresión de la enfermedad y el deterioro clínico, lo que sugiere que las mediciones de biomarcadores basados en el sistema inmunitario representan herramientas prometedoras para la detección temprana de la probabilidad de deterioro. Estos parámetros pueden estar disponibles en cuestión de minutos a través de pruebas en el punto de atención y la información proporcionada por los biomarcadores inmunitarios podría facilitar y acelerar el trabajo de diagnóstico.

Los microbiólogos médicos de la Universidad de Saarland (Homburg, Alemania), reclutaron en un estudio a 132 pacientes (edad media 64 años, 40,2 % mujeres) que tenían una infección confirmada por reacción en cadena de la polimerasa (PCR) con SARS-CoV-2 (excepto los controles), durante la segunda y tercera ola pandémica experimentada en Alemania (diciembre de 2020 a julio de 2021). El grupo de control estaba formado por 27 adultos (edad media 47,1 años, rango 22-83; 19 [70,4 %] mujeres), compuesto por 19 adultos en el grupo 1 y ocho adultos en el grupo 2. Se analizaron de rutina hisopos nasofaríngeos, muestras de sangre y RT-PCR para el SARS-CoV -2 al ingreso y regularmente durante la estancia en el hospital para tener en cuenta los cambios dinámicos en los niveles de biomarcadores a lo largo del tiempo.

Los investigadores utilizaron una plataforma novedosa, MeMed Key (MeMed, Tirat Carmel, Israel), que mide los niveles circulantes de las tres proteínas inmunitarias de respuesta del huésped: ligando inductor de apoptosis relacionado con TNF (TRAIL), proteína 10 inducida por interferón gamma (IP-10) y proteína C reactiva (PCR). El método se basa en un inmunoensayo quimioluminiscente. Los niveles de TRAIL, IP-10 y PCR se midieron en el sitio de estudio en muestras de suero.

Los científicos realizaron un total de 899 mediciones. Entre los pacientes con COVID-19, los niveles de TRAIL fueron significativamente más bajos (49,5 frente a 87 pg/mL), mientras que IP-10 y PCR mostraron niveles significativamente más altos (667,5 frente a 127 pg/mL) y 75,3 frente a 1,6 mg/L) que los controles sanos. TRAIL arrojó una correlación inversa con la duración de la estancia en el hospital y en la unidad de cuidados intensivos (UCI), la Puntuación de Fisiología Aguda Simplificada II y la Puntuación Nacional de Alerta Temprana, y la IP-10 mostró una correlación positiva con la gravedad de la enfermedad. La regresión

multivariable reveló que la obesidad (relación de probabilidad ajustada [aOR] 5,434), PCR (aOR 1,014) y la IP-10 pico (aOR 1,001) fueron predictores independientes de mortalidad en la UCI.

Los autores concluyeron que TRAIL e IP-10 mostraron una correlación significativa con la gravedad de la COVID-19, y que los niveles de PCR e IP-10 se asociaron con resultados adversos de la COVID-19. Esto sugiere que la inclusión de estos marcadores en modelos de evaluación de riesgo multivariable podría ser una herramienta prometedora en el manejo de pacientes con COVID-19. El estudio fue publicado el 1 de septiembre de 2022 en la revista *International Journal of Infectious Diseases*.

Fuente: LabMedica. Disponible en https://bit.ly/3BbMMrL

La Comisión Europea adquiere más de 170.000 dosis de la vacuna contra la viruela del mono

7 sep. La Comisión Europea adquirió este miércoles más de 170.000 dosis de la vacuna de tercera generación contra la viruela que comercializa la farmacéutica Bavarian Nordic's, para hacer frente al actual brote de la viruela del mono.

La Autoridad de Preparación y Respuesta Sanitaria (HERA) obtuvo 170.920 dosis de la vacuna, según informó este miércoles Bruselas en un comunicado, por lo que desde que estalló el brote, la Comisión ha comprado ya 334.540 en nombre de todos los países de la Unión Europea.

El Ejecutivo comunitario distribuirá las dosis a los países de la UE antes de que acabe el año, de forma proporcional a su población, como ha hecho durante la pandemia de coronavirus.

"Aunque hemos visto disminuir el número de casos de viruela del simio en la UE durante las últimas semanas, la amenaza no ha pasado y no podemos bajar la guardia. Debemos continuar manteniendo el ritmo de nuestros esfuerzos para proteger a nuestros ciudadanos, especialmente a los más vulnerables", dijo la comisaria europea de Sanidad, Stella Kyiriakides.

Según los datos ofrecidos por la Comisión, desde que empezó el brote de viruela del mono se han detectado 18.463 casos en los países del Espacio Económico Europeo (EEE), que incluye a los 27 Estados de la UE más Noruega, Islandia y Lichtenstein.

Fuente: HERALDO SALUDABLE. Disponible en https://bit.ly/3d8HhBZ

Nigeria, Cuba To Collaborate In Vaccine Production

Sep 7. Nigeria is set to enter into a partnership with the Republic of Cuba to produce vaccines collaboratively.

The Minister of Science, Technology and Innovation, Sen. Adeleke Mamora revealed this when he received the Ambassador of The Republic of Cuba, Mrs. Clara Pulido, who paid him a courtesy visit in his office in Abuja.

Mamora noted that the collaboration will ensure that companies producing vaccines in the Republic of Cuba can be established in Nigeria for fruitful bilateral relationship.

The minister conceded that, although Cuba has done so much in the primary health sector, Nigeria is replicating the same for her growth and development.

He expressed the willingness of the Federal Government to collaborate with the Republic of Cuba in vaccine production, to tap into Cuba's wealth of experience to achieve Nigeria's quest for health for all in the country.

"Vaccine production," the minister said, "will play a key role in tackling the emerging and re-emerging diseases in country, such as malaria, Lassa fever, monkey pox, as all diseases have been declared emergencies globally."

Mamora further revealed that Nigeria is making serious efforts in producing vaccines locally, to enable the country prevent childhood diseases such as polio, tetanus and tuberculosis.

In a statement by the ministry's deputy director, press and public relations, Atuora Obed, Mamora said "the knowledge and experience of those who are ahead of us in vaccine technology is something we must learn through technology transfer".

Puildo said the visit was to felicitate the minister on his appointment and resumption of duty and to seek the ministry's collaboration in vaccine production for betterment of the society.

Fuente: Science Nigeria. Disponible en https://bit.ly/3U04iHU

Cuba en el avance de candidatos vacunales contra el dengue

8 sep. Cuba centra esfuerzos en el avance de candidatos vacunales que inducen la respuesta inmunológica celular contra los cuatro serotipos del virus del dengue, estrategia que chequeó en el Centro de Ingeniería Genética y Biotecnología (CIGB), Eduardo Martínez Díaz, presidente de BioCubaFarma, según el perfil de Facebook de esa organización.

Igualmente, explicó el directivo que desde hace tiempo se labora en varios proyectos relacionados con esa enfermedad, que, se han acelerado en la actualidad, a partir de un pedido del Primer Secretario del Partido y Presidente de la República, Miguel Díaz-Canel Bermúdez.

El experto explicó que las investigaciones están a cargo del CIGB con el Instituto de Medicina Tropical Pedro Kourí (IPK), y destacó que cuentan con trabajos basados en la bioinformática y el estudio de la interacción del virus con su receptor.

Es a partir de esos conocimientos que se están diseñando moléculas que tengan un efecto antiviral específico contra el dengue; que eviten, por ejemplo, la entrada del virus a la célula.

Fuente: Radio Rebelde. Disponible en https://bit.ly/3U6Vd07

U.S. starts enrollment in trial testing Siga's antiviral for monkeypox

Sep 9. The National Institutes of Health (NIH) said on Friday it had started enrolling monkeypox patients in a late -stage study testing Siga Technologies Inc's (SIGA.O) antiviral pill Tpoxx against the disease.

The oral and intravenous formulations of Tpoxx are approved by the U.S. Food and Drug Administration for the treatment of smallpox, but does not yet have clearance to treat monkeypox.

It is, however, currently accessible by clinicians for treating monkeypox under a compassionate use request.

The NIH aims to enroll more than 500 patients, including both adults and children, who will then be randomized to receive either Tpoxx or placebo pills for 14 days.

Investigators will evalutate if participants receiving Tpoxx heal more quickly compared to placebo, as well as provide critical data on the optimal dosing and safety of the drug in children and people who are pregnant.

The United States has recorded more than 21,000 confirmed cases of monkeypox, according to data from the Centers for Disease Control and Prevention.

Fuente: Reuters. Disponible en https://reut.rs/3LbnYEU

Vacuna cubana Soberana recibe opinión técnica favorable en México

10 sep. El Comité de Moléculas Nuevas (CMN) de la Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) de México, emitió un voto favorable a la vacuna cubana Soberana 02.

La información aparece hoy publicada por Cofepris en un comunicado luego de una reunión la víspera para llevar a cabo la 165 Sesión Extraordinaria de la CMN.

Es la segunda vacuna latinoamericana en someterse a consideración del CMN y el resultado representa un paso previo a la autorización de uso de emergencia en el país, subraya el comunicado.

Agrega que en esa sesión fue expuesta la información técnico-científica para evaluación de la vacuna Soberana para adultos, recibiendo una opinión técnica favorable.

En esta ocasión, añade, se presentó la evidencia para el uso de la vacuna Soberana como primo

vacunación en adultos, es decir, para población que no ha sido inmunizada anteriormente.

Este producto consiste en un conjugado de proteína de dominio de unión a receptor de la proteína S de SARS-CoV-2 (RBD) recombinante con toxoide tetánico, e hidróxido de aluminio como adyuvante.

Cabe resaltar, expresa Cofepris, que esta vacuna, presentada por Neuronic Mexicana S.A. de C.V. e Instituto Finlay de Vacunas, es la segunda de origen latinoamericano en ser evaluada ante este grupo de expertos, seguida de Abdala, también de Cuba, primer biológico hispanoamericano contra Covid-19, presentado el 31 de agosto de 2021.

La Cofepris precisa que el CMN es un órgano auxiliar de consulta que forma parte de agencia reguladora; emite opiniones no vinculantes sobre medicamentos e insumos para la salud, basándose en la evidencia científica y médica presentada, por lo que este paso no representa la autorización final para uso de emergencia.

Fuente: ElPaís.cr. Disponible en https://bit.ly/3L75MMm

Vacunas Covid: un nuevo hallazgo podría eliminar la necesidad de tantas dosis de refuerzo

11 sep. Las nuevas vacunas contra la COVID-19 ya son eficaces contra las nuevas variantes de Ómicron, un aspecto que preocupaba a los expertos, debido a la facilidad con la que mutaba el virus. Las principales agencias de medicamentos ya las han aprobado, por lo que estas comenzarán a inocularse a partir de este mismo otoño.

Sin embargo, los científicos siguen preocupados de que estas nuevas vacunas pierdan efectividad en un futuro contra las variantes que aún están por llegar. Por eso, el descubrimiento de un grupo de investigadores de Tel Aviv (Israel) podría dar un giro radical a esta preocupación.

Y es que este grupo de científicos ha hecho un nuevo hallazgo sobre el virus y la gente que ya lo ha padecido que eliminaría la necesidad de vacunarse con dosis de refuerzo actuales y abriría la puerta a poder dejar de hacerlo con las dosis que se fabricarían por nuevas variantes aún inexistentes.

Importante descubrimiento sobre los anticuerpos

Según el estudio publicado en la revista 'Nature Communications Biology', el equipo ha demostrado que los anticuerpos aislados del sistema inmunitario de los pacientes que se han recuperado de la COVID-19 son eficaces para neutralizar todas las cepas conocidas del virus, incluidas las variantes Delta y la última, Ómicron.

¿Y cómo es posible esto? Porque el estudio es una extensión de otro que ya se realizó en octubre de 2020, en pleno momento crítico de la pandemia de la COVID-19. En ese momento, se secuenciaron todas las células del sistema inmunitario B de la sangre de los que se han recuperado de la primera cepa y se

aislaron nueve anticuerpos. Ahora, algunos de esos anticuerpos pueden neutralizar las nuevas variantes Delta y Ómicron.

¿Evitaría las dosis de refuerzo antes nuevas variantes aún no aparecidas?

Tal y como explica la doctora Natalia Freund, principal autora del estudio, los anticuerpos más eficaces eran los que se unían a la proteína espiga del virus. "En el estudio actual, demostramos que otros dos anticuerpos que se unen a la proteína viral de la espiga en una zona diferente de la región en la que se concentraban son en realidad muy eficaces para neutralizar las variantes", asegura la experta.

Los investigadores identificaron dos anticuerpos:

- TAU-1109: eficaz para neutralizar la cepa Ómicron es del 92% y para la cepa Delta del 90%.
- TAU-2310: neutraliza la variante Ómicron con una eficacia del 84%, y la variante Delta con una eficacia del 97%.

"Por razones que no comprendemos del todo, el nivel de anticuerpos contra la COVID-19 disminuye después de tres meses, por lo que vemos personas que se reinfectan incluso después de haber sido vacunadas tres veces. Por lo que el tratamiento dirigido con anticuerpos y su entrega en altas concentraciones puede servir como sustituto eficaz para los refuerzos de las vacunas", afirma, para concluir que "es posible que al usar este tratamiento no se tenga que proporcionar dosis de refuerzo a toda la población cada vez que haya una nueva variante".

Fuente: ONDA CERO. Disponible en https://bit.ly/3eH3rf1

Artículos científicos publicados en Medline

Filters activated: Publication date from 2022/09/01 to 2022/09/11. "Vaccine" (Title/Abstract) 929 records.

Risk of Myocarditis After Sequential Doses of COVID-19 **Vaccine** and SARS-CoV-2 Infection by Age and Sex.
Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti K, Harnden A, Coupland CAC, Channon KM, Mills NL, Sheikh A, Hippisley-Cox J. Circulation. 2022 Sep 6;146(10):743-754. doi: 10.1161/CIRCULATIONAHA.122.059970. Epub 2022 Aug 22. PMID: 35993236

Efficacy of COVID-19 vaccines.
Saadh MJ, Jaber SA. Microb Pathog. 2022 Sep 2;171:105729. doi: 10.1016/j.micpath.2022.105729. Online ahead of print. PMID: 36058411

Vaccine and smallpox vaccination in nineteenth century Bahia.
Hochman G, Souza CMC. Cien Saude Colet. 2022 Sep;27(9):3429-3440. doi: 10.1590/1413-81232022279.05082022. Epub 2022 Apr 14. PMID: 36000634

2022 AAHA Canine Vaccination Guidelines.
Ellis J, Marziani E, Aziz C, Brown CM, Cohn LA, Lea C, Moore GE, Taneja N. J Am Anim Hosp Assoc. 2022 Sep 1;58(5):213-230. doi: 10.5326/JAAHA-MS-Canine-Vaccination-Guidelines. PMID: 36049241

Access to the COVID-19 **Vaccine**.
Zavras D. Int J Environ Res Public Health. 2022 Sep 3;19(17):11054. doi: 10.3390/ijerph191711054. PMID: 36078766

4BNT162b2 mRNA COVID-19 **vaccine** and semen: What do we know?
Olana S, Mazzilli R, Salerno G, Zamponi V, Tarsitano MG, Simmaco M, Paoli D, Faggiano A. Andrology. 2022 Sep;10(6):1023-1029. doi: 10.1111/andr.13199. Epub 2022 Jun 8. PMID: 35647664

Emerging Concepts in Cholera **Vaccine** Design.
Sit B, Fakoya B, Waldor MK. Annu Rev Microbiol. 2022 Sep 8;76:681-702. doi: 10.1146/annurev-micro-041320-033201. Epub 2022 Jun 27. PMID: 35759873

COVID-19 **vaccine** hesitancy and its associated factors in Malaysia.
Lee KW, Gew LT, Siau CS, Peh SC, Chia YC, Yacob S, Chan NN, Seow VK, Ooi PB. PLoS One. 2022 Sep 1;17(9):e0266925. doi: 10.1371/journal.pone.0266925. eCollection 2022. PMID: 36048822

Measuring **vaccine** acceptance and knowledge within health professions education.
Singh H, Chase AJ. Vaccine. 2022 Sep 2;40(37):5452-5458. doi: 10.1016/j.vaccine.2022.07.039. Epub 2022 Aug 4. PMID: 35933277

Monkeypox: A clinical update for paediatricians.
Huang YA, Howard-Jones AR, Durrani S, Wang Z, Williams PC. J Paediatr Child Health. 2022 Sep;58(9):1532-1538. doi: 10.1111/jpc.16171. Epub 2022 Aug 18. PMID: 35979896

Statement of Retraction: [A lowered probability of pregnancy in females in the USA aged 25-29 who received a human papillomavirus **vaccine** injection].
[No authors listed] J Toxicol Environ Health A. 2022 Sep 2;85(17):i. doi: 10.1080/15287394.2019.1669991. Epub 2019 Dec 10. PMID: 31821111

Influenza Vaccination in Massachusetts Jails: A Mixed-Methods Analysis.
Khorasani S, Zubiago J, Carreiro J, Guardado R, Wurcel AG. Public Health Rep. 2022 Sep-Oct;137(5):936-943. doi: 10.1177/00333549211041659. Epub 2021 Sep 15. PMID: 34524903

Regional heterogeneity of in-hospital mortality of COVID-19 in Brazil.
Liu Y, Wang K, Yang L, He D. Infect Dis Model. 2022 Sep;7(3):364-373. doi: 10.1016/j.idm.2022.06.005. Epub 2022 Jul 3. PMID: 35815243

Educational videos to address **vaccine** hesitancy in childhood immunization.
Lubis TA, Gunardi H, Herqutanto, Soedjatmiko S, Satari HI, Alatas FS, Pulungan AB. Vaccine. 2022 Sep 6:S0264-410X(22)01035-0. doi: 10.1016/j.vaccine.2022.08.044. Online ahead of print. PMID: 36085255

A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.
Abdolmaleki G, Taheri MA, Paridehpour S, Mohammadi NM, Tabatabaei YA, Mousavi T, Amin M. Daru. 2022 Sep 2:1-28. doi: 10.1007/s40199-022-00446-8. Online ahead of print. PMID: 36050585

Vaccine-Induced Myocarditis: Correspondence.
Sookaromdee P, Wiwanitkit V. Prehosp Disaster Med. 2022 Sep 2:1. doi: 10.1017/S1049023X2200125X. Online ahead of print. PMID: 36052478

COVID-19 Vaccinations in EMS Professionals: Prevalence and Predictors.
Gregory ME, Powell JR, MacEwan SR, Kurth JD, Kenah E, Panchal AR, McAlearney AS. Prehosp Emerg Care. 2022 Sep-Oct;26(5):632-640. doi: 10.1080/10903127.2021.1993391. Epub 2021 Nov 3. PMID: 34644239

Maternal Attitudes and Intentions About the COVID-19 **Vaccine** for Children Aged 5-11 Years.
Limbers CA, Thompson R. J Pediatr Health Care. 2022 Sep-Oct;36(5):416-429. doi: 10.1016/j.pedhc.2022.05.015. Epub 2022 May 25. PMID: 35690507

Safety surveillance and challenges in accelerated COVID-19 **vaccine** development.
Cole A, Webster P, Van Liew D, Salas M, Aimer O, Malikova MA. Ther Adv Drug Saf. 2022 Sep 5;13:20420986221116452. doi: 10.1177/20420986221116452. eCollection 2022. PMID: 36072284

COVID-19 vaccination in people with multiple sclerosis, real-life experience.
Alroughani R, Al-Hashel J, Abokalawa F, AlMojel M, Farouk Ahmed S. Clin Neurol Neurosurg. 2022 Sep;220:107374. doi: 10.1016/j.clineuro.2022.107374. Epub 2022 Jul 19. PMID: 35961255

mRNA vaccines in the prevention and treatment of diseases.
Gu Y, Duan J, Yang N, Yang Y, Zhao X. MedComm (2020). 2022 Aug 25;3(3):e167. doi: 10.1002/mco2.167. eCollection 2022 Sep. PMID: 36033422

Planning for future COVID-19 **vaccine** procurement.
Teerawattananon Y, Botwright S, Ozturk MH. Bull World Health Organ. 2022 Sep 1;100(9):526-526A. doi: 10.2471/BLT.22.288729. PMID: 36062243

Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review.
Gonzalez D, Gupta L, Murthy V, Gonzalez EB, Williamson KA, Makol A, Tan CL, Sulaiman FN, Shahril NS, Isa LM, Martín-Nares E, Aggarwal R. Rheumatol Int. 2022 Sep;42(9):1629-1641. doi: 10.1007/s00296-022-05149-6. Epub 2022 Jun 4. PMID: 35661906

Humoral and adaptive immune responses to the SARS-CoV-2 **vaccine**.
Rizzo R, Bortolotti D, Morandi L, Rizzo S, Schiuma G, Beltrami S, Papi A, Contoli M. Int J Infect Dis. 2022 Sep;122:412-414. doi: 10.1016/j.ijid.2022.06.020. Epub 2022 Jun 21. PMID: 35750264

Bordetella pertussis and outer membrane vesicles.
Çolak ÇY, Tefon Öztürk BE. Pathog Glob Health. 2022 Sep 1:1-14. doi: 10.1080/20477724.2022.2117937. Online ahead of print. PMID: 36047634

Factors that Influence Healthcare Provider Recommendation of HPV Vaccination.
Btoush R, Kohler RK, Carmody DP, Hudson SV, Tsui J. Am J Health Promot. 2022 Sep;36(7):1152-1161. doi: 10.1177/08901171221091438. Epub 2022 Apr 20. PMID: 35442819

Costs of seasonal influenza vaccination in South Africa.
Fraser H, Tombe-Mdewa W, Kohli-Lynch C, Hofman K, Tempia S, McMorrow M, Lambach P, Ramkrishna W, Cohen C, Hutubessy R, Edoka I. Influenza Other Respir Viruses. 2022 Sep;16(5):873-880. doi: 10.1111/irv.12987. Epub 2022 Mar 30. PMID: 35355414

COVID-19 Vaccination Intentions for Children With Medical Complexity.
Howell KD, Kelly MM, DeMuri GP, McBride JA, Katz B, Edmonson MB, Sklansky DJ, Shadman KA, Ehlenbach ML, Butteris SM, Warner G, Zhao Q, Coller RJ. Hosp Pediatr. 2022 Sep 1;12(9):e295-e302. doi: 10.1542/hpeds.2022-006544. PMID: 36039687

Interleukin-12 as an in situ cancer **vaccine** component: a review.
Cheng EM, Tsarovsky NW, Sondel PM, Rakhmilevich AL. Cancer Immunol Immunother. 2022 Sep;71(9):2057-2065. doi: 10.1007/s00262-022-03144-1. Epub 2022 Jan 13. PMID: 35024897

Options for the development of a bivalent **vaccine** against SARS-CoV-2 and influenza.
Stepanova E, Isakova-Sivak I, Rudenko L. Expert Rev Vaccines. 2022 Sep 1:1-3. doi: 10.1080/14760584.2022.2117692. Online ahead of print. PMID: 36004567

Preparation and evaluation of a new combined conjugated **vaccine** against Klebsiella pneumonia and Pseudomonas aeruginosa.
Bahy R, Fatyan E, Saafan AE, El-Gebaly EAEA. J Appl Microbiol. 2022 Sep;133(3):1543-1554. doi: 10.1111/jam.15646. Epub 2022 Jun 24. PMID: 35652238

Towards a universal flu **vaccine**.
Crunkhorn S. Nat Rev Drug Discov. 2022 Sep;21(9):636. doi: 10.1038/d41573-022-00128-9. PMID: 35879557

Hemagglutinin-based DNA vaccines containing trimeric self-assembling nanoparticles confer protection against influenza.
Qiao Y, Jin S, Nie J, Chang Y, Wang B, Guan S, Li Q, Shi Y, Kong W, Shan Y. J Leukoc Biol. 2022 Sep;112(3):547-556. doi: 10.1002/JLB.6A1021-535R. Epub 2022 Jan 17. PMID: 35040188

Encouraging **vaccine** uptake: lessons from behavioural science.
Michie S. Nat Rev Immunol. 2022 Sep;22(9):527-528. doi: 10.1038/s41577-022-00769-2. PMID: 35896830

In silico identification of epitope-based **vaccine** candidates against HTLV-1.
Jahantigh HR, Stufano A, Lovreglio P, Rezaee SA, Ahmadi K. J Biomol Struct Dyn. 2022 Sep;40(15):6737-6754. doi: 10.1080/07391102.2021.1889669. Epub 2021 Mar 2. PMID: 33648421

Estimating Waning of **Vaccine** Effectiveness: a Simulation Study.
Nikas A, Ahmed H, Zarnitsyna VI. Clin Infect Dis. 2022 Sep 3:ciac725. doi: 10.1093/cid/ciac725. Online ahead of print. PMID: 36056892

Safety of Dengue **Vaccine**?
de Silva A. Clin Infect Dis. 2022 Sep 1:ciac690. doi: 10.1093/cid/ciac690. Online ahead of print. PMID: 36048521

Caregiver COVID-19 vaccination for solid organ transplant candidates.
Sun BZ, Wightman A, Diekema DS. Am J Transplant. 2022 Sep;22(9):2135-2138. doi: 10.1111/ajt.17078. Epub 2022 May 7. PMID: 35485987

Impact of societal resilience on **vaccine** hesitancy and uptake: Lessons learned from the Israeli experience.
Kimhi S, Eshel Y, Marciano H, Adini B. Int J Disaster Risk Reduct. 2022 Sep;79:103181. doi: 10.1016/j.ijdrr.2022.103181. Epub 2022 Jul 19. PMID: 35873193

Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
Powell J, Piszczatoski CR. Ann Pharmacother. 2022 Sep;56(9):1058-1064. doi: 10.1177/10600280211058387. Epub 2022 Jan 10. PMID: 35012364

In response to the Letter to the Editor by R. Mungmunpuntipantip and V. Wiwanitkit re/ our publication Gjini E, Moramarco S, Carestia MC, et al. "Parents' and caregivers' role toward childhood vaccination in Albania: assessment of predictors of **vaccine** hesitancy". (Ann Ig. 2022 May 6. doi: 10.7416/ai.2022.2521. Epub ahead of print. PMID: 35532052).
Gjini E, Moramarco S, Carestia MC, Cenko F, Ylli A, Mehmeti I, Palombi L, Buonomo E. Ann Ig. 2022 Sep-Oct;34(5):544-545. doi: 10.7416/ai.2022.2531. PMID: 35861725

Vaccination strategies for Korean patients with inflammatory bowel disease.
Lee YJ, Kim ES. Korean J Intern Med. 2022 Sep;37(5):920-930. doi: 10.3904/kjim.2022.149. Epub 2022 Aug 8. PMID: 35934888

COVID-19 Vaccination and Intent Among Pregnant Women, United States, April 2021.
Razzaghi H, Kahn KE, Masalovich S, Black CL, Nguyen KH, Barfield WD, Galang RR, Singleton JA. Public Health Rep. 2022 Sep-Oct;137(5):988-999. doi: 10.1177/00333549221099244. Epub 2022 Jun 14. PMID: 35699596

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
Nooka AK, Shanmugasundaram U, Cheedarla N, Verkerke H, Edara VV, Valanparambil R, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Azeem M, Manalo J, Switchenko JM, Chang A, Linderman SL, Roback JD, Dhodapkar KM, Ahmed R, Suthar MS, Neish AS, Dhodapkar MV. J Clin Oncol. 2022 Sep 10;40(26):3057-3064. doi: 10.1200/JCO.21.02257. Epub 2022 Mar 8. PMID: 35259002

Value of the Immunization Program for Children in the 2017 US Birth Cohort.
Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Mellott CE, Marshall GS, Roberts CS. Pediatrics. 2022 Sep 1;150(3):e2021056007. doi: 10.1542/peds.2021-056007. PMID: 35821603

COVID-19 **Vaccine** Hesitancy and Interpersonal Trust: Correspondence.
Kleebayoon A, Wiwanitkit V, Sookaromdee P. Asia Pac J Public Health. 2022 Sep;34(6-7):730. doi: 10.1177/10105395221110455. Epub 2022 Jul 9. PMID: 35815578

COVID-19 **vaccine** hesitancy cannot fully explain disparities in vaccination coverage across the contiguous United States.
Hu S, Xiong C, Li Q, Wang Z, Jiang Y. Vaccine. 2022 Sep 2;40(37):5471-5482. doi: 10.1016/j.vaccine.2022.07.051. Epub 2022 Aug 8. PMID: 35953322

Behavioural determinants of COVID-19 vaccination acceptance among healthcare workers: a rapid review.
Crawshaw J, Konnyu K, Castillo G, van Allen Z, Grimshaw JM, Presseau J. Public Health. 2022 Sep;210:123-133. doi: 10.1016/j.puhe.2022.06.003. Epub 2022 Jun 14. PMID: 35985082

SARS-CoV-2 **Vaccine** Breakthrough by Omicron and Delta Variants, New York, USA.
Keyel AC, Russell A, Plitnick J, Rowlands JV, Lamson DM, Rosenberg E, St George K. Emerg Infect Dis. 2022 Sep 1;28(10). doi: 10.3201/eid2810.221058. Online ahead of print. PMID: 36048774

Will anti-**vaccine** activism in the USA reverse global goals?
Hotez PJ. Nat Rev Immunol. 2022 Sep;22(9):525-526. doi: 10.1038/s41577-022-00770-9. PMID: 35915141

Analysis of **Vaccine** Reactions After COVID-19 **Vaccine** Booster Doses Among Pregnant and Lactating Individuals.
Kachikis A, Englund JA, Covelli I, Frank Y, Haghighi C, Singleton M, Drake AL, Eckert LO. JAMA Netw Open. 2022 Sep 1;5(9):e2230495. doi: 10.1001/jamanetworkopen.2022.30495. PMID: 36074467

Harnessing the Immune Response to Fungal Pathogens for **Vaccine** Development.
Rivera A, Lodge J, Xue C. Annu Rev Microbiol. 2022 Sep 8;76:703-726. doi: 10.1146/annurev-micro-041020-111511. Epub 2022 Jun 27. PMID: 35759871

KEYNOTE - D36: personalized immunotherapy with a neoepitope **vaccine**, EVX-01 and pembrolizumab in advanced melanoma.
Long GV, Ferrucci PF, Khattak A, Meniawy TM, Ott PA, Chisamore M, Trolle T, Hyseni A, Heegaard E. Future Oncol. 2022 Sep 1. doi: 10.2217/fon-2022-0694. Online ahead of print. PMID: 36047545

Public Preferences and Willingness to Pay for a COVID-19 **Vaccine** in Iran: A Discrete Choice Experiment.
Darrudi A, Daroudi R, Yunesian M, Akbari Sari A. Pharmacoecon Open. 2022 Sep;6(5):669-679. doi: 10.1007/s41669-022-00359-x. Epub 2022 Aug 23. PMID: 35997900

Duration of immunity following full vaccination against SARS-CoV-2: a systematic review.
Addo IY, Dadzie FA, Okeke SR, Boadi C, Boadu EF. Arch Public Health. 2022 Sep 2;80(1):200. doi: 10.1186/s13690-022-00935-x. PMID: 36050781

COVID-19 **vaccine** uptake among Arkansas public K-12 school teachers and staff.
Cima MJ, McCormick D, Porter A 3rd, Zohoori N, Alsbrook S, Romero JR. Vaccine. 2022 Sep 2;40(37):5523-5528. doi: 10.1016/j.vaccine.2022.07.045. Epub 2022 Aug 2. PMID: 35965240

Malaria **vaccine** booster prolongs protection.
Ledford H. Nature. 2022 Sep 9. doi: 10.1038/d41586-022-02902-6. Online ahead of print. PMID: 36085520

A protective AAV **vaccine** for SARS-CoV-2.
Zhao S, Ke J, Yang B, Tan F, Yang J, Lin CP, Wang H, Zhong G. Signal Transduct Target Ther. 2022 Sep 5;7(1):310. doi: 10.1038/s41392-022-01158-w. PMID: 36064820

Rare monkeypox: Is it really a threat to the elderly?
Chavda VP, Apostolopoulos V. Maturitas. 2022 Sep;163:90-91. doi: 10.1016/j.maturitas.2022.05.014. Epub 2022 Jun 9. PMID: 35710608

Factors associated with unvaccinated caregivers who plan to vaccinate their children.
Goldman RD, Seiler M, Olson PG, Hart RJ, Bone JN, Baumer-Mouradian SH; International COVID-19 Parental Attitude Study (COVIPAS) Group. Prev Med. 2022 Sep;162:107121. doi: 10.1016/j.ypmed.2022.107121. Epub 2022 Jul 18. PMID: 35863584

SARS-CoV-2 vaccination and uveitis: Are they linked?
Waseem S, Ahmed SH, Fatima S, Shaikh TG, Ahmed J. Ann Med Surg (Lond). 2022 Sep;81:104472. doi: 10.1016/j.amsu.2022.104472. Epub 2022 Aug 28. PMID: 36060437

Perceived health literacy and COVID-19 **vaccine** acceptance among Chinese college students: A mediation analysis.
Jiang F, Zhao Y, Bai J, Yang X, Zhang J, Lin D, Li X. PLoS One. 2022 Sep 2;17(9):e0273285. doi: 10.1371/journal.pone.0273285. eCollection 2022. PMID: 36054110

Is vaccination against Covid-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis.
Nakafero G, Grainge MJ, Card T, Mallen CD, Nguyen Van-Tam JS, Williams HC, Abhishek A. Rheumatology (Oxford). 2022 Sep 1:keac484. doi: 10.1093/rheumatology/keac484. Online ahead of print. PMID: 36048896

Glycans in HIV-1 **vaccine** design - engaging the shield.
Deimel LP, Xue X, Sattentau QJ. Trends Microbiol. 2022 Sep;30(9):866-881. doi: 10.1016/j.tim.2022.02.004. Epub 2022 Mar 9. PMID: 35279348

Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 **vaccine**.
Le Gars M, Hendriks J, Sadoff J, Ryser M, Struyf F, Douoguih M, Schuitemaker H. Immunol Rev. 2022 Sep;310(1):47-60. doi: 10.1111/imr.13088. Epub 2022 Jun 11. PMID: 35689434

Age and product dependent **vaccine** effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
Starrfelt J, Danielsen AS, Buanes EA, Juvet LK, Lyngstad TM, Rø GØI, Veneti L, Watle SV, Meijerink H. BMC Med. 2022 Sep 2;20(1):278. doi: 10.1186/s12916-022-02480-4. PMID: 36050718

Immunogenicity and safety of the mRNA-based BNT162b2 **vaccine** in systemic autoimmune rheumatic diseases patients.
Pri-Paz Basson Y, Tayar-Shifman OE, Naser R, Tartakover Matalon S, Kimhi O, Gepstein R, Halperin T, Ziv-Baran T, Ziv A, Parikh R, Kivity S, Levy Y. Clin Rheumatol. 2022 Sep 2:1-7. doi: 10.1007/s10067-022-06348-z. Online ahead of print. PMID: 36050514

Vaccine hesitancy in people with multiple sclerosis.
Lechner-Scott JS, Davis JS, Hawkes C, Giovannoni G, Levy M, Yeh A. Mult Scler Relat Disord. 2022 Sep;65:104102. doi: 10.1016/j.msard.2022.104102. Epub 2022 Aug 10. PMID: 35985058

Acute macular neuroretinopathy after COVID-19 **vaccine**.
Michel T, Stolowy N, Gascon P, Dupessey F, Comet A, Attia R, Denis D, David T. J Fr Ophtalmol. 2022 Sep;45(7):e299-e302. doi: 10.1016/j.jfo.2022.01.022. Epub 2022 May 25. PMID: 35717218

Stevens-Johnson syndrome after ChAdOx1 nCoV-19 **vaccine**.
da Cruz Gouveia PA, Cavalcanti LNF, Alves LCF, Almeida DM, Barretto LWA. Indian J Dermatol Venereol Leprol. 2022 Sep-Oct;88(5):702. doi: 10.25259/IJDVL_941_2021. PMID: 35986626

From Dimensions, Levels and Domains to Context-specific Conceptualizations of Health Literacy.
Atanasova S, Kamin T. Zdr Varst. 2022 Jun 28;61(3):133-136. doi: 10.2478/sjph-2022-0018. eCollection 2022 Sep. PMID: 35855378

The effect of helminth infection on **vaccine** responses in humans and animal models: A systematic review and meta-analysis.
Natukunda A, Zirimenya L, Nassuuna J, Nkurunungi G, Cose S, Elliott AM, Webb EL. Parasite Immunol. 2022 Sep;44(9):e12939. doi: 10.1111/pim.12939. Epub 2022 Jul 5. PMID: 35712983

Do disease prevalence and severity drive COVID-19 **vaccine** demand?
Sarkar J. Econ Anal Policy. 2022 Sep;75:310-319. doi: 10.1016/j.eap.2022.05.014. Epub 2022 May 28. PMID: 35664501

Cost-effectiveness analyses of monovalent mumps vaccination programs for Japanese children.
Hoshi SL, Okubo R, Tabuchi K, Seposo X, Shono A, Kondo M. Vaccine. 2022 Sep 2;40(37):5513-5522. doi: 10.1016/j.vaccine.2022.08.004. Epub 2022 Aug 12. PMID: 35965241

Current clinical status of new COVID-19 vaccines and immunotherapy.
Nagpal D, Nagpal S, Kaushik D, Kathuria H. Environ Sci Pollut Res Int. 2022 Sep 5:1-36. doi: 10.1007/s11356-022-22661-1. Online ahead of print. PMID: 36063274

Plausibility of Claimed Covid-19 **Vaccine** Efficacies by Age: A Simulation Study.
Sheldrick KA, Meyerowitz-Katz G, Tucker-Kellogg G. Am J Ther. 2022 Sep-Oct 01;29(5):e495-e499. doi: 10.1097/MJT.0000000000001528. Epub 2022 Jun 20. PMID: 35723559

Using Health Economics to Inform Immunization Policy Across All Levels of Government.
Rafferty E, Reifferscheid L, Assi A, MacDonald SE. Pharmacoecon Open. 2022 Sep;6(5):631-635. doi: 10.1007/s41669-022-00347-1. Epub 2022 Jul 13. PMID: 35829929

Bacterial growth comparison of **vaccine** and non-**vaccine** type Streptococcus pneumoniae in different enrichment broths.
Wulandari IGAI, Nainggolan HH, Tafroji W, Safari D. J Microbiol Methods. 2022 Sep;200:106539. doi: 10.1016/j.mimet.2022.106539. Epub 2022 Jul 18. PMID: 35863656

[Effectiveness of BNT162b2 **vaccine** to preventing COVID-19 in healthcare personnel].
Chico-Sánchez P, Gras-Valentí P, Algado-Sellés N, Merino-Lucas E, Rodríguez-Díaz JC, Ronda-Pérez E, Sánchez-Payá J; Grupo COVID-19 de Medicina Preventiva. Gac Sanit. 2022 Sep-Oct;36(5):484-487. doi: 10.1016/j.gaceta.2021.11.003. Epub 2021 Nov 26. PMID: 34952732

Triggers for Acceptance of COVID-19 Vaccination: A Community-Based Study.
Medhat MA, Nour MO, Yousef A, El-Raey F, Aly H, Mousa S, Makhlouf NA, Elbadry M, Baki AA, Saeed MA, Abd-Elsalam S, Hassan EA, Shaltout SW, Kh Fathelbab H, Zaky S. Recent Adv Antiinfect Drug Discov. 2022 Sep 7. doi: 10.2174/2772434417666220907151635. Online ahead of print. PMID: 36082863

Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH, Su JY, Li YM. Acc Chem Res. 2022 Sep 1. doi: 10.1021/acs.accounts.2c00360. Online ahead of print. PMID: 36048514

Psycho-behavioural factors influencing COVID-19 **vaccine** hesitancy among Korean adults: The moderating role of age.
Kim GY, Shin T, Son YJ, Choi J. J Adv Nurs. 2022 Sep;78(9):2904-2915. doi: 10.1111/jan.15273. Epub 2022 Apr 20. PMID: 35441742

A Social Media–Based Public Health Campaign Encouraging COVID-19 Vaccination Across the United States.
Hunt IV, Dunn T, Mahoney M, Chen M, Nava V, Linos E. Am J Public Health. 2022 Sep;112(9):1253-1256. doi: 10.2105/AJPH.2022.306934. Epub 2022 Jul 7. PMID: 35797502

Barriers and facilitators to nationwide implementation of the malaria **vaccine** in Ghana.
Adeshina OO, Nyame S, Milner J, Milojevic A, Asante KP. Health Policy Plan. 2022 Sep 9:czac077. doi: 10.1093/heapol/czac077. Online ahead of print. PMID: 36083007

Genome-Wide Subtraction Analysis and Reverse Vaccinology to Detect Novel Drug Targets and Potential **Vaccine** Candidates Against Ehrlichia chaffeensis.
Sabzi S, Shahbazi S, Noori Goodarzi N, Haririzadeh Jouriani F, Habibi M, Bolourchi N, Mirzaie A, Badmasti F. Appl Biochem Biotechnol. 2022 Sep 2:1-18. doi: 10.1007/s12010-022-04116-y. Online ahead of print. PMID: 36053401

Enhancement of live vaccines by co-delivery of immune modulating proteins.
Manohar MM, Campbell BE, Walduck AK, Moore RJ. Vaccine. 2022 Sep 22;40(40):5769-5780. doi: 10.1016/j.vaccine.2022.08.059. Epub 2022 Sep 3. PMID: 36064671

Impact of hemagglutination activity and M2e immunity on conferring protection against influenza viruses.
Oh J, Subbiah J, Kim KH, Park BR, Bhatnagar N, Garcia KR, Liu R, Jung YJ, Shin CH, Seong BL, Kang SM. Virology. 2022 Sep;574:37-46. doi: 10.1016/j.virol.2022.07.010. Epub 2022 Jul 16. PMID: 35914365

Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.
Manley HJ, Lacson EK Jr, Aweh G, Chen Li N, Weiner DE, Miskulin DC, Hsu CM, Kapoian T, Hayney MS, Meyer KB, Johnson DS. Am J Kidney Dis. 2022 Sep;80(3):309-318. doi: 10.1053/j.ajkd.2022.01.425. Epub 2022 Mar 12. PMID: 35288216

Acquired malaria immunity in the era of the malaria **vaccine**.
Afeke I, Orish VN, Adu-Amankwaah J. Future Microbiol. 2022 Sep 2. doi: 10.2217/fmb-2022-0154. Online ahead of print. PMID: 36052741

Recommendations for Prevention and Control of Influenza in Children, 2022-2023.
COMMITTEE ON INFECTIOUS DISEASES. Pediatrics. 2022 Sep 6:e2022059275. doi: 10.1542/peds.2022-059275. Online ahead of print. PMID: 36065750

A novel allergist-integrative model for **vaccine** allergy safety.
Pawankar R, Thong BY. Ann Allergy Asthma Immunol. 2022 Sep;129(3):263-264. doi: 10.1016/j.anai.2022.06.011. PMID: 35988970

In-silico designing of a multi-epitope **vaccine** against SARS-CoV2 and studying the interaction of the **vaccine** with Alpha, Beta, Delta, and Omicron variants of concern.
Pal A, Pyne N, Paul S. Curr Drug Discov Technol. 2022 Sep 9. doi: 10.2174/1570163819666220909114900. Online ahead of print. PMID: 36093818

Covid-19 vaccination in autoimmune rheumatic diseases: A multi-center survey from southern India.
Mohanasundaram K, Santhanam S, Natarajan R, Murugesan H, Nambi T, Chilikuri B, Nallasivan S. Int J Rheum Dis. 2022 Sep;25(9):1046-1052. doi: 10.1111/1756-185X.14378. Epub 2022 Jun 30. PMID: 35773944

Identification of novel neutralizing determinants for protection against hepatitis C virus.
Alzua GP, Pihl AF, Offersgaard A, Velázquez-Moctezuma R, Hernandez CRD, Augestad EH, Fahnøe U, Mathiesen CK, Krarup H, Law M, Prentoe J, Bukh J, Gottwein JM. Hepatology. 2022 Sep 3. doi: 10.1002/hep.32772. Online ahead of print. PMID: 36056620

Myocardial Injury Pattern at MRI in COVID-19 **Vaccine**-Associated Myocarditis.
Fronza M, Thavendiranathan P, Chan V, Karur GR, Udell JA, Wald RM, Hong R, Hanneman K. Radiology. 2022 Sep;304(3):553-562. doi: 10.1148/radiol.212559. Epub 2022 Feb 15. PMID: 35166587

Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: A Systematic Review of the Literature.
Chow KW, Pham NV, Ibrahim BM, Hong K, Saab S. Dig Dis Sci. 2022 Sep;67(9):4574-4580. doi: 10.1007/s10620-022-07504-w. Epub 2022 Apr 29. PMID: 35486203

Cardiac MRI and Clinical Follow-up in COVID-19 **Vaccine**-associated Myocarditis.
Fronza M, Thavendiranathan P, Karur GR, Abdel-Qadir H, Udell JA, Wald RM, Hanneman K. Radiology. 2022 Sep;304(3):E48-E49. doi: 10.1148/radiol.220802. Epub 2022 May 3. PMID: 35503017

Non-pharmaceutical interventions and their relevance in the COVID-19 **vaccine** rollout in Saudi Arabia and Arab Gulf countries.
Althobaity Y, Wu J, Tildesley MJ. Infect Dis Model. 2022 Sep;7(3):545-560. doi: 10.1016/j.idm.2022.08.005. Epub 2022 Aug 20. PMID: 36035780

Targeting bacterial transferrin and lactoferrin receptors for vaccines.
Schryvers AB. Trends Microbiol. 2022 Sep;30(9):820-830. doi: 10.1016/j.tim.2022.01.017. Epub 2022 Feb 26. PMID: 35232609

Heterologous Cancer Vaccines plus Checkpoint Inhibitors Show Therapeutic Benefit.
[No authors listed] Cancer Discov. 2022 Sep 2:OF1. doi: 10.1158/2159-8290.CD-RW2022-158. Online ahead of print. PMID: 36053149

Partnering With Faith-Based Organizations to Offer Flu Vaccination and Other Preventive Services.
Corley AMS, Gomes SM, Crosby LE, Hopkins M, Cranley D, Lynch B, Mitchell M. Pediatrics. 2022 Sep 1;150(3):e2022056193. doi: 10.1542/peds.2022-056193. PMID: 35982030

Evaluating the relationship between moral values and **vaccine** hesitancy in Great Britain during the COVID-19 pandemic: A cross-sectional survey.
Schmidtke KA, Kudrna L, Noufaily A, Stallard N, Skrybant M, Russell S, Clarke A. Soc Sci Med. 2022 Sep;308:115218. doi: 10.1016/j.socscimed.2022.115218. Epub 2022 Jul 14. PMID: 35870299

Effectiveness of mRNA **vaccine** boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
Monge S, Rojas-Benedicto A, Olmedo C, Mazagatos C, José Sierra M, Limia A, Martín-Merino E, Larrauri A, Hernán MA; IBERCovid. Lancet Infect Dis. 2022 Sep;22(9):1313-1320. doi: 10.1016/S1473-3099(22)00292-4. Epub 2022 Jun 2. PMID: 35658998

Applying Cultural Intelligence to Improve **Vaccine** Hesitancy Among Black, Indigenous, and People of Color.
Richard-Eaglin A, McFarland ML. Nurs Clin North Am. 2022 Sep;57(3):421-431. doi: 10.1016/j.cnur.2022.04.008. Epub 2022 Jul 20. PMID: 35985729

Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic.
Fuller A, Hancox J, Vedhara K, Card T, Mallen C, Van-Tam JSN, Abhishek A. PLoS One. 2022 Sep 9;17(9):e0267769. doi: 10.1371/journal.pone.0267769. eCollection 2022. PMID: 36084032

Contextualized impacts of an infodemic on **vaccine** hesitancy: The moderating role of socioeconomic and cultural factors.
Lin F, Chen X, Cheng EW. Inf Process Manag. 2022 Sep;59(5):103013. doi: 10.1016/j.ipm.2022.103013. Epub 2022 Jul 16. PMID: 35874146

Human Papillomavirus Vaccinations During the COVID-19 Pandemic in Middle Schools in the Rio Grande Valley of Texas.
Rodriguez AM, Do TQN, Jibaja-Weiss ML, Chen L, Schmeler KM, Montealegre JR, Kuo YF. Am J Public Health. 2022 Sep;112(9):1269-1272. doi: 10.2105/AJPH.2022.306970. Epub 2022 Jul 21. PMID: 35862887

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer.
Li T, Song R, Wang J, Zhang J, Cai H, He H, Hu W, Yu D, Wang C, Pan Q, Peng M, Ren H, Zhu P. Int J Infect Dis. 2022 Sep;122:874-884. doi: 10.1016/j.ijid.2022.07.050. Epub 2022 Jul 26. PMID: 35905950

Challenges and opportunities in current **vaccine** technology and administration: A comprehensive survey examining oral **vaccine** potential in the United States.
Rupassara SI, Kindt JW Jr, Kazi N, Kahanda I. Hum Vaccin Immunother. 2022 Sep 9:2114422. doi: 10.1080/21645515.2022.2114422. Online ahead of print. PMID: 36082816

Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review.
Franchini M, Cappello E, Valdiserra G, Bonaso M, Moretti U, Focosi D, Tuccori M. Semin Thromb Hemost. 2022 Sep 2. doi: 10.1055/s-0042-1754389. Online ahead of print. PMID: 36055265

COVID-19 **Vaccine** Hesitancy and Vaccination Status in a Community-Based Cohort of People Who Inject Drugs in Baltimore, Maryland, March-June 2021.
Cepeda JA, Feder KA, Astemborski J, Schluth C, Kirk GD, Mehta SH, Genberg BL. Public Health Rep. 2022 Sep-Oct;137(5):1031-1040. doi: 10.1177/00333549221110299. Epub 2022 Jul 16. PMID: 35848111

Diversity of rotavirus strains circulating in Haiti before and after introduction of monovalent **vaccine**.
Lucien MAB, Esona MD, Pierre M, Joseph G, Rivière C, Leshem E, Aliabadi N, Desormeaux AM, Andre-Alboth J, Fitter DL, Grant-Greene Y, Tate J, Boncy J, Patel R, Burnett E, Juin S, Parashar UD, Bowen MD. IJID Reg. 2022 Jul 14;4:146-151. doi: 10.1016/j.ijregi.2022.07.007. eCollection 2022 Sep. PMID: 35923644

Functional profiling of Covid 19 **vaccine** candidate by flow virometry.
Prout A, Rustandi RR, Tubbs C, Winters MA, McKenna P, Vlasak J. Vaccine. 2022 Sep 2;40(37):5529-5536. doi: 10.1016/j.vaccine.2022.08.006. Epub 2022 Aug 9. PMID: 35985887

Understanding the policy dynamics of COVID-19 vaccination in Ghana through the lens of a policy analytical framework.
Atinga RA, Koduah A, Abiiro GA. Health Res Policy Syst. 2022 Sep 1;20(1):94. doi: 10.1186/s12961-022-00896-1. PMID: 36050739

Provider Continuity and Human Papillomavirus **Vaccine** Refusal Among Adolescents.
Cutrone M, Tumin D, Buckman C, Baker KD. Clin Pediatr (Phila). 2022 Sep;61(8):526-529. doi: 10.1177/00099228221094130. Epub 2022 May 6. PMID: 35524346

Vaccine efficacy trials for Crimean-Congo haemorrhagic fever: Insights from modelling different epidemiological settings.
Vesga JF, Métras R, Clark MHA, Ayazi E, Apolloni A, Leslie T, Msimang V, Thompson PN, John Edmunds W. Vaccine. 2022 Sep 22;40(40):5806-5813. doi: 10.1016/j.vaccine.2022.08.061. Epub 2022 Sep 1. PMID: 36058795

Research Note: In-feed Bacteriophage does not impact efficacy of live Salmonella **vaccine**.
Kimminau EA, Karnezos TP, Russo KN, Baxter JA, Berghaus RD, Jones M, Hofacre CL. Poult Sci. 2022 Sep;101(9):102001. doi: 10.1016/j.psj.2022.102001. Epub 2022 Jun 12. PMID: 35908492

Comment on: Gjini E, Moramarco S, Carestia MC, et al. Parents' and caregivers' role toward childhood vaccination in Albania: assessment of predictors of **vaccine** hesitancy. (Ann Ig. 2022 May 6. doi: 10.7416/ai.2022.2521. Epub ahead of print. PMID: 35532052).
Mungmunpuntipantip R, Wiwanitkit V. Ann Ig. 2022 Sep-Oct;34(5):542-543. doi: 10.7416/ai.2022.2530. PMID: 35861724

Exploring Motivations for COVID-19 Vaccination Among Black Young Adults in 3 Southern US States: Cross-sectional Study.
Stoner MC, Browne EN, Tweedy D, Pettifor AE, Maragh-Bass AC, Toval C, Tolley EE, Comello MLG, Muessig KE, Budhwani H, Hightow-Weidman LB. JMIR Form Res. 2022 Sep 2;6(9):e39144. doi: 10.2196/39144. PMID: 35969516

Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy.
Bartsch YC, Atyeo C, Kang J, Cai Y, Chen B, Gray KJ, Edlow AG, Alter G. Am J Obstet Gynecol. 2022 Sep;227(3):493.e1-493.e7. doi: 10.1016/j.ajog.2022.04.009. Epub 2022 Apr 14. PMID: 35430229

Model-based evaluation of policy impacts and the continued COVID-19 risk at long term care facilities.
Fosdick BK, Bayham J, Dilliott J, Ebel GD, Ehrhart N. Infect Dis Model. 2022 Sep;7(3):463-472. doi: 10.1016/j.idm.2022.07.003. Epub 2022 Jul 15. PMID: 35854786

Evaluation of the diagnostic features and clinical course of COVID-19 **vaccine**-associated subacute thyroiditis.
Bostan H, Kayihan S, Calapkulu M, Hepsen S, Gul U, Ozturk Unsal I, Kizilgul M, Sencar ME, Cakal E, Ucan B. Hormones (Athens). 2022 Sep;21(3):447-455. doi: 10.1007/s42000-022-00380-z. Epub 2022 Jun 16. PMID: 35711078

What explains racial/ethnic inequities in the uptake of differentiated influenza vaccines?
Mahmud SM, Pabla G, Righolt CH, Loiacono MM, Thommes E, Chit A. Prev Med. 2022 Oct;163:107236. doi: 10.1016/j.ypmed.2022.107236. Epub 2022 Sep 1. PMID: 36058382

COVID-19 vaccination in the Gaza Strip: a cross-sectional study of **vaccine** coverage, hesitancy, and associated risk factors among community members and healthcare workers.
Majer J, Elhissi JH, Mousa N, Kostandova N. Confl Health. 2022 Sep 9;16(1):48. doi: 10.1186/s13031-022-00477-7. PMID: 36085165

Immunogenicity and safety of a RBD **vaccine** against SARS-CoV-2 in a murine model.
Díaz A, Serrano-Coll H, Botero Y, Calderón A, Arteta-Cueto A, Gastelbondo B, Guzmán C, Rivero R, Martínez C, Marquez T, Arrieta G, Mattar S. Travel Med Infect Dis. 2022 Sep-Oct;49:102427. doi: 10.1016/j.tmaid.2022.102427. Epub 2022 Aug 10. PMID: 35963556

Immune non-interference and safety study of Vi-DT typhoid conjugate **vaccine** with a measles, mumps and rubella containing **vaccine** in 9-15 months old Nepalese infants.
Saluja T, Rai GK, Chaudhary S, Kanodia P, Giri BR, Kim DR, Yang JS, Park IY, Kyung SE, Vemula S, Reddy E J, Kim B, Gupta BP, Jo SK, Ryu JH, Park HK, Shin JH, Lee Y, Kim H, Kim JH, Mojares ZR, Wartel TA, Sahastrabuddhe S. Vaccine. 2022 Sep 22;40(40):5828-5834. doi: 10.1016/j.vaccine.2022.08.034. Epub 2022 Sep 3. PMID: 36064672

Transient Pseudothrombocytopenia Detected 8 Months After COVID-19 Vaccination.
Higuchi T, Hoshi T, Nakajima A, Haruki K. Lab Med. 2022 Sep 1;53(5):540-541. doi: 10.1093/labmed/lmac031. PMID: 35640881

Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience.
Baratè C, Caruso T, Mavilia F, Sammuri P, Pratesi F, Motta G, Guerri V, Galimberti S, Migliorini P. Clin Exp Med. 2022 Sep 8:1-7. doi: 10.1007/s10238-022-00877-2. Online ahead of print. PMID: 36074205

Equine influenza **vaccine** supplies.
[No authors listed] Vet Rec. 2022 Sep;191(5):202. doi: 10.1002/vetr.2202. PMID: 36083048

Pfizer COVID **vaccine** efficacy in children aged 5-11 years.
[No authors listed] J Paediatr Child Health. 2022 Sep;58(9):1702. doi: 10.1111/jpc.16148. Epub 2022 Aug 8. PMID: 35938773

Highlights of the 3rd international BCG symposium: 100th anniversary of the first administration of BCG.
Locht C. Microbes Infect. 2022 Sep 6:105043. doi: 10.1016/j.micinf.2022.105043. Online ahead of print. PMID: 36084845

Generation of a live attenuated influenza A **vaccine** by proteolysis targeting.
Si L, Shen Q, Li J, Chen L, Shen J, Xiao X, Bai H, Feng T, Ye AY, Li L, Zhang C, Li Z, Wang P, Oh CY, Nurani A, Niu S, Zhang C, Wei X, Yuan W, Liao H, Huang X, Wang N, Tian WX, Tian H, Li L, Liu X, Plebani R. Nat Biotechnol. 2022 Sep;40(9):1370-1377. doi: 10.1038/s41587-022-01381-4. Epub 2022 Jul 4. PMID: 35788567

Orbital myositis and scleritis after anti-SARS-CoV-2 mRNA vaccines: A report of three cases.
Savino G, Gambini G, Scorcia G, Comi N, Fossataro C, Stanislao Rizzo. Eur J Ophthalmol. 2022 Sep 4:11206721221123780. doi: 10.1177/11206721221123780. Online ahead of print. PMID: 36062603

Polyphosphazene: A New Adjuvant Platform for Cocaine **Vaccine** Development.
Lin M, Marin A, Ellis B, Eubanks LM, Andrianov AK, Janda KD. Mol Pharm. 2022 Sep 5;19(9):3358-3366. doi: 10.1021/acs.molpharmaceut.2c00489. Epub 2022 Aug 19. PMID: 35984034

Chlamydia trachomatis **vaccine** development - a view on the current challenges and how to move forward.
Borges ÁH, Follmann F, Dietrich J. Expert Rev Vaccines. 2022 Sep 5:1-13. doi: 10.1080/14760584.2022.2117694. Online ahead of print. PMID: 36004386

Immune and Inflammatory Response in Horse Vaccinated Against Equine Herpesviruses 1 (EHV-1) and 4 (EHV-4) Assessed by Serum Protein Electrophoretic Pattern and Leukocyte Population.
Giannetto C, Giudice E, Piccione G, Castronovo C, Arfuso F. J Equine Vet Sci. 2022 Sep;116:104051. doi: 10.1016/j.jevs.2022.104051. Epub 2022 Jun 23. PMID: 35753636

COVID-19 **vaccine** for people who live and work in prisons worldwide: A scoping review.
Ismail N, Tavoschi L, Moazen B, Roselló A, Plugge E. PLoS One. 2022 Sep 9;17(9):e0267070. doi: 10.1371/journal.pone.0267070. eCollection 2022. PMID: 36084037

COVID-19 vaccination for patients with benign childhood epilepsy with centrotemporal spikes.
Yang X, Wu L, Zheng D, Yang B, Wu D. Epilepsy Behav. 2022 Sep;134:108744. doi: 10.1016/j.yebeh.2022.108744. Epub 2022 May 17. PMID: 35952506

Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA **vaccine** dose.
Nevo L, Cahen-Peretz A, Vorontsov O, Frenkel R, Kabessa M, Cohen SM, Hamrani A, Oiknine-Djian E, Lipschuetz M, Goldman-Wohl D, Walfisch A, Kovo M, Neeman M, Yagel S, Wolf DG, Beharier O. Am J Obstet Gynecol. 2022 Sep;227(3):486.e1-486.e10. doi: 10.1016/j.ajog.2022.04.010. Epub 2022 Apr 14. PMID: 35430228

COVID-19 **vaccine** acceptance and coverage among pregnant persons in the United States.
Regan AK, Kaur R, Nosek M, Aytha Swathi P, Yan Gu N. Prev Med Rep. 2022 Sep 7;29:101977. doi: 10.1016/j.pmedr.2022.101977. Online ahead of print. PMID: 36090471

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Lancet Infect Dis. 2022 Sep;22(9):1293-1302. doi: 10.1016/S1473-3099(22)00320-6. Epub 2022 Jun 23. PMID: 35753318

Methodology to estimate natural- and **vaccine**-induced antibodies to SARS-CoV-2 in a large geographic region.
DeSantis SM, León-Novelo LG, Swartz MD, Yaseen AS, Valerio-Shewmaker MA, Talebi Y, Brito FA, Ross JA, Kohl HW 3rd, Messiah SE, Kelder SH, Wu L, Zhang S, Aguillard KA, Gonzalez MO, Omega-Njemnob OS, Lakey D, Shuford JA, Pont S, Boerwinkle E. PLoS One. 2022 Sep 9;17(9):e0273694. doi: 10.1371/journal.pone.0273694. eCollection 2022. PMID: 36084125

Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm?
Oh KB, Doherty TM, Vetter V, Bonanni P. Expert Rev Vaccines. 2022 Sep 5:1-13. doi: 10.1080/14760584.2022.2117693. Online ahead of print. PMID: 36039786

Factors related to COVID-19 vaccination intention and uptake among childbearing women.
Preis H, Mahaffey B, Lobel M. Health Psychol. 2022 Sep 8. doi: 10.1037/hea0001221. Online ahead of print. PMID: 36074594

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera.
Hu J, Wei XY, Xiang J, Peng P, Xu FL, Wu K, Luo FY, Jin AS, Fang L, Liu BZ, Wang K, Tang N, Huang AL. Genes Dis. 2022 Sep;9(5):1290-1300. doi: 10.1016/j.gendis.2021.11.007. Epub 2021 Dec 3. PMID: 34877393

Age-Dependent Effects of COVID-19 **Vaccine** and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan.
Ko YK, Murayama H, Yamasaki L, Kinoshita R, Suzuki M, Nishiura H. Emerg Infect Dis. 2022 Sep;28(9):1777-1784. doi: 10.3201/eid2809.220377. Epub 2022 Jul 12. PMID: 35820166

Characterization of infectious laryngotracheitis virus isolates from laying hens during 2019-2020 outbreaks in Tamil Nadu, India.
Ponnusamy P, Sukumar K, Raja A, Saravanan S, Srinivasan P, Thangavelu A. Arch Virol. 2022 Sep;167(9):1819-1829. doi: 10.1007/s00705-022-05485-9. Epub 2022 Jun 18. PMID: 35716265

COVID-19 **vaccine**-related adverse events in solid cancer patients treated with immunotherapy.
Bouleftour W, Bonjean P, Grangeon K, Magné N. Cancer Invest. 2022 Sep 5:1-10. doi: 10.1080/07357907.2022.2121966. Online ahead of print. PMID: 36062881

Case report: **Vaccine** Brigade Chicago, Illinois: From founding February to July, 2021.
Blacksin BA. Public Health Nurs. 2022 Sep;39(5):1034-1040. doi: 10.1111/phn.13072. Epub 2022 Mar 30. PMID: 35352391

Vaccination of cats with Sad23L-nCoV-S **vaccine** candidate against major variants of SARS-CoV-2.
Zhang P, Luo S, Zou P, Liang C, Wang C, Li J, Li Y, Wang G, Zhang L, Li T, Li C. Mol Ther Methods Clin Dev. 2022 Sep 8;26:181-190. doi: 10.1016/j.omtm.2022.06.011. Epub 2022 Jun 22. PMID: 35756078

COVID-19 Vaccination Concerns and Reasons for Acceptance Among US Health Care Personnel.
Oberleitner LMS, Lucia VC, Navin MC, Ozdych M, M Afonso N, Kennedy RH, Keil H, Wu L, Mathew TA. Public Health Rep. 2022 Sep 8:333549221120590. doi: 10.1177/00333549221120590. Online ahead of print. PMID: 36073241

Implementing the COVID-19 Rapid Community Assessment on **Vaccine** Confidence: Lessons Learned From Alabama and Georgia.
Kobau R, Carry M, Rubenstein BL, Denson D, Uribe C, Zajac J, Kidder DP, Peacock G, Abad N. Public Health Rep. 2022 Sep-Oct;137(5):832-840. doi: 10.1177/00333549221112610. Epub 2022 Jul 21. PMID: 35861310

Strangles **vaccine** launched.
[No authors listed] Vet Rec. 2022 Sep;191(5):202. doi: 10.1002/vetr.2204. PMID: 36083050

Bioinformatics analysis of Muscovy duck parvovirus REP and VP1 proteins.
Zhang C, Li M, Yu T. J Biomol Struct Dyn. 2022 Sep 6:1-16. doi: 10.1080/07391102.2022.2118170. Online ahead of print. PMID: 36065642

Pemphigus vulgaris after COVID-19 infection and vaccination.
Zou H, Daveluy S. J Am Acad Dermatol. 2022 Sep;87(3):709-710. doi: 10.1016/j.jaad.2022.05.013. Epub 2022 May 13. PMID: 35569594

Nucleocapsid as a next-generation COVID-19 **vaccine** candidate.
Oronsky B, Larson C, Caroen S, Hedjran F, Sanchez A, Prokopenko E, Reid T. Int J Infect Dis. 2022 Sep;122:529-530. doi: 10.1016/j.ijid.2022.06.046. Epub 2022 Jul 3. PMID: 35788417

Efficacy of RTS,S/AS01$_E$ malaria **vaccine** administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial.
Samuels AM, Ansong D, Kariuki SK, Adjei S, Bollaerts A, Ockenhouse C, Westercamp N, Lee CK, Schuerman L, Bii DK, Osei-Tutu L, Oneko M, Lievens M, Attobrah Sarfo MA, Atieno C, Morelle D, Bakari A, Sang T, Jongert E, Kotoh-Mortty MF, Otieno K, Roman F, Buabeng PBY, Ntiamoah Y, Ofori-Anyinam O, Agbenyega T; RTS,S study group. Lancet Infect Dis. 2022 Sep;22(9):1329-1342. doi: 10.1016/S1473-3099(22)00273-0. Epub 2022 Jun 23. PMID: 35753316

Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 **vaccine**: prolonged protection from SARS-CoV-2 in newborns and older children.
Ricciardi A, Zelini P, Cassaniti I, Avanzini MA, Colaneri M, De Silvestri A, Baldanti F, Bruno R. Int J Infect Dis. 2022 Sep;122:905-909. doi: 10.1016/j.ijid.2022.06.055. Epub 2022 Jul 5. PMID: 35803470

A bivalent **vaccine** containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
Du P, Li N, Xiong X, Tang S, Dai Q, Liu Z, Wang T, Gu X, Zhou Z. J Med Virol. 2022 Sep;94(9):4287-4293. doi: 10.1002/jmv.27885. Epub 2022 Jun 2. PMID: 35614524

Neuroretinitis after the second injection of a SARS-CoV-2-**vaccine**: A case report.
Lee C, Park KA, Ham DI, Seong M, Kim HJ, Lee GI, Oh SY. Am J Ophthalmol Case Rep. 2022 Sep;27:101592. doi: 10.1016/j.ajoc.2022.101592. Epub 2022 May 25. PMID: 35642221

Effects of anti-SARS-CoV-2 vaccination on safety and disease exacerbation in patients with Behçet syndrome in a monocentric cohort.
Apaydin H, Erden A, Güven SC, Armağan B, Konak HE, Polat B, Afşin Y, Kaygisiz M, Omma A, Kucuksahin O. Int J Rheum Dis. 2022 Sep;25(9):1068-1077. doi: 10.1111/1756-185X.14387. Epub 2022 Jul 18. PMID: 35851753

Effectiveness of a vaccination education module for college freshmen.
Macintosh JLB, Behunin G, Luthy KEB, Beckstrand RL, Eden LM, Ray G. J Am Coll Health. 2022 Sep 9:1-4. doi: 10.1080/07448481.2022.2119399. Online ahead of print. PMID: 36084268

Evaluation of inactivated COVID-19 **vaccine** on semen parameters in reproductive-age males: a retrospective cohort study.
Zhu H, Wang X, Zhang F, Zhu Y, Du MR, Tao ZW, Sun C, Ma HT, Li YD, Liang GQ, Ren J, Feng BL, Jiang F. Asian J Androl. 2022 Sep-Oct;24(5):441-444. doi: 10.4103/aja202225. PMID: 35532560

Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy.
Yan WL, Lang TQ, Yuan WH, Yin Q, Li YP. Acta Pharmacol Sin. 2022 Sep 1. doi: 10.1038/s41401-022-00976-6. Online ahead of print. PMID: 36050519

Patient Perspectives on the COVID-19 **Vaccine**: A Pilot Survey Study of Patients in Endocrinology Clinics.
Mikkilineni P, Simon R, Bhan A, Rao SD. Endocr Pract. 2022 Sep;28(9):897-900. doi: 10.1016/j.eprac.2022.06.010. Epub 2022 Jul 3. PMID: 35787467

Travelers and travel vaccines at six health care systems in the **Vaccine** Safety Datalink.
Lewin B, Qian L, Huang R, Sy LS, Goddard K, Naleway AL, DeSilva M, Daley MF, McNeil MM, Jackson LA, Jacobsen SJ. Vaccine. 2022 Sep 2:S0264-410X(22)01002-7. doi: 10.1016/j.vaccine.2022.08.023. Online ahead of print. PMID: 36064668

SARS-CoV-2 **vaccine**-induced antibody levels: what lies beneath.
Lassaunière R, Tiemessen CT. Lancet Rheumatol. 2022 Sep;4(9):e579-e581. doi: 10.1016/S2665-9913(22)00225-9. Epub 2022 Aug 9. PMID: 35966646

Monkeypox response relies on three **vaccine** suppliers.
Harrison C. Nat Biotechnol. 2022 Sep;40(9):1306-1307. doi: 10.1038/s41587-022-01463-3. PMID: 36085508

Delivery of MERS antigen encapsulated in α-GalCer-bearing liposomes elicits stronger antigen-specific immune responses.
Khan MA, Malik A, Alruwetei AM, Alzohairy MA, Alhatlani BY, Al Rugaie O, Alhumaydhi FA, Khan A. J Drug Target. 2022 Sep;30(8):884-893. doi: 10.1080/1061186X.2022.2066681. Epub 2022 Apr 22. PMID: 35418263

A third dose of the BNT162b2 mRNA **vaccine** significantly improves immune responses among liver transplant recipients.
Davidov Y, Indenbaum V, Tsaraf K, Cohen-Ezra O, Likhter M, Ben Yakov G, Halperin R, Levy I, Mor O, Agmon-Levin N, Afek A, Rahav G, Lustig Y, Ben Ari Z. J Hepatol. 2022 Sep;77(3):702-709. doi: 10.1016/j.jhep.2022.03.042. Epub 2022 Apr 19. PMID: 35452692

Factors associated with COVID-19 **vaccine** intentions during the COVID-19 pandemic; a systematic review and meta-analysis of cross-sectional studies.
Terry E, Cartledge S, Damery S, Greenfield S. BMC Public Health. 2022 Sep 2;22(1):1667. doi: 10.1186/s12889-022-14029-4. PMID: 36056325

COVID-19 Vaccinations and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.

Rzymski P, Kasianchuk N, Sikora D, Poniedziałek B. J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28131. Online ahead of print. PMID: 36068643

An agent-based model to assess large-scale COVID-19 vaccination campaigns for the Italian territory: The case study of Lombardy region.
Cattaneo A, Vitali A, Mazzoleni M, Previdi F. Comput Methods Programs Biomed. 2022 Sep;224:107029. doi: 10.1016/j.cmpb.2022.107029. Epub 2022 Jul 16. PMID: 35908330

Infants' diminished response to DTaP **vaccine** is associated with exposure to organophosphate esters.
Hammel SC, Nordone S, Zhang S, Lorenzo AM, Eichner B, Moody MA, Harrington L, Gandee J, Schmidt L, Smith S, Stapleton HM, Hoffman K. Sci Total Environ. 2022 Sep 1;837:155782. doi: 10.1016/j.scitotenv.2022.155782. Epub 2022 May 6. PMID: 35533854

Circular RNA **vaccine**, a novel mRNA **vaccine** design strategy for SARS-CoV-2 and variants.
Su P, Zhang L, Zhou F, Zhang L. MedComm (2020). 2022 Jul 10;3(3):e153. doi: 10.1002/mco2.153. eCollection 2022 Sep. PMID: 35845353

Effectiveness of the third dose of BNT162b2 **vaccine** on neutralizing Omicron variant in the Japanese population.
Kawasuji H, Morinaga Y, Tani H, Saga Y, Kaneda M, Murai Y, Ueno A, Miyajima Y, Fukui Y, Nagaoka K, Ono C, Matsuura Y, Niimi H, Yamamoto Y. J Infect Chemother. 2022 Sep;28(9):1273-1278. doi: 10.1016/j.jiac.2022.05.009. Epub 2022 Jun 10. PMID: 35691864

Impact of Routine Childhood Immunization in Reducing **Vaccine**-Preventable Diseases in the United States.
Talbird SE, Carrico J, La EM, Carias C, Marshall GS, Roberts CS, Chen YT, Nyaku MK. Pediatrics. 2022 Sep 1;150(3):e2021056013. doi: 10.1542/peds.2021-056013. PMID: 35821599

The popularity of contradictory information about COVID-19 **vaccine** on social media in China.
Wang D, Zhou Y. Comput Human Behav. 2022 Sep;134:107320. doi: 10.1016/j.chb.2022.107320. Epub 2022 May 5. PMID: 35527790

Pfizer **vaccine** effectiveness against Omicron in children aged 5-11 years.
[No authors listed] J Paediatr Child Health. 2022 Sep 2. doi: 10.1111/jpc.16190. Online ahead of print. PMID: 36052702

Surveillance of influenza B severe hospitalized cases during 10 seasons in Catalonia: Does the lineage make a difference?
Soldevila N, Basile L, Martínez A, Torner N, Marcos MÁ, Mosquera MDM, Antón A, Andrés C, Rius C, Pumarola T, Domínguez Á; and the PIDIRAC Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group. J Med Virol. 2022 Sep;94(9):4417-4424. doi: 10.1002/jmv.27876. Epub 2022 Jun 4. PMID: 35593301

A SARS-CoV-2 outbreak associated with **vaccine** breakthrough in an acute care hospital.
Park SY, Kim TH, Lee E, Loeb M, Jeong YS, Kim JH, Oh SM, Cheong S, Park H, Jo S, Sim JW. Am J Infect Control. 2022 Sep;50(9):1006-1012. doi: 10.1016/j.ajic.2022.05.010. Epub 2022 May 20. PMID: 35605754

Medical students' knowledge of HPV, HPV **vaccine**, and HPV-associated head and neck cancer.
Du EY, Adjei Boakye E, Taylor DB, Kuziez D, Rohde RL, Pannu JS, Simpson MC, Patterson RH, Varvares MA, Osazuwa-Peters N. Hum Vaccin Immunother. 2022 Sep 7:2109892. doi: 10.1080/21645515.2022.2109892. Online ahead of print. PMID: 36070503

Vaccination and SARS-CoV-2 seroprevalence in blood donors: Correspondence.
Sookaromdee P, Wiwanitkit V. Transfus Clin Biol. 2022 Sep 1:S1246-7820(22)00243-9. doi: 10.1016/j.tracli.2022.08.150. Online ahead of print. PMID: 36058546

Impact of information framing and vaccination characteristics on parental COVID-19 **vaccine** acceptance for children: a discrete choice experiment.
Wang K, Wong EL, Cheung AW, Chung VC, Wong CH, Dong D, Wong SY, Yeoh EK. Eur J Pediatr. 2022 Sep 2:1-11. doi: 10.1007/s00431-022-04586-6. Online ahead of print. PMID: 36056176

Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for **Vaccine** Development.
Pandey A, Madan R, Singh S. Curr Microbiol. 2022 Sep 5;79(10):306. doi: 10.1007/s00284-022-03003-3. PMID: 36064873

SARS-CoV-2 mRNA-**vaccine** candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates.
Alimohammadi R, Porgoo M, Eftekhary M, Kiaie SH, Ansari Dezfouli E, Dehghani M, Nasrollahi K, Malekshahabi T, Heidari M, Pouya S, Alimohammadi M, Sattari Khavas D, Modaresi MS, Ghasemi MH, Ramyar H, Mohammadipour F, Hamzelouei F, Mofayezi A, Mottaghi SS, Rahmati A, Razzaznian M, Tirandazi V, Tat M, Borzouee F, Sadeghi H, Haji Mohammadi M, Rastegar L, Safar Sajadi SM, Ehsanbakhsh H, Bazmbar H, Baghernejadan Z, Shams Nouraei M, Pazooki P, Pahlavanneshan M, Alishah K, Nasiri F, Mokhberian N, Mohammadi SS, Akar S, Niknam H, Azizi M, Ajoudanian M, Moteallehi-Ardakani MH, Mousavi Shaegh SA, Ramezani R, Salimi V, Moazzami R, Hashemi SM, Dehghanizadeh S, Khoddami V. NPJ Vaccines. 2022 Sep 2;7(1):105. doi: 10.1038/s41541-022-00528-3. PMID: 36056015

Timing of Monovalent **Vaccine** Administration in Infants Receiving DTaP-based Combination Vaccines in the United States.
Marshall GS, Petigara T, Liu Z, Wolfson L, Johnson D, Goveia MG, Chen YT. Pediatr Infect Dis J. 2022 Sep 1;41(9):775-781. doi: 10.1097/INF.0000000000003609. Epub 2022 Jun 24. PMID: 35763699

SARS-CoV-2 vaccines: A double-edged sword throughout rapid evolution of COVID-19.
Zolfaghari MA, Ghadiri Moghaddam F, Rajput S, Karimi A, Naghi Vishteh M, Mahmoodpoor A, Dolati S, Yousefi M. Cell Biol Int. 2022 Sep 1. doi: 10.1002/cbin.11903. Online ahead of print. PMID: 36047303

Acceptance of COVID-19 booster vaccination based on the protection motivation theory: A cross-sectional study in China.
Wu F, Yuan Y, Deng Z, Yin D, Shen Q, Zeng J, Xie Y, Xu M, Yang M, Jiang S, Zhang C, Lu H, Sun C. J Med Virol. 2022 Sep;94(9):4115-4124. doi: 10.1002/jmv.27825. Epub 2022 May 9. PMID: 35506329

Barriers to Coronavirus Disease 19 vaccination in patients with obesity.
Kizilkaya MC, Kilic SS, Oncel D, Mamidanna S, Daliparty V, Yilmaz S, Bozkurt MA, Sibic O, Sayan M. Am J Surg. 2022 Sep 1:S0002-9610(22)00544-X. doi: 10.1016/j.amjsurg.2022.08.021. Online ahead of print. PMID: 36075763

In silico designing of a novel epitope-based candidate **vaccine** against Streptococcus pneumoniae with introduction of a new domain of PepO as adjuvant.
Bahadori Z, Shafaghi M, Madanchi H, Ranjbar MM, Shabani AA, Mousavi SF. J Transl Med. 2022 Sep 4;20(1):389. doi: 10.1186/s12967-022-03590-6. PMID: 36059030

Is Mexico's population hesitant towards COVID-19 vaccines? A 2021 survey on different levels of hesitancy and its determinants.
Echánove-Cuevas DA, Mejía-Domínguez NR, Castañeda-Sortibrán AN. SSM Popul Health. 2022 Sep;19:101207. doi: 10.1016/j.ssmph.2022.101207. Epub 2022 Aug 17. PMID: 35992966

Vaccine breakthrough infections with SARS-CoV-2: Why older adults need booster vaccinations.
Ventura MI, Azizian A, Evans SE, Velasquez S, Arguello JC, Warburton K. Public Health Pract (Oxf). 2022 Sep 7:100307. doi: 10.1016/j.puhip.2022.100307. Online ahead of print. PMID: 36092529

Clearance of recalcitrant verruca plana following COVID-19 vaccination.
Mohta A. JAAD Int. 2022 Sep;8:1-2. doi: 10.1016/j.jdin.2022.02.007. Epub 2022 Mar 16. PMID: 35308145

Acceptance, Attitudes, and Barriers of **Vaccine** Booster Dose among Nursing Students: A Multicounty Survey.
Al-Mugheed K, Al Rawajfah O, Bani-Issa W, Rababa M. J Nurs Manag. 2022 Sep 5. doi: 10.1111/jonm.13791. Online ahead of print. PMID: 36064189

Isolated abducens nerve palsy following AstraZeneca **vaccine**: A case report.
Basnet K, Bhandari R, Basnet K, Aryal A, Shrestha R. Ann Med Surg (Lond). 2022 Sep;81:104434. doi: 10.1016/j.amsu.2022.104434. Epub 2022 Aug 19. PMID: 35999834

Vaccine Effectiveness of BNT162b2 Against Delta and Omicron Variants in Adolescents.
Buchan SA, Nguyen L, Wilson SE, Kitchen SA, Kwong JC. Pediatrics. 2022 Sep 1;150(3):e2022057634. doi: 10.1542/peds.2022-057634. PMID: 35706105

Novel chikungunya **vaccine** shows promise for durable protection.
Stephenson KE. Lancet Infect Dis. 2022 Sep;22(9):1259-1261. doi: 10.1016/S1473-3099(22)00317-6. Epub 2022 Jun 13. PMID: 35709799

Improving COVID-19 **vaccine** immunogenicity by interrupting methotrexate treatment.
Sparks JA, Tedeschi SK. Lancet Respir Med. 2022 Sep;10(9):813-815. doi: 10.1016/S2213-2600(22)00224-7. Epub 2022 Jun 27. PMID: 35772415

The use of cholera oral **vaccine** for containment of the 2019 disease outbreak in Sudan.
Mohamed NS, Ali Y, Abdalrahman S, Ahmed A, Siddig EE. Trans R Soc Trop Med Hyg. 2022 Sep 10;116(9):763-766. doi: 10.1093/trstmh/trac041. PMID: 35537855

Managing the Impact of COVID-19 in Nursing Homes and Long-Term Care Facilities: An Update.
Dyer AH, Fallon A, Noonan C, Dolphin H, O'Farrelly C, Bourke NM, O'Neill D, Kennelly SP. J Am Med Dir Assoc. 2022 Sep;23(9):1590-1602. doi: 10.1016/j.jamda.2022.06.028. Epub 2022 Jul 4. PMID: 35922016

Western Australian health care workers' views on mandatory COVID-19 vaccination for the workplace.
Attwell K, Roberts L, Blyth CC, Carlson SJ. Health Policy Technol. 2022 Sep;11(3):100657. doi: 10.1016/j.hlpt.2022.100657. Epub 2022 Jul 26. PMID: 35910408

Between Healthcare Practitioners and Clergy: Evangelicals and COVID-19 **Vaccine** Hesitancy.
Guidry JPD, Miller CA, Perrin PB, Laestadius LI, Zurlo G, Savage MW, Stevens M, Fuemmeler BF, Burton CW, Gültzow T, Carlyle KE. Int J Environ Res Public Health. 2022 Sep 5;19(17):11120. doi: 10.3390/ijerph191711120. PMID: 36078836

Safety of Recombinant Zoster **Vaccine** in Patients with Inflammatory Bowel Disease.
Khan N, Trivedi C, Aberra F, Pernes T, Yang YX. J Crohns Colitis. 2022 Sep 8;16(9):1505-1507. doi: 10.1093/ecco-jcc/jjac040. PMID: 35350070

Potential Influencers of COVID-19 **Vaccine** Acceptance Among Adults Living in the United States Who Have Accepted or Plan to Accept the **Vaccine**: An Online Survey.
Duck AA, Hall KC, Douglas K, Price TS. Am J Health Promot. 2022 Sep;36(7):1193-1199. doi: 10.1177/08901171221095351. Epub 2022 Apr 19. PMID: 35439085

Vaccination nudges: A study of pre-booked COVID-19 vaccinations in Sweden.
Bonander C, Ekman M, Jakobsson N. Soc Sci Med. 2022 Sep;309:115248. doi: 10.1016/j.socscimed.2022.115248. Epub 2022 Aug 5. PMID: 35969977

The early-life gut microbiome and **vaccine** efficacy.
Jordan A, Carding SR, Hall LJ. Lancet Microbe. 2022 Sep 8:S2666-5247(22)00185-9. doi: 10.1016/S2666-5247(22)00185-9. Online ahead of print. PMID: 36088916

Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA, Emborg HD, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, Legarth R, Lam JUH, Chaine M, Malik AZ, Rasmussen M, Fonager J, Sieber RN, Stegger M, Ethelberg S, Valentiner-Branth P, Hansen CH. PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep. PMID: 36048766

Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for **vaccine** design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy.
Ezaj MMA, Junaid M, Akter Y, Nahrin A, Siddika A, Afrose SS, Nayeem SMA, Haque MS, Moni MA, Hosen SMZ. J Biomol Struct Dyn. 2022 Sep;40(14):6477-6502. doi: 10.1080/07391102.2021.1886171. Epub 2021 Feb 15. PMID: 33586620

The Challenges of Migrant Workers in the Maldives During a Pandemic and Efforts Toward **Vaccine** Equity.
Eya LI, Ibrahim M, Ahmadi A, Lucero-Prisno DE 3rd. Asia Pac J Public Health. 2022 Sep;34(6-7):734. doi: 10.1177/10105395221108962. Epub 2022 Jul 1. PMID: 35775624

Re: The Impact of COVID-19 **Vaccine** on Sperm Quality.
Cardona Maya WD, Omolaoye TS, du Plessis SS. Eur Urol. 2022 Sep;82(3):327-328. doi: 10.1016/j.eururo.2022.06.021. Epub 2022 Jun 24. PMID: 35787937

[Delayed acute urticaria after the third **vaccine** against SARS-CoV-2].
Gimeno Castillo J, Garrapiz Borderías I. Semergen. 2022 Sep;48(6):437-438. doi: 10.1016/j.semerg.2022.03.001. Epub 2022 Mar 22. PMID: 35527184

What strategies have been effective in optimising COVID-19 **vaccine** uptake in Australia and internationally?
Desborough J, Wright M, Parkinson A, Hall Dykgraaf S, Ball L, Dut GM, Sturgiss E, de Toca L, Kidd M. Aust J Gen Pract. 2022 Sep;51(9):725-730. doi: 10.31128/AJGP-05-22-6427. PMID: 36045631

Do coronavirus **vaccine** challenge trials have a distinctive generalisability problem?
Eyal N, Gerhard T. J Med Ethics. 2022 Sep;48(9):586-589. doi: 10.1136/medethics-2020-107109. Epub 2021 Jun 7. PMID: 34099541

Abducense nerve palsy following BBIBP-CorV (Sinopharm) COVID-19 **vaccine**.
Khalili MR, Khorrami S, Jahanbani-Ardakani H. J Fr Ophtalmol. 2022 Sep;45(7):e309-e310. doi: 10.1016/j.jfo.2022.03.001. Epub 2022 May 18. PMID: 35672156

Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.
Erdoğan AP, Ekinci F, Akçalı S, Göksel G. J Infect Chemother. 2022 Sep;28(9):1310-1316. doi: 10.1016/j.jiac.2022.05.021. Epub 2022 Jun 6. PMID: 35701330

COVID-19 **vaccine** hesitancy among health and social care workers during mass vaccination in Scotland.
Cogan N, Mcinnes L, Lingg V, Flowers P, Rasmussen S, Williams L. Psychol Health Med. 2022 Sep 8:1-15. doi: 10.1080/13548506.2022.2121975. Online ahead of print. PMID: 36082425

A novel strategy for developing **vaccine** candidate against Jaagsiekte sheep retrovirus from the envelope and gag proteins: an in-silico approach.
Mahmoud NA, Elshafei AM, Almofti YA. BMC Vet Res. 2022 Sep 10;18(1):343. doi: 10.1186/s12917-022-03431-0. PMID: 36085036

Racism as the fundamental cause of ethnic inequities in COVID-19 **vaccine** hesitancy: A theoretical framework and empirical exploration using the UK Household Longitudinal Study.
Bécares L, Shaw RJ, Katikireddi SV, Irizar P, Amele S, Kapadia D, Nazroo J, Taylor H. SSM Popul Health. 2022 Sep;19:101150. doi: 10.1016/j.ssmph.2022.101150. Epub 2022 Jun 24. PMID: 35765366

Covid-19 **Vaccine** Hesitancy: Text Mining, Sentiment Analysis and Machine Learning on COVID-19 Vaccination Twitter Dataset.
Qorib M, Oladunni T, Denis M, Ososanya E, Cotae P. Expert Syst Appl. 2022 Sep 5:118715. doi: 10.1016/j.eswa.2022.118715. Online ahead of print. PMID: 36092862

Human papillomavirus **vaccine** effectiveness by number of doses: Updated systematic review of data from national immunization programs.
Markowitz LE, Drolet M, Lewis RM, Lemieux-Mellouki P, Pérez N, Jit M, Brotherton JM, Ogilvie G, Kreimer AR, Brisson M. Vaccine. 2022 Sep 2;40(37):5413-5432. doi: 10.1016/j.vaccine.2022.06.065. Epub 2022 Aug 12. PMID: 35965239

Modern biotechnological strategies for **vaccine** development in aquaculture - Prospects and challenges.
Jose Priya TA, Kappalli S. Vaccine. 2022 Sep 7:S0264-410X(22)01083-0. doi: 10.1016/j.vaccine.2022.08.075. Online ahead of print. PMID: 36088192

Curbing COVID-19 **Vaccine** Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the **Vaccine** Adverse Event Reporting System (VAERS) Database.
Falotico JM, Desai AD, Shah A, Ricardo JW, Lipner SR. Am J Clin Dermatol. 2022 Sep;23(5):729-737. doi: 10.1007/s40257-022-00715-x. Epub 2022 Aug 5. PMID: 35931925

Delayed-type hypersensitivity reactions to Pfizer BioNTech SARS-CoV-2 **vaccine**.
Beyaz Ş, Öksüzer Çimşir D, Çelebi Sözener Z, Soyyiğit Ş, Öner Erkekol F. Postgrad Med J. 2022 Sep;98(1163):658-659. doi: 10.1136/postgradmedj-2021-141420. Epub 2021 Dec 22. PMID: 34937807

Immunoinformatics-guided designing of epitope-based subunit **vaccine** from Pilus assembly protein of Acinetobacter baumannii bacteria.
Mahapatra SR, Dey J, Jaiswal A, Roy R, Misra N, Suar M. J Immunol Methods. 2022 Sep;508:113325. doi: 10.1016/j.jim.2022.113325. Epub 2022 Jul 28. PMID: 35908655

COVID-19 mRNA **vaccine** effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
Tang F, Hammel IS, Andrew MK, Ruiz JG. Lancet Healthy Longev. 2022 Sep;3(9):e589-e598. doi: 10.1016/S2666-7568(22)00166-0. Epub 2022 Aug 1. PMID: 35935474

SARS-CoV-2-specific antibodies and neutralization capacity in breast milk following infection vs vaccination.
Leung HYH, Leung BW, Gil MM, Rolle V, Moungmaithong S, Wang CC, Poon LC. Ultrasound Obstet Gynecol. 2022 Sep;60(3):425-427. doi: 10.1002/uog.24965. PMID: 35653222

Postvaccinal GABA-B receptor antibody encephalitis after ChAdOx1 nCoV-19 vaccination.
Ahn SJ, Lee ST, Chu K. Ann Clin Transl Neurol. 2022 Sep 2. doi: 10.1002/acn3.51659. Online ahead of print. PMID: 36053935

Psoriasis with Sputnik V **vaccine**, a potential triggering factor.
Farouk S, Raslan G, El Waseef M. Dermatol Ther. 2022 Sep;35(9):e15702. doi: 10.1111/dth.15702. Epub 2022 Jul 16. PMID: 35802396

Perceived barriers to COVID-19 **vaccine** administration in Emergency Department.
Goodwin T, Boogaard C. Am J Emerg Med. 2022 Sep;59:205-206. doi: 10.1016/j.ajem.2022.05.045. Epub 2022 May 28. PMID: 35725688

Evaluation of five circulating strains of variant infectious bursal disease virus (varIBDV) for their immunogenicity as broiler breeder vaccines and protective efficacy in neonatal broiler chicks.
Kurukulasuriya S, Ahmed KA, Ojkic D, Gunawardana T, Goonewardene K, Gupta A, Popowich S, Willson P, Tikoo SK, Gomis S. Vaccine. 2022 Sep 9;40(38):5608-5614. doi: 10.1016/j.vaccine.2022.08.021. Epub 2022 Aug 22. PMID: 36008236

Acquired hemophilia A following SARS CoV-2 mRNA **vaccine**: Correspondence.
Sookaromdee P, Wiwanitkit V. J Oncol Pharm Pract. 2022 Sep;28(6):1434. doi: 10.1177/10781552221082575. Epub 2022 May 4. PMID: 35506898

Effectiveness of first, second, and third COVID-19 **vaccine** doses in solid organ transplant recipients: A population-based cohort study from Canada.
Naylor KL, Kim SJ, Smith G, McArthur E, Kwong JC, Dixon SN, Treleaven D, Knoll GA. Am J Transplant. 2022 Sep;22(9):2228-2236. doi: 10.1111/ajt.17095. Epub 2022 Jun 1. PMID: 35578576

Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS, Kugeler KJ, Bressler S, Massay SC, Schmoll E, Milroy L, Cavanaugh AM, Sierocki A; COVID-19 Vaccine Breakthrough Characterization Team, Fischer M, Nolen LD. BMC Infect Dis. 2022 Sep 1;22(1):718. doi: 10.1186/s12879-022-07702-x. PMID: 36050630

Midwives' attitudes toward participation of pregnant individuals in a preventive **vaccine** hypothetical clinical trial.
Gagneux-Brunon A, Guyot E, Detoc M, Botelho-Nevers E, Raia-Barjat T. Vaccine. 2022 Sep 2;40(37):5459-5463. doi: 10.1016/j.vaccine.2022.07.049. Epub 2022 Aug 6. PMID: 35941034

Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 **Vaccine** AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.
Lane S, Shakir S. Drug Saf. 2022 Sep;45(9):1003-1008. doi: 10.1007/s40264-022-01217-9. Epub 2022 Aug 4. PMID: 35927605

Methods to account for measured and unmeasured confounders in influenza relative **vaccine** effectiveness studies: A brief review of the literature.
Loiacono MM, Van Aalst R, Pokutnaya D, Mahmud SM, Nealon J. Influenza Other Respir Viruses. 2022 Sep;16(5):846-850. doi: 10.1111/irv.12999. Epub 2022 May 11. PMID: 35545260

A more comprehensive measure of **vaccine** hesitancy: Creation of the Multidimensional **Vaccine** Hesitancy Scale (MVHS).
Howard MC. J Health Psychol. 2022 Sep;27(10):2402-2419. doi: 10.1177/13591053211042062. Epub 2021 Sep 2. PMID: 34474616

Vaccines and dermatology: Expanding the role of dermatology clinics in the name of public health.
Dunn C, Faraj Y, Vesely N, Foss M, Ambur A, Nathoo R. JAAD Int. 2022 Jun 14;8:79-81. doi: 10.1016/j.jdin.2022.05.008. eCollection 2022 Sep. PMID: 35721300

Differences in stakeholder-reported barriers and implementation strategies between counties with high, middle, and low HPV **vaccine** initiation rates: a mixed methods study.

Staras SAS, Kastrinos AL, Wollney EN, Desai S, O'Neal TJ, Johnson-Mallard V, Bylund CL. Implement Sci Commun. 2022 Sep 6;3(1):95. doi: 10.1186/s43058-022-00341-y. PMID: 36068605

Community health workers willingness to participate in COVID-19 **vaccine** trials and intention to vaccinate: A cross-sectional survey in India.
Goel K, Sen A, Goel P, Satapathy P, Jain L, Vij J, Patro BK, Kar SS, Chakrapani V, Singh R, Pala S, Sankhe L, Modi B, Bali S, Rustagi N, Nadda A, Rajagopal V, Kiran T, Aggarwal AK, Gupta M, Padhi BK. Clin Epidemiol Glob Health. 2022 Sep-Oct;17:101113. doi: 10.1016/j.cegh.2022.101113. Epub 2022 Jul 30. PMID: 35935532

A case of an elderly female who developed subacute pleuropericarditis following BNT162b2 mRNA COVID-19 vaccination.
Mizoguchi T, Yokoi M, Shintani Y, Yamamoto J, Mori K, Fujita H, Ito T, Sugiura T, Seo Y. J Cardiol Cases. 2022 Sep;26(3):225-228. doi: 10.1016/j.jccase.2022.04.020. Epub 2022 May 17. PMID: 35600413

Concurrent Infection With Multiple Human Papillomavirus Types Among Unvaccinated and Vaccinated 17-Year-Old Norwegian Girls.
Laake I, Feiring B, Jonassen CM, Pettersson JHO, Frengen TG, Kirkeleite IØ, Trogstad L. J Infect Dis. 2022 Sep 4;226(4):625-633. doi: 10.1093/infdis/jiaa709. PMID: 33205203

Prospects of malaria vaccination in Nigeria: Anticipated challenges and lessons from previous vaccination campaigns.
Effiong FB, Makata VC, Elebesunu EE, Bassey EE, Salachi KI, Sagide MR, Abdulameed HT, Uwishema O. Ann Med Surg (Lond). 2022 Aug 17;81:104385. doi: 10.1016/j.amsu.2022.104385. eCollection 2022 Sep. PMID: 36046716

The Elderly Should Be Immunized With the COVID-19 **Vaccine** in China.
Zhou X, Xiang G, Chen L, Xiao Y, Cheng Z, Mou H. Asia Pac J Public Health. 2022 Sep;34(6-7):733. doi: 10.1177/10105395221110964. Epub 2022 Jul 9. PMID: 35815574

Anaphylaxis and allergic reactions to COVID-19 vaccines: A narrative review of characteristics and potential obstacles on achieving herd immunity.
Mahdiabadi S, Rezaei N. Health Sci Rep. 2022 Aug 24;5(5):e787. doi: 10.1002/hsr2.787. eCollection 2022 Sep. PMID: 36032518

Computational design of a broad-spectrum multi-epitope **vaccine** candidate against seven strains of human coronaviruses.
Kumar A, Rathi E, Kini SG. 3 Biotech. 2022 Sep;12(9):240. doi: 10.1007/s13205-022-03286-0. Epub 2022 Aug 23. PMID: 36003896

Efficacy and safety of an e-consult program for COVID-19 **vaccine** allergy concerns.
Kaddis T, Joshi S, Anstey KM. Allergy Asthma Proc. 2022 Sep 1;43(5):431-434. doi: 10.2500/aap.2022.43.220051. PMID: 36065101

Chitosan and anisodamine enhance the immersion immune efficacy of inactivated Elizabethkingia miricola **vaccine** in black spotted frogs.

Qiao M, Zhang L, Xu C, Huo X, Chang J, Su J. Fish Shellfish Immunol. 2022 Sep 7:S1050-4648(22)00547-2. doi: 10.1016/j.fsi.2022.08.072. Online ahead of print. PMID: 36087820

Effectiveness of CoronaVac and BNT162b2 **vaccine** against SARS-CoV-2 Omicron BA.2 infections in Hong Kong.
Yang B, Wong IOL, Xiao J, Tsang TK, Liao Q, Cowling BJ. J Infect Dis. 2022 Sep 2:jiac360. doi: 10.1093/infdis/jiac360. Online ahead of print. PMID: 36054016

Phenotypic and genetic characterization of a next generation live-attenuated yellow fever **vaccine** candidate.
Esson R, Rodrigues De Sousa E, Benair L, Devard N, Soulet D, Gillet A, Bassard I, Falque S, Chareyre A, Marmin M, Girerd-Chambaz Y, Logvinoff C, Navarro Sanchez ME. Vaccine. 2022 Sep 9;40(38):5641-5650. doi: 10.1016/j.vaccine.2022.07.043. Epub 2022 Aug 23. PMID: 36028455

Factors impacting severe disease from chikungunya infection: Prioritizing chikungunya **vaccine** when available.
Grobusch MP, Connor BA. Travel Med Infect Dis. 2022 Sep-Oct;49:102391. doi: 10.1016/j.tmaid.2022.102391. Epub 2022 Jun 22. PMID: 35752291

Expansion of community pharmacies' role in public **vaccine** delivery to children: Opportunities and need.
Alden J, Crane K, Robinson R, Rothholz M, Watkins T, Wu J, Wurtz R. J Am Pharm Assoc (2003). 2022 Sep-Oct;62(5):1514-1517. doi: 10.1016/j.japh.2022.05.002. Epub 2022 May 6. PMID: 35691859

Neutralization of hepatitis B virus with **vaccine**-escape mutations by hepatitis B **vaccine** with large-HBs antigen.
Washizaki A, Murayama A, Murata M, Kiyohara T, Yato K, Yamada N, Aly HH, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Goh Y, Ishii KJ, Yotsuyanagi H, Muramatsu M, Ishii K, Takahashi Y, Suzuki R, Akari H, Kato T. Nat Commun. 2022 Sep 5;13(1):5207. doi: 10.1038/s41467-022-32910-z. PMID: 36064848

Protective cellular and humoral immune responses to Edwardsiella tarda in flounder (Paralichthys olivaceus) immunized by an inactivated **vaccine**.
Wu X, Xing J, Tang X, Sheng X, Chi H, Zhan W. Mol Immunol. 2022 Sep;149:77-86. doi: 10.1016/j.molimm.2022.06.008. Epub 2022 Jun 28. PMID: 35777123

Spike-based adenovirus vectored COVID-19 **vaccine** does not aggravate heart damage after ischemic injury in mice.
Gu S, Chen Z, Meng X, Liu G, Xu H, Huang L, Wu L, Gong J, Chen D, Xue B, Zhu L, Wan Z, Lin J, Cai X, Zhang X, Wang J, Zhang D, Cao N. Commun Biol. 2022 Sep 2;5(1):902. doi: 10.1038/s42003-022-03875-y. PMID: 36056135

"The vaccination is positive; I don't think it's the panacea": A qualitative study on COVID-19 **vaccine** attitudes among ethnically diverse healthcare workers in the United Kingdom.
Gogoi M, Wobi F, Qureshi I, Al-Oraibi A, Hassan O, Chaloner J, Nellums LB, Pareek M; UK-REACH Collaborative Group. PLoS One. 2022 Sep 9;17(9):e0273687. doi: 10.1371/journal.pone.0273687. eCollection 2022. PMID: 36084076

Bivalent hemagglutinin and neuraminidase influenza replicon particle vaccines protect pigs against influenza a virus without causing **vaccine** associated enhanced respiratory disease.
Wymore Brand M, Anderson TK, Kitikoon P, Brian Kimble J, Otis N, Gauger PC, Souza CK, Kaplan B, Mogler M, Strait E, Vincent Baker AL. Vaccine. 2022 Sep 9;40(38):5569-5578. doi: 10.1016/j.vaccine.2022.07.042. Epub 2022 Aug 18. PMID: 35987871

Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System.
Semenzato L, Botton J, Baricault B, Deloumeaux J, Joachim C, Sylvestre E, Dray-Spira R, Weill A, Zureik M. PLoS One. 2022 Sep 9;17(9):e0274309. doi: 10.1371/journal.pone.0274309. eCollection 2022. PMID: 36084113

Changing Incidence of Invasive Pneumococcal Disease in Infants Less Than 90 Days of Age Before and After Introduction of the 13-Valent Pneumococcal Conjugate **Vaccine** in Blantyre, Malawi: A 14-Year Hospital Based Surveillance Study.
Koenraads M, Swarthout TD, Bar-Zeev N, Brown C, Msefula J, Denis B, Dube Q, Gordon SB, Heyderman RS, Gladstone MJ, French N. Pediatr Infect Dis J. 2022 Sep 1;41(9):764-768. doi: 10.1097/INF.0000000000003606. Epub 2022 Jun 13. PMID: 35703302

Improving management of **vaccine** supply chains: A multi-methods evaluation of vSTEP in Zambia.
Linnander E, Ineza L, Mupeta Bobo P, Bechtold K. Vaccine. 2022 Sep 9;40(38):5579-5584. doi: 10.1016/j.vaccine.2022.07.027. Epub 2022 Aug 18. PMID: 35987874

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 **vaccine** platform in macaques.
Zabaleta N, Bhatt U, Hérate C, Maisonnasse P, Sanmiguel J, Diop C, Castore S, Estelien R, Li D, Dereuddre-Bosquet N, Cavarelli M, Gallouët AS, Pascal Q, Naninck T, Kahlaoui N, Lemaitre J, Relouzat F, Ronzitti G, Thibaut HJ, Montomoli E, Wilson JM, Le Grand R, Vandenberghe LH. Mol Ther. 2022 Sep 7;30(9):2952-2967. doi: 10.1016/j.ymthe.2022.05.007. Epub 2022 May 10. PMID: 35546782

Optimizing global COVID-19 **vaccine** allocation: An agent-based computational model of 148 countries.
Li Q, Huang Y. PLoS Comput Biol. 2022 Sep 6;18(9):e1010463. doi: 10.1371/journal.pcbi.1010463. eCollection 2022 Sep. PMID: 36067157

Derisking Human Cytomegalovirus **Vaccine** Clinical Development in Relevant Preclinical Models.
Permar SR, Kaur A, Fruh K. J Infect Dis. 2022 Sep 4;226(4):563-565. doi: 10.1093/infdis/jiac131. PMID: 35415750

Modification of avian pathogenic Escherichia coli χ7122 lipopolysaccharide increases accessibility to glycoconjugate antigens.
Smith AA, Corona-Torres R, Hewitt RE, Stevens MP, Grant AJ; Glycoengineering of Veterinary Vaccines Consortium. Microb Cell Fact. 2022 Sep 7;21(1):181. doi: 10.1186/s12934-022-01903-4. PMID: 36071433

More than myocarditis, a rare adverse effect after the ChAdOx1 **vaccine**.
Gómez-Monterrosas O, Loyola-Rodríguez G, Martínez-Juárez D. Eur Heart J. 2022 Sep 7;43(34):3273. doi: 10.1093/eurheartj/ehac282. PMID: 35654764

Pneumococcal **Vaccine** Recommendations for Old-Age Home Indian Residents: A Literature Review.
Ghia CJ, Rambhad G. Gerontol Geriatr Med. 2022 Sep 1;8:23337214221118237. doi: 10.1177/23337214221118237. eCollection 2022 Jan-Dec. PMID: 36081416

Development of a cell line-based in vitro assay for assessment of Diphtheria, Tetanus and acellular Pertussis (DTaP)-induced inflammasome activation.
Vandebriel RJ, Stalpers CAL, Vermeulen JP, Remkes M, Schmelter M, Broere F, Hoefnagel MHN. Vaccine. 2022 Sep 9;40(38):5601-5607. doi: 10.1016/j.vaccine.2022.08.022. Epub 2022 Aug 20. PMID: 35999078

Parental hesitancy towards vaccinating their children with a booster dose against COVID-19: Real-world evidence from Taizhou, China.
Huang LL, Yang YP, Mao HP, Hu WW, Jiang YH, Jiesisibieke ZL, Tung TH. J Infect Public Health. 2022 Sep;15(9):1006-1012. doi: 10.1016/j.jiph.2022.08.002. Epub 2022 Aug 5. PMID: 35987122

A rational design of a multi-epitope **vaccine** against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein.
Martin WR, Cheng F. J Biomol Struct Dyn. 2022 Sep;40(15):7099-7113. doi: 10.1080/07391102.2021.1894986. Epub 2021 Mar 10. PMID: 33715598

In Torlak we (would) trust: domestic **vaccine** production in contemporary Serbia.
Brujić M. Med Humanit. 2022 Sep;48(3):e11. doi: 10.1136/medhum-2021-012212. Epub 2022 Feb 4. PMID: 35121620

Measuring concerns about the COVID-19 **vaccine** among Japanese internet users through search queries.
Uehara M, Fujita S, Shimizu N, Liew K, Wakamiya S, Aramaki E. Sci Rep. 2022 Sep 3;12(1):15037. doi: 10.1038/s41598-022-18307-4. PMID: 36057657

Immunogenicity of loop 3 of Omp34 from A. Baumannii in loopless C-lobe of TbpB of N. meningitidis.
Golestani F, Malekan M, Rasooli I, Jahangiri A, Ramezanalizadeh F, Chaudhuri S, Farshchi Andisi V, Schryvers AB. Int Immunopharmacol. 2022 Sep;110:109013. doi: 10.1016/j.intimp.2022.109013. Epub 2022 Jul 1. PMID: 35785727

Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA **vaccine** response in aged people.
Vitallé J, Pérez-Gómez A, Ostos FJ, Gasca-Capote C, Jiménez-León MR, Bachiller S, Rivas-Jeremías I, Silva-Sánchez MDM, Ruiz-Mateos AM, Martín-Sánchez MÁ, López-Cortes LF, Rafii-El-Idrissi Benhnia M, Ruiz-Mateos E. JCI Insight. 2022 Sep 8;7(17):e161045. doi: 10.1172/jci.insight.161045. PMID: 35943812

Mass spectrometry-based immunopeptidomics and computational vaccinology strategies for the identification of universal Shigella immunogenic candidates.
Mohammad Shabani NR, Khairul Hisyam Ismail CM, Anthony AA, Leow CH, Chuah C, Abdul Majeed AB, Nor NM, He Y, Banga Singh KK, Leow CY. Comput Biol Med. 2022 Sep;148:105900. doi: 10.1016/j.compbiomed.2022.105900. Epub 2022 Aug 3. PMID: 35952542

A Potential Association between Obesity and Reduced Effectiveness of COVID-19 **Vaccine**-Induced Neutralizing Humoral Immunity.

Faizo AA, Qashqari FS, El-Kafrawy SA, Barasheed O, Almashjary MN, Alfelali M, Bawazir AA, Albarakati BM, Khayyat SA, Hassan AM, Alandijany TA, Azhar EI. J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28130. Online ahead of print. PMID: 36068377

An overview of implementing an evidence based program to increase HPV vaccination in HIV community clinics.
Wells J, Klosky JL, Liu Y, Gillespie TW. BMC Public Health. 2022 Sep 7;22(1):1696. doi: 10.1186/s12889-022-14100-0. PMID: 36071389

BNT162b2 mRNA COVID-19 **vaccine** is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study.
Pellegrino R, Pellino G, Selvaggi L, Selvaggi F, Federico A, Romano M, Gravina AG. Expert Rev Clin Pharmacol. 2022 Sep 8:1-10. doi: 10.1080/17512433.2022.2120466. Online ahead of print. PMID: 36047032

Major Changes in Spatiotemporal Trends of US Rotavirus Laboratory Detections After Rotavirus **Vaccine** Introduction-2009-2021.
Burnett E, Parashar UD, Winn A, Curns AT, Tate JE. Pediatr Infect Dis J. 2022 Sep 1;41(9):759-763. doi: 10.1097/INF.0000000000003598. Epub 2022 Jun 1. PMID: 35703247

Influenza Vaccines in Maintenance Hemodialysis Patients: Does Seroresponse Vary With Different **Vaccine** Formulations?
Barbar T, Tummalapalli SL, Silberzweig J. Am J Kidney Dis. 2022 Sep;80(3):304-306. doi: 10.1053/j.ajkd.2022.02.014. Epub 2022 May 27. PMID: 35637062

Failure of desensitization with Pfizer-BioNTech COVID-19 **vaccine** in two asthmatic patients.
Iemoli E, Ortolani VGR, Preziosi D, Caron L, Giardina C, Carlevatti V, Giovine N. Eur Ann Allergy Clin Immunol. 2022 Sep;54(5):240-241. doi: 10.23822/EurAnnACI.1764-1489.236. Epub 2021 Nov 5. PMID: 34753281

The citizen preferences-positive externality trade-off: A survey study of COVID-19 **vaccine** deployment in Japan.
Iida T, Kawata K, Nakabayashi M. SSM Popul Health. 2022 Sep;19:101191. doi: 10.1016/j.ssmph.2022.101191. Epub 2022 Aug 17. PMID: 35992967

Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt.
Sevilla JP, Burnes D, El Saie RZ, Haridy H, Wasserman M, Pugh S, Perdrizet J, Bloom D. Hum Vaccin Immunother. 2022 Sep 7:2114252. doi: 10.1080/21645515.2022.2114252. Online ahead of print. PMID: 36070504

Acceptance of Seasonal Influenza **Vaccine** Following COVID-19 Vaccination: A Survey among Israel Defense Forces Soldiers.
Nitzan I, Akavian I, Adar O, Rittblat M, Tomer G, Shmueli O, Friedensohn L, Talmy T. Behav Med. 2022 Sep 8:1-8. doi: 10.1080/08964289.2022.2119361. Online ahead of print. PMID: 36073723

The need for serial monitoring of COVID-19 **vaccine** uptake among pregnant and postpartum individuals.
Mungmunpuntipantip R, Wiwanitkit V. BJOG. 2022 Sep;129(10):1801. doi: 10.1111/1471-0528.17233. Epub 2022 Jun 1. PMID: 35647698

Cataracts in setting of multisystem inflammation after COVID-19 vaccination.
Kim DH, Hsu D, Li Y, Sulewski ME. Am J Ophthalmol Case Rep. 2022 Sep;27:101654. doi: 10.1016/j.ajoc.2022.101654. Epub 2022 Jul 7. PMID: 35818371

COVID-19 **vaccine** hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort.
McMaster C, Liew DFL, Lester S, Rischin A, Black RJ, Chand V, Fletcher A, Lassere MN, March L, Robinson PC, Buchbinder R, Hill CL. Rheumatology (Oxford). 2022 Sep 7:keac503. doi: 10.1093/rheumatology/keac503. Online ahead of print. PMID: 36069664

Influences, Barriers, and Facillitators to COVID-19 Vaccination: A Cross-sectional Survey on **Vaccine** Hesitancy in Two Rural States.
Robinson R, Nguyen E, Wright M, Holmes J, Oliphant C, Nies M. JMIR Form Res. 2022 Sep 2. doi: 10.2196/39109. Online ahead of print. PMID: 36067411

Low post-transplant measles and varicella titers among pediatric liver transplant recipients: A 10-year single-center study.
Liman AYJ, Wozniak LJ, de St Maurice A, Dunkel GL, Wanlass EM, Venick RS, McDiarmid SV. Pediatr Transplant. 2022 Sep;26(6):e14322. doi: 10.1111/petr.14322. Epub 2022 May 17. PMID: 35582739

A Recombinant VSV-Based Bivalent **Vaccine** Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
Ao Z, Ouyang MJ, Olukitibi TA, Warner B, Vendramelli R, Truong T, Meilleur C, Zhang M, Kung S, Fowke KR, Kobasa D, Yao X. J Virol. 2022 Sep 7:e0133722. doi: 10.1128/jvi.01337-22. Online ahead of print. PMID: 36069551

Epitope identification of SARS-CoV-2 structural proteins using in silico approaches to obtain a conserved rational immunogenic peptide.
Araújo LP, Dias MEC, Scodeler GC, Santos AS, Soares LM, Corsetti PP, Padovan ACB, Silveira NJF, de Almeida LA. Immunoinformatics (Amst). 2022 Sep;7:100015. doi: 10.1016/j.immuno.2022.100015. Epub 2022 Jun 11. PMID: 35721890

Development of an attenuated **vaccine** against Koi Herpesvirus Disease (KHVD) suitable for oral administration and immersion.
Klafack S, Schröder L, Jin Y, Lenk M, Lee PY, Fuchs W, Avarre JC, Bergmann SM. NPJ Vaccines. 2022 Sep 6;7(1):106. doi: 10.1038/s41541-022-00525-6. PMID: 36068296

Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as **vaccine** candidates against COVID-19 in animal models.
Nazarian S, Olad G, Abdolhamidi R, Motamedi MJ, Kazemi R, Kordbacheh E, Felagari A, Olad H, Ahmadi A, Bahiraee A, Farahani P, Haghighi L, Hassani F, Hajhassan V, Nadi M, Sheikhi A, Salimian J, Amani J. Mol Immunol. 2022 Sep;149:107-118. doi: 10.1016/j.molimm.2022.06.007. Epub 2022 Jun 23. PMID: 35802999

COVID-19 **vaccine**-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third **vaccine** dose (VIP): a multicentre, prospective, case-control study.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, Bewshea C, D'Mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Goodhand JR, Hart AL, Lees CW, Boyton RJ, Kennedy NA, Ahmad T, Powell N; VIP study investigators. Lancet Gastroenterol Hepatol. 2022 Sep 8:S2468-1253(22)00274-6. doi: 10.1016/S2468-1253(22)00274-6. Online ahead of print. PMID: 36088954

Increased burden of booster shots for COVID-19 amidst **vaccine** hesitancy in Pakistan.
Lal PM, Shaikh OA, Vohra LI, Arif A, Ochani S, Ullah K. Ann Med Surg (Lond). 2022 Sep;81:104360. doi: 10.1016/j.amsu.2022.104360. Epub 2022 Aug 22. PMID: 36035595

Comparative proteomic analysis of PK15 swine kidney cells infected with a pseudorabies pathogenic variant and the Bartha-K/61 **vaccine** strain.
Zhang H, Zhang R, Wang F, Li G, Wen Y, Shan H. Microb Pathog. 2022 Sep;170:105698. doi: 10.1016/j.micpath.2022.105698. Epub 2022 Aug 5. PMID: 35934202

Parental perceptions of the COVID-19 **vaccine** for 5- to 11-year-old children: Focus group findings from Worcester Massachusetts.
Goulding M, Ryan GW, Minkah P, Borg A, Gonzalez M, Medina N, Suprenant P, Rosal MC, Lemon SC. Hum Vaccin Immunother. 2022 Sep 9:2120721. doi: 10.1080/21645515.2022.2120721. Online ahead of print. PMID: 36084287

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study.
González S, Olszevicki S, Gaiano A, Baino ANV, Regairaz L, Salazar M, Pesci S, Marín L, Martínez VVG, Varela T, Ceriani L, Garcia E, Kreplak N, Navarro A, Estenssoro E, Marsico F. Lancet Reg Health Am. 2022 Sep;13:100316. doi: 10.1016/j.lana.2022.100316. Epub 2022 Jul 16. PMID: 35872665

Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents.
Obach D, Solastie A, Liedes O, Vara S, Krzyżewska-Dudek E, Brinkmann L, Haveri A, Hammer CC, Dub T, Meri S, Freitag TL, Lyytikäinen O, Melin M. Immun Inflamm Dis. 2022 Sep;10(9):e679. doi: 10.1002/iid3.679. PMID: 36039644

Bilateral multifocal choroiditis with disc edema in a 15-year-old girl following COVID-19 vaccination.
Kakarla PD, Venugopal RYC, Manechala UB, Rijey J, Anthwal D. Indian J Ophthalmol. 2022 Sep;70(9):3420-3422. doi: 10.4103/ijo.IJO_861_22. PMID: 36018135

Screening of immune epitope in the proteome of the Dabie bandavirus, SFTS, to design a protein-specific and proteome-wide **vaccine** for immune response instigation using an immunoinformatics approaches.
Suleman M, Asad U, Arshad S, Rahman AU, Akbar F, Khan H, Hussain Z, Ali SS, Mohammad A, Khan A, Ali L, Wei DQ. Comput Biol Med. 2022 Sep;148:105893. doi: 10.1016/j.compbiomed.2022.105893. Epub 2022 Aug 7. PMID: 35961087

A dual-antigen self-amplifying RNA SARS-CoV-2 **vaccine** induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
McCafferty S, Haque AKMA, Vandierendonck A, Weidensee B, Plovyt M, Stuchlíková M, François N, Valembois S, Heyndrickx L, Michiels J, Ariën KK, Vandekerckhove L, Abdelnabi R, Foo CS, Neyts J, Sahu I, Sanders NN. Mol Ther. 2022 Sep 7;30(9):2968-2983. doi: 10.1016/j.ymthe.2022.04.014. Epub 2022 Apr 20. PMID: 35450821

Harnessing Fuzzy Rule Based System for Screening Major Histocompatibility Complex Class I Peptide Epitopes from the Whole Proteome: An Implementation on the Proteome of *Leishmania donovani*.
Vijayakumar S. J Comput Biol. 2022 Sep;29(9):1045-1058. doi: 10.1089/cmb.2021.0464. Epub 2022 Apr 11. PMID: 35404099

Myocarditis Following COVID-19 **Vaccine**: Incidence, Presentation, Diagnosis, Pathophysiology, Therapy, and Outcomes put into Perspective.
Heidecker B, Dagan N, Balicer R, Eriksson U, Rosano G, Coats A, Tschöpe C, Kelle S, Poland GA, Frustaci A, Klingel K, Martin P, Hare J, Cooper L, Pantazis A, Imazio M, Prasad S, Lüscher TF. Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2669. Online ahead of print. PMID: 36065751

Henoch-Schönlein purpura following COVID-19 **vaccine** in a child: a case report.
Casini F, Magenes VC, De Sanctis M, Gattinara M, Pandolfi M, Cambiaghi S, Zuccotti GV, Fabiano V. Ital J Pediatr. 2022 Sep 2;48(1):158. doi: 10.1186/s13052-022-01351-1. PMID: 36056360

Rural-Urban Disparities in HPV Vaccination Coverage Among Adolescents in the Central Part of the State of Illinois, USA.
Adjei Boakye E, Fedorovich Y, White M, Vohra S, Volle M, Osazuwa-Peters N, Gerend MA. J Community Health. 2022 Sep 6. doi: 10.1007/s10900-022-01136-x. Online ahead of print. PMID: 36066667

Understanding the dynamic relation between wastewater SARS-CoV-2 signal and clinical metrics throughout the pandemic.
Hegazy N, Cowan A, D'Aoust PM, Mercier É, Towhid ST, Jia JJ, Wan S, Zhang Z, Kabir MP, Fang W, Graber TE, MacKenzie AE, Guilherme S, Delatolla R. Sci Total Environ. 2022 Sep 5;853:158458. doi: 10.1016/j.scitotenv.2022.158458. Online ahead of print. PMID: 36075428

A replication-competent smallpox **vaccine** LC16m8Δ-based COVID-19 **vaccine**.
Sakamoto A, Osawa H, Hashimoto H, Mizuno T, Hasyim AA, Abe YI, Okahashi Y, Ogawa R, Iyori M, Shida H, Yoshida S. Emerg Microbes Infect. 2022 Sep 7:1-40. doi: 10.1080/22221751.2022.2122580. Online ahead of print. PMID: 36069348

Different T-cell and B-cell repertoire elicited by the SARS-CoV-2 inactivated **vaccine** and S1 subunit **vaccine** in rhesus macaques.
Qin L, Zuo Y, Liu S, Li B, Wang H, Li H, Li J, Chen Y, Sun M, Zheng H. Hum Vaccin Immunother. 2022 Sep 7:2118477. doi: 10.1080/21645515.2022.2118477. Online ahead of print. PMID: 36070519

[Vaccination coverage in children under one year of age in Minas Gerais state, Brazil].
Souza JFA, Silva TPRD, Silva TMRD, Amaral CD, Ribeiro EEN, Vimieiro AM, Oliveira MMM, Matozinhos FP. Cien Saude Colet. 2022 Sep;27(9):3659-3667. doi: 10.1590/1413-81232022279.07302022. Epub 2022 May 18. PMID: 36000652

Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential **vaccine** against SARS-CoV-2.
Moshref Javadi M, Taghdisi Hosseinzadeh M, Soleimani N, Rommasi F. Microb Pathog. 2022 Sep;170:105687. doi: 10.1016/j.micpath.2022.105687. Epub 2022 Jul 31. PMID: 35917987

A large cross-sectional survey of COVID-19 vaccination willingness amongst healthcare students and professionals: Reveals generational patterns.
Tomietto M, Simonetti V, Comparcini D, Stefanizzi P, Cicolini G. J Adv Nurs. 2022 Sep;78(9):2894-2903. doi: 10.1111/jan.15222. Epub 2022 Mar 17. PMID: 35301774

Safety of Immunizations for the Adult Patient With Inflammatory Bowel Disease-A Systematic Review and Meta-analysis.
Desalermos A, Pimienta M, Kalligeros M, Shehadeh F, Diamantopoulos L, Karamanolis G, Caldera F, Farraye FA. Inflamm Bowel Dis. 2022 Sep 1;28(9):1430-1442. doi: 10.1093/ibd/izab266. PMID: 34849941

Immunogenicity and protective efficacy of a DNA **vaccine** inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice.
Li ZX, Feng S, Zhang H, Zhuang XY, Shang C, Sun SY, Han JC, Xie YB, Zhang JY, Wang W, Li CH, Zhao GY, Hao PF, Ma JX, Gao Y, Zeng JQ, Tian MY, Ha Z, Lu HJ, Jin NY. Arch Virol. 2022 Sep 9:1-10. doi: 10.1007/s00705-022-05562-z. Online ahead of print. PMID: 36083350

Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N, Manopwisedjaroen S, Rattanapisit K, Panapitakkul C, Kemthong T, Suttisan N, Srisutthisamphan K, Malaivijitnond S, Thitithanyanont A, Jongkaewwattana A, Shanmugaraj B, Phoolcharoen W. J Med Virol. 2022 Sep;94(9):4265-4276. doi: 10.1002/jmv.27881. Epub 2022 Jun 1. PMID: 35615895

An intranasal lentiviral booster reinforces the waning mRNA **vaccine**-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B, Lopez J, Noirat A, Authié P, Fert I, Le Chevalier F, Moncoq F, Nemirov K, Blanc C, Planchais C, Mouquet H, Guinet F, Hardy D, Vives FL, Gerke C, Anna F, Bourgine M, Majlessi L, Charneau P. Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27. PMID: 35484842

Who Calls the Shots? A Legal and Historical Perspective on **Vaccine** Mandates.
Fraser EM, Neuss MJ. Chest. 2022 Sep;162(3):659-663. doi: 10.1016/j.chest.2022.04.142. PMID: 36088093

Flu Vaccination as a Key Prevention Recommendation for Patients at High Cardiovascular Risk: The Next Season's Scenario.
Battistoni A, Volpe M. High Blood Press Cardiovasc Prev. 2022 Sep 2:1-3. doi: 10.1007/s40292-022-00540-7. Online ahead of print. PMID: 36053448

Adverse events following introduction of the ChAdOx1 nCoV-19 **vaccine** in Somalia in 2021: findings from a fragile setting and implications for the future.

Hamayoun M, Abdulrazak I, Farid M, Malik MR, Mohamud MF. IJID Reg. 2022 Sep;4:47-52. doi: 10.1016/j.ijregi.2022.06.001. Epub 2022 Jun 6. PMID: 35720961

Horizontal Transmission of Cytomegalovirus in a Rhesus Model Despite High-Level, **Vaccine**-Elicited Neutralizing Antibody and T-Cell Responses.
Li J, Wellnitz S, Chi XS, Yue Y, Schmidt KA, Nguyen N, Chen W, Yurgelonis I, Rojas E, Liu Y, Loschko J, Pollozi E, Matsuka YV, Needle E, Vidunas E, Donald RGK, Moran J, Jansen KU, Dormitzer PR, Barry PA, Yang X. J Infect Dis. 2022 Sep 4;226(4):585-594. doi: 10.1093/infdis/jiac129. PMID: 35413121

Exploring the cancer-testis antigen BORIS to design a novel multi-epitope **vaccine** against breast cancer based on immunoinformatics approaches.
Mahdevar E, Safavi A, Abiri A, Kefayat A, Hejazi SH, Miresmaeili SM, Iranpur Mobarakeh V. J Biomol Struct Dyn. 2022 Sep;40(14):6363-6380. doi: 10.1080/07391102.2021.1883111. Epub 2021 Feb 18. PMID: 33599191

Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis.
Domnich A, de Waure C. Int J Infect Dis. 2022 Sep;122:855-863. doi: 10.1016/j.ijid.2022.07.048. Epub 2022 Jul 22. PMID: 35878803

Biomineralized hydrogel DC **vaccine** for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment.
Huo W, Yang X, Wang B, Cao L, Fang Z, Li Z, Liu H, Liang XJ, Zhang J, Jin Y. Biomaterials. 2022 Sep;288:121722. doi: 10.1016/j.biomaterials.2022.121722. Epub 2022 Aug 5. PMID: 35963815

PRISM and Emotions: Understanding the Role of Fear and Hope toward **Vaccine** Information Seeking Intentions.
Volkman JE, Day AM, McManus TG, Hokeness KL, Morse CR. Health Commun. 2022 Sep 7:1-12. doi: 10.1080/10410236.2022.2119689. Online ahead of print. PMID: 36073032

Protective antibody response to mRNA-1273 and BNT162b2 vaccines in patients on maintenance haemodialysis: a prospective cohort study.
Dimitrov Y, Krummel T, Chantrel F, Faller AL, Ott J, David D, Bazin-Kara D, Hannedouche T, Borni C. Clin Kidney J. 2022 Mar 21;15(9):1720-1726. doi: 10.1093/ckj/sfac082. eCollection 2022 Sep. PMID: 35999964

Clinician perspectives on pediatric COVID-19 vaccination: A qualitative study in central and western, Massachusetts.
Ryan GW, Goulding M, Borg A, Minkah P, Hermann S, Fisher L, Rosal MC, Lemon SC. Prev Med Rep. 2022 Oct;29:101966. doi: 10.1016/j.pmedr.2022.101966. Epub 2022 Sep 1. PMID: 36065256

Age-specific associations between underlying health conditions and hospitalisation, death and in-hospital death among confirmed COVID-19 cases: a multi-country study based on surveillance data, June to December 2020.
Funk T, Innocenti F, Gomes Dias J, Nerlander L, Melillo T, Gauci C, Melillo JM, Lenz P, Sebestova H, Slezak P, Vlckova I, Berild JD, Mauroy C, Seppälä E, Tønnessen R, Vergison A, Mossong J, Masi S, Huiart L, Cullen G, Murphy N, O'Connor L, O'Donnell J, Mook P, Pebody RG, Bundle N. Euro Surveill. 2022 Sep;27(35). doi: 10.2807/1560-7917.ES.2022.27.35.2100883. PMID: 36052721

Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers.
Oladipo HJ, Tajudeen YA, Oladunjoye IO, Yusuff SI, Yusuf RO, Oluwaseyi EM, AbdulBasit MO, Adebisi YA, El-Sherbini MS. Ann Med Surg (Lond). 2022 Aug 18;81:104366. doi: 10.1016/j.amsu.2022.104366. eCollection 2022 Sep. PMID: 36046715

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang A, Akhtar A, Linderman SL, Lai L, Orellana-Noia VM, Valanparambil R, Ahmed H, Zarnitsyna VI, McCook-Veal AA, Switchenko JM, Koff JL, Blum KA, Ayers AA, O'Leary CB, Churnetski MC, Sulaiman S, Kives M, Sheng P, Davis CW, Nooka AK, Antia R, Dhodapkar MV, Suthar MS, Cohen JB, Ahmed R. J Clin Oncol. 2022 Sep 10;40(26):3020-3031. doi: 10.1200/JCO.22.00088. Epub 2022 Apr 18. PMID: 35436146

COVID-19 vaccination: Conspiracy theories, demography, ideology, and personality disorders.
Haakonsen JMF, Furnham A. Health Psychol. 2022 Sep 5. doi: 10.1037/hea0001222. Online ahead of print. PMID: 36066859

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 **vaccine** VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
Lazarus R, Taucher C, Brown C, Čorbic Ramljak I, Danon L, Dubischar K, Duncan CJA, Eder-Lingelbach S, Faust SN, Green C, Gokani K, Hochreiter R, Wright JK, Kwon D, Middleditch A, Munro APS, Naker K, Penciu F, Price D, Querton B, Riaz T, Ross-Russell A, Sanchez-Gonzalez A, Wardle H, Warren S, Finn A; Valneva Phase 1 Trial Group. J Infect. 2022 Sep;85(3):306-317. doi: 10.1016/j.jinf.2022.06.009. Epub 2022 Jun 16. PMID: 35718205

Divergent clinical outcomes in a phase 2B trial of the TLPLDC **vaccine** in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial.
Adams AM, Carpenter EL, Clifton GT, Vreeland TJ, Chick RC, O'Shea AE, McCarthy PM, Kemp Bohan PM, Hickerson AT, Valdera FA, Tiwari A, Hale DF, Hyngstrom JR, Berger AC, Jakub JW, Sussman JJ, Shaheen MF, Yu X, Wagner TE, Faries MB, Peoples GE. Cancer Immunol Immunother. 2022 Sep 1:1-9. doi: 10.1007/s00262-022-03272-8. Online ahead of print. PMID: 36045304

Factors influencing COVID-19 **vaccine** decision-making among hesitant adopters in the United States.
Purvis RS, Moore R, Willis DE, Hallgren E, McElfish PA. Hum Vaccin Immunother. 2022 Sep 7:2114701. doi: 10.1080/21645515.2022.2114701. Online ahead of print. PMID: 36070518

Typhoid conjugate **vaccine**: are we heading towards the elimination of typhoid in endemic countries?
Yousafzai MT, Heywood AE. Lancet Glob Health. 2022 Sep;10(9):e1224-e1225. doi: 10.1016/S2214-109X(22)00328-X. PMID: 35961336

The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose.
Luque-Paz D, Sesques P, Wallet F, Bachy E, Ader F. Expert Rev Anti Infect Ther. 2022 Sep;20(9):1155-1162. doi: 10.1080/14787210.2022.2101448. Epub 2022 Jul 22. PMID: 35838042

COVID-19 infection after two doses of SARS-CoV-2 mRNA **vaccine** in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
Yeo T, Quek AML, Yong KP, Tye JSN, Ratnagopal P, Soon DTL, Tan K. Mult Scler Relat Disord. 2022 Sep;65:104003. doi: 10.1016/j.msard.2022.104003. Epub 2022 Jun 26. PMID: 35803084

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster **vaccine** immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A, Boyton RJ, Peckham N, McKnight Á, Coates LC, Bluett J, Barber V, Cureton L, Francis A, Appelbe D, Eldridge L, Julier P, Valdes AM, Brooks T, Rombach I, Altmann DM, Nguyen-Van-Tam JS, Williams HC, Cook JA; VROOM study investigators. Lancet Respir Med. 2022 Sep;10(9):840-850. doi: 10.1016/S2213-2600(22)00186-2. Epub 2022 Jun 27. PMID: 35772416

The impact of financial incentives on COVID-19 vaccination intention among a sample of U.S. adults.
Andresen JA, Harris JN, Mauro C, Zimet GD, Rosenthal SL. Prev Med Rep. 2022 Oct;29:101962. doi: 10.1016/j.pmedr.2022.101962. Epub 2022 Sep 1. PMID: 36065257

Suitable but requiring support: How the midwifery model of care offers opportunities to counsel the **vaccine** hesitant pregnant population.
Pringle W, Greyson D, Graham JE, Dubé È, Mitchell H, Trottier MÈ, Berman R, Russell ML, MacDonald SE, Bettinger JA. Vaccine. 2022 Sep 9;40(38):5594-5600. doi: 10.1016/j.vaccine.2022.07.055. Epub 2022 Aug 19. PMID: 35989134

Bilateral anterior uveitis after BNT162b2 mRNA **vaccine**: Case report.
Duran M. J Fr Ophtalmol. 2022 Sep;45(7):e311-e313. doi: 10.1016/j.jfo.2022.04.004. Epub 2022 Jun 4. PMID: 35672157

Author reply: "The need for serial monitoring of COVID-19 **vaccine** uptake among pregnant and postpartum individuals".
Venkatesh KK, Costantine MM, Rood KM. BJOG. 2022 Sep;129(10):1802. doi: 10.1111/1471-0528.17246. Epub 2022 Jun 19. PMID: 35718081

Perivaccination Antimetabolite Hold and Third Dose of SARS-CoV-2 **Vaccine** in Lung Transplant Recipients: Preliminary Report.
Frey S, Ruck JM, Alejo JL, Barker L, Matthew J, Werbel WA, Avery RK, Segev DL, Shah PD. Transplantation. 2022 Sep 1;106(9):e426-e428. doi: 10.1097/TP.0000000000004240. Epub 2022 Jun 14. PMID: 35698264

Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue **vaccine** efficacy trial in Asia.
Qi L, Sun Y, Juraska M, Moodie Z, Magaret CA, Heng F, Carpp LN, Gilbert PB. Vaccine. 2022 Sep 3:S0264-410X(22)01043-X. doi: 10.1016/j.vaccine.2022.08.055. Online ahead of print. PMID: 36068106

Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection.

La Verde N, Riva A, Cona MS, Gabrieli A, Cattaneo M, Fasola C, Lipari G, De Stradis C, Favorito V, Lombardi Stocchetti B, Chizzoniti D, Covizzi A, Rulli E, Galli F, Ruggieri L, Gambaro A, Ferrario S, Dalu D, Tarkowski MS. Int J Cancer. 2022 Sep 2. doi: 10.1002/ijc.34273. Online ahead of print. PMID: 36056571

Immunogenicity and safety of an inactivated whole-virus COVID-19 **vaccine** (VLA2001) compared with the adenoviral vector **vaccine** ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lazarus R, Querton B, Corbic Ramljak I, Dewasthaly S, Jaramillo JC, Dubischar K, Krammer M, Weisova P, Hochreiter R, Eder-Lingelbach S, Taucher C, Finn A; Valneva phase 3 trial group. Lancet Infect Dis. 2022 Sep 5:S1473-3099(22)00502-3. doi: 10.1016/S1473-3099(22)00502-3. Online ahead of print. PMID: 36075233

Immunogenicity of two doses of inactive COVID-19 **vaccine** and third booster dose mRNA **vaccine** in patients with cancer receiving active systemic therapy.
Guven DC, Gulbahce Incesu FG, Yildirim HC, Erul E, Chalabiyev E, Aktas BY, Yuce D, Arik Z, Kilickap S, Aksoy S, Erman M, Hayran KM, Unal S, Alp A, Dizdar O. Int J Cancer. 2022 Sep 8. doi: 10.1002/ijc.34280. Online ahead of print. PMID: 36082448

Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V.
Claro F, Silva D, Pérez Bogado JA, Rangel HR, de Waard JH. Int J Infect Dis. 2022 Sep;122:850-854. doi: 10.1016/j.ijid.2022.06.008. Epub 2022 Jun 8. PMID: 35690364

Patent intelligence of RNA viruses: Implications for combating emerging and re-emerging RNA virus based infectious diseases.
Devarapalli P, Kumari P, Soni S, Mishra V, Yadav S. Int J Biol Macromol. 2022 Sep 1;219:1208-1215. doi: 10.1016/j.ijbiomac.2022.08.169. Online ahead of print. PMID: 36058387

Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based **vaccine** by downregulation of PD-L1 expression.
Huang F, Li Z, Zhang W, Li J, Hao S. Cancer Immunol Immunother. 2022 Sep;71(9):2197-2212. doi: 10.1007/s00262-021-03138-5. Epub 2022 Jan 29. PMID: 35092480

Parents' views on the acceptability of a COVID-19 **vaccine** for their children: A cross-sectional study in Abu Dhabi-United Arab Emirates.
AlKetbi LMB, Al Hosani F, Al Memari S, Al Mazrouei S, Al Shehhi B, AlShamsi N, AlKwuiti MM, Saleheen HN, Al Mutairi H, Al Hajeri OM. Vaccine. 2022 Sep 9;40(38):5562-5568. doi: 10.1016/j.vaccine.2022.07.056. Epub 2022 Aug 15. PMID: 35987873

Ideology and COVID-19 Vaccination Intention: Perceptual Mediators and Communication Moderators.
Jiang X, Hwang J, Su MH, Wagner MW, Shah D. J Health Commun. 2022 Sep 7:1-11. doi: 10.1080/10810730.2022.2117438. Online ahead of print. PMID: 36069353

Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion.
Qin Z, Bouteau A, Herbst C, Igyártó BZ. PLoS Pathog. 2022 Sep 2;18(9):e1010830. doi: 10.1371/journal.ppat.1010830. Online ahead of print. PMID: 36054264

The CMS **Vaccine** Mandate at the Supreme Court: A Hippocratic Imperative.
Adashi EY, Cohen IG. Am J Med. 2022 Sep;135(9):1035-1036. doi: 10.1016/j.amjmed.2022.03.041. Epub 2022 Apr 23. PMID: 35472378

FDA Authorizes Intradermal **Vaccine**, Streamlines Rules to Increase Monkeypox Treatment Access.
Larkin HD. JAMA. 2022 Sep 6;328(9):819. doi: 10.1001/jama.2022.14692. PMID: 36066536

Antibody Response Post-COVID-19 Vaccination in Patients With Chronic Myeloid Leukemia With Comparison Between Comirnaty and CoronaVac **Vaccine**.
Kuan JW, Tan CS, Su AT, Noni V, Herman Ulok Melina WU, Abdorahman US, Bimbang JN, Su'ut L, Said A. Asia Pac J Public Health. 2022 Sep;34(6-7):725-727. doi: 10.1177/10105395221112836. Epub 2022 Jul 14. PMID: 35833616

Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses.
Li T, Chen J, Zheng Q, Xue W, Zhang L, Rong R, Zhang S, Wang Q, Hong M, Zhang Y, Cui L, He M, Lu Z, Zhang Z, Chi X, Li J, Huang Y, Wang H, Tang J, Ying D, Zhou L, Wang Y, Yu H, Zhang J, Gu Y, Chen Y, Li S, Xia N. Nat Commun. 2022 Sep 2;13(1):5182. doi: 10.1038/s41467-022-32926-5. PMID: 36056024

The intersectional importance of race/ethnicity, disability, and age in flu **vaccine** uptake for U.S. adults.
Breaux RD, Rooks RN. SSM Popul Health. 2022 Aug 20;19:101211. doi: 10.1016/j.ssmph.2022.101211. eCollection 2022 Sep. PMID: 36052156

Generalized morphea following the COVID **vaccine**: A series of two patients and a bibliographic review.
Antoñanzas J, Rodríguez-Garijo N, Estenaga Á, Morelló-Vicente A, España A, Aguado L. Dermatol Ther. 2022 Sep;35(9):e15709. doi: 10.1111/dth.15709. Epub 2022 Jul 20. PMID: 35811413

Supporting syringe services programs in the initiation and scale-up of **vaccine** administration: findings from in-depth interviews.
Carry M, Bixler D, Weng MK, Doshani M, Roberts E, Montgomery MP. Harm Reduct J. 2022 Sep 1;19(1):100. doi: 10.1186/s12954-022-00681-x. PMID: 36050735

Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on **vaccine** efficacy.
Sankaranarayanan S, Mohkhedkar M, Janakiraman V. Biochim Biophys Acta Mol Basis Dis. 2022 Sep 1;1868(9):166432. doi: 10.1016/j.bbadis.2022.166432. Epub 2022 May 12. PMID: 35568352

Is there a need of monkeypox **vaccine** amidst the hesitancy of COVID-19 immunization in Pakistan?
Ansari Z, Ramzan H, Shakeel R. Ann Med Surg (Lond). 2022 Sep;81:104391. doi: 10.1016/j.amsu.2022.104391. Epub 2022 Aug 23. PMID: 36035599

Relative Effectiveness of Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children and Adolescents in the United States During the 2019-2020 Influenza Season.
Imran M, Ortiz JR, McLean HQ, Fisher L, O'Brien D, Bonafede M, Mansi JA, Boikos C. Pediatr Infect Dis J. 2022 Sep 1;41(9):769-774. doi: 10.1097/INF.0000000000003620. Epub 2022 Jun 4. PMID: 35797705

Stamping the **vaccine** passport? Public support for lifting COVID-19 related restrictions for vaccinated citizens in France, Germany, and Sweden.
Stoeckel F, Stöckli S, Phillips J, Lyons B, Mérola V, Barnfield M, Szewach P, Thompson J, Reifler J. Vaccine. 2022 Sep 9;40(38):5615-5620. doi: 10.1016/j.vaccine.2022.08.009. Epub 2022 Aug 18. PMID: 36008231

COVID-19 exit strategy during **vaccine** implementation: a balance between social distancing and herd immunity.
Daher-Nashif S, Al-Anany R, Ali M, Erradi K, Farag E, Abdallah AM, Emara MM. Arch Virol. 2022 Sep;167(9):1773-1783. doi: 10.1007/s00705-022-05495-7. Epub 2022 Jun 20. PMID: 35723757

Myanmar's coup risks a flood of **vaccine**-preventable disease.
Lwin KS, Ghaznavi C, Win KL, Gilmour S, Hashizume M, Nomura S. J Glob Health. 2022 Sep 3;12:03060. doi: 10.7189/jogh.12.03060. PMID: 36056813

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 **vaccine**: A community-based, prospective, longitudinal cohort study.
Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, Guivel-Benhassine F, Attia M, Pelleau S, Woudenberg T, Duru C, Koffi AD, Castelain S, Fernandes-Pellerin S, Jolly N, De Facci LP, Roux E, Ungeheuer MN, Van Der Werf S, White M, Schwartz O, Fontanet A. EClinicalMedicine. 2022 Jul 22;51:101576. doi: 10.1016/j.eclinm.2022.101576. eCollection 2022 Sep. PMID: 35891947

The use of corticosteroids in patients with COVID-19 **vaccine**-related cerebral venous thrombosis.
Kow CS, Ramachandram DS, Hasan SS. Neurol Sci. 2022 Sep;43(9):5183-5184. doi: 10.1007/s10072-022-06177-7. Epub 2022 Jun 1. PMID: 35650457

Theater for **Vaccine** Hesitancy-Setting the Stage for Difficult Conversations.
Cullen JP, Russ S, Russell HA. JAMA. 2022 Sep 2. doi: 10.1001/jama.2022.14864. Online ahead of print. PMID: 36053542

Toll-like receptor-mediated innate immune responses by recognition of the recombinant dormancy-associated Mycobacterium tuberculosis proteins Rv2659c and Rv1738.
Saelee C, Hanthamrongwit J, Soe PT, Khaenam P, Inthasin N, Ekpo P, Chootong P, Leepiyasakulchai C. PLoS One. 2022 Sep 1;17(9):e0273517. doi: 10.1371/journal.pone.0273517. eCollection 2022. PMID: 36048884

Measles **vaccine**-associated rash illness amidst measles elimination: National surveillance data, South Korea.
Jeong SY, Choe YJ, Lee DH, Kim EY, Kim MN, Kim SJ, Lee GH, Kang HJ, Han MG. J Med Virol. 2022 Sep;94(9):4539-4541. doi: 10.1002/jmv.27827. Epub 2022 May 30. PMID: 35508758

Reflectance confocal microscopy examinations of COVID-19 vaccination sites: A prospective observational study.
Manci R, Nazir ZH, Mehta P, Kurtansky NR, Krug E, Marghoob AA, Cordova M. JAAD Int. 2022 Sep;8:160-162. doi: 10.1016/j.jdin.2022.05.009. Epub 2022 May 16. PMID: 35602913

Low human papillomavirus **vaccine** uptake among women engaged in HIV care in Ontario, Canada.
Chambers C, Gillis J, Lindsay J, Benoit AC, Kendall CE, Kroch A, Grewal R, Loutfy M, Mah A, O'Brien K, Ogilvie G, Raboud J, Rachlis A, Rachlis B, Yeung A, Yudin MH, Burchell AN; OHTN Cohort Study Team. Prev Med. 2022 Sep 5:107246. doi: 10.1016/j.ypmed.2022.107246. Online ahead of print. PMID: 36075492

Safety of COVID-19 **vaccine** delivery by dentists: An observational cohort study.
Kagawa K, Kuroda H, Kaneko D, Imura M, Imaizumi U, Kido K, Tsukimoto S, Kurata S, Kishimoto N, Sanuki T. J Dent Sci. 2022 Sep 2. doi: 10.1016/j.jds.2022.08.018. Online ahead of print. PMID: 36068849

COVID-19 mRNA **Vaccine** Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022.
Hause AM, Marquez P, Zhang B, Myers TR, Gee J, Su JR, Parker C, Thompson D, Panchanathan SS, Shimabukuro TT, Shay DK. MMWR Morb Mortal Wkly Rep. 2022 Sep 2;71(35):1115-1120. doi: 10.15585/mmwr.mm7135a3. PMID: 36048728

Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue: December 2020-August 2021.
Wisnewski AV, Cantley L, Campillo Luna J, Liu J, Smith RF, Hager K, Redlich CA. J Occup Environ Med. 2022 Sep 1;64(9):788-796. doi: 10.1097/JOM.0000000000002617. Epub 2022 Jul 7. PMID: 36054278

Differential **vaccine**-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers.
Smit W, Thijsen S, van der Kieft R, van Tol S, Reimerink J, Reusken C, Rumke L, Bossink A, Limonard G, Heron M. Pathog Dis. 2022 Sep 11:ftac035. doi: 10.1093/femspd/ftac035. Online ahead of print. PMID: 36089571

[A case of acute interstitial nephritis following the Pfizer-BioNTech COVID-19 **vaccine**].
de la Flor Merino JC, Linares Gravalos T, Alonso-Riaño M, Segura Cebollada P, Albarracin Serra C, Ruiz Cicero E, Gallegos Bayas G, Rodeles Del Pozo M. Nefrologia. 2022 Sep-Oct;42(5):617-620. doi: 10.1016/j.nefro.2021.05.004. Epub 2021 Jun 29. PMID: 34219853

The Role of the Allergist in Coronavirus Disease 2019 **Vaccine** Allergy Safety: A Pilot Study on a "Hub-and-Spoke" Model for Population-Wide Allergy Service.
Chiang V, Saha C, Yim J, Au EYL, Kan AKC, Hui KSH, Li TS, Lo WLW, Hong YD, Ye J, Ng C, Ko WWK, Ho CTK, Lau CS, Quan J, Li PH. Ann Allergy Asthma Immunol. 2022 Sep;129(3):308-312.e1. doi: 10.1016/j.anai.2022.05.011. Epub 2022 May 20. PMID: 35605815

SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review.
Imbalzano G, Ledda C, Artusi CA, Romagnolo A, Montanaro E, Rizzone MG, Lopiano L, Zibetti M. Neurol Sci. 2022 Sep;43(9):5165-5168. doi: 10.1007/s10072-022-06182-w. Epub 2022 Jun 6. PMID: 35666352

COVID-19 vaccination status and testing rates in Finland-A potential cause for bias in observational **vaccine** effectiveness analysis.
Kuitunen I, Uimonen M, Seppälä SJ, Ponkilainen VT. Influenza Other Respir Viruses. 2022 Sep;16(5):842-845. doi: 10.1111/irv.12993. Epub 2022 Apr 27. PMID: 35475567

Comment on the assesment of retina and optic disc vascular structures in people who received CoronaVac **vaccine**.
Panigrahi PK, Das S. Photodiagnosis Photodyn Ther. 2022 Sep;39:102909. doi: 10.1016/j.pdpdt.2022.102909. Epub 2022 May 14. PMID: 35580744

The therapeutic effect of an autologous and allogenic mixed glioma cell lysate **vaccine** in a rat model.
He H, Cen Y, Wang P, Zeng X, Zeng S, Li X, Lu X, Zhong C, Ming Y, Chen L, Peng L. J Cancer Res Clin Oncol. 2022 Sep 6. doi: 10.1007/s00432-022-04281-x. Online ahead of print. PMID: 36066620

Branch retinal vein occlusion following ChAdOx1 nCoV-19 (Oxford-AstraZeneca) **vaccine**.
Karageorgiou G, Chronopoulou K, Georgalas I, Kandarakis S, Tservakis I, Petrou P. Eur J Ophthalmol. 2022 Sep 4:11206721221124651. doi: 10.1177/11206721221124651. Online ahead of print. PMID: 36062592

HPV vaccination coverage in women between 15 and 55 years old in Spain: Temporal trend during the period 2007-2020.
Ramírez M, de la Fuente J, Andía D, José Hernández J, Fiol G, Torné A. Int J Gynaecol Obstet. 2022 Sep;158(3):705-713. doi: 10.1002/ijgo.14067. Epub 2022 Jan 7. PMID: 34905216

Lactobacillus casei displaying Clostridium perfringens NetB antigen protects chickens against necrotic enteritis.
Shamshirgaran MA, Golchin M, Mohammadi E. Appl Microbiol Biotechnol. 2022 Sep 5. doi: 10.1007/s00253-022-12155-y. Online ahead of print. PMID: 36063180

Efficacy test of a plant-based porcine circovirus type 2 (PCV2) virus-like particle **vaccine** against four PCV2 genotypes (2a, 2b, 2d, and 2e) in pigs.
Oh T, Suh J, Cho H, Min K, Choi BH, Chae C. Vet Microbiol. 2022 Sep;272:109512. doi: 10.1016/j.vetmic.2022.109512. Epub 2022 Jul 12. PMID: 35853407

In vitro **vaccine** challenge of PBMCs from BNT162b2 anaphylaxis patients reveals HSP90α-NOD2-NLRP3 nexus.
Ko HL, Zhuo N, Chang ZW, Santosa A, Kalimuddin S, Lim XR, Tan SY, Lye DC, Toh D, Young BE, Renia L, Lee HY, Ren EC. Allergy. 2022 Sep 3. doi: 10.1111/all.15503. Online ahead of print. PMID: 36056775

Tracheal cellular immune response in chickens inoculated with Mycoplasma synoviae **vaccine**, MS-H or its parent strain 86079/7NS.
Omotainse OS, Wawegama NK, Kulappu Arachchige SN, C Coppo MJ, Vaz PK, Woodward AP, Kordafshari S, Bogeski M, Stevenson M, Noormohammadi AH, Stent AW. Vet Immunol Immunopathol. 2022 Sep;251:110472. doi: 10.1016/j.vetimm.2022.110472. Epub 2022 Aug 4. PMID: 35940079

Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio **vaccine**.
Sáez-Llorens X, Chan M, DeAntonio R, Petersen T, Olesen C, Jensen JS, Sørensen C, Ekstrand LM, Czort MK, Kristensen HH, Thulstrup N, Christoffersen DB. Vaccine. 2022 Sep 22;40(40):5835-5841. doi: 10.1016/j.vaccine.2022.06.084. Epub 2022 Sep 3. PMID: 36064670

Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the **Vaccine** Adverse Event Reporting System.
Chen C, Fu F, Ding L, Xiao J. J Clin Pharm Ther. 2022 Sep 11. doi: 10.1111/jcpt.13767. Online ahead of print. PMID: 36089844

Vaccination with Live or Heat-Killed Aspergillus fumigatus Δ*sglA* Conidia Fully Protects Immunocompromised Mice from Invasive Aspergillosis.
Fernandes CM, Normile TG, Fabri JHTM, Brauer VS, de S Araújo GR, Frases S, Nimrichter L, Malavazi I, Del Poeta M. mBio. 2022 Sep 6:e0232822. doi: 10.1128/mbio.02328-22. Online ahead of print. PMID: 36066100

Finite element analysis and optimization of microneedle arrays for transdermal **vaccine** delivery: comparison of coated and dissolving microneedles.
Yolai N, Suttirat P, Leelawattanachai J, Boonyasiriwat C, Modchang C. Comput Methods Biomech Biomed Engin. 2022 Sep 1:1-9. doi: 10.1080/10255842.2022.2116576. Online ahead of print. PMID: 36048187

SARS-CoV-2 mRNA **Vaccine** Antibody Response in Patients with Asthma Receiving Biologic Therapy: A Real-World Analysis.
Liao SY, Gerber AN, Zelarney P, Make B, Wechsler ME. Am J Respir Crit Care Med. 2022 Sep 1;206(5):644-648. doi: 10.1164/rccm.202203-0599LE. PMID: 35549647

Split-Dosing of COVID-19 Vaccines Provides Non-Inferior Antibody Responsiveness to Conventional **Vaccine** Dosing.
Musa A, Wood M, Rorie A, May SM, Graaff JV, Poole JA. Ann Allergy Asthma Immunol. 2022 Sep 6:S1081-1206(22)01706-9. doi: 10.1016/j.anai.2022.08.995. Online ahead of print. PMID: 36084864

Semi-selective plasma filtration applied to the treatment of acquired thrombotic thrombocytopenic purpura following bnt162b2 administration.
Fenoglio R, Marchisio M, Baffa A, Quattrocchio G, Roccatello D. J Nephrol. 2022 Sep 3:1-4. doi: 10.1007/s40620-022-01402-0. Online ahead of print. PMID: 36057036

Two doses of the Pfizer-BioNTech **vaccine**, two different side effects: Skin and eye.
Gedik B, Erol MK, Bulut M, Suren E, Bozdogan YC, Seymen B. J Fr Ophtalmol. 2022 Sep;45(7):767-770. doi: 10.1016/j.jfo.2022.02.020. Epub 2022 Jun 1. PMID: 35659461

Long-term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 **vaccine**: real-world data from a large cohort of healthcare workers.
Oliveira-Silva J, Reis T, Lopes C, Batista-Silva R, Ribeiro R, Marques G, Pacheco V, Rodrigues T, Afonso A, Pinheiro V, Araújo L, Rodrigues F, Antunes I. Int J Infect Dis. 2022 Sep;122:1-7. doi: 10.1016/j.ijid.2022.05.026. Epub 2022 May 11. PMID: 35568366

Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) **Vaccine**: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule.
Hoes J, King AJ, Klooster TMSV, Berkhof J, Bogaards JA, de Melker HE. J Infect Dis. 2022 Sep 4;226(4):634-643. doi: 10.1093/infdis/jiab250. PMID: 33964158

Immune thrombocytopenic purpura induced by the COVID-19 **vaccine** after the second dose in a 78-year-old patient: A case report.
Liu W, Wu T, Xue F, Tian H, Song R, Bai H. Exp Ther Med. 2022 Jul 19;24(3):580. doi: 10.3892/etm.2022.11517. eCollection 2022 Sep. PMID: 35949340

Delayed urticaria after the third dose of mRNA COVID19 **vaccine**: A case series.
Bianchi L, Hansel K, Biondi F, Napolitano M, Patruno C, Fabbrocini G, Penchini L, Stingeni L. Dermatol Ther. 2022 Sep;35(9):e15680. doi: 10.1111/dth.15680. Epub 2022 Jul 11. PMID: 35770738

Acute Cardiac Events After ChAdOx1 nCoV-19 Corona Virus **Vaccine**: Report of Three Cases.
Singh R, Chakrabarti SS, Gambhir IS, Verma A, Kumar I, Ghosh S, Tiwari A, Chandan G, Chakrabarti S, Kaur U. Am J Ther. 2022 Sep-Oct 01;29(5):e579-e585. doi: 10.1097/MJT.0000000000001472. Epub 2022 Jan 11. PMID: 35175717

Axillary Adenopathy after COVID-19 **Vaccine**: No Reason to Delay Screening Mammogram.
Wolfson S, Kim E, Plaunova A, Bukhman R, Sarmiento RD, Samreen N, Awal D, Sheth MM, Toth HB, Moy L, Reig B. Radiology. 2022 Sep;304(3):E57. doi: 10.1148/radiol.229015. PMID: 35994402

"Why rush to get vaccinated earlier?": Regulatory focus and COVID-19 vaccination.
Ku X, Cha SE, Jeong J, Kim N, Kim Y, Kim JH, Choi I. Health Psychol. 2022 Sep 8. doi: 10.1037/hea0001237. Online ahead of print. PMID: 36074596

Multisystem inflammatory syndrome with erythema multiforme-like rash in an adult after mRNA COVID-19 vaccination.
Lefeuvre M, Kerneuzet I, Darrieux L, Safa G. Ann Dermatol Venereol. 2022 Sep;149(3):211-213. doi: 10.1016/j.annder.2022.02.001. Epub 2022 Feb 11. PMID: 35248401

Management of patients with immediate reactions to COVID vaccines.
Picard M, Stone CA Jr, Greenhawt M. J Allergy Clin Immunol. 2022 Sep 8:S0091-6749(22)01183-6. doi: 10.1016/j.jaci.2022.09.003. Online ahead of print. PMID: 36089078

Is the fourth COVID-19 **vaccine** dose urgently needed? Revelation from a prospective cohort study.
Xu QY, Li QL, Jia ZJ, Wu MJ, Liu YY, Lin LR, Liu LL, Yang TC. J Infect. 2022 Sep;85(3):e66-e68. doi: 10.1016/j.jinf.2022.06.003. Epub 2022 Jun 9. PMID: 35691516

Long-term memory CD8⁺ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA **vaccine**.
Kuse N, Zhang Y, Chikata T, Nguyen HT, Oka S, Gatanaga H, Takiguchi M. Nat Commun. 2022 Sep 6;13(1):5251. doi: 10.1038/s41467-022-32989-4. PMID: 36068240

Delayed large local reactions to Moderna COVID-19 **vaccine**: A follow-up report after booster vaccination.
Blumenthal KG, Ahola C, Anvari S, Samarakoon U, Freeman EE. JAAD Int. 2022 Sep;8:3-6. doi: 10.1016/j.jdin.2022.03.017. Epub 2022 Apr 8. PMID: 35434661

Eruptive halo nevi: A new COVID-19 **vaccine**-related cutaneous adverse event or a paraneoplastic phenomenon?

De Giorgi V, Colombo J, Salvati L, Gemignani A, Silvestri F, Venturi F, Zuccaro B, Trane L. Dermatol Ther. 2022 Sep;35(9):e15722. doi: 10.1111/dth.15722. Epub 2022 Aug 2. PMID: 35855542

Designing multi-epitope-based **vaccine** targeting surface immunogenic protein of Streptococcus agalactiae using immunoinformatics to control mastitis in dairy cattle.
Pathak RK, Lim B, Kim DY, Kim JM. BMC Vet Res. 2022 Sep 7;18(1):337. doi: 10.1186/s12917-022-03432-z. PMID: 36071517

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 **vaccine** booster.
Salvagno GL, Henry BM, Lippi G. Infect Dis Now. 2022 Sep;52(6):379-380. doi: 10.1016/j.idnow.2022.06.007. Epub 2022 Jul 6. PMID: 35809859

Complete remission of primary cutaneous follicle centre cell lymphoma associated with COVID-19 **vaccine**.
Aouali S, Benkaraache M, Almheirat Y, Zizi N, Dikhaye S. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e676-e678. doi: 10.1111/jdv.18246. Epub 2022 Jun 2. PMID: 35603449

Semen characteristics of individuals before and after CovishieldTM vaccination.
Meitei HY, Uppangala S, Lakshmi V, Kalthur G, Adiga SK. Reprod Fertil. 2022 Sep 1:RAF-22-0046. doi: 10.1530/RAF-22-0046. Online ahead of print. PMID: 36065800

Social and Behavioral Factors Associated with Lack of Intent to Receive COVID-19 **Vaccine**, Japan.
Arashiro T, Arima Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Emerg Infect Dis. 2022 Sep;28(9):1909-1910. doi: 10.3201/eid2809.220300. Epub 2022 Jul 6. PMID: 35793812

Effectiveness of Social Video Platforms in Promoting COVID-19 Vaccination Among Youth: A Content-Specific Analysis of COVID-19 Vaccination Topic Videos on Bilibili.
Gao H, Yin H, Peng L, Wang H. Risk Manag Healthc Policy. 2022 Sep 1;15:1621-1639. doi: 10.2147/RMHP.S374420. eCollection 2022. PMID: 36071816

Uptake of baits by wild badgers: Influences of deployment method, badger age and activity patterns on potential delivery of an oral **vaccine**.
Robertson A, Palphramand KL, McDonald RA, Middleton S, Chambers MA, Delahay RJ, Carter SP. Prev Vet Med. 2022 Sep;206:105702. doi: 10.1016/j.prevetmed.2022.105702. Epub 2022 Jun 30. PMID: 35797823

A case of adenoviral covid-19 vector **vaccine** possibly linked to severe but reversible interstitial lung injury post-vaccination.
Liatsos GD, Mavroudis A, Iliakis P, Karmpalioti M, Koullias E, Vassilopoulos D. Infect Dis (Lond). 2022 Sep;54(9):692-697. doi: 10.1080/23744235.2022.2072521. Epub 2022 May 12. PMID: 35546097

Adjuvanted versus non-adjuvanted standard-dose influenza vaccines in preventing all-cause hospitalizations in the elderly: a cohort study with nested case-control analyses over 18 influenza seasons.
Lapi F, Domnich A, Marconi E, Rossi A, Cricelli C. Expert Rev Vaccines. 2022 Sep 8:1-7. doi: 10.1080/14760584.2022.2115362. Online ahead of print. PMID: 35984048

[Effectiveness of vaccines against SARS-CoV-2 used in Spain: infection, hospitalization and mortality in people aged fifty/fifty-nine.].
Monge S, Mazagatos C, Olmedo C, Rojas-Benedicto A, Simón F, Vega-Piris L, Sierra MJ, Limia A, Larrauri A. Rev Esp Salud Publica. 2022 Sep 2;96:e202209060. PMID: 36052820

Protective immunity induced by ankyrin repeat-containing protein-based DNA **vaccine** against rock bream iridovirus (RBIV) in rock bream (Oplegnathus fasciatus).
Jung MH, Nikapitiya C, Kim SJ, Han HJ, Kim MS, Choi HS, Jung SJ. Virus Res. 2022 Sep;318:198827. doi: 10.1016/j.virusres.2022.198827. Epub 2022 May 27. PMID: 35644280

Three-Dose Primary Series of Inactivated COVID-19 **Vaccine** for Persons Living with HIV, Hong Kong.
Chan DPC, Wong NS, Wong BCK, Chan JMC, Lee SS. Emerg Infect Dis. 2022 Sep 1;28(10). doi: 10.3201/eid2810.220691. Online ahead of print. PMID: 36048772

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle **vaccine** (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.
Song JY, Choi WS, Heo JY, Lee JS, Jung DS, Kim SW, Park KH, Eom JS, Jeong SJ, Lee J, Kwon KT, Choi HJ, Sohn JW, Kim YK, Noh JY, Kim WJ, Roman F, Ceregido MA, Solmi F, Philippot A, Walls AC, Carter L, Veesler D, King NP, Kim H, Ryu JH, Lee SJ, Park YW, Park HK, Cheong HJ. EClinicalMedicine. 2022 Jul 22;51:101569. doi: 10.1016/j.eclinm.2022.101569. eCollection 2022 Sep. PMID: 35879941

Dual-Targeting Polymer Nanoparticles Efficiently Deliver DNA **Vaccine** and Induce Robust Prophylactic Immunity against Spring Viremia of Carp Virus Infection.
Zhang C, Zhang PQ, Guo S, Zhao Z, Wang GX, Zhu B. Microbiol Spectr. 2022 Sep 8:e0308522. doi: 10.1128/spectrum.03085-22. Online ahead of print. PMID: 36073822

The Fourth Dose of CoronaVac **Vaccine** Results in a Small Increase of Seroconversion and Antibody Values Among Kidney Transplant Recipients.
Cristelli MP, Nakamura MR, Viana LA, Tedesco-Silva H, Medina-Pestana J. Transplantation. 2022 Sep 1;106(9):e420-e421. doi: 10.1097/TP.0000000000004219. Epub 2022 Jun 14. PMID: 35698262

A Clinician's Obligation to be Vaccinated: Four Arguments that Establish a Duty for Healthcare Professionals to be Vaccinated Against COVID-19.
Bester JC. J Bioeth Inq. 2022 Sep;19(3):451-465. doi: 10.1007/s11673-022-10182-y. Epub 2022 Apr 1. PMID: 35362931

Emergence of **vaccine**-derived poliovirus in high-income settings in the absence of oral polio **vaccine** use.
Hill M, Bandyopadhyay AS, Pollard AJ. Lancet. 2022 Sep 3;400(10354):713-715. doi: 10.1016/S0140-6736(22)01582-3. Epub 2022 Aug 18. PMID: 35988575

Oral lichen planus arising after BNT162b2 mRNA COVID-19 **vaccine**: report of 2 cases.
Raccampo L, Sembronio S, Tel A, Cacitti V, Robiony M. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022 Sep;134(3):e54-e57. doi: 10.1016/j.oooo.2022.04.003. Epub 2022 Apr 11. PMID: 35851250

Induction of robust humoral immunity against SARS-CoV-2 after **vaccine** administration in previously infected haematological cancer patients.

Borgogna C, Bruna R, Griffante G, Martuscelli L, De Andrea M, Ferrante D, Patriarca A, Mahmoud AM, Ucciero MAM, Gaidano V, Marchetti M, Rapezzi D, Lai M, Pistello M, Ladetto M, Massaia M, Gaidano G, Gariglio M. Br J Haematol. 2022 Sep 5. doi: 10.1111/bjh.18429. Online ahead of print. PMID: 36062472

Public health perspective of a pentavalent meningococcal **vaccine** combining antigens of MenACWY-CRM and 4CMenB.
Bekkat-Berkani R, Fragapane E, Preiss S, Rappuoli R, Sohn WY, Soumahoro L, Vadivelu K. J Infect. 2022 Sep 7:S0163-4453(22)00530-8. doi: 10.1016/j.jinf.2022.09.001. Online ahead of print. PMID: 36087745

Efficacy and immunogenicity of R21/Matrix-M **vaccine** against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Datoo MS, Natama HM, Somé A, Bellamy D, Traoré O, Rouamba T, Tahita MC, Ido NFA, Yameogo P, Valia D, Millogo A, Ouedraogo F, Soma R, Sawadogo S, Sorgho F, Derra K, Rouamba E, Ramos-Lopez F, Cairns M, Provstgaard-Morys S, Aboagye J, Lawrie A, Roberts R, Valéa I, Sorgho H, Williams N, Glenn G, Fries L, Reimer J, Ewer KJ, Shaligram U, Hill AVS, Tinto H. Lancet Infect Dis. 2022 Sep 7:S1473-3099(22)00442-X. doi: 10.1016/S1473-3099(22)00442-X. Online ahead of print. PMID: 36087586

Mycophenolate mofetil discontinuation increases SARS-CoV-2 **vaccine** response in non-responders liver transplant recipients : a proof of concept.
Meunier L, Malezieux E, Ursic Bedoya J, Faure S, Echenne M, Debourdeau A, Meszaros M, Pageaux GP. Liver Transpl. 2022 Sep 1. doi: 10.1002/lt.26569. Online ahead of print. PMID: 36047916

GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer **vaccine** adjuvant.
Potluri HK, Ng TL, Newton MA, McNeel DG. Cancer Immunol Immunother. 2022 Sep;71(9):2267-2275. doi: 10.1007/s00262-022-03150-3. Epub 2022 Feb 8. PMID: 35133464

Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate **Vaccine**: A Population-Based Study.
Vadlamudi NK, Sadatsafavi M, Patrick DM, Rose C, Hoang L, Marra F. Value Health. 2022 Sep;25(9):1510-1519. doi: 10.1016/j.jval.2022.03.017. Epub 2022 Apr 21. PMID: 35466049

A severe presentation of breakthrough infection caused by the Omicron variant with radiological findings of COVID-19 pneumonia in an elderly woman.
Brogna B, Capasso C, Fontanella G, Bignardi E. Radiol Case Rep. 2022 Jul 12;17(9):3326-3330. doi: 10.1016/j.radcr.2022.06.034. eCollection 2022 Sep. PMID: 35846507

Myasthenia gravis with ocular symptoms following a ChAdOx1 nCoV-19 vaccination: A case report.
Kang MC, Park KA, Min JH, Oh SY. Am J Ophthalmol Case Rep. 2022 Jun 25;27:101620. doi: 10.1016/j.ajoc.2022.101620. eCollection 2022 Sep. PMID: 35800401

Development and evaluation of a multi-epitope subunit **vaccine** against group B *Streptococcus* infection.
Zhang Y, Liang S, Zhang S, Zhang S, Yu Y, Huochun Y, Liu Y, Zhang W, Liu G. Emerg Microbes Infect. 2022 Sep 7:1-30. doi: 10.1080/22221751.2022.2122585. Online ahead of print. PMID: 36069613

COVID-19 Vaccination Intake and Intention Among Black and White Residents in Southeast Michigan.
Taylor CAL, Sarathchandra D, Kessler M. J Immigr Minor Health. 2022 Sep 7:1-7. doi: 10.1007/s10903-022-01401-0. Online ahead of print. PMID: 36071335

Seed-Based System for Cost-Effective Production of **Vaccine** Against Chronic Respiratory Disease in Chickens.
Shi Y, Habibi P, Haq ANU, Saeed M, Gulghutay Amjad N, Khan I. Mol Biotechnol. 2022 Sep 10:1-11. doi: 10.1007/s12033-022-00554-5. Online ahead of print. PMID: 36087216

Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotype.
Elizondo CR, Bright JD, Bright RK. Hum Vaccin Immunother. 2022 Sep 7:2108656. doi: 10.1080/21645515.2022.2108656. Online ahead of print. PMID: 36069634

Reply to Liao *et al.*: SARS-CoV-2 mRNA **Vaccine** Antibody Response in Patients with Asthma Receiving Biologic Therapy: A Real-World Analysis.
Runnstrom MC, Lee FE. Am J Respir Crit Care Med. 2022 Sep 1;206(5):647-648. doi: 10.1164/rccm.202205-0979LE. PMID: 35612925

Is Measurement of Systemic IgG Antibodies the Wrong Way to Assess COVID-19 **Vaccine** Effectiveness for Breakthrough Infections?
Levinson SS. J Appl Lab Med. 2022 Sep 1;7(5):1242-1244. doi: 10.1093/jalm/jfac049. PMID: 35709225

Antibody response to the BNT162b2 SARS-CoV-2 **vaccine** in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy.
Shire ZJ, Reicherz F, Lawrence S, Sudan H, Golding L, Majdoubi A, Levett PN, Lavoie PM, Jacobson K. Gut. 2022 Sep;71(9):1922-1924. doi: 10.1136/gutjnl-2021-326196. Epub 2021 Nov 23. PMID: 34815272

Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost **vaccine** strategy.
Christensen D, Polacek C, Sheward DJ, Hanke L, Moliner-Morro A, McInerney G, Murrell B, Hartmann KT, Jensen HE, Jungersen G, Illigen K, Isling LK, Jensen RF, Hansen JS, Rosenkrands I, Fernandez-Antunez C, Ramirez S, Follmann F, Bukh J, Pedersen GK. EBioMedicine. 2022 Sep 5:104248. doi: 10.1016/j.ebiom.2022.104248. Online ahead of print. PMID: 36088218

De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy.
Yamaguchi C, Kunikata H, Hashimoto K, Yoshida M, Ninomiya T, Hariya T, Abe T, Nakazawa T. Am J Ophthalmol Case Rep. 2022 Jun 11;27:101616. doi: 10.1016/j.ajoc.2022.101616. eCollection 2022 Sep. PMID: 35719316

Live-attenuated influenza **vaccine** effectiveness against hospitalization in children aged 2-6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14-2015/16.
Boddington NL, Mangtani P, Zhao H, Verlander NQ, Ellis J, Andrews N, Pebody RG. Influenza Other Respir Viruses. 2022 Sep;16(5):897-905. doi: 10.1111/irv.12990. Epub 2022 May 9. PMID: 35531630

Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD).
Bello AM, Roshorm YM. Biologicals. 2022 Sep 8:S1045-1056(22)00056-2. doi: 10.1016/j.biologicals.2022.08.007. Online ahead of print. PMID: 36089444

Intranasal delivery of a synthetic Entamoeba histolytica **vaccine** containing adjuvant (LecA + GLA-3M-052 liposomes): in vitro characterization.
Murphy BM, Chen JZ, Rolo M, Eldam M, Jordan L, Sivananthan SJ, Kinsey R, Guderian JA, Pedersen K, Abhyankar M, Petri WA, Fox CB, Finlay WH, Vehring R, Martin AR. Int J Pharm. 2022 Sep 1:122141. doi: 10.1016/j.ijpharm.2022.122141. Online ahead of print. PMID: 36058408

Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report.
Zeng G, Tang J, Feng S, Xu L, Wang X, Yang Z. Hum Vaccin Immunother. 2022 Sep 1:2110799. doi: 10.1080/21645515.2022.2110799. Online ahead of print. PMID: 36048127

Strategies for Addressing **Vaccine** Hesitancy Within California State Prisons in 2021 and Beyond.
Garcia-Grossman IR, Gransee L, Williams B. Am J Public Health. 2022 Sep 8:e1-e3. doi: 10.2105/AJPH.2022.307042. Online ahead of print. PMID: 36075008

Investigating Media Coverage and Public Perceptions of the HPV **Vaccine** in China - A Content Analysis of Weibo Posts.
Hu J, Whyke TW, Lopez-Mugica J. Sex Cult. 2022 Sep 5:1-26. doi: 10.1007/s12119-022-10017-3. Online ahead of print. PMID: 36093363

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G. J Transl Med. 2022 Sep 11;20(1):419. doi: 10.1186/s12967-022-03624-z. PMID: 36089578

Intentions to receive COVID-19 vaccines in the united states: Sociodemographic factors and personal experiences with COVID-19.
Warren AM, Bennett MM, da Graca B, Waddimba AC, Gottlieb RL, Douglas ME, Powers MB. Health Psychol. 2022 Sep 5. doi: 10.1037/hea0001225. Online ahead of print. PMID: 36066860

Multi-dermatomal Herpes Zoster in a young patient with Crohn's disease on thiopurine therapy: Need for reconsidering **vaccine** recommendations.
Mangipudi UK, Jena A, Sharma V. Dig Liver Dis. 2022 Sep;54(9):1279-1280. doi: 10.1016/j.dld.2022.03.018. Epub 2022 Apr 28. PMID: 35491390

Development of delayed dermal hypersensitivity reaction following the second dose of COVID-19 **vaccine** - A series of 37 cases.
Mohta A, Sharma MK. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e666-e668. doi: 10.1111/jdv.18206. Epub 2022 May 18. PMID: 35536295

New-onset pemphigus vegetans and pemphigus foliaceus after SARS-CoV-2 vaccination: A report of 2 cases.
Gui H, Young PA, So JY, Pol-Rodriguez M, Rieger KE, Lewis MA, Winge MCG, Bae GH. JAAD Case Rep. 2022 Sep;27:94-98. doi: 10.1016/j.jdcr.2022.07.002. Epub 2022 Jul 9. PMID: 35845348

Corrigendum to "Natural history and epidemiology of respiratory syncytial virus infection in the Middle East: Hospital surveillance for children under age two in Jordan" [**Vaccine** 33(47) (2015) 6479-6487].
Halasa N, Williams J, Faouri S, Shehabi A, Vermund SH, Wang L, Fonnesbeck C, Khuri-Bulos N. Vaccine. 2022 Sep 2;40(37):5537. doi: 10.1016/j.vaccine.2022.08.003. Epub 2022 Aug 12. PMID: 35965242

When the first **vaccine** arrived: An investigation of factors that influenced the intention of health care workers in the national health system of Greece to be vaccinated against the SARS COV-2 virus during the first trimester of **vaccine** arrival.
Kipourgos G, Kourtis G, Papatheodorou M, Elesnitsalis G, Filtiseniou P, Albani E, Tzenalis A. Nurs

Combination therapy between prophylactic and therapeutic human papillomavirus (HPV) vaccines with special emphasis on implementation of nanotechnology.
Gohar A, Ali AA, Elkhatib WF, El-Sayyad GS, Elfadil D, Noreddin AM. Microb Pathog. 2022 Sep 5;171:105747. doi: 10.1016/j.micpath.2022.105747. Online ahead of print. PMID: 36064102

Investigation of the Neutralizing Antibody Response of Healthcare Workers at a Korean University Hospital Six Months After the Introduction of the COVID-19 **Vaccine**.
Choi SH, Park JY, Park JH, Kim MC, Kweon OJ, Chung JW. Ann Lab Med. 2022 Sep 1;42(5):612-615. doi: 10.3343/alm.2022.42.5.612. PMID: 35470282

Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice.
Shaikh MOF, Schaefers MM, Merakou C, DiBlasi M, Bonney S, Liao T, Zurakowski D, Kehl M, Tabor DE, DiGiandomenico A, Priebe GP. Infect Immun. 2022 Sep 7:e0020322. doi: 10.1128/iai.00203-22. Online ahead of print. PMID: 36069593

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate **Vaccine** Effectiveness.
Reynolds MW, Xie Y, Knuth KB, Mack CD, Brinkley E, Toovey S, Dreyer NA. Infect Drug Resist. 2022 Sep 3;15:5167-5182. doi: 10.2147/IDR.S373183. eCollection 2022. PMID: 36090603

Cutaneous reactions following booster dose administration of COVID-19 mRNA **vaccine**: A first look from the American Academy of Dermatology/International League of Dermatologic Societies registry.
Prasad S, McMahon DE, Tyagi A, Ali R, Singh R, Rosenbach M, Lim HW, Fox LP, Blumenthal K, Hruza GJ, French LE, Freeman EE. JAAD Int. 2022 Sep;8:49-51. doi: 10.1016/j.jdin.2022.04.004. Epub 2022 Apr 26. PMID: 35498758

Reply to: "Multi-dermatomal herpes zoster in a young patient with Crohn's disease on thiopurine therapy: Need for reconsidering **vaccine** recommendations".
Macaluso FS, Liguori G, Galli M. Dig Liver Dis. 2022 Sep;54(9):1281. doi: 10.1016/j.dld.2022.04.022. Epub 2022 May 23. PMID: 35614003

Co-administration of a plasmid encoding CD40 or CD63 enhances the immune responses to a DNA **vaccine** against bovine viral diarrhea virus in mice.
Leng D, Yamada S, Chiba Y, Yoneyama S, Sakai Y, Hikono H, Murakami K. J Vet Med Sci. 2022 Sep 1;84(9):1175-1184. doi: 10.1292/jvms.22-0085. Epub 2022 Jul 7. PMID: 35793950

Pemphigus Vulgaris and COVID-19 vaccination: Management and Treatment.
Martora F, Teresa B, Nappa P, Fabbrocini G, Megna M. J Cosmet Dermatol. 2022 Sep 9. doi: 10.1111/jocd.15374. Online ahead of print. PMID: 36083710

Production of a viral surface protein in Nannochloropsis oceanica for fish vaccination against infectious pancreatic necrosis virus.
Rout SS, de Grahl I, Yu X, Reumann S. Appl Microbiol Biotechnol. 2022 Sep 7:1-15. doi: 10.1007/s00253-022-12106-7. Online ahead of print. PMID: 36069927

COVID **vaccine** booster doses for omicron variants.
Burki T. Lancet Respir Med. 2022 Sep 2:S2213-2600(22)00361-7. doi: 10.1016/S2213-2600(22)00361-7. Online ahead of print. PMID: 36063833

BNT162b2 vaccination reduced infections and transmission in a COVID-19 outbreak in a nursing home in Germany, 2021.
Meyer ED, Sandfort M, Bender J, Matysiak-Klose D, Dörre A, Bojara G, Beyrer K, Hellenbrand W. Influenza Other Respir Viruses. 2022 Sep 9. doi: 10.1111/irv.13051. Online ahead of print. PMID: 36082799

Serum IgM antibody response to Clostridioides difficile polysaccharide PS-II vaccination in pony foals.
Arroyo LG, Hodgins DC, Guest B, Costa M, Ma Z, Monteiro MA. Anaerobe. 2022 Sep 3;77:102635. doi: 10.1016/j.anaerobe.2022.102635. Online ahead of print. PMID: 36064161

Correction to: Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 **Vaccine** AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.
Lane S, Shakir S. Drug Saf. 2022 Sep 3:1-2. doi: 10.1007/s40264-022-01233-9. Online ahead of print. PMID: 36057085

Myocarditis After *BNT162b2* COVID-19 Third Booster **Vaccine** in Israel.
Mevorach D, Anis E, Cedar N, Hasin T, Bromberg M, Goldberg L, Levi N, Perzon O, Magadle N, Barhoum B, Parnassa E, Dichtiar R, Hershkovitz Y, Green MS, Ash N, Keinan-Boker L, Alroy-Preis S. Circulation. 2022 Sep 6;146(10):802-804. doi: 10.1161/CIRCULATIONAHA.122.060961. Epub 2022 Sep 6. PMID: 36067275

Is Hepatitis-B Immunization Effective During Chronic Liver Fibrosis? Investigation of Secretory and Cellular Immune Responses on an Experimental Model.
Kayhan B, Karaca ZM, Canpolat E, Ersan V, Gül M, Yoloğolu S, Yilmaz S. Immunopharmacol Immunotoxicol. 2022 Sep 6:1-35. doi: 10.1080/08923973.2022.2121925. Online ahead of print. PMID: 36066099

Efficacy of hydrogen peroxide wipes for decontamination of AZD1222 adenovirus COVID-19 **vaccine** strain on pharmaceutical industry materials.
Rhodes VP, Ajorio ACFB, da Costa LV, Rodrigues AP, Diniz VA, da Silva Lage RV, da Silva IB, Brandão MLL. Lett Appl Microbiol. 2022 Sep 7. doi: 10.1111/lam.13831. Online ahead of print. PMID: 36073022

A detailed analysis of possible efficacy signals of NTHi-Mcat **vaccine** against severe COPD exacerbations in a previously reported randomised phase 2b trial.
Arora AK, Chinsky K, Keller C, Mayers I, Pascual-Guardia S, Vera MP, Lambert C, Lombardi S, Rondini S, Tian S, Ulloa-Montoya F, Moraschini L, Casula D; NTHi-Mcat-002 study group. Vaccine. 2022 Sep 3:S0264-410X(22)01042-8. doi: 10.1016/j.vaccine.2022.08.053. Online ahead of print. PMID: 36068109

The Effect of Buzzy Application on Pain Level During **Vaccine** Injection in Infants.
Şıktaş Ö, Uysal G. J Nurs Care Qual. 2022 Sep 5. doi: 10.1097/NCQ.0000000000000656. Online ahead of print. PMID: 36066846

Application of **vaccine** response in the evaluation of patients with suspected B-cell immunodeficiency: Assessment of responses and challenges with interpretation.
Peterson LK. J Immunol Methods. 2022 Sep 3:113350. doi: 10.1016/j.jim.2022.113350. Online ahead of print. PMID: 36067869

Detection of a Highly Divergent Type 3 **Vaccine**-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder - Chongqing, China, 2022.
Yao N, Liu Y, Xu JW, Wang Q, Yin ZD, Wen N, Yang H, Rodewald LE, Zhang ZY. MMWR Morb Mortal Wkly Rep. 2022 Sep 9;71(36):1148-1150. doi: 10.15585/mmwr.mm7136a2. PMID: 36074738

Lichen planus pigmentosus inversus with nail involvement following COVID-19 vaccination: A case report.
Edek YC, Tamer F, Öğüt B. Dermatol Ther. 2022 Sep 10:e15809. doi: 10.1111/dth.15809. Online ahead of print. PMID: 36086935

Should the COVID-19 lockdown be relaxed or intensified in case a **vaccine** becomes available?
Buratto A, Muttoni M, Wrzaczek S, Freiberger M. PLoS One. 2022 Sep 2;17(9):e0273557. doi: 10.1371/journal.pone.0273557. eCollection 2022. PMID: 36054113

Pediatric Solid Organ Transplant Recipients Demonstrate Robust Cell-Mediated and Humoral Responses to 3 Doses of mRNA SARS-CoV-2 **Vaccine**.
Bratic JS, Gans HA, Chen SF, Banaei N, Johnston EM, Sear K, Samreth S, Nadimpalli SS. Am J Transplant. 2022 Sep 9. doi: 10.1111/ajt.17195. Online ahead of print. PMID: 36083190

Estimating the Effectiveness of First Dose of COVID-19 **Vaccine** Against Mortality in England: A Quasi-Experimental Study.
Bermingham C, Morgan J, Ayoubkhani D, Glickman M, Islam N, Sheikh A, Sterne J, Walker AS, Nafilyan V. Am J Epidemiol. 2022 Sep 5:kwac157. doi: 10.1093/aje/kwac157. Online ahead of print. PMID: 36065824

Widespread cutaneous eruption following COVID-19 **vaccine** in the setting of immunotherapy.
El-Behaedi S, Ng S, Goyal PK, Choi JN. JAAD Case Rep. 2022 Sep 2. doi: 10.1016/j.jdcr.2022.08.043. Online ahead of print. PMID: 36068793

Relative Effectiveness of COVID-19 Vaccination in Healthcare Workers: 3-Dose Versus 2-Dose Vaccination.
Kim SR, Kang HJ, Jeong HR, Jang SY, Lee JE, Kim DE, Lee HR, Cho MH, Noh JY, Cheong HJ, Kim WJ, Song JY. J Korean Med Sci. 2022 Sep 5;37(35):e267. doi: 10.3346/jkms.2022.37.e267. PMID: 36065651

Crescentic Glomerulonephritis with Fibrinoid Vasculitis after Administration of Influenza **Vaccine**: A Case Report.
Hara R, Hasegawa E, Inoue N, Sekine A, Tanaka K, Ikuma D, Mizuno H, Oba Y, Yamanouchi M, Suwabe T, Sawa N, Kono K, Kinowaki K, Ohashi K, Ubara Y, Hoshino J. Intern Med. 2022 Sep 6. doi: 10.2169/internalmedicine.9410-22. Online ahead of print. PMID: 36070955

Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection.
Saunders KO, Edwards RJ, Tilahun K, Manne K, Lu X, Cain DW, Wiehe K, Williams WB, Mansouri K, Hernandez GE, Sutherland L, Scearce R, Parks R, Barr M, DeMarco T, Eater CM, Eaton A, Morton G, Mildenberg B, Wang Y, Rountree RW, Tomai MA, Fox CB, Moody MA, Alam SM, Santra S, Lewis MG, Denny TN, Shaw GM, Montefiori DC, Acharya P, Haynes BF. Sci Transl Med. 2022 Sep 7;14(661):eabo5598. doi: 10.1126/scitranslmed.abo5598. Epub 2022 Sep 7. PMID: 36070369

Bioaccessibility and oral immunization efficacy of a chimeric protein **vaccine** against Ascaris suum.
Castro JC, Magalhães LMD, Almeida RM, Oliveira FMS, Nogueira DS, Gazzinelli-Guimarães AC, Kraemer L, Barbosa FS, Santos FV, Minighin EC, Bueno LL, Bartholomeu DC, Labanca RA, Fujiwara RT. Microbes Infect. 2022 Sep 5:105042. doi: 10.1016/j.micinf.2022.105042. Online ahead of print. PMID: 36075515

Molecular modelling on multiepitope-based **vaccine** against SARS-CoV-2 using immunoinformatics, molecular docking, and molecular dynamics simulation.
Arwansyah A, Arif AR, Kade A, Taiyeb M, Ramli I, Santoso T, Ningsih P, Natsir H, Tahril T, Uday Kumar K. SAR QSAR Environ Res. 2022 Sep 9:1-27. doi: 10.1080/1062936X.2022.2117846. Online ahead of print. PMID: 36083166

Letter to the editor: antibody response to a third dose of SARS-CoV-2 **vaccine** in heart and lung transplant recipients.
Alejo JL, Ruck JM, Chiang TP, Abedon AT, Kim JD, Avery RK, Tobian AAR, Warren DS, Levan ML, Massie AB, Garonzik-Wang JM, Segev DL, Werbel WA. Clin Transplant. 2022 Sep 8:e14818. doi: 10.1111/ctr.14818. Online ahead of print. PMID: 36073912

A qualitative analysis of an online teaching intervention to encourage favorable attitudes toward influenza **vaccine** among community college students.
Heller JR, Thomas NM, Gruttadauria ES, Reader SM, Sarmiento AL. J Am Coll Health. 2022 Sep 9:1-6. doi: 10.1080/07448481.2022.2117555. Online ahead of print. PMID: 36084248

Durability of Booster mRNA **Vaccine** against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
Qu P, Faraone JN, Evans JP, Zheng YM, Yu L, Ma Q, Carlin C, Lozanski G, Saif LJ, Oltz EM, Gumina RJ, Liu SL. N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2210546. Online ahead of print. PMID:

Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic **Vaccine** Targeting Human Papillomavirus.
Da Silva DM, Martinez EA, Bogaert L, Kast WM. Cancers (Basel). 2022 Sep 5;14(17):4339. doi: 10.3390/cancers14174339. PMID: 36077873

Poliomyelitis outbreaks caused by circulation of the **vaccine**-derived poliovirus - Correspondence.
Rahimi F, Bezmin Abadi AT. Int J Surg. 2022 Sep 6:106893. doi: 10.1016/j.ijsu.2022.106893. Online ahead of print. PMID: 36084811

Rotavirus **Vaccine** Impact within an Integrated Healthcare Delivery System in the United States.
Burke RM, Tate JE, Groom H, Parashar UD, Mattison CP, Donald J, Salas SB, Naleway AL, Lee MH, Dickerson JF, Biggs C, Tsaknaridis L, Bowen MD, Schmidt M, Hall AJ. J Pediatric Infect Dis Soc. 2022 Sep 7:piac101. doi: 10.1093/jpids/piac101. Online ahead of print. PMID: 36070595

A case of BNT162b2 COVID-19 **vaccine**-associated fulminant myocarditis in a very elderly woman.
Otsuka K, Matsuo T, Ishimatsu T, Fukae A, Hamamoto T, Oku K, Ito M. Clin Case Rep. 2022 Sep 5;10(9):e6161. doi: 10.1002/ccr3.6161. eCollection 2022 Sep. PMID: 36093466

Does SARS-CoV2 **vaccine** exposure trigger acute-onset polyradiculopathy characterized by more common facial paralysis ?
Galassi G, Kaleci S. Muscle Nerve. 2022 Sep 4. doi: 10.1002/mus.27711. Online ahead of print. PMID: 36059144

Third-dose SARS-CoV-2 mRNA **vaccine** increases Omicron variant neutralisation in patients with chronic myeloid disorders.
Harrington P, Kurshan A, Delord M, Lechmere T, Sheikh A, Saunders J, Saha C, Dillon R, Woodley C, Asirvatham S, Curto-Garcia N, O'Sullivan J, Kordasti S, Radia DH, McLornan DP, Malim MH, Harrison CN, Doores KJ, de Lavallade H. Blood Adv. 2022 Sep 9:bloodadvances.2022008375. doi: 10.1182/bloodadvances.2022008375. Online ahead of print. PMID: 36083126

A citywide experiment testing the impact of geographically targeted, high-pay-off **vaccine** lotteries.
Milkman KL, Gandhi L, Ellis SF, Graci HN, Gromet DM, Mobarak RS, Buttenheim AM, Duckworth AL, Pope D, Stanford A, Thaler R, Volpp KG. Nat Hum Behav. 2022 Sep 1. doi: 10.1038/s41562-022-01437-0. Online ahead of print. PMID: 36050387

Does perceived scarcity of COVID-19 vaccines increase vaccination willingness? Results of an experimental study with German respondents in times of a national **vaccine** shortage.
Schnepf J. PLoS One. 2022 Sep 7;17(9):e0273441. doi: 10.1371/journal.pone.0273441. eCollection 2022. PMID: 36070254

The American Academy of Dermatology & International League of Dermatological Societies Monkeypox Registry: Expanding the COVID-19 Registry to Emerging Infections.
Freeman EE, Casas CG, Prasad S, Fuller C, Peebles K, Rosenbach M, Fox L, McMahon DE, Strahan A, Lubov J, Chen G, Nguyen CV, McMillen A, Lim HW, Stratigos AJ, Kaufmann MD, Hruza GJ, French L. J Am Acad Dermatol. 2022 Sep 5:S0190-9622(22)02630-5. doi: 10.1016/j.jaad.2022.08.053. Online ahead of print. PMID: 36075281

Correction: The Pitfalls of Abnormal Laboratory Value Interpretation in **Vaccine** Clinical Trials: The Example of Asymptomatic Transient Neutropenia.
Vella V, Schmidt JE, Cilio GL, De Ryck I, Podda A, Conti V, Auerbach J. Drugs R D. 2022 Sep;22(3):253. doi: 10.1007/s40268-022-00395-2. Epub 2022 Aug 22. PMID: 35994226

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability.
Shi W, Wang L, Zhou T, Sastry M, Yang ES, Zhang Y, Chen M, Chen X, Choe M, Creanga A, Leung K, Olia AS, Pegu A, Rawi R, Schön A, Shen CH, Stancofski ED, Talana CA, Teng IT, Wang S, Corbett KS, Tsybovsky Y, Mascola JR, Kwong PD. Structure. 2022 Sep 1;30(9):1233-1244.e7. doi: 10.1016/j.str.2022.06.004. Epub 2022 Jul 15. PMID: 35841885

FDG PET/CT radiomics as a tool to differentiate between reactive axillary lymphadenopathy following COVID-19 vaccination and metastatic breast cancer axillary lymphadenopathy: a pilot study.
Eifer M, Pinian H, Klang E, Alhoubani Y, Kanana N, Tau N, Davidson T, Konen E, Catalano OA, Eshet Y, Domachevsky L. Eur Radiol. 2022 Sep;32(9):5921-5929. doi: 10.1007/s00330-022-08725-3. Epub 2022 Apr 6. PMID: 35385985

Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 **vaccine**: a prospective cohort study.
Pertzov B, Shmueli E, Ben Zvi H, Massarweh A, Barkan T, Ness A, Shostak Y, Freidkin L, Shtraichman O, Kramer MR. Respir Res. 2022 Sep 1;23(1):226. doi: 10.1186/s12931-022-02155-x. PMID: 36045374

Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis.
Palmer M, Katanoda K, Saito E, Acuti Martellucci C, Tanaka S, Ikeda S, Sakamoto H, Machelek D, Ml Brotherton J, Hocking JS. Vaccine. 2022 Sep 6:S0264-410X(22)00950-1. doi: 10.1016/j.vaccine.2022.07.052. Online ahead of print. PMID: 36085257

Acute Idiopathic Maculopathy Following SARS-CoV-2 Vaccination.
Bleicher ID, Brill D, Wu F, Sobrin L, Patel N. Ocul Immunol Inflamm. 2022 Sep 2:1-4. doi: 10.1080/09273948.2022.2114915. Online ahead of print. PMID: 36053888

Virus-like particle vaccinology, from bench to bedside.
Mohsen MO, Bachmann MF. Cell Mol Immunol. 2022 Sep;19(9):993-1011. doi: 10.1038/s41423-022-00897-8. Epub 2022 Aug 12. PMID: 35962190

Responsiveness to second and third dose of mRNA COVID-19 vaccination in adolescent and young adult heart transplant recipients.
Feingold B, Berman P, Moninger A, Huston A, Stinner B, West SC, Rose-Felker K, Zinn MD, Miller SA, Michaels MG. Pediatr Transplant. 2022 Sep;26(6):e14272. doi: 10.1111/petr.14272. Epub 2022 Mar 27. PMID: 35340096

Predictors of poor serologic response to COVID-19 **vaccine** in patients with cancer: a systematic review and meta-analysis.
Yang W, Zhang D, Li Z, Zhang K. Eur J Cancer. 2022 Sep;172:41-50. doi: 10.1016/j.ejca.2022.05.031. Epub 2022 Jun 2. PMID: 35752155

Epidemiology and pre-**vaccine** burden of rotavirus diarrhea in Democratic Republic of Congo (DRC): Results of sentinel surveillance, 2009-2019.
Luhata Lungayo C, Burke RM, Cikomola A, Mukamba E, Burnett E, Tate JE, Samuel Otomba J, Albert MK, Nimpa MM, Dommergues MA, Pukuta E, Mwenda JM, Shaba K, Paluku GK, N'diaye A, Ditekemena J,

Launay O, Jouffroy R. Vaccine. 2022 Sep 3:S0264-410X(22)01031-3. doi: 10.1016/j.vaccine.2022.08.041. Online ahead of print. PMID: 36068112

Response to COVID19 vaccines is reduced in patients with inflammatory bowel disease, but improved with additional dose.
Shiga H, Kakuta Y, An K, Abe Y, Fujimaki S, Shimoyama Y, Naito T, Moroi R, Kuroha M, Khor SS, Kawai Y, Tokunaga K, Kinouchi Y, Masamune A. J Gastroenterol Hepatol. 2022 Sep 6. doi: 10.1111/jgh.16001. Online ahead of print. PMID: 36066279

Using mobile phone-based text message to recruit representative samples: Assessment of a cross-sectional survey about the COVID-19 **vaccine** hesitation.
Sartorao Filho CI, Sartorao Neto CI, Sartorao ALV, Terribile DC, Mello R, Mello BB, Zoqui MC, Duarte DO, Cachoni LEG, Bisseto VCQ, Ribeiro EAC. Int J Med Inform. 2022 Sep;165:104832. doi: 10.1016/j.ijmedinf.2022.104832. Epub 2022 Jul 14. PMID: 35842978

Effectiveness of human papillomavirus **vaccine** against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity.
Kudo R, Sekine M, Yamaguchi M, Hara M, Hanley SJB, Kurosawa M, Adachi S, Ueda Y, Miyagi E, Ikeda S, Yagi A, Enomoto T. Cancer Sci. 2022 Sep;113(9):3211-3220. doi: 10.1111/cas.15471. Epub 2022 Jul 11. PMID: 35730321

Defining the determinants of **vaccine** uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 **vaccine** uptake: a systematic review.
Crawshaw AF, Farah Y, Deal A, Rustage K, Hayward SE, Carter J, Knights F, Goldsmith LP, Campos-Matos I, Wurie F, Majeed A, Bedford H, Forster AS, Hargreaves S. Lancet Infect Dis. 2022 Sep;22(9):e254-e266. doi: 10.1016/S1473-3099(22)00066-4. Epub 2022 Apr 13. PMID: 35429463

Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland.
Nuorti JP, Rinta-Kokko H, Toropainen M, Siira L, Nohynek H, Palmu AA. Vaccine. 2022 Sep 5:S0264-410X(22)01037-4. doi: 10.1016/j.vaccine.2022.08.047. Online ahead of print. PMID: 36075797

Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa.
Katz S, Townsend-Payne K, Louth J, Lee-Jones L, Trotter C, Dan Dano I, Borrow R; MenAfriCar Consortium. Vaccine. 2022 Sep 8:S0264-410X(22)00977-X. doi: 10.1016/j.vaccine.2022.08.013. Online ahead of print. PMID: 36089429

Discontinuing methotrexate to enhance **vaccine** response.
Medeiros-Ribeiro AC, Aikawa NE. Nat Rev Rheumatol. 2022 Sep;18(9):497-498. doi: 10.1038/s41584-022-00817-0. PMID: 35869395

Moral expressions, sources, and frames: Examining COVID-19 vaccination posts by facebook public pages.
Zhang W, Wang R, Liu H. Comput Human Behav. 2022 Sep 7:107479. doi: 10.1016/j.chb.2022.107479. Online ahead of print. PMID: 36091923

Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
Yu G, He X, Li X, Wu Y. Biomed Pharmacother. 2022 Sep;153:113464. doi: 10.1016/j.biopha.2022.113464. Epub 2022 Aug 1. PMID: 36076493

A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.
Mohamed Y, El-Maradny YA, Saleh AK, Nayl AA, El-Gendi H, El-Fakharany EM. Biomed Pharmacother. 2022 Sep;153:113499. doi: 10.1016/j.biopha.2022.113499. Epub 2022 Aug 2. PMID: 36076589

Insights into COVID-19 vaccines development: Translation from benchside to bedside.
Houssein M, Al Hossainy AEA, Al Soussi J, El Batch J, El-Samadi L, El Imam S, Fakih R, Dakdouk H, Khalil M. Health Sci Rev (Oxf). 2022 Sep;4:100040. doi: 10.1016/j.hsr.2022.100040. Epub 2022 Jul 10. PMID: 35856085

Higher sensitivity monitoring of reactions to COVID-19 vaccination using smartwatches.
Guan G, Mofaz M, Qian G, Patalon T, Shmueli E, Yamin D, Brandeau ML. NPJ Digit Med. 2022 Sep 9;5(1):140. doi: 10.1038/s41746-022-00683-w. PMID: 36085312

Moral values predict county-level COVID-19 vaccination rates in the United States.
Reimer NK, Atari M, Karimi-Malekabadi F, Trager J, Kennedy B, Graham J, Dehghani M. Am Psychol. 2022 Sep;77(6):743-759. doi: 10.1037/amp0001020. PMID: 36074569

Prioritizing the vulnerable over the susceptible for COVID-19 vaccination.
Paloyo SR, Caballes AB, Hilvano-Cabungcal AM, De Castro L. Dev World Bioeth. 2022 Sep;22(3):162-169. doi: 10.1111/dewb.12327. Epub 2021 Jul 19. PMID: 34286905

NETosis and thrombosis in **vaccine**-induced immune thrombotic thrombocytopenia.
Leung HHL, Perdomo J, Ahmadi Z, Zheng SS, Rashid FN, Enjeti A, Ting SB, Chong JJH, Chong BH. Nat Commun. 2022 Sep 5;13(1):5206. doi: 10.1038/s41467-022-32946-1. PMID: 36064843

Selective transfer of maternal antibodies in preterm and fullterm children.
Dolatshahi S, Butler AL, Pou C, Henckel E, Bernhardsson AK, Gustafsson A, Bohlin K, Shin SA, Lauffenburger DA, Brodin P, Alter G. Sci Rep. 2022 Sep 2;12(1):14937. doi: 10.1038/s41598-022-18973-4. PMID: 36056073

Enhancing Meningococcal Genomic Surveillance in the Meningitis Belt Using High-Resolution Culture-Free Whole-Genome Sequencing.
Itsko M, Topaz N, Ousmane-Traoré S, Popoola M, Ouedraogo R, Gamougam K, Sadji AY, Abdul-Karim A, Lascols C, Wang X. J Infect Dis. 2022 Sep 4;226(4):729-737. doi: 10.1093/infdis/jiac104. PMID: 35325163

Designing and psychometric assessment of the scale of factors influencing HPV **vaccine** uptake behaviors in young adults.
Yarmohammadi S, Ghaffari M, Mehrabi Y, Mousavi S, Ramezankhani A. Infect Agent Cancer. 2022 Sep 10;17(1):48. doi: 10.1186/s13027-022-00461-z. PMID: 36088331

Zero- or missed-dose children in Nigeria: Contributing factors and interventions to overcome immunization service delivery challenges.

Mahachi K, Kessels J, Boateng K, Jean Baptiste AE, Mitula P, Ekeman E, Nic Lochlainn L, Rosewell A, Sodha SV, Abela-Ridder B, Gabrielli AF. Vaccine. 2022 Sep 2;40(37):5433-5444. doi: 10.1016/j.vaccine.2022.07.058. Epub 2022 Aug 13. PMID: 35973864

Cytosolic dsRNA improves neonatal innate immune responses to adjuvants in use in pediatric vaccines.
Brennan K, Craven S, Cheung M, Kane D, Noone E, O'Callaghan J, Molloy EJ, Walsh PT, McAuliffe FM, Doyle SL. J Leukoc Biol. 2022 Sep;112(3):523-537. doi: 10.1002/JLB.5A0521-242R. Epub 2022 Jan 31. PMID: 35098572

An Evaluation of Different Types of Peptone as Partial Substitutes for Animal-derived Serum in Vero Cell Culture.
Lezin C, Mauduit P, Uzan G, Abdelgawad ME. Altern Lab Anim. 2022 Sep 3:2611929221122780. doi: 10.1177/02611929221122780. Online ahead of print. PMID: 36062749

Changes in interferon-γ release assay readout after COVID-19 vaccination: A prospective cohort study.
Chen NY, Liu ZH, Kao SW, Lin HS, Lee IK, Zheng JY, Wang SW, Hsiao YH, Lin HC, Wu TS. Int J Infect Dis. 2022 Sep;122:537-542. doi: 10.1016/j.ijid.2022.06.044. Epub 2022 Jul 1. PMID: 35788418

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
Goldstein N, Bockstal V, Bart S, Luhn K, Robinson C, Gaddah A, Callendret B, Douoguih M. J Infect Dis. 2022 Sep 4;226(4):595-607. doi: 10.1093/infdis/jiaa586. PMID: 32939546

Diversity of SAT2 foot-and-mouth disease virus in Sudan: implication for diagnosis and control.
A/Raouf Y, Ibrahim I. Vet Res Commun. 2022 Sep;46(3):789-798. doi: 10.1007/s11259-022-09899-3. Epub 2022 Mar 1. PMID: 35233700

Safety and immunogenicity of heterologous COVID-19 **vaccine** regimens to deal with product shortage: A randomised clinical trial in an elderly population.
Kundro MA, Losso MH, Macchia A, Pastor I, Alonso Serena M, Gestoso C, Moreno Macías L, Crupi F, Acosta MC, Ivalo S, Ghioldi M, Bouzas MB, Mammana L, Zapiola I, Mazzitelli I, Varese A, Geffner J, Biscayart C, Angeleri P, Lopez E, Gentile A, Ferrante D, de Quiros FGB. Public Health Pract (Oxf). 2022 Dec;4:100313. doi: 10.1016/j.puhip.2022.100313. Epub 2022 Sep 6. PMID: 36090797

SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis.
Efe C, Taşçılar K, Gerussi A, Bolis F, Lammert C, Ebik B, Stättermayer AF, Cengiz M, Gökçe DT, Cristoferi L, Peralta M, Massoumi H, Montes P, Cerda E, Rigamonti C, Yapalı S, Adali G, Çalışkan AR, Balaban Y, Eren F, Eşkazan T, Barutçu S, Lytvyak E, Zazueta GM, Kayhan MA, Heurgue-Berlot A, De Martin E, Yavuz A, Bıyık M, Narro GC, Duman S, Hernandez N, Gatselis NK, Aguirre J, Idilman R, Silva M, Mendizabal M, Atay K, Güzelbulut F, Dhanasekaran R, Montano-Loza AJ, Dalekos GN, Ridruejo E, Invernizzi P, Wahlin S. J Autoimmun. 2022 Sep 7;132:102906. doi: 10.1016/j.jaut.2022.102906. Online ahead of print. PMID: 36088883

Evaluating the Breadth of Neutralizing Antibody Responses Elicited by Infectious Bursal Disease Virus Genogroup A1 Strains Using a Novel Chicken B-Cell Rescue System and Neutralization Assay.
Reddy VRAP, Nazki S, Brodrick AJ, Asfor A, Urbaniec J, Morris Y, Broadbent AJ. J Virol. 2022 Sep 7:e0125522. doi: 10.1128/jvi.01255-22. Online ahead of print. PMID: 36069547

Cardiac MRI in Suspected Acute Myocarditis After COVID-19 mRNA Vaccination.
Kravchenko D, Isaak A, Mesropyan N, Endler C, Bischoff L, Vollbrecht T, Pieper CC, Sedaghat A, Kuetting D, Hart C, Feisst A, Attenberger U, Luetkens JA. Rofo. 2022 Sep;194(9):1003-1011. doi: 10.1055/a-1752-0951. Epub 2022 Mar 10. PMID: 35272355

Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination.
Safary A, Esalatmanesh K, Eftekharsadat AT, Jafari Nakjavani MR, Khabbazi A. Int Immunopharmacol. 2022 Sep;110:109061. doi: 10.1016/j.intimp.2022.109061. Epub 2022 Jul 15. PMID: 35978510

Text Message Reminders for the Second Dose of Influenza **Vaccine** for Children: An RCT.
Stockwell MS, Shone LP, Nekrasova E, Wynn C, Torres A, Griffith M, Shults J, Unger R, Ware LA, Kolff C, Harris D, Berrigan L, Montague H, Localio AR, Fiks AG. Pediatrics. 2022 Sep 1;150(3):e2022056967. doi: 10.1542/peds.2022-056967. PMID: 35965283

Monkeypox caused less worry than COVID-19 among the general population during the first month of the WHO Monkeypox alert: Experience from Saudi Arabia.
Temsah MH, Aljamaan F, Alenezi S, Alhasan K, Saddik B, Al-Barag A, Alhaboob A, Bahabri N, Alshahrani F, Alrabiaah A, Alaraj A, Bahkali F, Alkriadees K, Jamal A, Halwani R, AlZamil F, Al-Subaie S, Barry M, Memish ZA, Al-Tawfiq JA. Travel Med Infect Dis. 2022 Sep-Oct;49:102426. doi: 10.1016/j.tmaid.2022.102426. Epub 2022 Aug 11. PMID: 35963555

The effect of BCG vaccination and risk factors for latent tuberculosis infection among college freshmen in China.
Huang W, Fang Z, Luo S, Lin S, Xu L, Yan B, Yang Y, Liu X, Xia L, Fan X, Lu S. Int J Infect Dis. 2022 Sep;122:321-326.2. doi: 10.1016/j.ijid.2022.06.010. Epub 2022 Jun 11. PMID: 35700876

Subacute thyroiditis post viral vector **vaccine** for COVID-19.
Casey C, Higgins T. Endocrinol Diabetes Metab Case Rep. 2022 Sep 1;2022:21-0193. doi: 10.1530/EDM-21-0193. Online ahead of print. PMID: 36053182

Network analysis of the relationships between conspiracy beliefs towards COVID-19 **vaccine** and symptoms of fear of COVID-19 in a sample of latin american countries.
Caycho-Rodríguez T, Ventura-León J, Valencia PD, Vilca LW, Carbajal-León C, Reyes-Bossio M, Delgado-Campusano M, Rojas-Jara C, Polanco-Carrasco R, Gallegos M, Cervigni M, Martino P, Palacios DA, Moreta-Herrera R, Samaniego-Pinho A, Elías Lobos Rivera M, Figares AB, Puerta-Cortés DX, Corrales-Reyes IE, Calderón R, Tapia BP, Arias Gallegos WL, Petzold O. Curr Psychol. 2022 Sep 7:1-16. doi: 10.1007/s12144-022-03622-w. Online ahead of print. PMID: 36090914

Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus.
Zhang Y, Yang L, Zhang J, Huang K, Sun X, Yang Y, Wang T, Zhang Q, Zou Z, Jin M. Microb Cell Fact. 2022 Sep 9;21(1):185. doi: 10.1186/s12934-022-01911-4. PMID: 36085207

SARS-CoV-2 **Vaccine** Response in Patients With Autoimmune Hepatitis.
Schneider L, Schubert L, Winkler F, Munda P, Winkler S, Tobudic S. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2145-2147.e2. doi: 10.1016/j.cgh.2022.04.006. Epub 2022 Apr 26. PMID: 35487452

Impact of genetic polymorphisms related to innate immune response on respiratory syncytial virus infection in children.
Córdova-Dávalos LE, Hernández-Mercado A, Barrón-García CB, Rojas-Martínez A, Jiménez M, Salinas E, Cervantes-García D. Virus Genes. 2022 Sep 9:1-14. doi: 10.1007/s11262-022-01932-6. Online ahead of print. PMID: 36085536

Secondary cross infection with dengue virus serotype 2/3 aggravates vascular leakage in BALB/c mice.
Qiu L, Huang X, Luo J, Zhao Y, Hong S, Wang X, Feng K, Pan Y, Sun Q. J Med Virol. 2022 Sep;94(9):4338-4347. doi: 10.1002/jmv.27826. Epub 2022 May 14. PMID: 35510565

COVID-19 **vaccine** inquiries regarding children ages 5-11 years received by NIP-INFO.
Hall E, Morales S, Wolicki J, Schillie S. Public Health Nurs. 2022 Sep;39(5):1119-1122. doi: 10.1111/phn.13079. Epub 2022 Apr 12. PMID: 35413142

A Listeria ivanovii balanced-lethal system may be a promising antigen carrier for **vaccine** construction.
Lei Y, Zhou Y, Zhang Y, Liu S, Tian S, Ou Q, Liu T, Huang H, Tang T, Wang C. Microb Biotechnol. 2022 Sep 7. doi: 10.1111/1751-7915.14137. Online ahead of print. PMID: 36069650

Conformation-Stabilized Amorphous Nanocoating for Rational Design of Long-Term Thermostable Viral Vaccines.
Zhang Y, Hao H, Lin J, Ma Z, Li H, Nie Z, Cui Y, Guo Z, Zhang Y, Wang X, Tang R. ACS Appl Mater Interfaces. 2022 Sep 7;14(35):39873-39884. doi: 10.1021/acsami.2c12065. Epub 2022 Aug 26. PMID: 36018064

Inhalable dry powder mRNA vaccines based on extracellular vesicles.
Popowski KD, Moatti A, Scull G, Silkstone D, Lutz H, López de Juan Abad B, George A, Belcher E, Zhu D, Mei X, Cheng X, Cislo M, Ghodsi A, Cai Y, Huang K, Li J, Brown AC, Greenbaum A, Dinh PC, Cheng K. Matter. 2022 Sep 7;5(9):2960-2974. doi: 10.1016/j.matt.2022.06.012. Epub 2022 Jul 11. PMID: 35847197

COVID-19 mortality and excess mortality among working-age residents in California, USA, by occupational sector: a longitudinal cohort analysis of mortality surveillance data.
Chen YH, Riley AR, Duchowny KA, Aschmann HE, Chen R, Kiang MV, Mooney AC, Stokes AC, Glymour MM, Bibbins-Domingo K. Lancet Public Health. 2022 Sep;7(9):e744-e753. doi: 10.1016/S2468-2667(22)00191-8. PMID: 36057273

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based **Vaccine** in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V. J Clin Oncol. 2022 Sep 7:JCO2200096. doi: 10.1200/JCO.22.00096. Online ahead of print. PMID: 36070539

Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.

Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Kaku N, Matsumoto K, Suita A, Komiya E, Mukai E, Nitahara Y, Konishi A, Kasamatsu A, Nakagami-Yamaguchi E, Ohfuji S, Kaneko Y, Kaneko A, Kakeya H, Hirota Y. Vaccine. 2022 Sep 9;40(38):5631-5640. doi: 10.1016/j.vaccine.2022.08.018. Epub 2022 Aug 15. PMID: 36028457

Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?
Paybast S, Emami A, Baghalha F, Naser Moghadasi A. Mult Scler Relat Disord. 2022 Sep;65:103960. doi: 10.1016/j.msard.2022.103960. Epub 2022 Jun 10. PMID: 35763914

Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 **vaccine** in adults aged 18 years and above.
Li ZP, Shi YF, Hou LH, Jin PF, Ma SH, Pan HX, Zhang JL, Shan YM, Huang HT, Wu SP, Du P, Wang X, Wang LL, Wang RJ, Wang Y, Wang XW, Zhu FC, Li JX. Expert Rev Vaccines. 2022 Sep 1. doi: 10.1080/14760584.2022.2119133. Online ahead of print. PMID: 36048417

Evolving spectrum but persistent high mortality of COVID-19 among patients on kidney replacement therapy in the **vaccine** era: the Spanish COVID-19 KRT Registry.
Quiroga B, Ortiz A, Cabezas-Reina CJ, Ruiz Fuentes MC, Jiménez VL, Larrondo SZ, Toapanta N, Gómez MM, de Sequera P, Sánchez-Álvarez E; Spanish COVID-19 KRT Registry collaborative group. Clin Kidney J. 2022 Jun 3;15(9):1685-1697. doi: 10.1093/ckj/sfac135. eCollection 2022 Sep. PMID: 35999961

Inactivation of SARS-CoV-2 by charged particles for Future **Vaccine** Production Applications: A Monte Carlo study.
Rafiepour P, Sina S, Mortazavi SMJ. Radiat Phys Chem Oxf Engl 1993. 2022 Sep;198:110265. doi: 10.1016/j.radphyschem.2022.110265. Epub 2022 May 28. PMID: 35663798

A specific Leishmania infantum polyepitope **vaccine** triggers Th1-type immune response and protects against experimental visceral leishmaniasis.
Lopes Valentim Di Paschoale Ostolin T, Rodrigues Gusmão M, Augusto Siqueira Mathias F, Mirelle de Oliveira Cardoso J, Mendes Roatt B, Dian de Oliveira Aguiar-Soares R, Conceição Ruiz J, de Melo Resende D, Cristiane Fortes de Brito R, Barbosa Reis A. Cell Immunol. 2022 Sep 5;380:104592. doi: 10.1016/j.cellimm.2022.104592. Online ahead of print. PMID: 36084402

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell **vaccine** in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
Español-Rego M, Fernández-Martos C, Elez E, Foguet C, Pedrosa L, Rodríguez N, Ruiz-Casado A, Pineda E, Cid J, Cabezón R, Oliveres H, Lozano M, Ginés A, García-Criado A, Ayuso JR, Pagés M, Cuatrecasas M, Torres F, Thomson T, Cascante M, Benítez-Ribas D, Maurel J. Cancer Immunol Immunother. 2022 Sep 9. doi: 10.1007/s00262-022-03283-5. Online ahead of print. PMID: 36083313

Serum Proteome Signatures of Anti-SARS-CoV-2 Vaccinated Healthcare Workers in Greece Associated with Their Prior Infection Status.
Stamoula E, Sarantidi E, Dimakopoulos V, Ainatzoglou A, Dardalas I, Papazisis G, Kontopoulou K, Anagnostopoulos AK. Int J Mol Sci. 2022 Sep 5;23(17):10153. doi: 10.3390/ijms231710153. PMID: 36077551

COVID-19 Vaccines for Children with Developmental Disabilities: Survey of New York State Parents' Willingness and Concerns.
Bonuck K, Iadarola S, Gao Q, Siegel JF. J Dev Behav Pediatr. 2022 Sep 2. doi: 10.1097/DBP.0000000000001113. Online ahead of print. PMID: 36067424

Evaluation of long-term antibody kinetics in healthcare workers vaccinated with inactivated COVID-19 Vero cell **vaccine** (CoronaVac), a propensity score-matched observational study.
Yildiz Y, Ozger HS, Senol E, Karakus R, Buyukkoruk M, Altin FB, Ozcan FZ, Yaman M, Oruklu N, Yucel AA, Bagriacik EU. Int J Infect Dis. 2022 Sep;122:99-106. doi: 10.1016/j.ijid.2022.05.007. Epub 2022 May 11. PMID: 35568368

Retrospective record review on timing of COVID-19 vaccination and cardiac surgery.
Ho JYK, Siu ICH, Ng KHL, Tam M, Chow SCY, Lim K, Kwok MWT, Wan S, Fujikawa T, Wong RHL. J Card Surg. 2022 Sep 2. doi: 10.1111/jocs.16883. Online ahead of print. PMID: 36054404

Timing of primary three-dose hepatitis B vaccination and postvaccination serologic testing among a large cohort of healthy adults.
Koc ÖM, van Oorschot E, Brandts L, Oude Lashof A. J Med Virol. 2022 Sep;94(9):4433-4439. doi: 10.1002/jmv.27848. Epub 2022 May 17. PMID: 35538595

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 **vaccine**.
Huhn G, Poorbaugh J, Zhang L, Beasley S, Nirula A, Brothers J, Welbel S, Wilson J, Gillani S, Weber KM, Morack R, Keckler K, Benschop RJ. PLoS One. 2022 Sep 9;17(9):e0273323. doi: 10.1371/journal.pone.0273323. eCollection 2022. PMID: 36083883

Development and implementation of an online community as a strategy for mixed methods research during a pandemic.
Shea L, Bushen J, Ahmad N, Geonnotti G, LaMori J, Terrey S, Gonzalez P, Shuman J. Res Involv Engagem. 2022 Sep 5;8(1):47. doi: 10.1186/s40900-022-00383-5. PMID: 36064454

A prime-boost combination of a three-protein cocktail and multiepitopic MVA as a **vaccine** against Babesia bigemina elicits neutralizing antibodies and a Th1 cellular immune response in mice.
Montenegro VN, Jaramillo-Ortiz JM, Paoletta MS, Gravisaco MJ, Del Médico Zajac MP, Garanzini DP, Valenzano MN, Calamante G, Wilkowsky SE. Ticks Tick Borne Dis. 2022 Sep;13(5):101991. doi: 10.1016/j.ttbdis.2022.101991. Epub 2022 Jun 23. PMID: 35792436

Matched Versus Mixed COVID-19 Vaccinations in Korean Solid Organ Transplant Recipients: An Observational Study.
Kang JM, Lee J, Huh KH, Joo DJ, Lee JG, Kim HR, Kim HY, Lee M, Jung I, Kim MY, Kim S, Park Y, Kim MS. Transplantation. 2022 Sep 1;106(9):e392-e403. doi: 10.1097/TP.0000000000004241. Epub 2022 Jun 24. PMID: 35749755

Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.

Cerna K, Duricova D, Hindos M, Hindos Hrebackova J, Lukas M, Machkova N, Hruba V, Mitrova K, Kubickova K, Kastylova K, Teplan V, Lukas M. J Crohns Colitis. 2022 Sep 8;16(9):1347-1353. doi: 10.1093/ecco-jcc/jjac048. PMID: 35358307

The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria **Vaccine**.
Sagara I, Zongo I, Cairns M, Yerbanga RS, Mahamar A, Nikièma F, Tapily A, Sompougdou F, Diarra M, Zoungrana C, Issiaka D, Haro A, Sanogo K, Aziz Sienou A, Kaya M, Traore S, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Ouedraogo JB, Dicko A, Chandramohan D, Greenwood B. Clin Infect Dis. 2022 Sep 10;75(4):613-622. doi: 10.1093/cid/ciab1017. PMID: 34894221

Effects of active immunization against a 13-amino acid receptor-binding epitope of FSHβ on fertility regulation in female mice.
Meng F, Yao H, Li J, Zhuo Y, Yu G, Bu G, Cao X, Du X, Liang Q, Zeng X, Han X. Reprod Biol. 2022 Sep;22(3):100669. doi: 10.1016/j.repbio.2022.100669. Epub 2022 Jun 27. PMID: 35772190

Safety and Feasibility of Infliximab Therapy in Children With Kawasaki Disease Who Received Live Vaccinations.
Ohnishi Y, Okada S, Kawakami-Miyake A, Furuta T, Fukano R, Yasudo H, Shimokawa M, Hasegawa S. Pediatr Infect Dis J. 2022 Sep 1;41(9):e388-e392. doi: 10.1097/INF.0000000000003611. Epub 2022 Jul 27. PMID: 35895884

Detecting COVID-19 **vaccine** hesitancy in India: a multimodal transformer based approach.
Borah A. J Intell Inf Syst. 2022 Sep 7:1-17. doi: 10.1007/s10844-022-00745-1. Online ahead of print. PMID: 36091222

Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
Shivji R, Conocchia R, Korakianiti E, Jekerle V. Vaccine. 2022 Sep 9;40(38):5539-5541. doi: 10.1016/j.vaccine.2022.06.058. Epub 2022 Jun 24. PMID: 35779964

The impact of state capacity on the cross-country variations in COVID-19 vaccination rates.
Tevdovski D, Jolakoski P, Stojkoski V. Int J Health Econ Manag. 2022 Sep;22(3):237-255. doi: 10.1007/s10754-021-09319-0. Epub 2022 Jan 29. PMID: 35091867

Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders.
Montague BT, Wipperman MF, Chio E, Crow R, Hooper AT, O'Brien MP, Simões EAF. Sci Rep. 2022 Sep 2;12(1):14932. doi: 10.1038/s41598-022-19095-7. PMID: 36056118

Antibodies to combat viral infections: development strategies and progress.
Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Nat Rev Drug Discov. 2022 Sep;21(9):676-696. doi: 10.1038/s41573-022-00495-3. Epub 2022 Jun 20. PMID: 35725925

COVID-19: Consequences on pregnant women and neonates.
Sharma KS, Sharma R, Nehra S, Rajpurohit NA, Bhakar K, Kumar D. Health Sci Rev (Oxf). 2022 Sep;4:100044. doi: 10.1016/j.hsr.2022.100044. Epub 2022 Jul 19. PMID: 35875514

Genetic and phylogenetic analysis of capsid gene of feline calicivirus in Nanjing, China.
Liang J, Zang M, Zhou Z. Infect Genet Evol. 2022 Sep;103:105323. doi: 10.1016/j.meegid.2022.105323. Epub 2022 Jun 28. PMID: 35777531

Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines.
Beeraka NM, Sukocheva OA, Lukina E, Liu J, Fan R. Rev Med Virol. 2022 Sep;32(5):e2346. doi: 10.1002/rmv.2346. Epub 2022 Apr 13. PMID: 35416390

Control methods for Aedes aegypti: Have we lost the battle?
Lorenz C, Chiaravalloti-Neto F. Travel Med Infect Dis. 2022 Sep-Oct;49:102428. doi: 10.1016/j.tmaid.2022.102428. Epub 2022 Aug 17. PMID: 35985534

Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020-January, 2022: an observational cohort study.
Wong KK, Heilig CM, Hause A, Myers TR, Olson CK, Gee J, Marquez P, Strid P, Shay DK. Lancet Digit Health. 2022 Sep;4(9):e667-e675. doi: 10.1016/S2589-7500(22)00125-X. Epub 2022 Aug 9. PMID: 35961858

An in silico pipeline approach uncovers a potentially intricate network involving spike SARS-CoV-2 RNA, RNA vaccines, host RNA-binding proteins (RBPs), and host miRNAs at the cellular level.
Chetta M, Tarsitano M, Oro M, Rivieccio M, Bukvic N. J Genet Eng Biotechnol. 2022 Sep 6;20(1):129. doi: 10.1186/s43141-022-00413-5. PMID: 36066672

Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.
Mai AS, Lee ARYB, Tay RYK, Shapiro L, Thakkar A, Halmos B, Grinshpun A, Herishanu Y, Benjamini O, Tadmor T, Shroff RT, LaFleur BJ, Bhattacharya D, Peng S, Tey J, Lee SC, Chai LYA, Soon YY, Sundar R, Lee MX. Eur J Cancer. 2022 Sep;172:65-75. doi: 10.1016/j.ejca.2022.05.029. Epub 2022 Jun 3. PMID: 35753213

Immunogenicity and safety of an inactivated SARS-CoV-2 **vaccine** in people living with HIV: A cross-sectional study.
Cai S, Liao G, Yu T, Gao Q, Zou L, Zhang H, Xu X, Chen J, Lu A, Wu Y, Li B, Peng J. J Med Virol. 2022 Sep;94(9):4224-4233. doi: 10.1002/jmv.27872. Epub 2022 May 28. PMID: 35585023

Effects of a web-based HPV vaccination intervention on cognitive outcomes among young gay, bisexual, and other men who have sex with men.
Reiter PL, Gower AL, Kiss DE, Shoben AB, Katz ML, Bauermeister JA, Paskett ED, McRee AL. Hum Vaccin Immunother. 2022 Sep 7:2114261. doi: 10.1080/21645515.2022.2114261. Online ahead of print. PMID: 36069662

Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.

Wasserbauer M, Hlava S, Trojanek M, Stovicek J, Milota T, Drabek J, Koptová P, Cupkova A, Pichlerová D, Kucerova B, Coufal S, Keil R. PLoS One. 2022 Sep 2;17(9):e0273612. doi: 10.1371/journal.pone.0273612. eCollection 2022. PMID: 36054100

SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis.
Boettler T, Csernalabics B, Salié H, Luxenburger H, Wischer L, Salimi Alizei E, Zoldan K, Krimmel L, Bronsert P, Schwabenland M, Prinz M, Mogler C, Neumann-Haefelin C, Thimme R, Hofmann M, Bengsch B. J Hepatol. 2022 Sep;77(3):653-659. doi: 10.1016/j.jhep.2022.03.040. Epub 2022 Apr 21. PMID: 35461912

RNA biology takes root in plant systems.
Yu D, McKinley L, Nien Y, Prall W, Zvarick A. Plant Direct. 2022 Sep 6;6(9):e445. doi: 10.1002/pld3.445. eCollection 2022 Sep. PMID: 36091875

Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials.
Perez Navarro A, Pilkington V, Pepperrell T, Mirchandani M, Levi J, Hill A. Open Forum Infect Dis. 2022 Aug 22;9(9):ofac408. doi: 10.1093/ofid/ofac408. eCollection 2022 Sep. PMID: 36092832

Post-marketing Surveillance of a Quadrivalent Influenza **Vaccine** (Vaxigrip Tetra) in South Korea.
Lim S, Li X, Syrkina O, Fournier M. Infect Dis Ther. 2022 Sep 7:1-9. doi: 10.1007/s40121-022-00685-x. Online ahead of print. PMID: 36070176

The effect of a proof-of-vaccination requirement, incentive payments, and employer-based mandates on COVID-19 vaccination rates in New York City: a synthetic-control analysis.
Cohn E, Chimowitz M, Long T, Varma JK, Chokshi DA. Lancet Public Health. 2022 Sep;7(9):e754-e762. doi: 10.1016/S2468-2667(22)00196-7. PMID: 36057274

Menstrual irregularities following COVID-19 vaccination: A global cross-sectional survey.
Sarfraz A, Sarfraz Z, Sarfraz M, Nadeem Z, Felix M, Cherrez-Ojeda I. Ann Med Surg (Lond). 2022 Sep;81:104220. doi: 10.1016/j.amsu.2022.104220. Epub 2022 Aug 6. PMID: 35957648

Effects of a community-driven water, sanitation, and hygiene programme on COVID-19 symptoms, **vaccine** acceptance and non-COVID illnesses: A cluster-randomised controlled trial in rural Democratic Republic of Congo.
Croke K, Coville A, Mvukiyehe E, Dohou CJ, Zibika JP, Ghib LS, Andreottola M, Bokasola YL, Quattrochi JP. Trop Med Int Health. 2022 Sep;27(9):795-802. doi: 10.1111/tmi.13799. Epub 2022 Aug 14. PMID: 35832019

Pyoderma caused by Proteus mirabilis in sheep.
Abdollahi M, Javan AJ, Shokrpoor S, Beidokhtinezhad M, Tamai IA. Vet Med Sci. 2022 Sep 1. doi: 10.1002/vms3.926. Online ahead of print. PMID: 36049140

Commercial vaccines used in China do not protect against a novel infectious bursal disease virus variant isolated in Fujian.
Hou B, Wang CY, Luo ZB, Shao GQ. Vet Rec. 2022 Sep 7:e1840. doi: 10.1002/vetr.1840. Online ahead of print. PMID: 36073006

Low COVID-19 Vaccination Rates Among Psychiatric Inpatients: Implications for Institutional Settings and Outreach Efforts.
Shaffer CW, Wyka K, Ewing J, Russ MJ, Kanellopoulos D, Brody BD. Psychiatr Serv. 2022 Sep 6:appips20220222. doi: 10.1176/appi.ps.20220222. Online ahead of print. PMID: 36065578

mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
Bevers S, Kooijmans SAA, Van de Velde E, Evers MJW, Seghers S, Gitz-Francois JJJM, van Kronenburg NCH, Fens MHAM, Mastrobattista E, Hassler L, Sork H, Lehto T, Ahmed KE, El Andaloussi S, Fiedler K, Breckpot K, Maes M, Van Hoorick D, Bastogne T, Schiffelers RM, De Koker S. Mol Ther. 2022 Sep 7;30(9):3078-3094. doi: 10.1016/j.ymthe.2022.07.007. Epub 2022 Jul 12. PMID: 35821637

An Overview of Strategies to Improve Vaccination Compliance before and during the COVID-19 Pandemic.
Charrier L, Garlasco J, Thomas R, Gardois P, Bo M, Zotti CM. Int J Environ Res Public Health. 2022 Sep 3;19(17):11044. doi: 10.3390/ijerph191711044. PMID: 36078757

Physical, Chemical, and Biological Properties of Chitosan-Coated Alginate Microparticles Loaded with Porcine Interleukin-1β: A Potential Protein Adjuvant Delivery System.
Ho WX, Chen WT, Lien CH, Yang HY, Chen KH, Wei YF, Wang MH, Ko IT, Tseng FG, Yin HS. Int J Mol Sci. 2022 Sep 1;23(17):9959. doi: 10.3390/ijms23179959. PMID: 36077367

Development of a farm-specific real-time quantitative RT-PCR assay for the detection and discrimination of wild-type porcine reproductive respiratory syndrome virus and the **vaccine** strain in a farm under eradication.
Fornyos K, Szabó I, Lebhardt K, Bálint Á. Acta Vet Hung. 2022 Sep 1. doi: 10.1556/004.2022.00020. Online ahead of print. PMID: 36053720

Immune responses to SARS-CoV-2 vaccines in celiac disease.
Ibsen JH, Chopra A, Vaage EB, Vaage JT, Lund-Johansen F, Lundin KEA. Scand J Gastroenterol. 2022 Sep 1:1-6. doi: 10.1080/00365521.2022.2114809. Online ahead of print. PMID: 36049123

A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination.
Fu PA, Chen CW, Hsu YT, Wei KC, Lin PC, Chen TY. J Formos Med Assoc. 2022 Sep;121(9):1872-1876. doi: 10.1016/j.jfma.2022.02.017. Epub 2022 Mar 14. PMID: 35321820

COVID-19 Mass Vaccination and Flu season: Concern for Decreased Public Health Measures and worsening the influenza situation.
Kenarkoohi A, Mohamadi J, Pakzad I, Sayyadi H, Falahi S. Infect Disord Drug Targets. 2022 Sep 3. doi: 10.2174/1871526522666220903145208. Online ahead of print. PMID: 36056829

Pituitary apoplexy after COVID-19 vaccination: A case report.
Zainordin NA, Hatta SFWM, Ab Mumin N, Shah FZM, Ghani RA. J Clin Transl Endocrinol Case Rep. 2022 Sep;25:100123. doi: 10.1016/j.jecr.2022.100123. Epub 2022 Aug 4. PMID: 35942396

Thermostable H1 hemagglutinin stem with M2e epitopes provides broad cross-protection against group1 and 2 influenza A viruses.

Subbbiah J, Oh J, Kim KH, Shin CH, Park BR, Bhatnagar N, Jung YJ, Lee Y, Wang BZ, Seong BL, Kang SM. Mol Ther Methods Clin Dev. 2022 May 29;26:38-51. doi: 10.1016/j.omtm.2022.05.007. eCollection 2022 Sep 8. PMID: 35755946

In vivo monitoring of Lactiplantibacillus plantarum in the nasal and vaginal mucosa using infrared fluorescence.
Silva-Bea S, Francisco-Tomé M, Cabrera-Alvargonzález JJ, Potel C, Álvarez M, Pérez S, Regueiro B, Cabral MP. Appl Microbiol Biotechnol. 2022 Sep;106(18):6239-6251. doi: 10.1007/s00253-022-12121-8. Epub 2022 Aug 24. PMID: 35999391

Immunoprophylaxis using polypeptide chimera vaccines plus adjuvant system promote Th1 response controlling the spleen parasitism in hamster model of visceral leishmaniasis.
Gusmão MR, Ostolin TLVDP, Carvalho LM, Costa AFP, Moreira GJL, Cardoso JMO, Aguiar-Soares RDO, Reis AB, de Brito RCF, Roatt BM. Vaccine. 2022 Sep 2;40(37):5494-5503. doi: 10.1016/j.vaccine.2022.08.005. Epub 2022 Aug 10. PMID: 35963820

Safety and immunogenicity of a simian-adenovirus-vectored rabies **vaccine**: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Jenkin D, Ritchie AJ, Aboagye J, Fedosyuk S, Thorley L, Provstgaad-Morys S, Sanders H, Bellamy D, Makinson R, Xiang ZQ, Bolam E, Tarrant R, Ramos Lopez F, Platt A, Poulton I, Green C, Ertl HCJ, Ewer KJ, Douglas AD. Lancet Microbe. 2022 Sep;3(9):e663-e671. doi: 10.1016/S2666-5247(22)00126-4. Epub 2022 Jul 27. PMID: 35907430

Pathogenesis and Transmissibility of North American Highly Pathogenic Avian Influenza A(H5N1) Virus in Ferrets.
Pulit-Penaloza JA, Belser JA, Brock N, Thakur PB, Tumpey TM, Maines TR. Emerg Infect Dis. 2022 Sep;28(9):1913-1915. doi: 10.3201/eid2809.220879. Epub 2022 Jul 15. PMID: 35840125

Monkeypox emergency: Urgent questions and perspectives.
Rothenburg S, Yang Z, Beard P, Sawyer SL, Titanji B, Gonsalves G, Kindrachuk J. Cell. 2022 Sep 1;185(18):3279-3281. doi: 10.1016/j.cell.2022.08.002. Epub 2022 Aug 10. PMID: 35998628

COVID-19 Booster **Vaccine** Equity for Patients With Cancer.
Prasad RN, Patel M, Palmer JD. Adv Radiat Oncol. 2022 Sep-Oct;7(5):100939. doi: 10.1016/j.adro.2022.100939. Epub 2022 Mar 9. PMID: 35280348

Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis.
Hernández-Porto M, García S, Delgado T, Rodriguez Y, Aguirre-Jaime A, Campos S, Hernández C, Lorenzo C, Lecuona M. Int J Infect Dis. 2022 Sep;122:327-331. doi: 10.1016/j.ijid.2022.05.065. Epub 2022 Jun 4. PMID: 35671949

Endovascular treatment for **vaccine**-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: a report of three cases.
Cleaver J, Ibitoye R, Morrison H, Flood R, Crewdson K, Marsh A, Abhinav K, Bosnell R, Crossley R, Mortimer A. J Neurointerv Surg. 2022 Sep;14(9):853-857. doi: 10.1136/neurintsurg-2021-018238. Epub 2021 Nov 15. PMID: 34782400

Smart and connected devices in point-of-care molecular diagnostics: what role can they play in the response to COVID-19?
Kaushik A, Gupta S, Sood M, Steussy BW, Noll BW. Expert Rev Mol Diagn. 2022 Sep 11:1-7. doi: 10.1080/14737159.2022.2122711. Online ahead of print. PMID: 36069357

Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review.
Zhao Z, Zhang X, Wang R, Wang Y, Gong L, Li C. Dermatol Ther. 2022 Sep;35(9):e15684. doi: 10.1111/dth.15684. Epub 2022 Jul 14. PMID: 35789520

Molasses, Antox® and EN-FLORAX® decreased antibody decay rate and enhanced response to a very virulent infectious bursal disease virus and Newcastle disease **vaccine** La Sota in ISA Brown chicks.
Andamin A, Abdu P, Orakpoghenor O, Markus T, Oladele S, Akade F, Aluwong T. J Immunoassay Immunochem. 2022 Sep 3;43(5):546-556. doi: 10.1080/15321819.2022.2036188. Epub 2022 Feb 13. PMID: 35156530

"A comparative evaluation of therapeutic response in warts to intralesional vitamin D3 versus intralesional MMR **vaccine**.".
Singh AK, Devi KN, Bist JS. Dermatol Ther. 2022 Sep 11:e15813. doi: 10.1111/dth.15813. Online ahead of print. PMID: 36088627

Adverse Events Related to COVID-19 Vaccines Reported in Pregnant Women in Brazil.
Kobayashi CD, Porto VBG, da Nóbrega MEB, Cabral CM, Barros TD, Martins CMR. Rev Bras Ginecol Obstet. 2022 Sep 6. doi: 10.1055/s-0042-1755461. Online ahead of print. PMID: 36067796

Moving the Needle: Association Between a Vaccination Reward Lottery and COVID-19 Vaccination Uptake in Louisiana.
Wang Y, Hernandez J, Stoecker C. Public Health Rep. 2022 Sep 5:333549221120676. doi: 10.1177/00333549221120676. Online ahead of print. PMID: 36062380

COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer.
Andresciani F, Ricci M, Grasso RF, Zobel BB, Quattrocchi CC. Radiol Case Rep. 2022 Jun 17;17(9):2996-2999. doi: 10.1016/j.radcr.2022.05.072. eCollection 2022 Sep. PMID: 35747740

Should I stay or should I go? Observation post-vaccination during the COVID-19 pandemic and the law of unintended consequences.
Ingham G, Kippen R. Aust J Prim Health. 2022 Sep 8. doi: 10.1071/PY22074. Online ahead of print. PMID: 36070885

The mechanisms of immune response and evasion by the main SARS-CoV-2 variants.
Chen Q, Zhang J, Wang P, Zhang Z. iScience. 2022 Sep 2:105044. doi: 10.1016/j.isci.2022.105044. Online ahead of print. PMID: 36068846

Validation of an FFF-MALS Method to Characterize the Production and Functionalization of Outer-Membrane Vesicles for Conjugate Vaccines.
van der Put RMF, Spies A, Metz B, Some D, Scherrers R, Pieters R, Danial M. Anal Chem. 2022 Sep 6;94(35):12033-12041. doi: 10.1021/acs.analchem.2c01590. Epub 2022 Aug 25. PMID: 36007249

Clinical characteristics of patients with COVID-19 **vaccine**-related pneumonitis: a case series and literature review.
Park JY, Kim JH, Park S, Hwang YI, Kim HI, Jang SH, Jung KS, Kim YK, Kim HA, Lee IJ. Korean J Intern Med. 2022 Sep;37(5):989-1001. doi: 10.3904/kjim.2022.072. Epub 2022 Aug 22. PMID: 35989064

New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review.
Wu PC, Huang IH, Wang CW, Tsai CC, Chung WH, Chen CB. Am J Clin Dermatol. 2022 Sep 1:1-25. doi: 10.1007/s40257-022-00721-z. Online ahead of print. PMID: 36048409

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 **vaccine** (CVnCOV) followed by a third-fourth shot with a standard mRNA **vaccine** (BNT162b2): RescueVacs multicenter cohort study.
Ascaso-Del-Rio A, García-Pérez J, Pérez-Olmeda M, Arana-Arri E, Vergara I, Pérez-Ingidua C, Bermejo M, Castillo de la Osa M, Imaz-Ayo N, Riaño Fernández I, Astasio González O, Díez-Fuertes F, Meijide S, Arrizabalaga J, Hernández Gutiérrez L, de la Torre-Tarazona HE, Mariano Lázaro A, Vargas-Castrillón E, Alcamí J, Portolés A; RescueVac study Group. EClinicalMedicine. 2022 Jul 1;51:101542. doi: 10.1016/j.eclinm.2022.101542. eCollection 2022 Sep. PMID: 35795398

Absence of SARS-CoV-2 Spike glycoprotein expression in placentas from individuals after mRNA SARS-CoV-2 vaccination.
Santos A, Sauer M, Neil AJ, Solomon IH, Hornick JL, Roberts DJ, Quade BJ, Parra-Herran C. Mod Pathol. 2022 Sep;35(9):1175-1180. doi: 10.1038/s41379-022-01061-3. Epub 2022 Mar 31. PMID: 35361888

Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, Chatfield MD, Lehmann D, Binks M, Chang AB, Carapetis J, Krause V, Andrews R, Snelling T, Skull SA, Licciardi PV, Oguoma VM, Morris PS. Lancet Infect Dis. 2022 Sep;22(9):1374-1387. doi: 10.1016/S1473-3099(22)00272-9. Epub 2022 Jun 27. PMID: 35772449

Hepatitis B and Acute Liver Failure.
Ledoux N. Crit Care Nurs Clin North Am. 2022 Sep;34(3):259-265. doi: 10.1016/j.cnc.2022.04.012. Epub 2022 Jul 20. PMID: 36049845

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle **vaccine**: a randomised, double-blind, parallel-group, phase 2 trial.
Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, Alexander J, Ledgerwood JE, de Lame PA, Royalty Tredo S, Warfield KL, Bedell L. Lancet Infect Dis. 2022 Sep;22(9):1343-1355. doi: 10.1016/S1473-3099(22)00226-2. Epub 2022 Jun 13. PMID: 35709798

COVID-19 vaccination not associated with increased risk of erectile dysfunction.
Diaz P, Zizzo J, Blachman-Braun R, Gandhi DA, Reddy R, Zucker IJ, Dullea A, Khodamoradi K, Ramasamy R. Andrologia. 2022 Sep 8:e14563. doi: 10.1111/and.14563. Online ahead of print. PMID: 36073235

The 'best friend effect': a promising tool to encourage HPV vaccination in Japan.
Yagi A, Ueda Y, Tomine Y, Ikeda S, Kakuda M, Nakagawa S, Hiramatsu K, Miyoshi A, Kobayashi E, Kimura T, Hirai K, Kimura T. Int J Clin Oncol. 2022 Sep 3:1-8. doi: 10.1007/s10147-022-02240-7. Online ahead of print. PMID: 36057048

Immunization with placenta-specific 1 (plac1) induces potent anti-tumor responses and prolongs survival in a mouse model of melanoma.
Rahdan S, Razavi SA, Shojaeian S, Shokri F, Amiri MM, Zarnani AH. Adv Med Sci. 2022 Sep 6;67(2):338-345. doi: 10.1016/j.advms.2022.08.002. Online ahead of print. PMID: 36084365

How to cope with emerging viral diseases: Lessons from South Korea's strategy for COVID-19, and collateral damage to cardiometabolic health.
Lim S, Sohn M. Lancet Reg Health West Pac. 2022 Sep 5:100581. doi: 10.1016/j.lanwpc.2022.100581. Online ahead of print. PMID: 36093123

Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination.
Feng Y, Quan Y, Cassady K, Zou Z, Gao Y, Zhang X. Hum Vaccin Immunother. 2022 Sep 7:2119043. doi: 10.1080/21645515.2022.2119043. Online ahead of print. PMID: 36069667

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis.
Allen-Philbey K, Stennett A, Begum T, Johnson AC, MacDougall A, Green S, Dobson R, Giovannoni G, Gnanapavan S, Marta M, Smets I, Turner BP, Baker D, Mathews J, Schmierer K. Mult Scler Relat Disord. 2022 Sep;65:104022. doi: 10.1016/j.msard.2022.104022. Epub 2022 Jul 3. PMID: 35816953

Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic.
Heidler F, Baldt J, Frahm N, Langhorst SE, Mashhadiakbar P, Streckenbach B, Burian K, Zettl UK, Richter J. Sci Rep. 2022 Sep 7;12(1):15147. doi: 10.1038/s41598-022-18912-3. PMID: 36071083

Vaccination, life expectancy, and trust: patterns of COVID-19 and measles vaccination rates around the world.
Rughiniș C, Vulpe SN, Flaherty MG, Vasile S. Public Health. 2022 Sep;210:114-122. doi: 10.1016/j.puhe.2022.06.027. Epub 2022 Jul 4. PMID: 35963036

Association of Pneumococcal and Influenza Vaccination With Patient-Physician Communication in Older Adults: A Nationwide Cross-sectional Study From the JAGES 2016.
Sato K, Kondo N, Murata C, Shobugawa Y, Saito K, Kondo K. J Epidemiol. 2022 Sep 5;32(9):401-407. doi: 10.2188/jea.JE20200505. Epub 2021 Jul 17. PMID: 33551389

Single-cell views of the Plasmodium life cycle.
Real E, Mancio-Silva L. Trends Parasitol. 2022 Sep;38(9):748-757. doi: 10.1016/j.pt.2022.05.009. Epub 2022 Jun 4. PMID: 35672200

Evaluation of Effectiveness of Global COVID-19 Vaccination Campaign.
He D, Ali ST, Fan G, Gao D, Song H, Lou Y, Zhao S, Cowling BJ, Stone L. Emerg Infect Dis. 2022 Sep;28(9):1873-1876. doi: 10.3201/eid2809.212226. Epub 2022 Aug 1. PMID: 35914516

SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 **vaccine**: Looking for correlates of protection.
Torres I, Giménez E, Albert E, Zulaica J, Álvarez-Rodríguez B, Burgos JS, Peiró S, Limón R, Vanaclocha H, Rodado C, Botija P, Sifre A, Tur B, Lozano RA, Orosa I, Vicente-Ruiz M, Carrión RJ, Clari MÁ, Sánchez-Payá J, Díez-Domingo J, Comas I, González-Candelas F, Geller R, Navarro D; Valencian vaccine research program (ProVaVac) study group. J Med Virol. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. Epub 2022 May 25. PMID: 35585782

Frequency of serious bacterial infection among febrile sickle cell disease children in the era of the conjugate **vaccine**: A retrospective study.
Alzomor O, Aljobair F, Al Kasim F, Azmet F, Alorini S, Alshihayb Y, Bahamdan Y. Int J Pediatr Adolesc Med. 2022 Sep;9(3):165-170. doi: 10.1016/j.ijpam.2022.05.002. Epub 2022 May 31. PMID: 36090129

Sports Imaging of COVID-19: A Multi-Organ System Review of Indications and Imaging Findings.
Rashidi A, Fritz J. Sports Health. 2022 Sep-Oct;14(5):618-631. doi: 10.1177/19417381221106448. Epub 2022 Jun 23. PMID: 35746891

Enhanced *In Vitro* and *In Vivo* Potency of a T Cell Epitope in the Ebola Virus Glycoprotein Following Amino Acid Replacement at HLA-A*02:01 Binding Positions.
Chabot S, Gimie Y, Obeid K, Kim J, Meseda CA, Konduru K, Kaplan G, Sheng Fowler L, Weir JP, Peden K, Major ME. J Virol. 2022 Sep 7:e0116621. doi: 10.1128/jvi.01166-21. Online ahead of print. PMID: 36069549

Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on Immunosuppression.
Manjappa S, Phi HQ, Lee LW, Onstad L, Gill DB, Connelly-Smith L, Krakow EF, Flowers ME, Carpenter PA, Hill JA, Lee SJ. Transplant Cell Ther. 2022 Sep 1:S2666-6367(22)01595-0. doi: 10.1016/j.jtct.2022.08.026. Online ahead of print. PMID: 36058550

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza **vaccine** in children and adolescents 6 months through 17 years of age in India.
Kalappanavar NK, Ghosh A, Sharma M, Ravichandran L, Choraria N, P S, Pandey M, N P, Shah P, Nair S, Shaikh A, van de Witte S. Hum Vaccin Immunother. 2022 Sep 2:2104527. doi: 10.1080/21645515.2022.2104527. Online ahead of print. PMID: 36053721

Engineered coxsackievirus B3 containing multiple organ-specific miRNA targets showed attenuated viral tropism and protective immunity.
Xiao Z, He F, Feng M, Liu Z, Liu Z, Li S, Wang W, Yao H, Wu J. Infect Genet Evol. 2022 Sep;103:105316. doi: 10.1016/j.meegid.2022.105316. Epub 2022 Jun 17. PMID: 35718333

Evaluating complete surface-associated and secretory proteome of Leishmania donovani for discovering novel vaccines and diagnostic targets.
Karim M, Singh G, Thakur S, Rana A, Rub A, Akhter Y. Arch Microbiol. 2022 Sep 7;204(10):604. doi: 10.1007/s00203-022-03219-8. PMID: 36069945

Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Variants of Concern in Real-world: a Literature Review and Meta-analysis.

Shao W, Chen X, Zheng C, Liu H, Wang G, Zhang B, Li Z, Zhang W. Emerg Microbes Infect. 2022 Sep 7:1-75. doi: 10.1080/22221751.2022.2122582. Online ahead of print. PMID: 36069511

Kidney Transplantation From Deceased Donors With **Vaccine**-induced Immune Thrombocytopenia and Thrombosis: An Updated Analysis of the UK Experience.
Greenhall GHB, Ushiro-Lumb I, Pavord S, Hunt BJ, Sharma H, Mehra S, Calder F, Kessaris N, Kilbride H, Jones G, Motallebzadeh R, Arslan Z, Marks SD, Graetz K, Pettigrew GJ, Torpey N, Watson C, Roy D, Casey J, Oniscu GC, Currie I, Sutherland A, Clancy M, Dor F, Willicombe M, Sandhu B, Nath J, Weston C, van Dellen D, Roberts DJ, Madden S, Ravanan R, Forsythe J, Khurram MA, Mohamed I, Callaghan CJ. Transplantation. 2022 Sep 1;106(9):1824-1830. doi: 10.1097/TP.0000000000004190. Epub 2022 Jul 13. PMID: 35821588

Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA **vaccine**, successfully treated with prednisolone and rituximab.
Murali A, Wong P, Gilbar PJ, Mangos HM. J Oncol Pharm Pract. 2022 Sep;28(6):1450-1453. doi: 10.1177/10781552221075545. Epub 2022 Jan 28. PMID: 35088622

Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group.
Kirson N, Swallow E, Lu J, Foroughi C, Bookhart B, DeMartino JK, Maynard J, Shivdasani Y, Eid D, Lefebvre P. Public Health. 2022 Sep;210:99-106. doi: 10.1016/j.puhe.2022.06.019. Epub 2022 Jun 23. PMID: 35921739

Assessing the impact of non-pharmaceutical interventions (NPIs) and BCG **vaccine** cross-protection in the transmission dynamics of SARS-CoV-2 in eastern Africa.
Kilonzo CM, Wamalwa M, Whegang SY, Tonnang HEZ. BMC Res Notes. 2022 Sep 4;15(1):283. doi: 10.1186/s13104-022-06171-4. PMID: 36059028

Effectiveness and profitability of preventive veterinary interventions in controlling infectious diseases of ruminant livestock in sub-Saharan Africa: a scoping review.
Nuvey FS, Arkoazi J, Hattendorf J, Mensah GI, Addo KK, Fink G, Zinsstag J, Bonfoh B. BMC Vet Res. 2022 Sep 2;18(1):332. doi: 10.1186/s12917-022-03428-9. PMID: 36056387

Understanding Variation in Rotavirus **Vaccine** Effectiveness Estimates in the United States: The Role of Rotavirus Activity and Diagnostic Misclassification.
Amin AB, Lash TL, Tate JE, Waller LA, Wikswo ME, Parashar UD, Stewart LS, Chappell JD, Halasa NB, Williams JV, Michaels MG, Hickey RW, Klein EJ, Englund JA, Weinberg GA, Szilagyi PG, Staat MA, McNeal MM, Boom JA, Sahni LC, Selvarangan R, Harrison CJ, Moffatt ME, Schuster JE, Pahud BA, Weddle GM, Azimi PH, Johnston SH, Payne DC, Bowen MD, Lopman BA. Epidemiology. 2022 Sep 1;33(5):660-668. doi: 10.1097/EDE.0000000000001501. Epub 2022 May 18. PMID: 35583516

Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus **Vaccine** in Burundi.
Niyibitegeka F, Thavorncharoensap M, Riewpaiboon A, Youngkong S. Appl Health Econ Health Policy. 2022 Sep;20(5):707-716. doi: 10.1007/s40258-022-00722-3. Epub 2022 Apr 26. PMID: 35469393

Cardiomyopathy following COVID-19 vaccination in a patient with SLE.
Bhullar AK, Chee CZ, Seung OP, Gek KC, Amin NHM. Mod Rheumatol Case Rep. 2022 Sep 7:rxac070. doi: 10.1093/mrcr/rxac070. Online ahead of print. PMID: 36069645

Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022.
Mefsin YM, Chen D, Bond HS, Lin Y, Cheung JK, Wong JY, Ali ST, Lau EHY, Wu P, Leung GM, Cowling BJ. Emerg Infect Dis. 2022 Sep;28(9):1856-1858. doi: 10.3201/eid2809.220613. Epub 2022 Aug 1. PMID: 35914518

COVID-19 in patients with B cell immune deficiency.
Vergidis P, Levy ER, Ristagno EH, Iyer VN, O'Horo JC, Joshi AY. J Immunol Methods. 2022 Sep 7;510:113351. doi: 10.1016/j.jim.2022.113351. Online ahead of print. PMID: 36087764

Impact of the expanded program on immunization on the incidence of Japanese encephalitis in different regions of Mainland China: An interrupt time series analysis.
Shi T, Meng L, Li D, Jin N, Zhao X, Zhang X, Liu Y, Zheng H, Zhao X, Li J, Shen X, Ren X. Acta Trop. 2022 Sep;233:106575. doi: 10.1016/j.actatropica.2022.106575. Epub 2022 Jun 26. PMID: 35768039

Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
Hirai K, Shimotashiro M, Sonoda T, Okumura T, Ookawara S, Morishita Y. Clin Exp Nephrol. 2022 Sep;26(9):925-932. doi: 10.1007/s10157-022-02223-y. Epub 2022 Apr 15. PMID: 35426594

Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks.
Islam MR, Hossain MJ, Roy A, Hasan AHMN, Rahman MA, Shahriar M, Bhuiyan MA. Health Sci Rep. 2022 Aug 23;5(5):e798. doi: 10.1002/hsr2.798. eCollection 2022 Sep. PMID: 36032515

Effects of detoxification process on toxicity and foreign protein of tetanus toxoid and diphtheria toxoid.
Long Z, Wei C, Ross R, Luo X, Ma X, Qi Y, Chai R, Cao J, Huang M, Bo T. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Sep 1;1207:123377. doi: 10.1016/j.jchromb.2022.123377. Epub 2022 Jul 14. PMID: 35905569

Factors Associated With COVID-19 Behavioral Intentions: Findings From an Online Survey.
Lama Y, Budenz A, Gaysynsky A, Iles IA, Sylvia Chou WY. Am J Health Promot. 2022 Sep;36(7):1183-1192. doi: 10.1177/08901171221093036. Epub 2022 Apr 22. PMID: 35459412

Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients.
Toapanta-Yanchapaxi L, Chiquete E, Ávila-Rojo E, López-Yánez S, Luna Del Villar Velasco S, Rivera Monroy S, López Gómez T, Andrés Aguilar JB, Balcázar Antonio DF, Alcaraz-Fuerte C, García Baysa M, López Jiménez JL, Márquez-Guillén E, Vilatobá M, Cruz-Martínez R, Carpinteyro-Espin P, Chávez-Villa M, Romero Morelos RD, Torres-Del Real D, Uscanga-Domínguez LF, García-Alanis M, Tapia Sosa R, Servín-Rojas M, Valdez-Echeverria RD, García-Juárez I. Vaccine. 2022 Sep 9;40(38):5621-5630. doi: 10.1016/j.vaccine.2022.08.027. Epub 2022 Aug 22. PMID: 36028456

COVID-19 **vaccine** humoral response in frequent platelet donors with plateletpheresis-associated lymphopenia.

Laumaea AE, Lewin A, Chatterjee D, Marchitto L, Ding S, Gendron-Lepage G, Goyette G, Allard MÈ, Simard C, Tremblay T, Perreault J, Duerr R, Finzi A, Bazin R. Transfusion. 2022 Sep;62(9):1779-1790. doi: 10.1111/trf.17037. Epub 2022 Aug 2. PMID: 35919021

Tannic Acid, as a Structural Moiety Coupled to a Protein Antigen, Exhibiting a Molecular-Structure Adjuvant Activity for Antibody Specificity Enhancement.
Molina-Ramírez B, Cabral-Hipólito N, Castillo-Maldonado I, Delgadillo-Guzmán D, Meza-Velázquez R, Ramírez-Moreno A, Flores-Loyola E, Ruíz-Flores P, Cruz JH, Espino-Silva PK, Avalos-Soto J, Téllez-López MÁ, Vertti RDAP, Rosales-González MG, Pedroza-Escobar D. Protein Pept Lett. 2022 Sep 2. doi: 10.2174/0929866529666220902152147. Online ahead of print. PMID: 36056859

Recommendations for Prevention and Control of Influenza in Children, 2022-2023.
COMMITTEE ON INFECTIOUS DISEASES. Pediatrics. 2022 Sep 6:e2022059274. doi: 10.1542/peds.2022-059274. Online ahead of print. PMID: 36065749

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
Bhatnagar T, Chaudhuri S, Ponnaiah M, Yadav PD, Sabarinathan R, Sahay RR, Ahmed F, Aswathy S, Bhardwaj P, Bilimale A, Kumar MS, Logaraj M, Narlawar U, Palanivel C, Patel P, Rai SK, Saxena V, Singh A, Thangaraj JW, Agarwal A, Alvi Y, Amoghashree, Ashok P, Babu D, Bahurupi Y, Bhalavi S, Behera P, Biswas PP, Charan J, Chauhan NK, Chetak KB, Dar L, Das A, Deepashree R, Dhar M, Dhodapkar R, Dipu TS, Dudeja M, Dudhmal M, Gadepalli R, Garg MK, Gayathri AV, Goel AD, Gowdappa HB, Guleria R, Gupta MK, Islam F, Jain M, Jain V, Jawahar MLS, Joshi R, Kant S, Kar SS, Kalita D, Khapre M, Khichar S, Kombade SP, Kohli S, Kumar A, Kumar A, Kumar D, Kulirankal KG, Leela KV, Majumdar T, Mishra B, Misra P, Misra S, Mohapatra PR, Murthy MN, Nyayanit DA, Patel M, Pathania M, Patil S, Patro BK, Jalandra R, Rathod P, Shah N, Shete A, Shukla D, Shwethashree M, Sinha S, Sumana MN, Surana A, Trikha A, Tejashree A, Venkateshan M, Vijaykrishnan G, Wadhava S, Wig N, Gupta N, Abraham P, Murhekar MV. Int J Infect Dis. 2022 Sep;122:693-702. doi: 10.1016/j.ijid.2022.07.033. Epub 2022 Jul 16. PMID: 35843496

Brain dural arteriovenous fistulas in the COVID-19 Era: A warning and rationale for association.
Garcia-Garcia S, Cepeda S, Arrese I, Sarabia R. Clin Neurol Neurosurg. 2022 Sep;220:107367. doi: 10.1016/j.clineuro.2022.107367. Epub 2022 Jul 14. PMID: 35843195

Medium-vessel Vasculitis Presenting with Myalgia Following COVID-19 Moderna Vaccination: A Case Report.
Ohmura SI, Ohkubo Y, Ishihara R, Otsuki Y, Miyamoto T. Intern Med. 2022 Sep 6. doi: 10.2169/internalmedicine.0293-22. Online ahead of print. PMID: 36070946

Infection with SARS-CoV-2 Omicron Variant 24 Days after Non-Omicron Infection, Pennsylvania, USA.
Seid AG, Yirko T, Sayeed S, Plipat N. Emerg Infect Dis. 2022 Sep;28(9):1911-1913. doi: 10.3201/eid2809.220539. Epub 2022 Aug 1. PMID: 35914519

Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next.
Corey KB, Koo G, Phillips EJ. J Allergy Clin Immunol Pract. 2022 Sep;10(9):2254-2266. doi: 10.1016/j.jaip.2022.04.035. Epub 2022 May 10. PMID: 35550878

Optimal allocation strategies for prioritized geographical vaccination for Covid-19.
Ghazal I, Rachadi A, Ez-Zahraouy H. Physica A. 2022 Sep 6:128166. doi: 10.1016/j.physa.2022.128166. Online ahead of print. PMID: 36090308

Nanotoxoid vaccination protects against opportunistic bacterial infections arising from immunodeficiency.
Zhou J, Krishnan N, Guo Z, Ventura CJ, Holay M, Zhang Q, Wei X, Gao W, Fang RH, Zhang L. Sci Adv. 2022 Sep 9;8(36):eabq5492. doi: 10.1126/sciadv.abq5492. Epub 2022 Sep 9. PMID: 36083909

Additional Evidence for Commonalities between COVID-19 and Radiation Injury: Novel Insight into COVID-19 Candidate Drugs.
Geng F, Chen J, Tang S, Azzam EI, Zhang J, Zhang S. Radiat Res. 2022 Sep 1;198(3):306-317. doi: 10.1667/RADE-22-00058.1. PMID: 35834824

Missed Opportunities for Human Papillomavirus Vaccination by Parental Nativity, Minnesota, 2015-2018.
Groene EA, Horvath KJ, Yared N, Mohammed I, Muscoplat M, Kuramoto S, Richter T, Kulasingam S. Public Health Rep. 2022 Sep-Oct;137(5):867-877. doi: 10.1177/00333549211027244. Epub 2021 Jul 12. PMID: 34252324

Outcomes of Cerebral Venous Thrombosis due to **Vaccine**-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase.
van de Munckhof A, Lindgren E, Kleinig TJ, Field TS, Cordonnier C, Krzywicka K, Poli S, Sánchez van Kammen M, Borhani-Haghighi A, Lemmens R, Scutelnic A, Ciccone A, Gattringer T, Wittstock M, Dizonno V, Devroye A, Elkady A, Günther A, Cervera A, Mengel A, Chew BLA, Buck B, Zanferrari C, Garcia-Esperon C, Jacobi C, Soriano C, Michalski D, Zamani Z, Blacquiere D, Johansson E, Cuadrado-Godia E, Vuillier F, Bode FJ, Caparros F, Maier F, Tsivgoulis G, Katzberg HD, Duan J, Burrow J, Pelz J, Mbroh J, Oen J, Schouten J, Zimmermann J, Ng K, Garambois K, Petruzzellis M, Carvalho Dias M, Ghiasian M, Romoli M, Miranda M, Wronski M, Skjelland M, Almasi-Dooghaee M, Cuisenier P, Murphy S, Timsit S, Coutts SB, Schönenberger S, Nagel S, Hiltunen S, Chatterton S, Cox T, Bartsch T, Shaygannejad V, Mirzaasgari Z, Middeldorp S, Levi MM, Kremer Hovinga JA, Jood K, Tatlisumak T, Putaala J, Heldner MR, Arnold M, Aguiar de Sousa D, Ferro JM, Coutinho JM. Stroke. 2022 Sep 9:101161STROKEAHA122039575. doi: 10.1161/STROKEAHA.122.039575. Online ahead of print. PMID: 36082668

Beyond coverage: Rural-urban disparities in the timeliness of childhood vaccinations in Tanzania.
Yelverton V, Hair NL, Ghosh SH, Mfinanga SG, Ngadaya E, Baumgartner JN, Ostermann J, Vasudevan L. Vaccine. 2022 Sep 2;40(37):5483-5493. doi: 10.1016/j.vaccine.2022.07.020. Epub 2022 Aug 10. PMID: 35961796

Longitudinal dynamics of SARS-CoV-2 anti-receptor binding domain IgG antibodies in a wide population of health care workers after BNT162b2 vaccination.
Bordi L, Sberna G, Piscioneri CN, Cocchiara RA, Miani A, Grammatico P, Mariani B, Parisi G. Int J Infect Dis. 2022 Sep;122:174-177. doi: 10.1016/j.ijid.2022.05.061. Epub 2022 May 31. PMID: 35661687

Protective effect of pneumococcal conjugate vaccination on the short-term association between low temperatures and childhood pneumonia hospitalizations: Interrupted time-series and case-crossover analyses in Matlab, Bangladesh.

Tao J, Hossain MZ, Xu Z, Ho HC, Khan MA, Huang C, Zheng H, Ni J, Fan Y, Bogale D, Su H, Cheng J. Environ Res. 2022 Sep;212(Pt A):113156. doi: 10.1016/j.envres.2022.113156. Epub 2022 Mar 21. PMID: 35331698

Pregnancy status at the time of COVID-19 vaccination and incidence of SARS-CoV-2 infection.
Magnus MC, Håberg SE, Carlsen EØ, Kwong JC, Buchan SA, Fell DB. Clin Infect Dis. 2022 Sep 8:ciac739. doi: 10.1093/cid/ciac739. Online ahead of print. PMID: 36071540

COVID-19 vaccination coverage and **vaccine** hesitancy among people with opioid use disorder in Barcelona, Spain.
Vallecillo G, Durán X, Canosa I, Roquer A, Martinez MC, Perelló R. Drug Alcohol Rev. 2022 Sep;41(6):1311-1318. doi: 10.1111/dar.13502. Epub 2022 Jun 6. PMID: 35668697

"Vaccination saves lives: a real-time study of patients with chronic diseases and severe COVID-19 infection".
Mukherjee A, Kumar G, Turuk A, Bhalla A, Bingi TC, Bhardwaj P, Baruah TD, Mukherjee S, Talukdar A, Ray Y, John M, Khambholja JR, Patel AH, Bhuniya S, Joshi R, Menon GR, Sahu D, Rao VV, Bhargava B, Panda S; NCRC Study team. QJM. 2022 Sep 2:hcac202. doi: 10.1093/qjmed/hcac202. Online ahead of print. PMID: 36053197

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
Meyer-Arndt L, Braun J, Fauchere F, Vanshylla K, Loyal L, Henze L, Kruse B, Dingeldey M, Jürchott K, Mangold M, Maraj A, Braginets A, Böttcher C, Nitsche A, de la Rosa K, Ratswohl C, Sawitzki B, Holenya P, Reimer U, Sander LE, Klein F, Paul F, Bellmann-Strobl J, Thiel A, Giesecke-Thiel C. J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):960-971. doi: 10.1136/jnnp-2022-329395. Epub 2022 Jul 14. PMID: 35835468

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 **vaccine** (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
Vadrevu KM, Reddy S, Jogdand H, Ganneru B, Mirza N, Tripathy VN, Singh C, Khalatkar V, Prasanth S, Rai S, Ella R, Blackwelder W, Prasad S, Ella K. Lancet Infect Dis. 2022 Sep;22(9):1303-1312. doi: 10.1016/S1473-3099(22)00307-3. Epub 2022 Jun 16. PMID: 35717995

Measles outbreak in sub-Saharan Africa amidst COVID-19: A rising concern, efforts, challenges, and future recommendations.
Nchasi G, Paul IK, Sospeter SB, Mallya MR, Ruaichi J, Malunga J. Ann Med Surg (Lond). 2022 Sep;81:104264. doi: 10.1016/j.amsu.2022.104264. Epub 2022 Jul 31. PMID: 35937634

Stochastic optimal control of pre-exposure prophylaxis for HIV infection.
Đorđević J, Rognlien Dahl K. Math Med Biol. 2022 Sep 8;39(3):197-225. doi: 10.1093/imammb/dqac003. PMID: 35642745

Differences in moral judgment predict behavior in a Covid triage game scenario.
Clarkson E, Jasper JD, Gugle B. Pers Individ Dif. 2022 Sep;195:111671. doi: 10.1016/j.paid.2022.111671. Epub 2022 Apr 22. PMID: 35475240

Shortening Duration of Swine Exhibitions to Reduce Risk for Zoonotic Transmission of Influenza A Virus.
McBride DS, Nolting JM, Nelson SW, Spurck MM, Bliss NT, Kenah E, Trock SC, Bowman AS. Emerg Infect Dis. 2022 Sep 9;28(10). doi: 10.3201/eid2810.220649. Online ahead of print. PMID: 36084650

Not all T cell epitopes are equally desired: a review of in silico tools for the prediction of cytokine-inducing potential of T-cell epitopes.
Dhanda SK, Malviya J, Gupta S. Brief Bioinform. 2022 Sep 6:bbac382. doi: 10.1093/bib/bbac382. Online ahead of print. PMID: 36070623

Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus.
Zhao F, Berndsen ZT, Pedreño-Lopez N, Burns A, Allen JD, Barman S, Lee WH, Chakraborty S, Gnanakaran S, Sewall LM, Ozorowski G, Limbo O, Song G, Yong P, Callaghan S, Coppola J, Weisgrau KL, Lifson JD, Nedellec R, Voigt TB, Laurino F, Louw J, Rosen BC, Ricciardi M, Crispin M, Desrosiers RC, Rakasz EG, Watkins DI, Andrabi R, Ward AB, Burton DR, Sok D. Nat Commun. 2022 Sep 6;13(1):5236. doi: 10.1038/s41467-022-32783-2. PMID: 36068229

New-onset Seropositive Rheumatoid Arthritis Following COVID-19 Vaccination in a Patient with Seronegative Status.
Yonezawa H, Ohmura SI, Ohkubo Y, Miyamoto T. Intern Med. 2022 Sep 6. doi: 10.2169/internalmedicine.0257-22. Online ahead of print. PMID: 36070943

Pathogen diversity, immunity, and the fate of infections: lessons learned from Trypanosoma cruzi human-host interactions.
Magalhães LMD, Gollob KJ, Zingales B, Dutra WO. Lancet Microbe. 2022 Sep;3(9):e711-e722. doi: 10.1016/S2666-5247(21)00265-2. Epub 2022 Mar 10. PMID: 36058233

A workshop to co-design messages that may increase uptake of vaccines: A case study.
Schmidtke KA, Skrybant M, Kudrna L, Russell S, Ding IL, Clarke A. Vaccine. 2022 Sep 2;40(37):5407-5412. doi: 10.1016/j.vaccine.2022.07.053. Epub 2022 Aug 13. PMID: 35970640

Frosted branch angiitis after smallpox vaccination.
Collister K, Dahr SS. Am J Ophthalmol Case Rep. 2022 Jul 9;27:101622. doi: 10.1016/j.ajoc.2022.101622. eCollection 2022 Sep. PMID: 35880209

Safety and immunogenicity of a typhoid conjugate **vaccine** among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.
Nampota-Nkomba N, Nyirenda OM, Khonde L, Mapemba V, Mbewe M, Ndaferankhande JM, Msuku H, Masesa C, Misiri T, Mwakiseghile F, Patel PD, Patel P, Johnson-Mayo I, Pasetti MF, Heyderman RS, Tracy JK, Datta S, Liang Y, Neuzil KM, Gordon MA, Laurens MB; Typhoid Vaccine Acceleration Consortium team. Lancet Glob Health. 2022 Sep;10(9):e1326-e1335. doi: 10.1016/S2214-109X(22)00275-3. PMID: 35961356

A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M, Azizi S, Abbasi Varaki F, Nejadghaderi SA, Bashash D. Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12. PMID: 35843148

Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Piñana JL, Rodríguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol MJ, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual MJ, Rodriguez-Fernandez A, Olave MT, Cascales-Hernandez A, Gago B, Hernández-Rivas JÁ, Villalon L, Corona M, Roldán-Pérez A, Ribes-Amoros J, González-Santillana C, Garcia-Sanz R, Navarro D, Serrano-López AJ, Cedillo Á, Soria-Olivas E, Sureda A, Solano C; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Ann Hematol. 2022 Sep;101(9):2053-2067. doi: 10.1007/s00277-022-04906-8. Epub 2022 Jul 2. PMID: 35780254

Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination.
Chiang TP, Alejo JL, Mitchell J, Kim JD, Abedon AT, Karaba AH, Thomas L, Levan ML, Garonzik-Wang JM, Avery RK, Pekosz A, Clarke WA, Warren DS, Tobian AAR, Massie AB, Segev DL, Werbel WA. Am J Transplant. 2022 Sep;22(9):2254-2260. doi: 10.1111/ajt.17061. Epub 2022 May 3. PMID: 35429211

Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
Maeda H, Gopal Dhoubhadel B, Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K. Vaccine. 2022 Sep 2;40(37):5504-5512. doi: 10.1016/j.vaccine.2022.07.041. Epub 2022 Aug 10. PMID: 35963821

Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays.
Inglefield J, Catania J, Harris A, Hickey T, Ma Z, Minang J, Baranji K, Spangler T, Look J, Ruiz C, Lu H, Alleva D, Reece JJ, Lacy MJ. Vaccine. 2022 Sep 9;40(38):5544-5555. doi: 10.1016/j.vaccine.2022.06.017. Epub 2022 Jun 27. PMID: 35773119

Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: A population-level observational study.
Medić S, Anastassopoulou C, Lozanov-Crvenković Z, Vuković V, Dragnić N, Petrović V, Ristić M, Pustahija T, Gojković Z, Tsakris A, Ioannidis JPA. Lancet Reg Health Eur. 2022 Sep;20:100453. doi: 10.1016/j.lanepe.2022.100453. Epub 2022 Jul 1. PMID: 35791336

Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].
Doherty J, Morain NO, Stack R, Girod P, Tosetto M, Inzitiari R, Sheridan J, Cullen G, McDermott E, Buckley M, Horgan G, Mulcahy H, Ryan EJ, Daghfal D, Doran P, Morain CO, Doherty GA. J Crohns Colitis. 2022 Sep 8;16(9):1354-1362. doi: 10.1093/ecco-jcc/jjac029. PMID: 35176770

Covid-19 vaccination BNT162b2 temporarily impairs semen concentration and total motile count among semen donors.
Gat I, Kedem A, Dviri M, Umanski A, Levi M, Hourvitz A, Baum M. Andrology. 2022 Sep;10(6):1016-1022. doi: 10.1111/andr.13209. Epub 2022 Jun 27. PMID: 35713410

Epidemiological and clinical characteristics of pregnant women and neonates with COVID-19 in Northwest Mexico.
Leon-Sicairos N, Angulo-Zamudio UA, Pacheco-Avila M, Medina-Ramirez I, Velazquez-Roman J, Angulo-Rocha J, Martínez-Villa FA, Flores-Villaseñor H, Martinez-Garcia JJ, Sanchez-Cuen J, Garzon-Lopez O, Guel-Gomez M, Cuen-Diaz HM, Barajas-Olivas MF, Campos-Romero A, Alcántar-Fernández J, Esparza MAL, Canizalez-Roman A. Am J Reprod Immunol. 2022 Sep;88(3):e13583. doi: 10.1111/aji.13583. Epub 2022 Jun 10. PMID: 35661465

A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and **vaccine** development.
Fowler K, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Grys M, Schmidt E, Natenshon A, Talarico C, Buck PO, Diaz-Decaro J. BMC Public Health. 2022 Sep 1;22(1):1659. doi: 10.1186/s12889-022-13971-7. PMID: 36050659

Kidney replacement therapy patients with COVID-19 in the **vaccine** era: what do we need to know?
Vehbi S, Yildiz AB, Kanbay M. Clin Kidney J. 2022 May 2;15(9):1639-1642. doi: 10.1093/ckj/sfac122. eCollection 2022 Sep. PMID: 36003662

Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses.
Zhang H, Deng T, Fang Q, Li S, Gao S, Jiang W, Chen G, Yu K, Zhou L, Li T, Zheng Q, Yu H, Li S, Xia N, Gu Y. Virology. 2022 Sep;574:1-8. doi: 10.1016/j.virol.2022.07.003. Epub 2022 Jul 12. PMID: 35858511

Rational attenuation of RNA viruses with zinc finger antiviral protein.
Gonçalves-Carneiro D, Mastrocola E, Lei X, DaSilva J, Chan YF, Bieniasz PD. Nat Microbiol. 2022 Sep 8. doi: 10.1038/s41564-022-01223-8. Online ahead of print. PMID: 36075961

Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy.
Dammeijer F, van Gulijk M, Klaase L, van Nimwegen M, Bouzid R, Hoogenboom R, Joosse ME, Hendriks RW, van Hall T, Aerts JG. Mol Cancer Ther. 2022 Sep 6;21(9):1393-1405. doi: 10.1158/1535-7163.MCT-21-0943. PMID: 35732501

The epidemiology of infectious diseases in Europe in 2020 versus 2017-2019 and the rise of tick-borne encephalitis (1995-2020).
Jenkins VA, Silbernagl G, Baer LR, Hoet B. Ticks Tick Borne Dis. 2022 Sep;13(5):101972. doi: 10.1016/j.ttbdis.2022.101972. Epub 2022 May 23. PMID: 35662067

Pharmacological approaches to target type 2 cytokines in asthma.
Guilleminault L, Conde E, Reber LL. Pharmacol Ther. 2022 Sep;237:108167. doi: 10.1016/j.pharmthera.2022.108167. Epub 2022 Mar 10. PMID: 35283171

Course of Cardiac Magnetic Resonance Imaging Findings in Acute Myocarditis after COVID-19 mRNA Vaccination.
Kawauchi H, Mitsuhashi Y, Nakamura S, Ogawa R, Miyabe T, Kato K, Tanaka H. Intern Med. 2022 Sep 1;61(17):2625-2629. doi: 10.2169/internalmedicine.9797-22. Epub 2022 Jun 21. PMID: 35732458

Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease.
Monteiro A, Chang AJ, Welliver RR, Baron S, Hicar MD. Virology. 2022 Sep 2;575:83-90. doi: 10.1016/j.virol.2022.08.010. Online ahead of print. PMID: 36088793

From pandemic to a new normal: Strategies to optimise governmental interventions in Indonesia based on an SVEIQHR-type mathematical model.
Yong B, Hoseana J, Owen L. Infect Dis Model. 2022 Sep;7(3):346-363. doi: 10.1016/j.idm.2022.06.004. Epub 2022 Jun 30. PMID: 35789595

Combining epidemiology and economics to assess control of a viral endemic animal disease: Porcine Reproductive and Respiratory Syndrome (PRRS).
Valdes-Donoso P, Jarvis LS. PLoS One. 2022 Sep 9;17(9):e0274382. doi: 10.1371/journal.pone.0274382. eCollection 2022. PMID: 36084100

Navigating diagnostic options for inborn errors of immunity in children: a case-based illustration.
Khan YW, Minnicozzi SC, Lawrence MG. Curr Opin Pediatr. 2022 Sep 9. doi: 10.1097/MOP.0000000000001178. Online ahead of print. PMID: 36081368

Spatiotemporally controllable diphtherin transgene system and neoantigen immunotherapy.
He M, Sun Y, Cheng Y, Wang J, Zhang M, Sun R, Hou X, Xu J, He H, Wang H, Yuan Z, Lan M, Zhao Y, Yang Y, Chen X, Gao F. J Control Release. 2022 Sep 2:S0168-3659(22)00582-X. doi: 10.1016/j.jconrel.2022.08.059. Online ahead of print. PMID: 36063962

Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan.
Chen CY, Chen TT, Hsieh CY, Lien MY, Yeh SP, Chen CC. Int J Hematol. 2022 Sep 4:1-4. doi: 10.1007/s12185-022-03445-2. Online ahead of print. PMID: 36057889

Haemaphysalis longicornis calreticulin is not an effective molecular tool for tick bite diagnosis and disruption of tick infestations.
Zheng W, Hu H, Jiang J, Sun X, Fu R, Tao H, Liu Y, Chen H, Ma H, Chen S. Vet Parasitol. 2022 Sep;309:109775. doi: 10.1016/j.vetpar.2022.109775. Epub 2022 Aug 4. PMID: 35939902

Attitudes, Perceptions and Practices of Influenza Vaccination in the Adult Population: Results of a Cross-Sectional Survey in Spain.
Prada-García C, Fernández-Espinilla V, Hernán-García C, Sanz-Muñoz I, Martínez-Olmos J, Eiros JM, Castrodeza-Sanz J. Int J Environ Res Public Health. 2022 Sep 5;19(17):11139. doi: 10.3390/ijerph191711139. PMID: 36078854

Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Hu T, Song Y, Done N, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T. BMC Public Health. 2022 Sep 5;22(1):1677. doi: 10.1186/s12889-022-14051-6. PMID: 36064378

Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study.

Chevet B, Figueroa-Parra G, Yang JX, Hocaoglu M, Osei-Onomah SA, Hulshizer CA, Gunderson TM, Cornec D, Barbour KE, Greenlund KJ, Crowson CS, Duarte-García A. Arthritis Res Ther. 2022 Sep 1;24(1):211. doi: 10.1186/s13075-022-02878-8. PMID: 36050780

Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis.
Yang IN, Lu CL, Tang HJ, Kuo YC, Tsai LH, Tu KC, Wang JJ, Chien CC. PLoS One. 2022 Sep 9;17(9):e0273676. doi: 10.1371/journal.pone.0273676. eCollection 2022. PMID: 36084024

Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein **vaccine** (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Marshall HS, Vesikari T, Richmond PC, Wysocki J, Szenborn L, Beeslaar J, Maguire JD, Balmer P, O'Neill R, Anderson AS, Prégaldien JL, Maansson R, Jiang HQ, Perez JL. Lancet Infect Dis. 2022 Sep 7:S1473-3099(22)00424-8. doi: 10.1016/S1473-3099(22)00424-8. Online ahead of print. PMID: 36087588

Exposure of aluminium to C6 glioma cells modulates molecular and functional neurotoxic markers.
Dey M, Singh RK. J Biochem Mol Toxicol. 2022 Sep 3:e23210. doi: 10.1002/jbt.23210. Online ahead of print. PMID: 36056780

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.
Fenwick C, Turelli P, Ni D, Perez L, Lau K, Herate C, Marlin R, Lana E, Pellaton C, Raclot C, Esteves-Leuenberger L, Campos J, Farina A, Fiscalini F, Dereuddre-Bosquet N, Relouzat F, Abdelnabi R, Foo CS, Neyts J, Leyssen P, Lévy Y, Pojer F, Stahlberg H, LeGrand R, Trono D, Pantaleo G. Nat Microbiol. 2022 Sep;7(9):1376-1389. doi: 10.1038/s41564-022-01198-6. Epub 2022 Jul 25. PMID: 35879526

Antimicrobial peptides and their potential application in antiviral coating agents.
Freitas ED, Bataglioli RA, Oshodi J, Beppu MM. Colloids Surf B Biointerfaces. 2022 Sep;217:112693. doi: 10.1016/j.colsurfb.2022.112693. Epub 2022 Jul 8. PMID: 35853393

Deciphering the substrate specificity of housekeeping sortase A and pilus-specific sortase C of probiotic bacterium Lactococcus lactis.
Kumar V, Murmu S, Krishnan V. Biochimie. 2022 Sep;200:140-152. doi: 10.1016/j.biochi.2022.05.017. Epub 2022 May 30. PMID: 35654243

Use of the ISU *FLU*ture multisequence identity tool for rapid interpretation of swine influenza A virus sequences in the United States.
Zeller MA, Saxena A, Anderson TK, Vincent AL, Gauger PC. J Vet Diagn Invest. 2022 Sep;34(5):874-878. doi: 10.1177/10406387221111128. Epub 2022 Jul 25. PMID: 35879873

Archaic chaperone-usher pili self-secrete into superelastic zigzag springs.
Pakharukova N, Malmi H, Tuittila M, Dahlberg T, Ghosal D, Chang YW, Myint SL, Paavilainen S, Knight SD, Lamminmäki U, Uhlin BE, Andersson M, Jensen G, Zavialov AV. Nature. 2022 Sep;609(7926):335-340. doi: 10.1038/s41586-022-05095-0. Epub 2022 Jul 19. PMID: 35853476

Protective neutralizing epitopes in SARS-CoV-2.
Liu H, Wilson IA. Immunol Rev. 2022 Sep;310(1):76-92. doi: 10.1111/imr.13084. Epub 2022 May 22. PMID: 35599305

Flow cytometry-based multiplexing antibody detection for diagnosis of African swine fever virus.
Li C, Zou Z, Lv C, Zhao Y, Han P, Sun X, Jin M. Anal Chim Acta. 2022 Sep 8;1225:340244. doi: 10.1016/j.aca.2022.340244. Epub 2022 Aug 10. PMID: 36038241

Personal Assistants' role in infection prevention and control: Their experiences during the Covid-19 pandemic.
Norrie C, Woolham J, Samsi K, Manthorpe J. Health Soc Care Community. 2022 Sep;30(5):e1926-e1934. doi: 10.1111/hsc.13624. Epub 2021 Nov 3. PMID: 34730260

Social effects of rabies infection in male vampire bats (*Desmodus rotundus*).
Cárdenas-Canales EM, Stockmaier S, Cronin E, Rocke TE, Osorio JE, Carter GG. Biol Lett. 2022 Sep;18(9):20220298. doi: 10.1098/rsbl.2022.0298. Epub 2022 Sep 7. PMID: 36069068

Identification and analysis of B cell epitopes of hemagglutinin of H1N1 influenza virus.
Feng Q, Huang XY, Feng YM, Sun LJ, Sun JY, Li Y, Xie X, Hu J, Guo CY. Arch Microbiol. 2022 Sep 2;204(9):594. doi: 10.1007/s00203-022-03133-z. PMID: 36053375

Spinosad topical suspension (0.9%): a new topical treatment for scabies.
Fernando DD, Fischer K. Expert Rev Anti Infect Ther. 2022 Sep;20(9):1149-1154. doi: 10.1080/14787210.2022.2099376. Epub 2022 Aug 9. PMID: 35799317

An immunologist's guide to immunosenescence and its treatment.
Caruso C, Ligotti ME, Accardi G, Aiello A, Candore G. Expert Rev Clin Immunol. 2022 Sep;18(9):961-981. doi: 10.1080/1744666X.2022.2106217. PMID: 35876758

Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice.
Jiang Y, Zhang H, Yu J, Huang D, Zhai L, Li M, Wang Y, Ren Z, Zou L, Zheng Z, Hu H, Zhang J, Zhang B, Zhao W, Yang X, Li B, Shen C. J Med Virol. 2022 Sep;94(9):4533-4538. doi: 10.1002/jmv.27882. Epub 2022 Jun 3. PMID: 35614018

Dual display hemagglutinin 1 and 5 on the surface of enveloped virus-like particles in silkworm expression system.
Goffar MG, Deo VK, Kato T, Park EY. Protein Expr Purif. 2022 Sep;197:106106. doi: 10.1016/j.pep.2022.106106. Epub 2022 May 4. PMID: 35525404

Characterization of a novel aminopeptidase P from Trichinella spiralis and its participation in the intrusion of intestinal epithelial cells.
Zeng J, Zhang R, Ning Ma K, Han LL, Yan SW, Liu RD, Zhang X, Wang ZQ, Cui J. Exp Parasitol. 2022 Sep 8:108376. doi: 10.1016/j.exppara.2022.108376. Online ahead of print. PMID: 36089006

Co-administration of chicken IL-7 or NK-lysin peptide 2 enhances the efficacy of Eimeria elongation factor-1α vaccination against Eimeria maxima infection in broiler chickens.

Lee Y, Park I, Wickramasuriya SS, Arous JB, Koziol ME, Lillehoj HS. Poult Sci. 2022 Sep;101(9):102013. doi: 10.1016/j.psj.2022.102013. Epub 2022 Jun 17. PMID: 35905546

Rapid Evaluation of **Vaccine** Booster Effectiveness against SARS-CoV-2 Variants.
Cheng HL, Lim SM, Jia H, Chen MW, Ng SY, Gao X, Somani J, Sengupta S, Tay DMY, Chua PWL, R A, Ling SYH, McBee ME, Young BE, Sikes HD, Preiser PR. Microbiol Spectr. 2022 Sep 7:e0225722. doi: 10.1128/spectrum.02257-22. Online ahead of print. PMID: 36069616

Vaccination decreases the risk of influenza A virus reassortment but not genetic variation in pigs.
Li C, Culhane MR, Schroeder DC, Cheeran MC, Galina Pantoja L, Jansen ML, Torremorell M. Elife. 2022 Sep 2;11:e78618. doi: 10.7554/eLife.78618. PMID: 36052992

A cost-benefit analysis of Vietnam's 2006-2010 foot-and-mouth disease control program.
Do H, Nguyen HT, Van Ha P, Dang Van K. Prev Vet Med. 2022 Sep;206:105703. doi: 10.1016/j.prevetmed.2022.105703. Epub 2022 Jul 1. PMID: 35797822

Serum albumin and nucleic acids biodistribution: From molecular aspects to biotechnological applications.
Vita GM, De Simone G, De Marinis E, Nervi C, Ascenzi P, di Masi A. IUBMB Life. 2022 Sep;74(9):866-879. doi: 10.1002/iub.2653. Epub 2022 Jun 1. PMID: 35580148

Comparison of sample preparation techniques for the physicochemical characterization of Orf virus particles.
Eilts F, Steger M, Pagallies F, Rziha HJ, Hardt M, Amann R, Wolff MW. J Virol Methods. 2022 Sep 6:114614. doi: 10.1016/j.jviromet.2022.114614. Online ahead of print. PMID: 36084768

Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs.
Falope O, Nyaku MK, O'Rourke C, Hermany LV, Plavchak B, Mauskopf J, Hartley L, Kruk ME. Expert Rev Vaccines. 2022 Sep 5:1-16. doi: 10.1080/14760584.2022.2116007. Online ahead of print. PMID: 36063485

Racial concentration and dynamics of COVID-19 vaccination in the United States.
Wu C. SSM Popul Health. 2022 Sep;19:101198. doi: 10.1016/j.ssmph.2022.101198. Epub 2022 Aug 18. PMID: 35996681

Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention.
Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A, An X, Zhao Y, Song L, Tong Y, Fan H. MedComm (2020). 2022 Aug 16;3(3):e172. doi: 10.1002/mco2.172. eCollection 2022 Sep. PMID: 35992968

Fostering New Scientific Networks in the COVID Era and Beyond.
Alfaidi M, Zhang H, Oliveira SD. Arterioscler Thromb Vasc Biol. 2022 Sep;42(9):1113-1120. doi: 10.1161/ATVBAHA.122.317452. Epub 2022 Jul 21. PMID: 35861068

Deep venous sinus thrombosis with right thalamic infarction in a young patient after COVID-19 vaccination.
Sharma S, Dhakal P, Sharma A, Aryal S, Bhandari S, Rajak A. Radiol Case Rep. 2022 Jul 9;17(9):3298-3301. doi: 10.1016/j.radcr.2022.06.027. eCollection 2022 Sep. PMID: 35846505

"I feel more protective over my body:" A brief report on pregnant women's embodied experiences during the COVID-19 pandemic.
Nolen E, Siegel JA, Pownall M, Talbot C, Dann C. Body Image. 2022 Sep;42:197-204. doi: 10.1016/j.bodyim.2022.06.007. Epub 2022 Jun 16. PMID: 35753096

Measles, Media and Memory: Journalism's Role in Framing Collective Memory of Disease.
Conis E, Hoenicke S. J Med Humanit. 2022 Sep;43(3):405-420. doi: 10.1007/s10912-021-09705-2. Epub 2021 Aug 3. PMID: 34341891

Using Environmental Sampling to Enable Zoonotic Pandemic Preparedness.
Sanyal A, Agarwal S, Ramakrishnan U, Garg KM, Chattopadhyay B. J Indian Inst Sci. 2022 Sep 7:1-20. doi: 10.1007/s41745-022-00322-z. Online ahead of print. PMID: 36093274

The Role of Psychobiotics to Ensure Mental Health during the COVID-19 Pandemic-A Current State of Knowledge.
Zielińska D, Karbowiak M, Brzezicka A. Int J Environ Res Public Health. 2022 Sep 3;19(17):11022. doi: 10.3390/ijerph191711022. PMID: 36078738

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations.
Trombetta CM, Piccini G, Pierleoni G, Leonardi M, Dapporto F, Marchi S, Andreano E, Paciello I, Benincasa L, Lovreglio P, Buonvino N, Decaro N, Stufano A, Lorusso E, Bombardieri E, Ruello A, Viviani S, Rappuoli R, Molesti E, Manenti A, Montomoli E. Commun Biol. 2022 Sep 2;5(1):903. doi: 10.1038/s42003-022-03849-0. PMID: 36056181

Recognition of specific immunogenic antigens with potential diagnostic value in multi-drug resistant Mycobacterium tuberculosis inducing humoral immunity in MDR-TB patients.
Hadizadeh Tasbiti A, Badmasti F, Siadat SD, Fateh A, Yari F, GHzanfari Jajin M, Yari S. Infect Genet Evol. 2022 Sep;103:105328. doi: 10.1016/j.meegid.2022.105328. Epub 2022 Jul 3. PMID: 35788051

Collection, compilation and analysis of bacterial vaccines.
Gupta S, Sharma N, Naorem LD, Jain S, Raghava GPS. Comput Biol Med. 2022 Sep 2;149:106030. doi: 10.1016/j.compbiomed.2022.106030. Online ahead of print. PMID: 36084380

Papillomavirus Infection and Prevention: How Much Does the Sicilian Population Know? An Observational Study.
Verro B, Gallina S, Saraniti C. Int J Environ Res Public Health. 2022 Sep 3;19(17):11032. doi: 10.3390/ijerph191711032. PMID: 36078747

Effect of delayed mating on reproductive performance and life-history parameters of dengue vector *Aedes aegypti*.
Gunathilaka RAKM, Jayatunga DPW, Ganehiarachchi GASM. Bull Entomol Res. 2022 Sep 6:1-7. doi: 10.1017/S0007485322000396. Online ahead of print. PMID: 36065760

Sialic Acid and Fucose Residues on the SARS-CoV-2 Receptor-Binding Domain Modulate IgG Antibody Reactivity.

Samuelsson E, Mirgorodskaya E, Nyström K, Bäckström M, Liljeqvist JÅ, Nordén R. ACS Infect Dis. 2022 Sep 9;8(9):1883-1893. doi: 10.1021/acsinfecdis.2c00155. Epub 2022 Aug 18. PMID: 35980012

Genetic basis underlying the serological affinity of leptospiral serovars from serogroups Sejroe, Mini and Hebdomadis.
Medeiros EJS, Ferreira LCA, Ortega JM, Cosate MRV, Sakamoto T. Infect Genet Evol. 2022 Sep;103:105345. doi: 10.1016/j.meegid.2022.105345. Epub 2022 Jul 30. PMID: 35917899

Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.
Sette A, Crotty S. Immunol Rev. 2022 Sep;310(1):27-46. doi: 10.1111/imr.13089. Epub 2022 Jun 22. PMID: 35733376

Inhibitory effects of cedar pine needle extract on H9N2 avian influenza virus in vitro and in vivo.
Han M, Gao S, Hu W, Zhou Q, Li H, Lin W, Chen F. Virology. 2022 Sep;574:25-36. doi: 10.1016/j.virol.2022.07.011. Epub 2022 Jul 19. PMID: 35878455

Emerging immune-based technologies for high-grade gliomas.
Giotta Lucifero A, Luzzi S. Expert Rev Anticancer Ther. 2022 Sep;22(9):957-980. doi: 10.1080/14737140.2022.2110072. Epub 2022 Aug 12. PMID: 35924820

The impact of COVID-19 and catch-up strategies on routine childhood **vaccine** coverage trends in Latin America: A systematic literature review and database analysis.
Castrejon MM, Leal I, de Jesus Pereira Pinto T, Guzmán-Holst A. Hum Vaccin Immunother. 2022 Sep 9:2102353. doi: 10.1080/21645515.2022.2102353. Online ahead of print. PMID: 36084255

Effect of medium-chain fatty acids on growth, health, and immune response of dairy calves.
Klopp RN, Hernandez Franco JF, Hogenesch H, Dennis TS, Cowles KE, Boerman JP. J Dairy Sci. 2022 Sep;105(9):7738-7749. doi: 10.3168/jds.2021-21567. Epub 2022 Aug 6. PMID: 35940917

Redefining the importance of polylactide-co-glycolide acid (PLGA) in drug delivery.
Chavan YR, Tambe SM, Jain DD, Khairnar SV, Amin PD. Ann Pharm Fr. 2022 Sep;80(5):603-616. doi: 10.1016/j.pharma.2021.11.009. Epub 2021 Dec 9. PMID: 34896382

Understanding the psychosocial determinants of Italian parents' intentions not to vaccinate their children: an extended theory of planned behaviour model.
Caso D, Capasso M, Fabbricatore R, Conner M. Psychol Health. 2022 Sep;37(9):1111-1131. doi: 10.1080/08870446.2021.1936522. Epub 2021 Jun 27. PMID: 34180333

Building Indian Biomedical Leadership to Bridge the Gap Between Science, Primary Health Care and Public Health.
Krishna S, Prasad R. J Indian Inst Sci. 2022 Sep 7:1-7. doi: 10.1007/s41745-022-00320-1. Online ahead of print. PMID: 36093272

Barriers and enablers to pharmacists' involvement in a novel immunisation programme.
Rathbone AP, Baqir W, Campbell D. Explor Res Clin Soc Pharm. 2022 Aug 20;7:100173. doi: 10.1016/j.rcsop.2022.100173. eCollection 2022 Sep. PMID: 36082145

Germline IgM predicts T cell immunity to Pneumocystis.
Noell K, Dai G, Pungan D, Ebacher A, McCombs JE, Landry SJ, Kolls JK. JCI Insight. 2022 Sep 8;7(17):e161450. doi: 10.1172/jci.insight.161450. PMID: 35917185

Review on the COVID-19 pandemic prevention and control system based on AI.
Yi J, Zhang H, Mao J, Chen Y, Zhong H, Wang Y. Eng Appl Artif Intell. 2022 Sep;114:105184. doi: 10.1016/j.engappai.2022.105184. Epub 2022 Jul 11. PMID: 35846728

Genome-wide analysis reveals allelic variation and chromosome copy number variation in paromomycin-resistant Leishmania donovani.
Ghosh S, Kumar V, Verma A, Sharma T, Pradhan D, Selvapandiyan A, Salotra P, Singh R. Parasitol Res. 2022 Sep 3. doi: 10.1007/s00436-022-07645-x. Online ahead of print. PMID: 36056959

An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID **Vaccine**.
Davoudi F, Miyashita S, Yoo TK, Lee PT, Foster GP. Crit Pathw Cardiol. 2022 Sep 1;21(3):123-129. doi: 10.1097/HPC.0000000000000290. Epub 2022 Apr 28. PMID: 35994720

Serological survey for maternal antibodies to Borreliella burgdorferi and Anaplasma phagocytophilum in dogs from endemic and non-endemic regions of the United States.
Stasiak KL, Cramer NA, Chambers GZ, Marconi RT. Vet Immunol Immunopathol. 2022 Sep;251:110471. doi: 10.1016/j.vetimm.2022.110471. Epub 2022 Aug 4. PMID: 35940078

Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces.
Mazire PH, Saha B, Roy A. Int Immunopharmacol. 2022 Sep;110:108969. doi: 10.1016/j.intimp.2022.108969. Epub 2022 Jun 20. PMID: 35738089

Efficient compression of SARS-CoV-2 genome data using Nucleotide Archival Format.
Kryukov K, Jin L, Nakagawa S. Patterns (N Y). 2022 Sep 9;3(9):100562. doi: 10.1016/j.patter.2022.100562. Epub 2022 Jul 7. PMID: 35818472

Effectiveness of a brief intervention for acceptance of influenza **vaccine** in reluctant primary care patients.
Muñoz-Miralles R, Bonvehí Nadeu S, Sant Masoliver C, Martín Gallego A, Gómez Del Canto J, Mendioroz Peña J, Bonet Esteve AM. Gac Sanit. 2022 Sep-Oct;36(5):446-451. doi: 10.1016/j.gaceta.2021.01.002. Epub 2021 Feb 19. PMID: 33618930

IgD^{+} age-associated B cells are the progenitors of the main T-independent B cell response to infection that generates protective Ab and can be induced by an inactivated **vaccine** in the aged.
Kugler-Umana O, Zhang W, Kuang Y, Liang J, Castonguay CH, Tonkonogy SL, Marshak-Rothstein A, Devarajan P, Swain SL. Aging Cell. 2022 Sep 2:e13705. doi: 10.1111/acel.13705. Online ahead of print. PMID: 36056604

Immunogenicity of COVID-19 vaccines in patients with diverse health conditions: A comprehensive systematic review.
Cho K, Park S, Kim EY, Koyanagi A, Jacob L, Yon DK, Lee SW, Kim MS, Radua J, Elena D, Il Shin J, Smith L. J Med Virol. 2022 Sep;94(9):4144-4155. doi: 10.1002/jmv.27828. Epub 2022 May 27. PMID: 35567325

Ischemia and reperfusion injury combined with cisplatin induces immunogenic cell death in lung cancer cells.
Zhang S, Li Y, Liu S, Ma P, Guo M, Zhou E, Duan L, Fan J, Liao T, Tan Q, Wang X, Wu F, Jin Y. Cell Death Dis. 2022 Sep 3;13(9):764. doi: 10.1038/s41419-022-05176-y. PMID: 36057637

Increased outbreaks of monkeypox highlight gaps in actual disease burden in Sub-Saharan Africa and in animal reservoirs.
Haider N, Guitian J, Simons D, Asogun D, Ansumana R, Honeyborne I, Velavan TP, Ntoumi F, Valdoleiros SR, Petersen E, Kock R, Zumla A. Int J Infect Dis. 2022 Sep;122:107-111. doi: 10.1016/j.ijid.2022.05.058. Epub 2022 May 29. PMID: 35640830

Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
Debnath SK, Debnath M, Srivastava R, Omri A. Expert Rev Anti Infect Ther. 2022 Sep;20(9):1187-1204. doi: 10.1080/14787210.2022.2082944. Epub 2022 Jun 6. PMID: 35615888

Gene expression and involvement of signaling pathways during host-pathogen interplay in *Orientia tsutsugamushi* infection.
Panda S, Swain SK, Sahu BP, Sarangi R. 3 Biotech. 2022 Sep;12(9):180. doi: 10.1007/s13205-022-03239-7. Epub 2022 Jul 19. PMID: 35860421

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
Sobhani N, Scaggiante B, Morris R, Chai D, Catalano M, Tardiel-Cyril DR, Neeli P, Roviello G, Mondani G, Li Y. Cancer Treat Rev. 2022 Sep;109:102429. doi: 10.1016/j.ctrv.2022.102429. Epub 2022 Jun 22. PMID: 35759856

Computational evidence based perspective on the plausible repositioning of fluoroquinolones for COVID-19 treatment.
Yadav V. Curr Comput Aided Drug Des. 2022 Sep 9. doi: 10.2174/1573409918666220909094645. Online ahead of print. PMID: 36093826

[Analysis of vaccination strategy against COVID-19 in Spain. The scientific basics (may 2022).].
Navarro Alonso JA, Limia Sánchez A. Rev Esp Salud Publica. 2022 Sep 7;96:e202209066. PMID: 36073060

Social-contextual factors interact with masculinity to influence college men's HPV vaccination intentions: The role of descriptive norms, prototypes, and physician gender.
Peterson LM, Orr JA, Rogelberg SD, Olsen N. J Behav Med. 2022 Sep 6:1-16. doi: 10.1007/s10865-022-00350-1. Online ahead of print. PMID: 36066688

A novel clinic structure for exposure counseling during pregnancy.
Pressman K, Müller R, Krstić N, Običan S. Birth Defects Res. 2022 Sep 1;114(15):855-862. doi: 10.1002/bdr2.2069. Epub 2022 Aug 1. PMID: 35912974

Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.
Kara Z, Akçin R, Demir AN, Dinç HÖ, Taşkın HE, Kocazeybek B, Yumuk VD. Obes Surg. 2022 Sep;32(9):2987-2993. doi: 10.1007/s11695-022-06181-y. Epub 2022 Jul 8. PMID: 35802279

Identification of characteristics frequency and hot-spots in protein sequence of COVID-19 disease.
Pathak V, Nanda SJ, Joshi AM, Sahu SS. Biomed Signal Process Control. 2022 Sep;78:103909. doi: 10.1016/j.bspc.2022.103909. Epub 2022 Jun 16. PMID: 35756718

Seroprevalence of neutralizing antibodies against the respiratory syncytial virus in healthy adults in Guangzhou, southern China.
Liu Z, Wu S, Xian Y, Gu Z, Liu W, Chen D, Zhou R. J Med Virol. 2022 Sep;94(9):4378-4382. doi: 10.1002/jmv.27815. Epub 2022 May 4. PMID: 35474462

An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope.
Liu Z, Xu W, Chen Z, Fu W, Zhan W, Gao Y, Zhou J, Zhou Y, Wu J, Wang Q, Zhang X, Hao A, Wu W, Zhang Q, Li Y, Fan K, Chen R, Jiang Q, Mayer CT, Schoofs T, Xie Y, Jiang S, Wen Y, Yuan Z, Wang K, Lu L, Sun L, Wang Q. Protein Cell. 2022 Sep;13(9):655-675. doi: 10.1007/s13238-021-00871-6. Epub 2021 Sep 23. PMID: 34554412

A simple nanobody-based competitive ELISA to detect antibodies against African swine fever virus.
Zhao J, Zhu J, Wang Y, Yang M, Zhang Q, Zhang C, Nan Y, Zhou EM, Sun Y, Zhao Q. Virol Sin. 2022 Sep 8:S1995-820X(22)00152-3. doi: 10.1016/j.virs.2022.09.004. Online ahead of print. PMID: 36089216

Genetic Diversity of Fowlpox Virus and Putative Genes Involved in Its Pathogenicity.
Kim HR, Jang I, Song HS, Kim SH, Kim HS, Kwon YK. Microbiol Spectr. 2022 Sep 8:e0141522. doi: 10.1128/spectrum.01415-22. Online ahead of print. PMID: 36073826

Genetic and immunological characterization of G9 group A porcine rotaviruses in China.
Li Y, Wang F, Kan R, Cao H, Tang C, Yue H, Zhang B. Zoonoses Public Health. 2022 Sep;69(6):694-703. doi: 10.1111/zph.12958. Epub 2022 May 24. PMID: 35608375

Leveraging South African HIV research to define SARS-CoV-2 immunity triggered by sequential variants of concern.
Bhiman JN, Moore PL. Immunol Rev. 2022 Sep;310(1):61-75. doi: 10.1111/imr.13086. Epub 2022 May 22. PMID: 35599324

Applications of discrete choice experiments in COVID-19 research: Disparity in survey qualities between health and transport fields.
Haghani M, Bliemer MCJ, de Bekker-Grob EW. J Choice Model. 2022 Sep;44:100371. doi: 10.1016/j.jocm.2022.100371. Epub 2022 Jul 21. PMID: 35880141

A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.
Guyon J, Novion M, Fulda V, Ducint D, Molimard M, Couzi L, Kaminski H, Salvo F, Bouchet S. J Am Soc Mass Spectrom. 2022 Sep 9. doi: 10.1021/jasms.2c00204. Online ahead of print. PMID: 36084269

Phylogenetic analysis and searching bovine papillomaviruses in teat papillomatosis cases in cattle by performing histopathology, immunohistochemistry, and transmission electron microscopy.
Yıldırım Y, Kale M, Özmen Ö, Çağırgan AA, Hasırcıoğlu S, Küçük A, Usta A, Sökel S. Microb Pathog. 2022 Sep;170:105713. doi: 10.1016/j.micpath.2022.105713. Epub 2022 Aug 14. PMID: 35977649

Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study.
Arroyo Mühr LS, Eklund C, Lagheden C, Forslund O, Robertsson KD, Dillner J. J Clin Virol. 2022 Sep;154:105237. doi: 10.1016/j.jcv.2022.105237. Epub 2022 Jul 5. PMID: 35820294

Molecular identification and risk factor analysis of the first Lumpy skin disease outbreak in cattle in Mongolia.
Odonchimeg M, Erdenechimeg D, Tuvshinbayar A, Tsogtgerel M, Bazarragchaa E, Ulaankhuu A, Selenge T, Munkhgerel D, Munkhtsetseg A, Altanchimeg A, Odbileg R, Soyolmaa G, Enkhmandakh Y, Batmagnai E, Sugar S, Kimura T, Sugimoto C, Isoda N, Batsukh B, Sakoda Y. J Vet Med Sci. 2022 Sep 5;84(9):1244-1252. doi: 10.1292/jvms.22-0250. Epub 2022 Jul 18. PMID: 35851266

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.
Bessede A, Marabelle A, Guégan JP, Danlos FX, Cousin S, Peyraud F, Chaput N, Spalato M, Roubaud G, Cabart M, Khettab M, Chaibi A, Rey C, Nafia I, Mahon FX, Soria JC, Italiano A. Ann Oncol. 2022 Sep;33(9):909-915. doi: 10.1016/j.annonc.2022.05.010. Epub 2022 May 30. PMID: 35654248

Outbreak control management: Lessons from SARS-CoV-2 infections in 2020-2022 in Hong Kong, an international municipality with high-frequency travelers.
Feng Y, Young CH, Lau SH, He ML. MedComm (2020). 2022 Jul 25;3(3):e158. doi: 10.1002/mco2.158. eCollection 2022 Sep. PMID: 35898696

Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines.
Maior CBS, Lins ID, Raupp LS, Moura MC, Felipe F, Santana JMM, Fernandes MP, Araújo AV, Gomes ALV. Acta Trop. 2022 Sep;233:106551. doi: 10.1016/j.actatropica.2022.106551. Epub 2022 Jun 9. PMID: 35691330

Monitoring the COVID-19 immune landscape in Japan.
Sasanami M, Kayano T, Nishiura H. Int J Infect Dis. 2022 Sep;122:300-306. doi: 10.1016/j.ijid.2022.06.005. Epub 2022 Jun 8. PMID: 35688309

Detection of Equus caballus papillomavirus-2 in equine penile/preputial papillomas and squamous cell carcinomas in southern Brazil.
da Silva TRO, Gonçalves PNC, Marcus VB, Mucellini CI, Dos Santos IR, Kommers G, Driemeier D, Flores EF, Cargnelutti JF, Flores MM. Braz J Microbiol. 2022 Sep;53(3):1707-1713. doi: 10.1007/s42770-022-00769-3. Epub 2022 May 16. PMID: 35570259

Neonatal and postneonatal tetanus at a referral hospital in Kamsar, Guinea: a retrospective audit of paediatric records (2014-2018).
Condé I, Cherif MS, Dahal P, Hyjazi ME, Camara F, Diaby M, Diallo AS, Aderoba AK, Conde F, Diallo ML, Diallo FB, Dia H, Diallo MP, Delamou A, Sy T. Int Health. 2022 Sep 7;14(5):468-474. doi: 10.1093/inthealth/ihab021. PMID: 34048561

Characterization of the duration of immunity of Brucella abortus strain RB51 vaccination in cattle after experimental challenge.

Olsen SC, Boggiatto PM. Prev Vet Med. 2022 Sep;206:105705. doi: 10.1016/j.prevetmed.2022.105705. Epub 2022 Jul 8. PMID: 35850072

The association between household and neighborhood characteristics and COVID-19 related ICU admissions.
Stephen AH, Andrea SB, Banerjee D, Arafeh M, Askew M, Lueckel SN, Kheirbek T, Mermel LA, Adams CA Jr, Levy MM, Heffernan DS. SSM Popul Health. 2022 Jun 15;19:101133. doi: 10.1016/j.ssmph.2022.101133. eCollection 2022 Sep. PMID: 35756546

The A2c$_{111nt\text{-}dup}$ variants of human metapneumovirus predominantly circulating in Qingdao, China, during 2018 and 2019.
Liu Z, Xie Z, Sun R, Zhang F, Xu W, Wang Z, Zhang Y. J Med Virol. 2022 Sep;94(9):4301-4308. doi: 10.1002/jmv.27888. Epub 2022 Jun 22. PMID: 35656887

Crowdsourcing interventions to promote uptake of COVID-19 booster vaccines.
Böhm R, Betsch C, Litovsky Y, Sprengholz P, Brewer NT, Chapman G, Leask J, Loewenstein G, Scherzer M, Sunstein CR, Kirchler M. EClinicalMedicine. 2022 Nov;53:101632. doi: 10.1016/j.eclinm.2022.101632. Epub 2022 Sep 5. PMID: 36090456

A 2019 Outbreak Investigation of Hepatitis A Virus Infections in the United States Linked to Imported Fresh Blackberries.
McClure M, Nsubuga J, Montgomery MP, Jenkins E, Crosby A, Schoelen D, Basler C, Ramachandran S, Lin Y, Xia GL, Khudaykov Y, Suktankar V, Wagley A, Thomas V, Woods J, Hintz L, Oliveira J, Sandoval AL, Frederick J, Hendrickson B, Gieraltowski L, Viazis S. Food Environ Virol. 2022 Sep;14(3):236-245. doi: 10.1007/s12560-022-09527-y. Epub 2022 Jul 23. PMID: 35871245

Unilateral recurrent central serous chorioretinopathy (CSCR) following COVID-19 vaccination- A multimodal imaging study.
Sanjay S, Acharya I, Kawali A, Shetty R, Mahendradas P. Am J Ophthalmol Case Rep. 2022 Sep;27:101644. doi: 10.1016/j.ajoc.2022.101644. Epub 2022 Jul 6. PMID: 35818570

Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and **vaccine** design.
Ghotloo S, Maghsood F, Golsaz-Shirazi F, Amiri MM, Moog C, Shokri F. Rev Med Virol. 2022 Sep;32(5):e2347. doi: 10.1002/rmv.2347. Epub 2022 Apr 8. PMID: 35394093

Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep.
Rghei AD, van Lieshout LP, Cao W, He S, Tierney K, Lopes JA, Zielinska N, Baracuhy EM, Campbell ESB, Minott JA, Guilleman MM, Hasson PC, Thompson B, Karimi K, Bridle BW, Susta L, Qiu X, Banadyga L, Wootton SK. Gene Ther. 2022 Sep 1. doi: 10.1038/s41434-022-00361-2. Online ahead of print. PMID: 36050451

Rapid and accurate identification of SARS-CoV-2 Omicron variants using droplet digital PCR (RT-ddPCR).
Mills MG, Hajian P, Bakhash SM, Xie H, Mantzke D, Zhu H, Perchetti GA, Huang ML, Pepper G, Jerome KR, Roychoudhury P, Greninger AL. J Clin Virol. 2022 Sep;154:105218. doi: 10.1016/j.jcv.2022.105218. Epub 2022 Jun 18. PMID: 35779343

Promoting vaccination during rapid HIV testing: Recommendations from men who have sex with men in California.
Polonijo AN, Sein S, Maldonado R, Delos Santos J, Brown B. Health Soc Care Community. 2022 Sep;30(5):e2580-e2589. doi: 10.1111/hsc.13702. Epub 2022 Jan 5. PMID: 34985804

Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R, Sk MF, Jonniya NA, Poddar S, Kar P. J Biomol Struct Dyn. 2022 Sep;40(14):6556-6568. doi: 10.1080/07391102.2021.1897680. Epub 2021 Mar 8. PMID: 33682642

Targeting the N-terminal domain of the RNA-binding protein of the SARS-CoV-2 with high affinity natural compounds to abrogate the protein-RNA interaction: a molecular dynamics study.
Khan S, Hussain Z, Safdar M, Khan A, Wei DQ. J Biomol Struct Dyn. 2022 Sep;40(14):6286-6294. doi: 10.1080/07391102.2021.1882337. Epub 2021 Feb 8. PMID: 33554747

The Role of HPV in Determining Treatment, Survival, and Prognosis of Head and Neck Squamous Cell Carcinoma.
Sharkey Ochoa I, O'Regan E, Toner M, Kay E, Faul P, O'Keane C, O'Connor R, Mullen D, Nur M, O'Murchu E, Barry-O'Crowley J, Kernan N, Tewari P, Keegan H, O'Toole S, Woods R, Kennedy S, Feeley K, Sharp L, Gheit T, Tommasino M, O'Leary JJ, Martin CM. Cancers (Basel). 2022 Sep 3;14(17):4321. doi: 10.3390/cancers14174321. PMID: 36077856

High Uptake and Series Completion of COVID-19 **Vaccine** at Community-Based Vaccination for Latinos With Limited English Proficiency.
Bigelow BF, Saxton RE, Martínez DA, Flores-Miller A, Shin JM, Parent C, Williams S, Phillips KH, Yang C, Page KR. J Public Health Manag Pract. 2022 Sep 5. doi: 10.1097/PHH.0000000000001625. Online ahead of print. PMID: 36074797

Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions.
Binns E, Tuckerman J, Licciardi PV, Wurzel D. J Paediatr Child Health. 2022 Sep 8. doi: 10.1111/jpc.16197. Online ahead of print. PMID: 36073299

Understanding the transmission dynamics of a large-scale measles outbreak in Southern Vietnam.
Nguyen THT, Nguyen TV, Luong QC, Ho TV, Faes C, Hens N. Int J Infect Dis. 2022 Sep;122:1009-1017. doi: 10.1016/j.ijid.2022.07.055. Epub 2022 Jul 28. PMID: 35907478

Antiviral effect of vesatolimod (GS-9620) against foot-and-mouth disease virus both in vitro and invivo.
Lee G, Kang HR, Kim A, Park JH, Lee MJ, Kim SM. Antiviral Res. 2022 Sep;205:105384. doi: 10.1016/j.antiviral.2022.105384. Epub 2022 Jul 19. PMID: 35863499

Progress towards the elimination of hepatitis B in children in Colombia: A novel two-phase study approach.
Ríos-Hincapié CY, Murad-Rivera R, Tohme RA, Ropero AM, Gómez B, Librado Cardona D, Forest Duque BN, Cuellar D, Cardenas I, Krow-Lucal E, Wannemuehler K, de la Hoz Restrepo F, Sánchez-Molano SM, Delgado CE, Rivillas-Garcia JC, Wasley A. J Viral Hepat. 2022 Sep;29(9):737-747. doi: 10.1111/jvh.13719. Epub 2022 Jul 7. PMID: 35707957

The heat-labile toxin B subunit of E. coli fused with VP6 from GCRV (Grass carp reovirus) was expressed and folded into an active protein in rice calli.
Jin S, Wang T, Zhao Y, Liu X, Wang Y, Jiang L, Zhang Q. Protein Expr Purif. 2022 Sep;197:106099. doi: 10.1016/j.pep.2022.106099. Epub 2022 May 5. PMID: 35525405

Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies.
He Q, Zhang F, Shu J, Li S, Liang Z, Du M, Liu X, Liu T, Li M, Yin X, Pan Q, Lu F, Wang L, Wang L. Hepatology. 2022 Sep;76(3):788-802. doi: 10.1002/hep.32455. Epub 2022 Mar 30. PMID: 35278241

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Mongkolsapaya J, Wanlapakorn N, Honsawek S, Poovorawan Y. Int J Infect Dis. 2022 Sep;122:793-801. doi: 10.1016/j.ijid.2022.07.038. Epub 2022 Jul 19. PMID: 35863731

Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection.
Kumar S, Dutta D, Ravichandiran V, Sukla S. 3 Biotech. 2022 Sep;12(9):227. doi: 10.1007/s13205-022-03281-5. Epub 2022 Aug 17. PMID: 35982759

Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma.
Wong GL, Hui VW, Yip TC, Liang LY, Zhang X, Tse YK, Lai JC, Chan HL, Wong VW. Aliment Pharmacol Ther. 2022 Sep;56(5):869-877. doi: 10.1111/apt.17120. Epub 2022 Jul 21. PMID: 35864571

Consistency of self-reported and documented historical influenza vaccination status of US healthcare workers.
Regan AK, Wesley MG, Gaglani M, Kim SS, Edwards LJ, Murthy K, Jeddy Z, Naleway AL, Flannery B, Dawood FS, Groom H. Influenza Other Respir Viruses. 2022 Sep;16(5):881-890. doi: 10.1111/irv.12988. Epub 2022 Apr 12. PMID: 35415884

Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review.
Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, Yap EPH, Martinez-Sobrido L, B Torrelles J, Lippi G, Henry BM. Crit Rev Clin Lab Sci. 2022 Sep;59(6):373-390. doi: 10.1080/10408363.2022.2038539. Epub 2022 Feb 28. PMID: 35220860

MnO_2-melittin nanoparticles serve as an effective anti-tumor immunotherapy by enhancing systemic immune response.
Tang S, Zhou L, He H, Cui L, Ren Z, Tai Y, Xie Z, Cao Y, Meng D, Liu Q, Wu Y, Jiang J, Zhou X. Biomaterials. 2022 Sep;288:121706. doi: 10.1016/j.biomaterials.2022.121706. Epub 2022 Aug 7. PMID: 35953328

Effect of Oral Streptococci Expressing Pneumococcus-like Cross-Reactive Capsule Types on World Health Organization Recommended Pneumococcal Carriage Detection Procedure.

Ganaie F, Branche AR, Peasley M, Rosch JW, Nahm MH. Clin Infect Dis. 2022 Sep 10;75(4):647-656. doi: 10.1093/cid/ciab1003. PMID: 34891152

[Risk mapping associated with organization of a COVID-19 immunization campaign].
Le Tohic S, Basso S, Peillard L. Ann Pharm Fr. 2022 Sep;80(5):697-710. doi: 10.1016/j.pharma.2022.01.006. Epub 2022 Jan 24. PMID: 35085572

An early return-to-work program for COVID-19 close contacts in healthcare during the Omicron wave in Japan.
Naruse H, Doi Y, Iwata M, Ishikawa K. J Infect Chemother. 2022 Sep 7:S1341-321X(22)00257-4. doi: 10.1016/j.jiac.2022.09.004. Online ahead of print. PMID: 36087922

Proteomic and immunoproteomic insights into the exoproteome of Actinobacillus pleuropneumoniae, the causative agent of porcine pleuropneumonia.
Stancheva SG, Frömbling J, Sassu EL, Hennig-Pauka I, Ladinig A, Gerner W, Grunert T, Ehling-Schulz M. Microb Pathog. 2022 Sep 7:105759. doi: 10.1016/j.micpath.2022.105759. Online ahead of print. PMID: 36087692

The COVID-19 pandemic and its consequences for chronic pain: a narrative review.
Shanthanna H, Nelson AM, Kissoon N, Narouze S. Anaesthesia. 2022 Sep;77(9):1039-1050. doi: 10.1111/anae.15801. Epub 2022 Jul 18. PMID: 35848380

Investigation of the inhibitory activity of some dietary bioactive flavonoids against SARS-CoV-2 using molecular dynamics simulations and MM-PBSA calculations.
Varughese JK, Joseph Libin KL, Sindhu KS, Rosily AV, Abi TG. J Biomol Struct Dyn. 2022 Sep;40(15):6755-6770. doi: 10.1080/07391102.2021.1891139. Epub 2021 Feb 23. PMID: 33618628

Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an *H . pylori* immunostimulatory bacterial transgene.
Viker KB, Steele MB, Iankov ID, Concilio SC, Ammayappan A, Bolon B, Jenks NJ, Goetz MP, Panagioti E, Federspiel MJ, Liu MC, Peng KW, Galanis E. Mol Ther Methods Clin Dev. 2022 Jul 31;26:532-546. doi: 10.1016/j.omtm.2022.07.014. eCollection 2022 Sep 8. PMID: 36092362

Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group.
Pletz MW, Jensen AV, Bahrs C, Davenport C, Rupp J, Witzenrath M, Barten-Neiner G, Kolditz M, Dettmer S, Chalmers JD, Stolz D, Suttorp N, Aliberti S, Kuebler WM, Rohde G. Respir Res. 2022 Sep 10;23(1):239. doi: 10.1186/s12931-022-02117-3. PMID: 36088316

Duty to Work During the COVID-19 Pandemic: A Cross-Sectional Study of Perceptions of Health Care Providers in Jordan.
Alwidyan MT, Oteir AO, Mohammad AA, Al-Sheyab NA. J Emerg Nurs. 2022 Sep;48(5):589-602.e1. doi: 10.1016/j.jen.2022.04.004. PMID: 36084983

Outreach to the Veterans Crisis Line During the COVID-19 Pandemic: A Mixed-Methods Analysis.
Krishnamurti LS, Agha A, Iverson KM, Monteith LL, Dichter ME. Psychiatr Serv. 2022 Sep 6:appips202200044. doi: 10.1176/appi.ps.202200044. Online ahead of print. PMID: 36065583

Genomic surveillance of SARS-COV-2 reveals diverse circulating variant lineages in Nairobi and Kiambu Counties, Kenya.
Kuja JO, Kanoi BN, Balboa RF, Shiluli C, Maina M, Waweru H, Gathii K, Mungai M, Masika M, Anzala O, Mwau M, Clark TG, Waitumbi J, Gitaka J. BMC Genomics. 2022 Sep 1;23(1):627. doi: 10.1186/s12864-022-08853-6. PMID: 36050650

Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy.
Rovida F, Esposito GL, Rissone M, Novelli V, Cutti S, Muzzi A, Rona C, Bertoli E, Daglio M, Piralla A, Paolucci S, Campanini G, Ferrari G, Giardina F, Zavaglio F, Lilleri D, Grugnetti AM, Grugnetti G, Odone A, Marena C, Baldanti F. Int J Infect Dis. 2022 Sep;122:420-426. doi: 10.1016/j.ijid.2022.06.028. Epub 2022 Jun 22. PMID: 35750265

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study.
Simon D, Tascilar K, Fagni F, Kleyer A, Krönke G, Meder C, Dietrich P, Orlemann T, Mößner J, Taubmann J, Mutlu MY, Knitza J, Kemenes S, Liphardt AM, Schönau V, Bohr D, Schuster L, Hartmann F, Minopoulou I, Leppkes M, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Hueber AJ, Manger K, Manger B, Atreya R, Berking C, Sticherling M, Neurath MF, Schett G. Lancet Rheumatol. 2022 Sep;4(9):e614-e625. doi: 10.1016/S2665-9913(22)00191-6. Epub 2022 Aug 9. PMID: 35966645

Triiodothyronine-stimulated dendritic cell vaccination boosts antitumor immunity against murine colon cancer.
Florencia Soler M, Del Carmen Bravo-Miana R, María Negretti-Borga D, Subirada P, Alejandra Alamino V, Cecilia Sánchez M, Carolina Donadio A, Gabriela Pellizas C, Del Mar Montesinos M. Int Immunopharmacol. 2022 Sep;110:109016. doi: 10.1016/j.intimp.2022.109016. Epub 2022 Aug 1. PMID: 35978502

Pneumococcal nasopharyngeal carriage in children under 5 years of age at an outpatient healthcare facility in Novi Sad, Serbia during the COVID-19 pandemic.
Petrović V, Milosavljević B, Djilas M, Marković M, Vuković V, Andrijević I, Ristić M. IJID Reg. 2022 Jul 7;4:88-96. doi: 10.1016/j.ijregi.2022.07.001. eCollection 2022 Sep. PMID: 35865274

First identification of Nocardia seriolae GapA adhesion function and its three B-cell epitopes with cell-binding activity.
Guo J, Yue X, Chang J, Zhang Z, Li J, Liu X. J Fish Dis. 2022 Sep 1. doi: 10.1111/jfd.13709. Online ahead of print. PMID: 36048577

Perfluorooctanesulfonate (PFOS) and perfluorooctanoic acid (PFOA) modify *in vitro* mitogen- and antigen-induced human peripheral blood mononuclear cell (PBMC) responses.
Kasten-Jolly J, Lawrence DA. J Toxicol Environ Health A. 2022 Sep 2;85(17):715-737. doi: 10.1080/15287394.2022.2075816. Epub 2022 May 24. PMID: 35611390

In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.
Mosayebnia M, Hajiagha Bozorgi A, Rezaeianpour M, Kobarfard F. J Biomol Struct Dyn. 2022 Sep;40(14):6569-6586. doi: 10.1080/07391102.2021.1886991. Epub 2021 Feb 18. PMID: 33599180

Strategies for Cardio-Oncology Care During the COVID-19 Pandemic.
Abraham S, Manohar SA, Patel R, Saji AM, Dani SS, Ganatra S. Curr Treat Options Cardiovasc Med. 2022 Sep 6:1-17. doi: 10.1007/s11936-022-00965-2. Online ahead of print. PMID: 36090762

Vaccine target and carrier molecule nontypeable Haemophilus influenzae protein D dimerizes like the close Escherichia coli GlpQ homolog but unlike other known homolog dimers.
Jones SP, Cook KH, Holmquist ML, Almekinder LJ, Delaney AM, Charles R, Labbe N, Perdue J, Jackson N, Pichichero ME, Kaur R, Michel LV, Gleghorn ML. Proteins. 2022 Sep 6. doi: 10.1002/prot.26418. Online ahead of print. PMID: 36065600

Taxanes Hypersensitivity is not a risk factor for severe reactions to SARS-Cov-2 Vaccines.
Cortellini G, Raiteri A, Biagioni B, Liberati S, Lippolis D, Cortellini G, Piscaglia F. Eur Ann Allergy Clin Immunol. 2022 Sep 1. doi: 10.23822/EurAnnACI.1764-1489.265. Online ahead of print. PMID: 36047485

Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to **vaccine** coverage: a world-wide review.
Wang C, Liu B, Zhang S, Huang N, Zhao T, Lu QB, Cui F. J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28118. Online ahead of print. PMID: 36056540

Progress towards elimination of viral hepatitis by 2030 in the WHO Eastern Mediterranean Region, 2019.
Alaama AS, Khattabi H, Mugisa B, Atta H, Hermez J, Hutin YJ. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):862-870. doi: 10.1016/S2468-1253(22)00082-6. Epub 2022 Jul 9. PMID: 35817075

Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.
Etemadifar M, Nouri H, Pitzalis M, Idda ML, Salari M, Baratian M, Mahdavi S, Abhari AP, Sedaghat N. J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):986-994. doi: 10.1136/jnnp-2022-329123. Epub 2022 Jun 10. PMID: 35688629

Willingness to Receive COVID-19 Vaccination Among Adult Diabetes Patients in Woldia Comprehensive Specialized Hospital, North Ethiopia; A Cross-Sectional Study.
Mesele H, Shiferaw M, Tunta A, Seid A, Kassahun W. Patient Prefer Adherence. 2022 Sep 2;16:2451-2459. doi: 10.2147/PPA.S379531. eCollection 2022. PMID: 36081925

Prevalence of oral and anal human papillomavirus infection in Czech predominantly Human immunodeficiency virus-positive men having sex with men - data from a previously unreported population.
Nemcova J, Riegert J, Cerna K, Rob F, Smahelova J, Hercogova JT, Martinek P, Ondic O. Int J STD AIDS. 2022 Sep 8:9564624221123869. doi: 10.1177/09564624221123869. Online ahead of print. PMID: 36073929

CCL2: a Chemokine Potentially Promoting Early Seeding of the Latent HIV Reservoir.
Packard TA, Schwarzer R, Herzig E, Rao D, Luo X, Egedal JH, Hsiao F, Widera M, Hultquist JF, Grimmett ZW, Messer RJ, Krogan NJ, Deeks SG, Roan NR, Dittmer U, Hasenkrug KJ, Greene WC. mBio. 2022 Sep 8:e0189122. doi: 10.1128/mbio.01891-22. Online ahead of print. PMID: 36073812

Early but reversible haemostatic changes in a-symptomatic females expressing COVID-19 antibodies.
Williams JO, Nash J, Whelan C, Raven BM, Davies AJ, Evans J, Watkeys L, Morris K, James PE. Thromb Res. 2022 Sep;217:76-85. doi: 10.1016/j.thromres.2022.07.012. Epub 2022 Jul 25. PMID: 35908384

Decreased severity of COVID-19 in vaccinated pregnant individuals during predominance of different SARS-CoV-2 variants.
Eid J, Abdelwahab M, Williams H, Caplan M, Hajmurad S, Venkatesh KK, Costantine MM, Rood KM. Am J Reprod Immunol. 2022 Sep;88(3):e13596. doi: 10.1111/aji.13596. Epub 2022 Jul 15. PMID: 35789021

Plasmablast-like Phenotype Among Antigen-Experienced CXCR5-CD19^{low} B Cells in Systemic Lupus Erythematosus.
Szelinski F, Stefanski AL, Schrezenmeier E, Rincon-Arevalo H, Wiedemann A, Reiter K, Ritter J, Lettau M, Dang VD, Fuchs S, Frei AP, Alexander T, Lino AC, Dörner T. Arthritis Rheumatol. 2022 Sep;74(9):1556-1568. doi: 10.1002/art.42157. Epub 2022 Aug 2. PMID: 35507291

Description of Hospitalizations due to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Based on Vaccination Status.
Moffa MA, Shively NR, Carr DR, Bremmer DN, Buchanan C, Trienski TL, Jacobs MW, Saini V, Walsh TL. Open Forum Infect Dis. 2022 Aug 25;9(9):ofac438. doi: 10.1093/ofid/ofac438. eCollection 2022 Sep. PMID: 36092825

Temporary reduction of immunosuppression enhances production of anti-S antibody against severe acute respiratory syndrome coronavirus 2 after vaccination in kidney transplant recipients.
Miura M, Fukumoto M, Komatsu N, Shuto R, Harada H, Sasaki H. Int J Urol. 2022 Sep 7. doi: 10.1111/iju.15027. Online ahead of print. PMID: 36070502

Immunisation with Coronavirus-2 vaccines induces potent antibody responses and does not aggravate the lymphocyte compartment of primary Sjögren's syndrome patients.
Steinmetz TD, de Wolff L, Terpstra JH, Visser A, Bootsma H, Kroese FGM, Verstappen GM. Clin Exp Rheumatol. 2022 Sep 5. doi: 10.55563/clinexprheumatol/1iaqnu. Online ahead of print. PMID: 36063118

Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M, Borkotoky M, Borchetia S, Chowdhury P, Mahanta S, Barooah AK. J Biomol Struct Dyn. 2022 Sep;40(15):7143-7166. doi: 10.1080/07391102.2021.1897679. Epub 2021 Mar 10. PMID: 33715595

High prevalence of IgE sensitization to inactivated influenza vaccines, yet robust IgG4 responses, in a healthy pediatric population.
Tonto PB, Nagao M, Suga S, Taniguchi K, Hirayama M, Nakayama T, Kumagai T, Fujisawa T; Influenza Vaccine Study Group. Influenza Other Respir Viruses. 2022 Sep 9. doi: 10.1111/irv.13053. Online ahead of print. PMID: 36086810

Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.
Nepali K, Sharma R, Sharma S, Thakur A, Liou JP. J Biomed Sci. 2022 Sep 6;29(1):65. doi: 10.1186/s12929-022-00847-6. PMID: 36064696

The impact of pharmacist involvement on immunization uptake and other outcomes: An updated systematic review and meta-analysis.
Le LM, Veettil SK, Donaldson D, Kategeaw W, Hutubessy R, Lambach P, Chaiyakunapruk N. J Am Pharm Assoc (2003). 2022 Sep-Oct;62(5):1499-1513.e16. doi: 10.1016/j.japh.2022.06.008. Epub 2022 Jun 24. PMID: 35961937

Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVac.
Zhou X, Wang Y, Huang B, Feng R, Zhou X, Li C, Zhang X, Shao M, Gan Y, Jin Y, An Y, Xiao X, Wang S, Liu Q, Cheng G, Zhu F, Zhang K, Wang N, Xing X, Li R, Li Y, Liu Y, Lu D, Sun X, Li Z, Liu Y, He J. Immunology. 2022 Sep 3. doi: 10.1111/imm.13572. Online ahead of print. PMID: 36057099

The practicality of Malaysia dengue outbreak forecasting model as an early warning system.
Ismail S, Fildes R, Ahmad R, Wan Mohamad Ali WN, Omar T. Infect Dis Model. 2022 Aug 8;7(3):510-525. doi: 10.1016/j.idm.2022.07.008. eCollection 2022 Sep. PMID: 36091345

Clinical, Laboratory, and Imaging Findings of Pregnant Women with Possible Vertical Transmission of SARS-CoV-2-Case Series.
Craina M, Iacob D, Dima M, Bernad S, Silaghi C, Moza A, Pantea M, Gluhovschi A, Bernad E. Int J Environ Res Public Health. 2022 Sep 1;19(17):10916. doi: 10.3390/ijerph191710916. PMID: 36078626

The impact of the COVID-19 pandemic on Fabry Disease Patients: an examination of Mood Status, Therapy Adherence, and COVID-19 infection.
Karaca C, Dincer MT, Ozcan SG, Sarac B, Ahmadzada S, Alagoz S, Bakir A, Kiykim E, Trabulus S, Seyahi N. Orphanet J Rare Dis. 2022 Sep 5;17(1):338. doi: 10.1186/s13023-022-02491-7. PMID: 36064417

Steric accessibility of the N-terminus improves the titer and quality of recombinant proteins secreted from Komagataella phaffii.
Dalvie NC, Naranjo CA, Rodriguez-Aponte SA, Johnston RS, Christopher Love J. Microb Cell Fact. 2022 Sep 5;21(1):180. doi: 10.1186/s12934-022-01905-2. PMID: 36064410

Observational retrospective analysis of vaccination against SARS-CoV-2 and seizures: VACCI-COVID registry.
Martinez-Fernandez I, Sanchez-Larsen A, Gonzalez-Villar E, Martínez-Martín Á, von Quednow E, Del Valle-Pérez JA, Andrés-López A, Restrepo-Carvajal LC, Cuenca-Juan F, Ballesta-García M, Sopelana D. Epilepsy Behav. 2022 Sep;134:108808. doi: 10.1016/j.yebeh.2022.108808. Epub 2022 Jun 22. PMID: 35809503

Reframe the pain: Divided attention and positive memory reframing to reduce needle pain and distress in children-A feasibility randomized controlled trial.
Braithwaite FA, Noel M, Jones HG, Wiese MD, Nania CG, Watson E, Stanton TR. Eur J Pain. 2022 Sep;26(8):1702-1722. doi: 10.1002/ejp.1992. Epub 2022 Jul 1. PMID: 35671133

Electronic cigarette use and risk of COVID-19 among young adults without a history of cigarette smoking.
Young-Wolff KC, Slama NE, Alexeeff SE, Prochaska JJ, Fogelberg R, Sakoda LC. Prev Med. 2022 Sep;162:107151. doi: 10.1016/j.ypmed.2022.107151. Epub 2022 Jul 6. PMID: 35809821

Trends in the Use of Face Coverings in Publicly Accessible Spaces During the COVID-19 Pandemic, King County, Washington, November 2020-May 2021.
Tolentino L, Guthrie B, Baker MG, Beck NK, Chan N, Duchin JS, Gomez A, Simckes M, Wasserman C, Cohen MA, Wasserheit JN. Public Health Rep. 2022 Sep-Oct;137(5):841-848. doi: 10.1177/00333549221100795. Epub 2022 Jul 4. PMID: 35786234

High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study.
Struck NS, Lorenz E, Deschermeier C, Eibach D, Kettenbeil J, Loag W, Brieger SA, Ginsbach AM, Obirikorang C, Maiga-Ascofare O, Sarkodie YA, Boham EEA, Adu EA, Asare G, Amoako-Adusei A, Yawson A, Boakye AO, Deke J, Almoustapha NS, Adu-Amoah L, Duah IK, Ouedraogo TA, Boudo V, Rushton B, Ehmen C, Fusco D, Gunga L, Benke D, Höppner Y, Rasolojaona ZT, Rasamoelina T, Rakotoarivelo RA, Rakotozandrindrainy R, Coulibaly B, Sié A, Awuah AA, Amuasi JH, Souares A, May J. BMC Public Health. 2022 Sep 5;22(1):1676. doi: 10.1186/s12889-022-13918-y. PMID: 36064368

Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Rev Med Virol. 2022 Sep;32(5):e2381. doi: 10.1002/rmv.2381. Epub 2022 Jul 20. PMID: 35856385

Immune-mediated liver injury following COVID-19 vaccination: A systematic review.
Roy A, Verma N, Singh S, Pradhan P, Taneja S, Singh M. Hepatol Commun. 2022 Sep;6(9):2513-2522. doi: 10.1002/hep4.1979. Epub 2022 May 4. PMID: 35507736

Epidemiology and economic impact of lumpy skin disease of cattle in Mymensingh and Gaibandha districts of Bangladesh.
Chouhan CS, Parvin MS, Ali MY, Sadekuzzaman M, Chowdhury MGA, Ehsan MA, Islam MT. Transbound Emerg Dis. 2022 Sep 2. doi: 10.1111/tbed.14697. Online ahead of print. PMID: 36056232

High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2.
Pourcher V, Belin L, Soulie C, Rosenzwajg M, Marot S, Lacombe K, Valin N, Pialoux G, Calin R, Palacios C, Malet I, Zafilaza K, Tubiana R, Valantin MA, Klatzmann D, Calvez V, Simon-Tillaux N, Marcelin AG. AIDS. 2022 Sep 1;36(11):1545-1552. doi: 10.1097/QAD.0000000000003300. Epub 2022 Jun 22. PMID: 35730380

Use of a multiplex polymerase chain reaction assay for the early detection of an outbreak of human parainfluenza virus type 3 infection in a nursery school during the COVID-19 pandemic.
Suzuki J, Endo S, Mizuno T, Takahashi S, Horiuchi Y, Ami Y, Imai H, Shimada D, Yoshida M, Kaku M, Seki M. Infect Prev Pract. 2022 May 25;4(3):100221. doi: 10.1016/j.infpip.2022.100221. eCollection 2022 Sep. PMID: 35677593

Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).
Kanji JN, Nguyen LT, Plitt SS, Charlton CL, Fenton J, Braun S, Marohn C, Lau C, Svenson LW, Hinshaw D, Lutsiak C, Zelyas N, Mengel M, Tipples G. Infect Dis (Lond). 2022 Sep;54(9):666-676. doi: 10.1080/23744235.2022.2080250. Epub 2022 May 31. PMID: 35642330

Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses.
Mehta P, Gasparyan AY, Zimba O, Kitas GD, Yessirkepov M. Clin Rheumatol. 2022 Sep 9:1-17. doi: 10.1007/s10067-022-06365-y. Online ahead of print. PMID: 36076125

Longitudinal determination of BNT162b2 **vaccine** induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.
Korodi M, Horváth I, Rákosi K, Jenei Z, Hudák G, Kákes M, Dallos-Fejér K, Simai E, Páll O, Staver N, Briciu V, Lupșe M, Flonta M, Almaș A, Birlutiu V, Daniela Lupu C, Magdalena Ghibu A, Pianoschi D, Terza LM, Fejer SN. Vaccine. 2022 Sep 2;40(37):5445-5451. doi: 10.1016/j.vaccine.2022.07.040. Epub 2022 Aug 1. PMID: 35931634

Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation.
Chaekal OK, Gomez-Arteaga A, Chen Z, Soave R, Shore T, Mayer S, Phillips A, Hsu JM, Drelick A, Kodiyanplakkal RPL, Plate M, Satlin MJ, van Besien K. Transplant Cell Ther. 2022 Sep;28(9):618.e1-618.e10. doi: 10.1016/j.jtct.2022.06.012. Epub 2022 Jun 18. PMID: 35724850

Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings.
Talcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):30-38. doi: 10.1016/j.ijrobp.2022.05.002. Epub 2022 May 20. PMID: 35598798

Comparison of Transcriptomic Signatures between Monkeypox-Infected Monkey and Human Cell Lines.
Xuan DTM, Yeh IJ, Wu CC, Su CY, Liu HL, Chiao CC, Ku SC, Jiang JZ, Sun Z, Ta HDK, Anuraga G, Wang CY, Yen MC. J Immunol Res. 2022 Sep 1;2022:3883822. doi: 10.1155/2022/3883822. eCollection 2022. PMID: 36093436

The Molecular Epidemiology of Prevalent Klebsiella pneumoniae Strains and Humoral Antibody Responses against Carbapenem-Resistant K. pneumoniae Infections among Pediatric Patients in Shanghai.
Wang J, Ma R, Pan F, Wu Y, Pan Y, Liu Y, Yu F, Yu J, Lun H, Shi Y, Zhang H, He P. mSphere. 2022 Sep 7:e0027122. doi: 10.1128/msphere.00271-22. Online ahead of print. PMID: 36069436

Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination.
Chua GT, Kwan MYW, Chui CSL, Smith RD, Cheung ECL, Ma T, Leung MTY, Tsao SSL, Kan E, Ng WKC, Chan VCM, Tai SM, Yu TC, Lee KP, Wong JSC, Lin YK, Shek CC, Leung ASY, Chow CK, Li KW, Ma J, Fung WY, Lee D, Ng MY, Wong WHS, Tsang HW, Kwok J, Leung D, Chung KL, Chow CB, Chan GCF, Leung WH, To KKW, Yuen KY, Lau YL, Wong ICK, Ip P. Clin Infect Dis. 2022 Sep 10;75(4):673-681. doi: 10.1093/cid/ciab989. PMID: 34849657

Level of screening for and vaccination against hepatitis B among healthcare workers in the Eastern Democratic Republic of the Congo: a public health concern.
Sikakulya FK, Munyambalu DK, Mambo SB, Mutsunga AK, Djuma SF, Djuna PA, Ndiwelubula E, Ngavo WA, Sahika SM, Kumbakulu PK, Adelard KN, Shindano TA. Infect Prev Pract. 2022 Jun 24;4(3):100226. doi: 10.1016/j.infpip.2022.100226. eCollection 2022 Sep. PMID: 35898603

Production, purification, and characterization of recombinant rabies virus glycoprotein expressed in PichiaPink™ yeast.
Askri H, Akrouti I, Rourou S, Kallèl H. Biotechnol Rep (Amst). 2022 May 13;35:e00736. doi: 10.1016/j.btre.2022.e00736. eCollection 2022 Sep. PMID: 35646619

Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers.
Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V, Paitoonpong L, Suwanpimolkul G, Torvorapanit P, Pradit R, Sophonphan J, Putcharoen O. Asian Pac J Allergy Immunol. 2022 Sep;40(3):269-277. doi: 10.12932/AP-250721-1197. PMID: 34717527

45 and Up COVID Insights: a dynamic and collaborative approach to evidence-making during the COVID-19 pandemic.
Dawson G, Bleicher K, Blaynes S, D'Este C, Steinberg J, Weber MF, Newby J, Ding D, Liu B, Edwards B, Milat A, McNamara M. Public Health Res Pract. 2022 Sep 6:32232214. doi: 10.17061/phrp32232214. Online ahead of print. PMID: 36065021

Influenza infection is not associated with phenotypical frailty in older patients, a prospective cohort study.
Takahashi P, Wi CI, Ryu E, King K, Hickman J, Pignolo R, Juhn Y. Health Sci Rep. 2022 Aug 14;5(5):e750. doi: 10.1002/hsr2.750. eCollection 2022 Sep. PMID: 35989948

Active Surveillance With Seroprevalence-based Infection Rates Indicates Racial Disparities With Pediatric SARS-CoV-2 Requiring Hospitalization in Mississippi, March 2020-February 2021.
Hobbs CV, Kim SS, Vemula P, Inagaki K, Harrison VA, Malloch L, Martin LM, Singh G, Agana U, Williams JM, Patterson K, Kittle T, Byers P, Palmer A, Santos RP, Dhanrajani A, Stephenson M, Hung L, Hankins P, Thornburg N, Drobeniuc J, Flannery B; CDC COVID-19 Response Team. Pediatr Infect Dis J. 2022 Sep 1;41(9):736-741. doi: 10.1097/INF.0000000000003593. Epub 2022 Jun 7. PMID: 35703309

Clinical manifestations of COVID-19 breakthrough infections: A systematic review and meta-analysis.
Lee CJ, Woo W, Kim AY, Yon DK, Lee SW, Koyanagi A, Kim MS, Tizaoui K, Dragioti E, Radua J, Lee S, Smith L, Il Shin J. J Med Virol. 2022 Sep;94(9):4234-4245. doi: 10.1002/jmv.27871. Epub 2022 Jun 1. PMID: 35588301

Impact of $PM_{2.5}$ and ozone on incidence of influenza in Shijiazhuang, China: a time-series study.
Wang X, Cai J, Liu X, Wang B, Yan L, Liu R, Nie Y, Wang Y, Zhang X, Zhang X. Environ Sci Pollut Res Int. 2022 Sep 8:1-18. doi: 10.1007/s11356-022-22814-2. Online ahead of print. PMID: 36076137

Orthopoxvirus Testing Challenges for Persons in Populations at Low Risk or Without Known Epidemiologic Link to Monkeypox - United States, 2022.
Minhaj FS, Petras JK, Brown JA, Mangla AT, Russo K, Willut C, Lee M, Beverley J, Harold R, Milroy L, Pope B, Gould E, Beeler C, Schneider J, Mostafa HH, Godfred-Cato S, Click ES, Borah BF, Galang RR, Cash-Goldwasser S, Wong JM, McCormick DW, Yu PA, Shelus V, Carpenter A, Schatzman S, Lowe D, Townsend MB, Davidson W, Wynn NT, Satheshkumar PS, O'Connor SM, O'Laughlin K, Rao AK, McCollum AM, Negrón ME, Hutson CL, Salzer JS; CDC Monkeypox Emergency Response Team; CDC Monkeypox Emergency Response Team. MMWR Morb Mortal Wkly Rep. 2022 Sep 9;71(36):1155-1158. doi: 10.15585/mmwr.mm7136e1. PMID: 36074752

Factors influencing the COVID-19 pandemic situation in Indonesia, Malaysia and Taiwan in 2021.
Lubis R, Satria FB, Zaki RA, Nurjazuli N, Hendrati LY. Public Health Pract (Oxf). 2022 Dec;4:100311. doi: 10.1016/j.puhip.2022.100311. Epub 2022 Sep 2. PMID: 36072129

Should patients with epilepsy be vaccinated against coronavirus disease 2019? A systematic review and meta-analysis.
Lin K, Huang H, Fang S, Zheng G, Fu K, Liu N, Du H. Epilepsy Behav. 2022 Sep;134:108822. doi: 10.1016/j.yebeh.2022.108822. Epub 2022 Jun 29. PMID: 35853315

Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections.
Pramanik A, Mayer J, Sinha SS, Sharma PC, Patibandla S, Gao Y, Corby LR, Bates JT, Bierdeman MA, Tandon R, Seshadri R, Ray PC. ACS Appl Bio Mater. 2022 Sep 2. doi: 10.1021/acsabm.2c00573. Online ahead of print. PMID: 36053723

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.
Räuber S, Korsen M, Huntemann N, Rolfes L, Müntefering T, Dobelmann V, Hermann AM, Kölsche T, von Wnuck Lipinski K, Schroeter CB, Nelke C, Regner-Nelke L, Ingwersen J, Pawlitzki M, Teegen B, Barnett MH, Hartung HP, Aktas O, Albrecht P, Levkau B, Melzer N, Ruck T, Meuth SG, Kremer D. J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):978-985. doi: 10.1136/jnnp-2021-328197. Epub 2022 Feb 22. PMID: 35193952

High Incidence and Unique Features of Cerebral Venous Sinus Thrombosis in Hospitalized Patients With COVID-19 Infection.
McCullough-Hicks ME, Halterman DJ, Anderson D, Cohen K, Lakshminarayan K. Stroke. 2022 Sep;53(9):e407-e410. doi: 10.1161/STROKEAHA.122.038955. Epub 2022 Aug 3. PMID: 35920155

The Combined Escherichia coli Nissle 1917 and Tryptophan Treatment Modulates Immune and Metabolome Responses to Human Rotavirus Infection in a Human Infant Fecal Microbiota-Transplanted Malnourished Gnotobiotic Pig Model.
Michael H, Srivastava V, Deblais L, Amimo JO, Chepngeno J, Saif LJ, Rajashekara G, Vlasova AN. mSphere. 2022 Sep 8:e0027022. doi: 10.1128/msphere.00270-22. Online ahead of print. PMID: 36073800

COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes.
Wong G, Rowlandson M, Sabanayagam D, Ginn AN, Kable K, Sciberras F, Au E, Draper J, Arnott A, Sintchenko V, Dwyer DE, Chen SCA, Kok J. Transplantation. 2022 Sep 1;106(9):1860-1866. doi: 10.1097/TP.0000000000004203. Epub 2022 Aug 19. PMID: 35675438

The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence.
Carle C, Hughes S, Freeman V, Campbell D, Egger S, Caruana M, Hui H, Yap S, Deandrea S, Onyeka TC, IJzerman MJ, Ginsburg O, Bray F, Sullivan R, Aggarwal A, Peacock SJ, Chan KKW, Hanna TP, Soerjomataram I, O'Connell DL, Canfell K, Steinberg J. J Cancer Policy. 2022 Sep;33:100338. doi: 10.1016/j.jcpo.2022.100338. Epub 2022 Jun 6. PMID: 35671919

Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2 N and S proteins: mass screening.
Srivastava AK, Gupta A, Chauhan D, Meena RC, Sugadev R, Eslavath MR, Gupta H, Karuna, Singh S, Singh Y, Tiwari RP, Kohli V, Varshney R, Ganju L. Appl Microbiol Biotechnol. 2022 Sep;106(18):6225-6238. doi: 10.1007/s00253-022-12113-8. Epub 2022 Aug 17. PMID: 35976427

Validation of laboratory developed serology assays for detection of IgG antibody to severe acute respiratory syndrome coronavirus 2 in the South African population.
Matefo L, Cloete VV, Armand BP, Dominique G, Samantha P, John F, Craig T, Daniel W, Theresa L, Sunetra G, Maréza B, Danelle VJ, Jane BF. J Virol Methods. 2022 Sep;307:114571. doi: 10.1016/j.jviromet.2022.114571. Epub 2022 Jun 21. PMID: 35750222

Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
Mok CC, Chan KL, Tse SM. Vaccine. 2022 Sep 6:S0264-410X(22)01067-2. doi: 10.1016/j.vaccine.2022.08.068. Online ahead of print. PMID: 36085256

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates.
Bai Y, He Q, Yang J, Lu S, Mao Q, Gao F, Bian L, Zhang J, An C, Liu J, Wu X, Yu W, Wang Z, Peng X, Wang J, Liang Z, Xu M. Microbiol Spectr. 2022 Sep 7:e0226322. doi: 10.1128/spectrum.02263-22. Online ahead of print. PMID: 36069561

Effects of meteorological factors on the incidence of varicella in Lu'an, Eastern China, 2015-2020.
Zhang T, Qin W, Nie T, Zhang D, Wu X. Environ Sci Pollut Res Int. 2022 Sep 6. doi: 10.1007/s11356-022-22878-0. Online ahead of print. PMID: 36066801

Low prevalence of hepatitis B virus infection in HIV-uninfected pregnant women in Cape Town, South Africa: implications for oral pre-exposure prophylaxis roll out.
Joseph Davey D, Hsiao NY, Wendy Spearman C, Sonderup M, Hu NC, Mashele N, Mvududu R, Myer L. BMC Infect Dis. 2022 Sep 1;22(1):719. doi: 10.1186/s12879-022-07697-5. PMID: 36050648

The COVID-19 pandemic and disruptions to essential health services in Kenya: a retrospective time-series analysis.
Kiarie H, Temmerman M, Nyamai M, Liku N, Thuo W, Oramisi V, Nyaga L, Karimi J, Wamalwa P, Gatheca G, Mwenda V, Ombajo LA, Thumbi SM; Essential Health Services Data Monitoring and Evaluation sub-working group. Lancet Glob Health. 2022 Sep;10(9):e1257-e1267. doi: 10.1016/S2214-109X(22)00285-6. PMID: 35961349

SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study.
Al-Otaiby M, Krissaane I, Al Seraihi A, Alshenaifi J, Qahtani MH, Aljeri T, Zaatari E, Hassanain M, Algwizani A, Albarrag A, Al-Mozaini M, Alabdulaali M. Int J Infect Dis. 2022 Sep;122:758-766. doi: 10.1016/j.ijid.2022.07.025. Epub 2022 Jul 14. PMID: 35840098

Systematic review and critical evaluation of quality of clinical practice guidelines on the management of SARS-CoV-2 infection in pregnancy.

Di Girolamo R, Khalil A, Rizzo G, Capannolo G, Buca D, Liberati M, Acharya G, Odibo AO, D'Antonio F. Am J Obstet Gynecol MFM. 2022 Sep;4(5):100654. doi: 10.1016/j.ajogmf.2022.100654. Epub 2022 May 2. PMID: 35504493

Measuring inequalities in COVID-19 vaccination uptake and intent: results from the Canadian Community Health Survey 2021.
Guay M, Maquiling A, Chen R, Lavergne V, Baysac DJ, Racine A, Dubé E, MacDonald SE, Gilbert NL. BMC Public Health. 2022 Sep 8;22(1):1708. doi: 10.1186/s12889-022-14090-z. PMID: 36076208

Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.
Lawal B, Kuo YC, Rachmawati Sumitra M, Wu ATH, Huang HS. Comput Biol Med. 2022 Sep;148:105814. doi: 10.1016/j.compbiomed.2022.105814. Epub 2022 Jul 11. PMID: 35841781

Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis.
Yao N, Fu S, Wu Y, Tian Z, Feng Y, Li J, Luo X, Yang Y, Ji F, Chen Y, Liu J, Zhao Y, Chen T. Acta Obstet Gynecol Scand. 2022 Sep 9. doi: 10.1111/aogs.14448. Online ahead of print. PMID: 36082797

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20220901:20220911 as the publication date.*

58 records

1.20220280631VIRAL PANDEMIC VACCINE
US - 08.09.2022
Int.Class A61K 39/12 Appl.No 17194308 Applicant Henry J. Smith Inventor Henry J. Smith

This invention teaches a means of rapidly producing a vaccine following a viral outbreak and using said vaccine to prevent the outbreak from becoming a pandemic. Said vaccine is composed of multiple immunostimulatory agents (agonists) incorporated in liposomes. Each agonist will bind to its specific cellular receptor and induce the cell to produce type 1 interferons which has strong anti-viral activity. The agonists are Poly IC, ssRNA, CpG-ODN and MPL-A incorporated in a liposomal vaccine. Using multiple different agonists in the vaccine will elicit a stronger innate immune response than using a single agonist. This vaccine can be enhanced by combining a viral antigen with the agonists in the liposome. Said enhanced vaccine will provide immediate and prolonged immunity to viral infection by stimulating both the innate immune response and the adaptive immune response against the virus.

2.WO/2022/186661MULTIVALENT VACCINE COMPOSITION FOR PREVENTION OF PORCINE MYCOPLASMA AND PORCINE CIRCOVIRUS INFECTION
WO - 09.09.2022
Int.Class A61K 39/295 Appl.No PCT/KR2022/003112 Applicant INNOVAC Inventor HAHN, Tae Wook
The present invention relates to a multivalent vaccine composition for prevention of porcine mycoplasma and porcine circovirus infections and an infection prevention method using same. The multivalent vaccine composition according to the present invention exhibits a reciprocally supplemental effect on immune responses in pigs used as experimental animals and target animals and does not allow for interference between antigens. When inoculated into pigs, the vaccine composition induces high serological levels of

antibody titers and neutralizing antibody titers and produces a high level of IFN-γ for Mhp or PCV2 sensitization in PBMC. Thus, the vaccine composition can find advantageous applications for preventing porcine mycoplasma and porcine circovirus infections.

3.WO/2022/181897RECOMBINANT ADENOVIRUS VACCINE FOR CORONAVIRUS DISEASE 19 (COVID-19), AND COMBINATION THERAPY USING SAME
WO - 01.09.2022
Int.Class A61K 39/42 Appl.No PCT/KR2021/009108 Applicant GENEUIN-TECH CO., LTD. Inventor HAN, Eun Yeong
The present invention relates to a recombinant adenovirus live vaccine for preventing coronavirus disease 19 (COVID-19) infection, which broke out in Wuhan, China in 2019, and to a combination therapy using the recombinant adenovirus live vaccine. The recombinant adenovirus according to the present invention can be used to produce an antibody specific to a novel coronavirus antigen, and thereby develop a COVID-19 vaccine which is fast-acting and harmless to the human body. In addition, the combination therapy of the recombinant adenovirus vaccine and a compound according to the present invention can be used to more effectively and safely prevent or treat not only COVID-19 but also viral diseases such as herpes simplex virus (HSV) infection.

4.WO/2022/180534VACCINE COMPOSITION COMPRISING A LEISHMANIA HOST CELL EXPRESSING AT LEAST ONE PROTEIN OF THE FAMILY CORONAVIRIDAE
WO - 01.09.2022
Int.Class C07K 14/005 Appl.No PCT/IB2022/051585 Applicant UNIVERSITA' DEGLI STUDI DI MILANO Inventor BANDI, Claudio
The present invention relates to a vaccine composition comprising a host cell belonging to the genus Leishmania, wherein the host cell comprises a polynucleotide coding for at least one protein of a virus belonging to the family Coronaviridae. Furthermore, the invention relates to the medical and veterinary use of the vaccine composition and to a process for preparing the vaccine composition.

5.WO/2022/179318S PROTEIN R815 SITE-BASED CORONAVIRUS INTERVENTION METHOD AND PRODUCT
WO - 01.09.2022
Int.Class C07K 14/165 Appl.No PCT/CN2022/070763 Applicant INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES Inventor MENG, Guangxun
Provided in the present invention are an S protein R815 site-based novel coronavirus intervention method and a product. Particularly, provided in the present invention are an antigen peptide and a vaccine polypeptide of novel coronavirus. Further provided in the present invention are a vaccine composition containing the antigen peptide or the vaccine polypeptide and the use thereof. Experiments show that the antigen peptide or the vaccine polypeptide of the present invention can effectively prevent S protein from producing cell fusion and infection effects, thereby effectively preventing the infection of novel coronavirus.

6.WO/2022/182940NEURAL CONTROL OF ADAPTIVE IMMUNITY
WO - 01.09.2022
Int.Class A61K 39/00 Appl.No PCT/US2022/017819 Applicant THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH Inventor CHAVAN, Sangeeta S.
The present invention provides methods for modulating antigen-specific antibody responses by administering to a mammal a compound that selectively either activates or inhibits a specific subset of sensory neurons that express TRPVI. The methods include providing a vaccine adjuvant in a subject who is being administered an immunogen-specific vaccine, which comprises administering to said subject an immunogen-specific antibody production enhancing amount of a TRPVI nociceptor agonist. The methods

also include increasing antibody production in a subject to at least one antigen contained in a vaccine that is being administered to said subject, which comprises administering to said subject an antibody-production increasing amount of a TRPVI nociceptor agonist.

7.20220280630VACCINE COMPOSITIONS AND METHODS OF SELECTING ANTIGENS
US - 08.09.2022
Int.Class A61K 39/095 Appl.No 17631694 Applicant Trustees of Tufts College Inventor Paola MASSARI

Described herein are vaccine compositions and methods of selecting an antigen or fragment thereof for the preparation of a vaccine composition. The methods and vaccine compositions described herein are based, in part, on the discovery that certain polypeptides not previously identified or considered for potential use as antigens from pathogenic microorganisms (e.g., *N. gonorrhoeae*) can provoke an immune response in a subject. The methods of identifying and selecting the antigens described herein rely, in part, on approaches that identify polypeptides (e.g., hypothetical proteins) predicted to be immunogenic.

8.4051296FIBROBLAST-DERIVED UNIVERSAL IMMUNOLOGICAL COMPOSITION
EP - 07.09.2022
Int.Class A61K 35/17 Appl.No 20880517 Applicant FIGENE LLC Inventor O'HEERON PETE
Described are means of generating immunological compositions that are universally applicable for induction of immunity to neoplasia regardless of histological origin of tissue. Certain methods concern fibroblasts that are manipulated or dedifferentiated in a manner to induce expression of tumor associated antigens including cancer testis antigens. These cells are used as a source of antigenic stimuli for creation of a cellular vaccine, and/or an exosome vaccine, and/or a lysate-based vaccine.

9.20220273787CO-ADMINISTRATION OF SEASONAL INFLUENZA VACCINE AND AN ADENOVIRUS BASED RESPIRATORY SYNCYTIAL VIRUS VACCINE
US - 01.09.2022
Int.Class A61K 39/12 Appl.No 17595255 Applicant Janssen Vaccines & Prevention B.V. Inventor Benoit Christophe Stephan CALLENDRET

Methods of inducing a protective immune response against respiratory syncytial virus (RSV) and against influenza virus, without inducing a severe adverse event in human subjects are described. The methods include administering to the subjects an effective amount of an adenoviral vector encoding a recombinant RSV F polypeptide that is stabilized in a pre-fusion conformation, along with an effective amount of an influenza vaccine.

10.20220280629ANTIMICROBIAL VACCINE COMPOSITIONS
US - 08.09.2022
Int.Class A61K 39/08 Appl.No 17638732 Applicant ONEBIOPHARMA, INC. Inventor Rebecca DABORA

This invention is directed to antimicrobial vaccine compounds and compositions comprising oligosaccharide β-(1→6)-glucosamine groups having from 3 to 12 glucosamine units linked through a linker group to tetanus toxoid wherein the toxoid is primarily in its monomeric form This invention is also directed to vaccine compositions that provide natural immunity against microbes possessing a cell wall structure that comprises oligosaccharide N-acetyl-β-(1→6)-glucosamine (PNAG) structures.

11.WO/2022/180648ACTIVATED-QUENCHED POLYSACCHARIDE AND IMPROVED METHODS FOR QUANTIFICATION OF POLYSACCHARIDE IN A VACCINE COMPOSITION
WO - 01.09.2022

Int.Class A61K 39/09 Appl.No PCT/IN2022/050168 Applicant BIOLOGICAL E LIMITED Inventor BURKI, Rajendar
The present invention provides a novel reference standard, comprising of activated-quenched polysaccharide, for quantifying polysaccharide content in a vaccine composition using nephelometry. The invention also provides a method for preparing the activated-quenched polysaccharide, for use as a reference standard. Further, a nephelometry based method for quantifying the polysaccharides in a multivalent conjugate vaccine is also provided. The reference standard of the present invention, comprising of the activated-quenched polysaccharide, is stable and can be used for accurate quantification of polysaccharides through nephelometry.

12.20220273788VACCINE
US - 01.09.2022
Int.Class A61K 39/12 Appl.No 17628286 Applicant THE PIRBRIGHT INSTITUTE Inventor Linda Dixon

The present invention provides an African swine fever virus (ASFV) subunit vaccine which comprises: (i) one or more recombinant polynucleotides which encode polypeptides shown as SEQ ID NO: 1, 2 and 3 or an immunogenic fragment thereof; or a variant with at least 70% sequence identity to one of SEQ ID NO: 1, 2 or 3; wherein the total number of different ASFV polypeptides encoded by the one or more recombinant polynucleotides is 10 or fewer; or (ii) recombinant polypeptides shown as SEQ ID NO: 1, 2 and 3 or an immunogenic fragment thereof; or a variant with at least 70% sequence identity to one of SEQ ID NO: 1, 2 and 3; wherein vaccine comprises 10 or fewer different ASFV polypeptides.

13.20220280441FILM WITH LATERALLY ADJOINED STRIPS FOR ADMINISTRATION OF A VACCINE
US - 08.09.2022
Int.Class A61K 9/70 Appl.No 17752325 Applicant CA Pharma Inc. Inventor Michael Bousfield

A film for administration to a mucosal membrane is provided. The film comprises a first film strip comprising a vaccine in a first film matrix comprising at least one film-forming agent, and at least one of a surfactant, emulsifier and/or a plasticizer, and a second film strip comprising an adjuvant in a second film matrix comprising at least one film-forming agent, and at least one of a surfactant, emulsifier and/or a plasticizer. The first and second strips of the film are laterally adjoined along an edge of the first and second strips to provide a single layer film in which the vaccine and adjuvant are not admixed prior to administration.

14.20220273790RATIONALLY ENGINEERED CARRIER PROTEINS FOR VACCINES
US - 01.09.2022
Int.Class A61K 39/385 Appl.No 17618122 Applicant Citranvi Biosciences, LLC Inventor Avvari Krishna Prasad

The invention relates to the design of rationally engineered Carrier Proteins (reCaPs) geared towards producing Multifunctional Chimeric recombinant Fusion Proteins (MCFPs) useful as vaccine candidates. The key components of the MCFPs are (i) genetically engineered carrier proteins; (ii) polypeptide antigens; (iii) linker peptides, optionally fused to heterologous T-cell epitopes; (iv) Dual Function Peptides (DFP) which can act as a purification aids as well having the non-covalent affinity to bind to an adjuvant. The present invention also relates to recombinantly expressed Self-Assembling Adjuvanted Nanoparticles (SAANPs), comprising reCaPs fused with various polypeptide and protein antigens, useful as vaccine candidates. The present invention also provides novel ‘integrated Multiple Conjugate Antigen displayed Adjuvanted Systems’ [iMCAAS], comprising rationally engineered Carrier Proteins, based on ‘Self Assembling Adjuvanted Nanoparticles’ [SAANPs]. These adjuvanted nanoparticles, eventually provide

stronger antigen-antibody interactions compared to the low affinity interactions provided by the monovalent binding generated by single antigen immunogens.

15.20220280633VIRUS-LIKE PARTICLE VACCINES
US - 08.09.2022
Int.Class A61K 39/12 Appl.No 17631435 Applicant Verndari, Inc. Inventor Daniel R. Henderson

Provided, herein, in certain embodiments are virus-like particles such as synthetic enveloped VLPs or synthetic membrane VLPs. In some embodiments, the VLPs comprise a lipid bilayer. In some embodiments, the VLPs comprise a purified antigen anchored to the lipid bilayer. Some embodiments relate to vaccines comprising the VLP, methods of using the vaccine, and methods of making the vaccine or VLP.

16.WO/2022/184287FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES
WO - 09.09.2022
Int.Class A61K 39/12 Appl.No PCT/EP2021/074738 Applicant ROCKETVAX AG Inventor CHRISTEN, Matthias
This invention describes a fully synthetic, long-chain nucleic acid that can be used in biotechnological manufacturing processes to produce envelope proteins, virus envelopes and fragments of virus envelopes of SARS-CoV-2 and related coronaviruses in highly purified form, which, as a vaccine protect against COVID-19 and other viral diseases

17.20220280628SELF-ADJUVANTING YERSINIA OUTER MEMBRANE VESICLE AS A VACCINE AGAINST PLAGUE, ANTHRAX AND PSEUDOMONAS INFECTION
US - 08.09.2022
Int.Class A61K 39/02 Appl.No 17482527 Applicant Albany Medical College Inventor Wei Sun

A vaccine platform using a *Yersinia pestis* mutant synthesizing an adjuvant form lipid A (monophosphoryl lipid A, MPLA) for the increased biogenesis of bacterial outer membrane vesicles (OMVs). To enhance the immunogenicity of the OMVs, an Asd-based balanced-lethal host-vector system was constructed to oversynthesize the LcrV antigen of *Y. pestis,* raise the amounts of LcrV enclosed in OMVs by Type II secretion system, and eliminate harmful factors like plasminogen activator (Pla) and murine toxin from the OMVs. Vaccination with OMVs containing MPLA and increased amounts of LcrV with diminished toxicity afforded complete protection in mice against subcutaneous challenge and intranasal challenge and was significantly superior to that resulting from vaccination with LcrV/alhydrogel. Additionally, the *Yersinia* OMV can be used as a platform to deliver the heterologous antigens of *Bacillus anthraces.* Vaccination with multiantigenic self-adjuvanting bionanoparticles from *Pseudomonas* was also successfully tested in connection with *Pseudomonas aeruginosa.*

18.202217029494CHIKUNGUNYA VIRUS-LIKE PARTICLE VACCINE AND METHODS OF USING THE SAME
IN - 02.09.2022
Int.Class A61K / Appl.No 202217029494 Applicant EMERGENT TRAVEL HEALTH INC. Inventor ALEXANDER, Jeffery L.
The present disclosure is directed to improved virus-like particle (VLP) compositions and vaccines for use in inducing an immune response and/or protective immunity against a Chikungunya virus (CHIKV) infection in a subject, e.g., by inducing a neutralizing antibody response against CHIKV in a subject within 7 days after administration of a single dose of the composition or vaccine.

19.20220280619DNA VACCINE AGAINST AMYLOID-BETA AND TAU

US - 08.09.2022
Int.Class A61K 39/00 Appl.No 17734512 Applicant IMMUNOTHERAPY DEVELOPMENT INC. Inventor Yoh MATSUMOTO

An object of the present invention is to provide a vaccine that can simultaneously reduce Aβ deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-β, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau.

20.20220273563VACCINE ADJUVANT FORMULATION
US - 01.09.2022
Int.Class A61K 9/127 Appl.No 17570635 Applicant Sumitomo Dainippon Pharma Co., Ltd. Inventor Akihisa Fukushima

The present invention provides a liposome useful as a vaccine adjuvant. More specifically, the present invention provides a liposome which comprises a lipid bilayer comprising dimyristoylphosphatidylcholine and egg phosphatidylglycerol and a conjugated compound in which a low-molecular weight compound enhancing the physiological activity of TLR7 is bound to squalene via a linker, said conjugated compound being encapsulated in the lipid bilayer.

21.20220282322INDIVIDUALIZED VACCINES FOR CANCER
US - 08.09.2022
Int.Class C12Q 1/6869 Appl.No 17576170 Applicant TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG Inventor Ugur Sahin

The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

22.20220282264Endotoxin-free Production of Recombinant Subunit Vaccine Components
US - 08.09.2022
Int.Class C12N 15/75 Appl.No 17651476 Applicant Ingenza Ltd. Inventor Ian Fotheringham

An endotoxin-free production of recombinant subunit vaccine components, and production methods thereof, using a synthetic virus-like-particle (VLP) to which is attached (and displayed) a fragment of the coronavirus “spike” protein, the Receptor Binding Domain (RBD) and wherein the VLP is produced very effectively using engineered *B. subtilis.*

23.WO/2022/183120DEVELOPMENT OF COVID-19 VACCINE USING A DUAL TLR LIGAND LIPOSOME ADJUVANT
WO - 01.09.2022
Int.Class A61K 9/127 Appl.No PCT/US2022/018188 Applicant UNIVERSITY OF VIRGINIA PATENT FOUNDATION Inventor POMÉS, Anna
Disclosed are compositions for eliciting anti-SARS-CoV-2 immune responses in subjects. In some embodiments, the compositions include one or more SARS-CoV-2 antigens and one or more PEGylated liposomal adjuvants, wherein at least one of the PEGylated liposomal adjuvants includes a cholesterol, a

non-PEGylated neutral lipid, and a PEGylated lipid. Also provided are methods for using the presently disclosed compositions for stimulating anti-SARS-CoV-2 immune responses, for inducing anti- SARS-CoV-2 Thl responses, for stimulating systemic immune responses and/or mucosal immune responses, for inducing anti-SARS-CoV-2 IgA responses, for reducing SARS- CoV-2-induced lung injuries, and for inducing anti-SARS-CoV-2 neutralizing antibodies in subjects in need thereof.

24.20220281960COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUBERCULOSIS
US - 08.09.2022
Int.Class C07K 16/12 Appl.No 17627167 Applicant Ramot at Tel-Aviv University Ltd. Inventor Natalia FREUND

A human antibody comprising an antigen binding domain which binds PstS1 of *Mycobacterium tuberculosis* (TB) for use in preventing or treating TB infection in a subject in need thereof is provided. Also provided are vaccine compositions and conjugates of such antibodies.

25.2022902404Wearable animal vaccine insulation apparatus
AU - 01.09.2022
Int.Class Appl.No 2022902404 Applicant Fisher, Marnie Inventor Fisher, Marnie

26.WO/2022/186384VACCINE AGAINST CYPRINID HERPESVIRUS 2
WO - 09.09.2022
Int.Class A61K 39/245 Appl.No PCT/JP2022/009448 Applicant NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF MARINE SCIENCE AND TECHNOLOGY Inventor SANO, Motohiko
The purpose of the present invention is to provide a method for controlling CyHV-2 infectious diseases in fish. The present invention pertains to a composition for use in controlling cyprinid herpesvirus 2 (CyHV-2) infectious diseases in fish, the composition containing attenuated CyHV-2.

27.20220283161METHODS AND COMPOSITIONS FOR HEPATITIS C VIRUS (HCV)
US - 08.09.2022
Int.Class G01N 33/576 Appl.No 17630104 Applicant The Johns Hopkins University Inventor Valerie Kinchen

Provided herein are, inter alia, methods, compositions and kits for HCV antigen and vaccine design. Preferred methods include measuring neutralization of HCV pseudoparticles (HCVpp) by antibodies specific for an HCV in the biological sample, generating a neutralizations profile of each biological sample; deconvoluting the HCV-specific neutralizing antibodies by generating reference antibody neutralization profiles; correlating the reference antibody neutralization profiles to the biological sample's neutralization profile; and, identifying the HCV neutralizing antibodies.

28.3299030PARENTERALE NOROVIRUS-VACCINEFORMULERINGER
DK - 05.09.2022
Int.Class A61K 39/125 Appl.No 17199372 Applicant Takeda Vaccines, Inc. Inventor RICHARDSON, Charles
The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed.

29.WO/2022/180219OPTIMIZED VACCINE TO ELICIT A T CELL IMMUNITY AGAINST SARS-COV-2
WO - 01.09.2022
Int.Class A61K 39/12 Appl.No PCT/EP2022/054809 Applicant KOSMATOPOULOS, Kostantinos (Kostas) Inventor KOSMATOPOULOS, Kostantinos (Kostas)

The invention pertains to immunogenic compositions designed to elicit both a humoral and a T-cell immunity against SARS-CoV-2. To this aim, the invention provides modified sequences of the S protein and/or the N protein of SARS-CoV-2, in which each of the introduced modifications is likely to increase the affinity of a cryptic epitope presented by one of the major HLA-I molecules (HLA-A1, -A2, -A3, -A24, -B7, - B35 and Cw7) for this HLA-I molecule.

30.20220280623NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS
US - 08.09.2022
Int.Class A61K 39/00 Appl.No 17743778 Applicant Immatics Biotechnologies GmbH Inventor Andrea MAHR

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

31.4052575USE OF A GRAPE EXTRACT AS A VIRUCIDE AGAINST VIRUSES FROM THE CORONAVIRUS FAMILY
EP - 07.09.2022
Int.Class A01N 43/16 Appl.No 22305245 Applicant BERKEM DEV Inventor MESSAOUDI DAOUIA
La présente invention est du domaine de la désinfection et de l'antisepsie et concerne plus particulièrement l'utilisation d'un extrait de raisin en tant que virucide à l'encontre des virus de la famille des coronavirus, des adénovirus, des norovirus murins, des virus de la vaccine et des poliovirus.

32.20220282330HLA-H IN MEDICINE AND DIAGNOSTICS
US - 08.09.2022
Int.Class C12Q 1/6881 Appl.No 17625063 Applicant Intellexon GmbH Inventor Wolfgang WÜRFEL

The present invention relates to a nucleic acid molecule, a vector, a host cell, or a protein or peptide, or combinations thereof for use as an immunosuppressant, as a tumor vaccine or as a pregnancy promoter wherein (I) the nucleic acid molecule is (a) encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; or (b) consisting of the nucleotide sequence of SEQ ID NO: 2; or (c) encoding a polypeptide which is at least 70%, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the amino acid sequence of SEQ ID NO: 1; or (d) consisting of a nucleotide sequence which is at least 70% identical, preferably at least 80% identical, more preferably at least 90% identical, and most preferred at least 95% identical to the nucleotide sequence of SEQ ID NO: 2; or (e) consisting of a nucleotide sequence which is degenerate with respect to the nucleic acid molecule of (d); or (f) a fragment of the nucleic acid molecule of any one of (a) to (e), said fragment comprising at least 150 nucleotides, preferably at least 300 nucleotides, more preferably at least 450 nucleotides, and most preferably at least 600 nucleotides; or (g) corresponding to the nucleic acid molecule of any one of (a) to (f), wherein T is replaced by U; (II) the vector comprises the nucleic acid molecule of (I); (III) the host cell is transformed, transduced or transfected with the vector of (II); and (IV) the protein or peptide being encoded by the nucleic acid molecule of (I).

33.20220275041MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES

US - 01.09.2022
Int.Class C07K 14/555 Appl.No 17269363 Applicant Exalt Therapeutics, LLC Inventor John W. WALLEN, III

Non-human IFNL3 polypeptides and their uses thereof are provided. Exemplary embodiments provide IFNL3 polypeptides which include one or more amino acid substitutions, additions, or deletions with natural or non-naturally encoded amino acids, and/or linkage or fusion to other biologically active molecules including other IFNL3 polypeptides, as well as PK enhancing moieties (PKEMs). Additionally, use of said IFNL3 polypeptides for innate immune system stimulation, as a vaccine adjuvant, as well as treatment or prevention of diseases such as viral and bacterial infections, and inflammation, is also provided.

34.20220280626CIRCUMSPOROZOITE PROTEINS WITH INCREASED EXPRESSION IN MAMMALIAN CELLS
US - 08.09.2022
Int.Class A61K 39/015 Appl.No 17440597 Applicant Fred Hutchinson Cancer Research Center Inventor Marie Pancera

Mutated and/or truncated malarial circumsporozoite proteins (CSP) and associated nucleic acids that are more stable and highly expressed in mammalian cells are described. The mutated and/or truncated CSP and associated nucleic acids can be expressed to produce malaria vaccine antigens.

35.20220273782Novel PD-L1 Targeting DNA Vaccine for Cancer Immunotherapy
US - 01.09.2022
Int.Class A61K 39/00 Appl.No 17730909 Applicant Vaximm AG Inventor Heinz Lubenau

The present invention relates to an attenuated strain of *Salmonella* comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain of *Salmonella* for use in the treatment of cancer.

36.20220273786ZIKA VIRUS VACCINE
US - 01.09.2022
Int.Class A61K 39/12 Appl.No 17548721 Applicant Valneva Austria GmbH Inventor Jana Barbero Calzado

Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

37.20220273789THERAPEUTIC VIRAL VACCINE
US - 01.09.2022
Int.Class A61K 39/245 Appl.No 17627998 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor Normand BLAIS

The present invention relates to viral Fc receptor or immunogenic fragments thereof for treating a viral infection in a subject and, in particular, a herpes vims infection. The present invention also relates to a heterodimer comprising or consisting of an Fc receptor from a HSV vims or an immunogenic fragment thereof and a binding partner from said HSV vims or a fragment thereof, for use in therapy.

38.20220283158METHOD OF IDENTIFYING PEPTIDE ANTIGENS AND USES THEREOF
US - 08.09.2022

Int.Class G01N 33/564 Appl.No 17634164 Applicant HUMANIRAS MIRASOLE S.P.A. Inventor Marinos KALLIKOURDIS

The invention provides a new method for identifying peptide antigens relevant to a non-autoimmune disease involving T cell activation as well as novel peptides identified therefrom. The isolated peptides of the invention are useful in the diagnosis, prevention and/or treatment of a cardiovascular disease, more specifically heart failure (HF). The invention further provides a pharmaceutical composition comprising at least one isolated peptide of the invention and a pharmaceutically acceptable carrier, vehicle, excipient and/or diluent. The pharmaceutical composition of the invention is suitable to be orally administered as a tolerizing vaccine.

39.20220275068COMPOSITIONS AND METHODS OF USING A HUMANIZED ANTI-DKK2 ANTIBODY
US - 01.09.2022
Int.Class C07K 16/18 Appl.No 17625683 Applicant YALE UNIVERSITY Inventor Le SUN

The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases $CD8^+$ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

40.WO/2022/183689HER2 AFFIBODY RADIONUCLIDE MARKER COMPOSITION AND APPLICATION THEREOF
WO - 09.09.2022
Int.Class A61K 51/08 Appl.No PCT/CN2021/112782 Applicant JIANGSU YUANBEN BIOTECHNOLOGY CO., LTD. Inventor CAI, Jiong
The present invention relates to the fields of radiopharmaceuticals and nuclear medicine, and provides a HER2 affibody 99mTc marker composition and an application thereof. The HER2 affibody 99mTc marker composition in the present invention comprises HEPES, sodium glucoheptonate, vitamin C, cysteine, stannous chloride, and HER2 affibody.

41.4051318ENGINEERED ANTIBODIES TO HIV ENV
EP - 07.09.2022
Int.Class A61K 39/42 Appl.No 20883493 Applicant INT AIDS VACCINE INITIATIVE Inventor SOK DEVIN
The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS. In one aspect, provided herein are enhanced engineered anti-HIV Env antibodies that were derived from the PGDM1400 parent antibody using directed-evolution and yeast display. In one aspect, provided herein are pharmaceutical compositions comprising the enhanced engineered anti-HIV Env antibodies disclosed herein.

42.3197487VACCINATION AF IMMUNSVÆKKEDE INDIVIDER
DK - 05.09.2022
Int.Class A61K 39/145 Appl.No 15781436 Applicant Seqirus UK Limited Inventor DEL GIUDICE, Giuseppe

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a statin therapy. Related products are also provided.

43.294859METHODS OF INDUCING NEOEPITOPE-SPECIFIC T CELLS WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE
IL - 01.09.2022
Int.Class A61K 39/00 Appl.No 294859 Applicant GENENTECH, INC. Inventor

44.295142CORONAVIRUS VACCINE FORMULATIONS
IL - 01.09.2022
Int.Class A61K 39/00 Appl.No 295142 Applicant NOVAVAX, INC. Inventor SMITH, Gale

45.WO/2022/180263CARRIER PROTEIN FOR PEPTIDE ANTIGEN
WO - 01.09.2022
Int.Class A61K 39/00 Appl.No PCT/EP2022/054911 Applicant CURAVAC EUROPE Inventor HAVELANGE, Nicolas
Pharmaceutical composition comprising a conjugated peptide of SEQ ID NO: 1 to which multiple peptide epitopes are covalently grafted, kit comprising the elements for producing said conjugated peptide, synthesis method, and vaccine use.

46.WO/2022/186677METHOD FOR DETECTION OF SARS-CoV-2 MUTATIONS
WO - 09.09.2022
Int.Class C12Q 1/70 Appl.No PCT/KR2022/003219 Applicant SEEGENE, INC. Inventor KIM, Yun Jee
Disclosed herein is a method for detecting SARS-CoV-2 mutations in a sample comprising a nucleic acid molecule. By the method, rapid detection can be made of SARS-CoV-2 variants that has changed in viral characteristics (e.g., infectivity, mortality, vaccine effect, therapeutic effect, etc.), thus early preventing and promptly coping with the spread of infection of SARS-CoV-2 variants.

47.20220280624VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOF
US - 08.09.2022
Int.Class A61K 39/00 Appl.No 17697623 Applicant IO BIOTECH APS Inventor Mads Hald ANDERSEN

The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression.

48.20220273785MODIFIED BRUCELLA VACCINE STRAIN FOR THE TREATMENT OF BRUCELLOSIS
US - 01.09.2022
Int.Class A61K 39/02 Appl.No 17687313 Applicant CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) Inventor María Jesús GRILLÓ DOLSET

The present application provides a modified *Brucella* strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The *Brucella* strain has been modified through an inactivation of the wzm gene. Further, the present application provides a pharmaceutical composition which comprises the modified *Brucella* strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The present application also provides a kit which comprises the modified *Brucella* strain and a pharmaceutically acceptable carrier or diluent and its use for the treatment and/or prevention of brucellosis.

49.20220280622NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS
US - 08.09.2022

Int.Class A61K 39/00 Appl.No 17743685 Applicant Immatics Biotechnologies GmbH Inventor Andrea MAHR

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

50.20220280636ANTIGENIC GLYCOPROTEIN E POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USE THEREOF
US - 08.09.2022
Int.Class A61K 39/245 Appl.No 17626206 Applicant Arthur FRIDMAN Inventor Arthur Fridman

The disclosure relates to HSV glycoprotein E antigenic peptide constructs and HSV protein vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. The present invention directed to immunogenic polypeptides of use for a vaccine against Herpes Simplex Vims (HSV). The polypeptides are glycoprotein E peptides that are mutated to reduce their binding to antibody Fc domain.

51.4052724FORMULATIONS FOR NEOPLASIA VACCINES
EP - 07.09.2022
Int.Class A61K 39/00 Appl.No 22162718 Applicant BROAD INST INC Inventor FRITSCH EDWARD F
The present invention relates to neoplasia vaccine or immunogenic composition formulation for the treatment or prevention of neoplasia in a subject.

52.WO/2022/187230METHODS AND COMPOSITIONS FOR DETECTING AND PRODUCING PORCINE MORBILLIVIRUS AND IMMUNOGENIC COMPOSITIONS THEREOF
WO - 09.09.2022
Int.Class Appl.No PCT/US2022/018319 Applicant IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor LI, Ganwu
Disclosed herein are methods for detecting and producing PoMV. Further, disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing PoMV. The compositions and methods include immunogenic portions of PoMV including entry proteins. In at least particular cases, a mutated version of a portion of the PoMV is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.

53.202117041510VACCINE ADJUVANTS AND FORMULATIONS
IN - 02.09.2022
Int.Class A61K / Appl.No 202117041510 Applicant CLEVELAND CLINIC FOUNDATION Inventor TUOHY, Vincent, Kevin
Compositions comprising an antigen, a carbohydrate, and a metabolizable oil, methods of administering such compositions to a subject, methods of making such compounds, and related compositions, methods, and uses.

54.202217028862ENGINEERED ANTIBODIES TO HIV ENV
IN - 02.09.2022
Int.Class C07K / Appl.No 202217028862 Applicant INTERNATIONAL AIDS VACCINE INITIATIVE Inventor SOK, Devin

The present disclosure relates to anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS. In one aspect, provided herein are enhanced engineered anti-HIV Env antibodies that were derived from the PGDM1400 parent antibody using directed-evolution and yeast display. In one aspect, provided herein are pharmaceutical compositions comprising the enhanced engineered anti-HIV Env antibodies disclosed herein.

55.WO/2022/183278RECOMBINANT VSV-SARS-COV-2 VACCINE
WO - 09.09.2022
Int.Class C12N 7/01 Appl.No PCT/CA2022/050277 Applicant SUMAGEN CANADA INC. Inventor KANG, Chil-Yong
A recombinant vesicular stomatitis virus (rVSV) carrying one or more genes that encode for the spike protein of SARS-CoV-2 or for both the S protein and the envelope protein of the SARS-CoV-2. Vaccines, regimens and kits having the rVSV are used for the prevention of infections caused by SARS-CoV-2.

56.WO/2022/180262VACCINE FOR THERAPEUTIC OR PROPHYLACTIC TREATMENT OF MYASTHENIA GRAVIS
WO - 01.09.2022
Int.Class A61K 39/00 Appl.No PCT/EP2022/054909 Applicant CURAVAC EUROPE Inventor HAVELANGE, Nicolas
A pharmaceutical composition for treating myasthenia gravis, comprising a carrier protein of SEQ ID NO: 1 coupled to a plurality of peptide epitopes, the corresponding peptide epitopes, and the method of synthesizing the conjugate.

57.20220273783NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS
US - 01.09.2022
Int.Class A61K 39/00 Appl.No 17734997 Applicant Immatics Biotechnologies GmbH Inventor Andrea MAHR

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

58.WO/2022/182902SEQUENCING POLYCLONAL ANTIBODIES DIRECTLY FROM SINGLE PARTICLE CRYOEM DATA
WO - 01.09.2022
Int.Class G16B 20/00 Appl.No PCT/US2022/017756 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor WARD, Andrew B.
Provided herein are methods for discovery of epitope specific monoclonal antibodies to pathogens directly from immune sera for immunotherapeutic use. Further provided herein are methods to determine molecular structure of antibodies targeting an antigen from convalescent or vaccinated individuals for the purpose of rational vaccine design.

Patentes registradas en la United States Patent and Trademark Office (USPTO)

Results Search in US Patent Collection db for: (ABST/vaccine AND ISD/20220901->20220911), 8 records.

	PAT. NO.	Title
1	11,435,351	Methods for determining vaccine potency
2	11,434,273	Peptides and combination of peptides for use in immunotherapy against various tumors
3	11,434,261	Optimized Zika virus envelope gene and expression thereof
4	11,434,259	Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
5	11,433,139	Peptide vaccines against interleukin-31
6	11,433,129	Compositions and methods of manufacturing trivalent filovirus vaccines
7	11,433,124	Peptides and combination of peptides for use in immunotherapy against various cancers
8	11,433,099	Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES